Level/ Type |
Code |
Display Name |
Code System |
Description |
0-L |
A |
ALIMENTARY TRACT AND METABOLISM |
WHO ATC |
|
0-L |
A01 |
STOMATOLOGICAL PREPARATIONS |
WHO ATC |
|
0-L |
A01A |
STOMATOLOGICAL PREPARATIONS |
WHO ATC |
|
0-L |
A01AA |
Caries prophylactic agents |
WHO ATC |
|
0-L |
A01AA01 |
sodium fluoride |
WHO ATC |
|
0-L |
A01AA02 |
sodium monofluorophosphate |
WHO ATC |
|
0-L |
A01AA03 |
olaflur |
WHO ATC |
|
0-L |
A01AA04 |
stannous fluoride |
WHO ATC |
|
0-L |
A01AA30 |
combinations |
WHO ATC |
|
0-L |
A01AA51 |
sodium fluoride, combinations |
WHO ATC |
|
0-L |
A01AB |
Antiinfectives and antiseptics for local oral treatment |
WHO ATC |
|
0-L |
A01AB02 |
hydrogen peroxide |
WHO ATC |
|
0-L |
A01AB03 |
chlorhexidine |
WHO ATC |
|
0-L |
A01AB04 |
amphotericin B |
WHO ATC |
|
0-L |
A01AB05 |
polynoxylin |
WHO ATC |
|
0-L |
A01AB06 |
domiphen |
WHO ATC |
|
0-L |
A01AB07 |
oxyquinoline |
WHO ATC |
|
0-L |
A01AB08 |
neomycin |
WHO ATC |
|
0-L |
A01AB09 |
miconazole |
WHO ATC |
|
0-L |
A01AB10 |
natamycin |
WHO ATC |
|
0-L |
A01AB11 |
various |
WHO ATC |
|
0-L |
A01AB12 |
hexetidine |
WHO ATC |
|
0-L |
A01AB13 |
tetracycline |
WHO ATC |
|
0-L |
A01AB14 |
benzoxonium chloride |
WHO ATC |
|
0-L |
A01AB15 |
tibezonium iodide |
WHO ATC |
|
0-L |
A01AB16 |
mepartricin |
WHO ATC |
|
0-L |
A01AB17 |
metronidazole |
WHO ATC |
|
0-L |
A01AB18 |
clotrimazole |
WHO ATC |
|
0-L |
A01AB19 |
sodium perborate |
WHO ATC |
|
0-L |
A01AB21 |
chlortetracycline |
WHO ATC |
|
0-L |
A01AB22 |
doxycycline |
WHO ATC |
|
0-L |
A01AB23 |
minocycline |
WHO ATC |
|
0-L |
A01AC |
Corticosteroids for local oral treatment |
WHO ATC |
|
0-L |
A01AC01 |
triamcinolone |
WHO ATC |
|
0-L |
A01AC02 |
dexamethasone |
WHO ATC |
|
0-L |
A01AC03 |
hydrocortisone |
WHO ATC |
|
0-L |
A01AC54 |
prednisolone, combinations |
WHO ATC |
|
0-L |
A01AD |
Other agents for local oral treatment |
WHO ATC |
|
0-L |
A01AD01 |
epinephrine |
WHO ATC |
|
0-L |
A01AD02 |
benzydamine |
WHO ATC |
|
0-L |
A01AD05 |
acetylsalicylic acid |
WHO ATC |
|
0-L |
A01AD06 |
adrenalone |
WHO ATC |
|
0-L |
A01AD07 |
amlexanox |
WHO ATC |
|
0-L |
A01AD08 |
becaplermin |
WHO ATC |
|
0-L |
A01AD11 |
various |
WHO ATC |
|
0-L |
A02 |
DRUGS FOR ACID RELATED DISORDERS |
WHO ATC |
|
0-L |
A02A |
ANTACIDS |
WHO ATC |
|
0-L |
A02AA |
Magnesium compounds |
WHO ATC |
|
0-L |
A02AA01 |
magnesium carbonate |
WHO ATC |
|
0-L |
A02AA02 |
magnesium oxide |
WHO ATC |
|
0-L |
A02AA03 |
magnesium peroxide |
WHO ATC |
|
0-L |
A02AA04 |
magnesium hydroxide |
WHO ATC |
|
0-L |
A02AA05 |
magnesium silicate |
WHO ATC |
|
0-L |
A02AA10 |
combinations |
WHO ATC |
|
0-L |
A02AB |
Aluminium compounds |
WHO ATC |
|
0-L |
A02AB01 |
aluminium hydroxide |
WHO ATC |
|
0-L |
A02AB02 |
algeldrate |
WHO ATC |
|
0-L |
A02AB03 |
aluminium phosphate |
WHO ATC |
|
0-L |
A02AB04 |
dihydroxialumini sodium carbonate |
WHO ATC |
|
0-L |
A02AB05 |
aluminium acetoacetate |
WHO ATC |
|
0-L |
A02AB06 |
aloglutamol |
WHO ATC |
|
0-L |
A02AB07 |
aluminium glycinate |
WHO ATC |
|
0-L |
A02AB10 |
combinations |
WHO ATC |
|
0-L |
A02AC |
Calcium compounds |
WHO ATC |
|
0-L |
A02AC01 |
calcium carbonate |
WHO ATC |
|
0-L |
A02AC02 |
calcium silicate |
WHO ATC |
|
0-L |
A02AC10 |
combinations |
WHO ATC |
|
0-L |
A02AD |
Combinations and complexes of aluminium, calcium and magnesium compounds |
WHO ATC |
|
0-L |
A02AD01 |
ordinary salt combinations |
WHO ATC |
|
0-L |
A02AD02 |
magaldrate |
WHO ATC |
|
0-L |
A02AD03 |
almagate |
WHO ATC |
|
0-L |
A02AD04 |
hydrotalcite |
WHO ATC |
|
0-L |
A02AD05 |
almasilate |
WHO ATC |
|
0-L |
A02AF |
Antacids with antiflatulents |
WHO ATC |
|
0-L |
A02AF01 |
magaldrate and antiflatulents |
WHO ATC |
|
0-L |
A02AF02 |
ordinary salt combinations and antiflatulents |
WHO ATC |
|
0-L |
A02AG |
Antacids with antispasmodics |
WHO ATC |
|
0-L |
A02AH |
Antacids with sodium bicarbonate |
WHO ATC |
|
0-L |
A02AX |
Antacids, other combinations |
WHO ATC |
|
0-L |
A02B |
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) |
WHO ATC |
|
0-L |
A02BA |
H2-receptor antagonists |
WHO ATC |
|
0-L |
A02BA01 |
cimetidine |
WHO ATC |
|
0-L |
A02BA02 |
ranitidine |
WHO ATC |
|
0-L |
A02BA03 |
famotidine |
WHO ATC |
|
0-L |
A02BA04 |
nizatidine |
WHO ATC |
|
0-L |
A02BA05 |
niperotidine |
WHO ATC |
|
0-L |
A02BA06 |
roxatidine |
WHO ATC |
|
0-L |
A02BA07 |
ranitidine bismuth citrate |
WHO ATC |
|
0-L |
A02BA08 |
lafutidine |
WHO ATC |
|
0-L |
A02BA51 |
cimetidine, combinations |
WHO ATC |
|
0-L |
A02BA53 |
famotidine, combinations |
WHO ATC |
|
0-L |
A02BB |
Prostaglandins |
WHO ATC |
|
0-L |
A02BB01 |
misoprostol |
WHO ATC |
|
0-L |
A02BB02 |
enprostil |
WHO ATC |
|
0-L |
A02BC |
Proton pump inhibitors |
WHO ATC |
|
0-L |
A02BC01 |
omeprazole |
WHO ATC |
|
0-L |
A02BC02 |
pantoprazole |
WHO ATC |
|
0-L |
A02BC03 |
lansoprazole |
WHO ATC |
|
0-L |
A02BC04 |
rabeprazole |
WHO ATC |
|
0-L |
A02BC05 |
esomeprazole |
WHO ATC |
|
0-L |
A02BD |
Combinations for eradication of Helicobacter pylori |
WHO ATC |
|
0-L |
A02BD01 |
omeprazole, amoxicillin and metronidazole |
WHO ATC |
|
0-L |
A02BD02 |
lansoprazole, tetracycline and metronidazole |
WHO ATC |
|
0-L |
A02BD03 |
lansoprazole, amoxicillin and metronidazole |
WHO ATC |
|
0-L |
A02BD04 |
pantoprazole, amoxicillin and clarithromycin |
WHO ATC |
|
0-L |
A02BD05 |
omeprazole, amoxicillin and clarithromycin |
WHO ATC |
|
0-L |
A02BD06 |
esomeprazole, amoxicillin and clarithromycin |
WHO ATC |
|
0-L |
A02BD07 |
lansoprazole, amoxicillin and clarithromycin |
WHO ATC |
|
0-L |
A02BX |
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) |
WHO ATC |
|
0-L |
A02BX01 |
carbenoxolone |
WHO ATC |
|
0-L |
A02BX02 |
sucralfate |
WHO ATC |
|
0-L |
A02BX03 |
pirenzepine |
WHO ATC |
|
0-L |
A02BX04 |
methiosulfonium chloride |
WHO ATC |
|
0-L |
A02BX05 |
bismuth subcitrate |
WHO ATC |
|
0-L |
A02BX06 |
proglumide |
WHO ATC |
|
0-L |
A02BX07 |
gefarnate |
WHO ATC |
|
0-L |
A02BX08 |
sulglicotide |
WHO ATC |
|
0-L |
A02BX09 |
acetoxolone |
WHO ATC |
|
0-L |
A02BX10 |
zolimidine |
WHO ATC |
|
0-L |
A02BX11 |
troxipide |
WHO ATC |
|
0-L |
A02BX12 |
bismuth subnitrate |
WHO ATC |
|
0-L |
A02BX13 |
alginic acid |
WHO ATC |
|
0-L |
A02BX51 |
carbenoxolone, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
A02BX71 |
carbenoxolone, combinations with psycholeptics |
WHO ATC |
|
0-L |
A02BX77 |
gefarnate, combinations with psycholeptics |
WHO ATC |
|
0-L |
A02X |
OTHER DRUGS FOR ACID RELATED DISORDERS |
WHO ATC |
|
0-L |
A03 |
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS |
WHO ATC |
|
0-L |
A03A |
DRUGS FOR FUNCTIONAL BOWEL DISORDERS |
WHO ATC |
|
0-L |
A03AA |
Synthetic anticholinergics, esters with tertiary amino group |
WHO ATC |
|
0-L |
A03AA01 |
oxyphencyclimine |
WHO ATC |
|
0-L |
A03AA03 |
camylofin |
WHO ATC |
|
0-L |
A03AA04 |
mebeverine |
WHO ATC |
|
0-L |
A03AA05 |
trimebutine |
WHO ATC |
|
0-L |
A03AA06 |
rociverine |
WHO ATC |
|
0-L |
A03AA07 |
dicycloverine |
WHO ATC |
|
0-L |
A03AA08 |
dihexyverine |
WHO ATC |
|
0-L |
A03AA09 |
difemerine |
WHO ATC |
|
0-L |
A03AA30 |
piperidolate |
WHO ATC |
|
0-L |
A03AB |
Synthetic anticholinergics, quaternary ammonium compounds |
WHO ATC |
|
0-L |
A03AB01 |
benzilone |
WHO ATC |
|
0-L |
A03AB02 |
glycopyrronium |
WHO ATC |
|
0-L |
A03AB03 |
oxyphenonium |
WHO ATC |
|
0-L |
A03AB04 |
penthienate |
WHO ATC |
|
0-L |
A03AB05 |
propantheline |
WHO ATC |
|
0-L |
A03AB06 |
otilonium bromide |
WHO ATC |
|
0-L |
A03AB07 |
methantheline |
WHO ATC |
|
0-L |
A03AB08 |
tridihexethyl |
WHO ATC |
|
0-L |
A03AB09 |
isopropamide |
WHO ATC |
|
0-L |
A03AB10 |
hexocyclium |
WHO ATC |
|
0-L |
A03AB11 |
poldine |
WHO ATC |
|
0-L |
A03AB12 |
mepenzolate |
WHO ATC |
|
0-L |
A03AB13 |
bevonium |
WHO ATC |
|
0-L |
A03AB14 |
pipenzolate |
WHO ATC |
|
0-L |
A03AB15 |
diphemanil |
WHO ATC |
|
0-L |
A03AB16 |
(2-benzhydryloxyethyl)diethyl-methylammonium iodide |
WHO ATC |
|
0-L |
A03AB17 |
tiemonium iodide |
WHO ATC |
|
0-L |
A03AB18 |
prifinium bromide |
WHO ATC |
|
0-L |
A03AB19 |
timepidium bromide |
WHO ATC |
|
0-L |
A03AB21 |
fenpiverinium |
WHO ATC |
|
0-L |
A03AB53 |
oxyphenonium, combinations |
WHO ATC |
|
0-L |
A03AC |
Synthetic antispasmodics, amides with tertiary amines |
WHO ATC |
|
0-L |
A03AC02 |
dimethylaminopropionylphenothiazine |
WHO ATC |
|
0-L |
A03AC04 |
nicofetamide |
WHO ATC |
|
0-L |
A03AC05 |
tiropramide |
WHO ATC |
|
0-L |
A03AD |
Papaverine and derivatives |
WHO ATC |
|
0-L |
A03AD01 |
papaverine |
WHO ATC |
|
0-L |
A03AD02 |
drotaverine |
WHO ATC |
|
0-L |
A03AD30 |
moxaverine |
WHO ATC |
|
0-L |
A03AE |
Drugs acting on serotonin receptors |
WHO ATC |
|
0-L |
A03AE01 |
alosetron |
WHO ATC |
|
0-L |
A03AE02 |
tegaserod |
WHO ATC |
|
0-L |
A03AE03 |
cilansetron |
WHO ATC |
|
0-L |
A03AE04 |
prucalopride |
WHO ATC |
|
0-L |
A03AX |
Other drugs for functional bowel disorders |
WHO ATC |
|
0-L |
A03AX01 |
fenpiprane |
WHO ATC |
|
0-L |
A03AX02 |
diisopromine |
WHO ATC |
|
0-L |
A03AX03 |
chlorbenzoxamine |
WHO ATC |
|
0-L |
A03AX04 |
pinaverium |
WHO ATC |
|
0-L |
A03AX05 |
fenoverine |
WHO ATC |
|
0-L |
A03AX06 |
idanpramine |
WHO ATC |
|
0-L |
A03AX07 |
proxazole |
WHO ATC |
|
0-L |
A03AX08 |
alverine |
WHO ATC |
|
0-L |
A03AX09 |
trepibutone |
WHO ATC |
|
0-L |
A03AX10 |
isometheptene |
WHO ATC |
|
0-L |
A03AX11 |
caroverine |
WHO ATC |
|
0-L |
A03AX12 |
phloroglucinol |
WHO ATC |
|
0-L |
A03AX13 |
silicones |
WHO ATC |
|
0-L |
A03AX30 |
trimethyldiphenylpropylamine |
WHO ATC |
|
0-L |
A03AX58 |
alverine, combinations |
WHO ATC |
|
0-L |
A03B |
BELLADONNA AND DERIVATIVES, PLAIN |
WHO ATC |
|
0-L |
A03BA |
Belladonna alkaloids, tertiary amines |
WHO ATC |
|
0-L |
A03BA01 |
atropine |
WHO ATC |
|
0-L |
A03BA03 |
hyoscyamine |
WHO ATC |
|
0-L |
A03BA04 |
belladonna total alkaloids |
WHO ATC |
|
0-L |
A03BB |
Belladonna alkaloids, semisynthetic, quaternary ammonium compounds |
WHO ATC |
|
0-L |
A03BB01 |
butylscopolamine |
WHO ATC |
|
0-L |
A03BB02 |
methylatropine |
WHO ATC |
|
0-L |
A03BB03 |
methylscopolamine |
WHO ATC |
|
0-L |
A03BB04 |
fentonium |
WHO ATC |
|
0-L |
A03BB05 |
cimetropium bromide |
WHO ATC |
|
0-L |
A03C |
ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS |
WHO ATC |
|
0-L |
A03CA |
Synthetic anticholinergic agents in combination with psycholeptics |
WHO ATC |
|
0-L |
A03CA01 |
isopropamide and psycholeptics |
WHO ATC |
|
0-L |
A03CA02 |
clidinium and psycholeptics |
WHO ATC |
|
0-L |
A03CA03 |
oxyphencyclimine and psycholeptics |
WHO ATC |
|
0-L |
A03CA04 |
otilonium bromide and psycholeptics |
WHO ATC |
|
0-L |
A03CA05 |
glycopyrronium and psycholeptics |
WHO ATC |
|
0-L |
A03CA06 |
bevonium and psycholeptics |
WHO ATC |
|
0-L |
A03CA07 |
ambutonium and psycholeptics |
WHO ATC |
|
0-L |
A03CA08 |
diphemanil and psycholeptics |
WHO ATC |
|
0-L |
A03CA30 |
emepronium and psycholeptics |
WHO ATC |
|
0-L |
A03CA34 |
propantheline and psycholeptics |
WHO ATC |
|
0-L |
A03CB |
Belladonna and derivatives in combination with psycholeptics |
WHO ATC |
|
0-L |
A03CB01 |
methylscopolamine and psycholeptics |
WHO ATC |
|
0-L |
A03CB02 |
belladonna total alkaloids and psycholeptics |
WHO ATC |
|
0-L |
A03CB03 |
atropine and psycholeptics |
WHO ATC |
|
0-L |
A03CB04 |
methylhomatropine and psycholeptics |
WHO ATC |
|
0-L |
A03CB31 |
hyoscyamine and psycholeptics |
WHO ATC |
|
0-L |
A03CC |
Other antispasmodics in combination with psycholeptics |
WHO ATC |
|
0-L |
A03D |
ANTISPASMODICS IN COMBINATION WITH ANALGESICS |
WHO ATC |
|
0-L |
A03DA |
Synthetic anticholinergic agents in combination with analgesics |
WHO ATC |
|
0-L |
A03DA01 |
tropenzilone and analgesics |
WHO ATC |
|
0-L |
A03DA02 |
pitofenone and analgesics |
WHO ATC |
|
0-L |
A03DA03 |
bevonium and analgesics |
WHO ATC |
|
0-L |
A03DA04 |
ciclonium and analgesics |
WHO ATC |
|
0-L |
A03DA05 |
camylofin and analgesics |
WHO ATC |
|
0-L |
A03DA06 |
trospium and analgesics |
WHO ATC |
|
0-L |
A03DA07 |
tiemonium iodide and analgesics |
WHO ATC |
|
0-L |
A03DB |
Belladonna and derivatives in combination with analgesics |
WHO ATC |
|
0-L |
A03DB04 |
butylscopolamine and analgesics |
WHO ATC |
|
0-L |
A03DC |
Other antispasmodics in combination with analgesics |
WHO ATC |
|
0-L |
A03E |
ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS |
WHO ATC |
|
0-L |
A03EA |
Antispasmodics, psycholeptics and analgesics in combination |
WHO ATC |
|
0-L |
A03ED |
Antispasmodics in combination with other drugs |
WHO ATC |
|
0-L |
A03F |
PROPULSIVES |
WHO ATC |
|
0-L |
A03FA |
Propulsives |
WHO ATC |
|
0-L |
A03FA01 |
metoclopramide |
WHO ATC |
|
0-L |
A03FA02 |
cisapride |
WHO ATC |
|
0-L |
A03FA03 |
domperidone |
WHO ATC |
|
0-L |
A03FA04 |
bromopride |
WHO ATC |
|
0-L |
A03FA05 |
alizapride |
WHO ATC |
|
0-L |
A03FA06 |
clebopride |
WHO ATC |
|
0-L |
A04 |
ANTIEMETICS AND ANTINAUSEANTS |
WHO ATC |
|
0-L |
A04A |
ANTIEMETICS AND ANTINAUSEANTS |
WHO ATC |
|
0-L |
A04AA |
Serotonin (5HT3) antagonists |
WHO ATC |
|
0-L |
A04AA01 |
ondansetron |
WHO ATC |
|
0-L |
A04AA02 |
granisetron |
WHO ATC |
|
0-L |
A04AA03 |
tropisetron |
WHO ATC |
|
0-L |
A04AA04 |
dolasetron |
WHO ATC |
|
0-L |
A04AA05 |
palonosetron |
WHO ATC |
|
0-L |
A04AD |
Other antiemetics |
WHO ATC |
|
0-L |
A04AD01 |
scopolamine |
WHO ATC |
|
0-L |
A04AD02 |
cerium oxalate |
WHO ATC |
|
0-L |
A04AD04 |
chlorobutanol |
WHO ATC |
|
0-L |
A04AD05 |
metopimazine |
WHO ATC |
|
0-L |
A04AD10 |
dronabinol |
WHO ATC |
|
0-L |
A04AD11 |
nabilone |
WHO ATC |
|
0-L |
A04AD12 |
aprepitant |
WHO ATC |
|
0-L |
A04AD13 |
casopitant |
WHO ATC |
|
0-L |
A04AD51 |
scopolamine, combinations |
WHO ATC |
|
0-L |
A04AD54 |
chlorobutanol, combinations |
WHO ATC |
|
0-L |
A05 |
BILE AND LIVER THERAPY |
WHO ATC |
|
0-L |
A05A |
BILE THERAPY |
WHO ATC |
|
0-L |
A05AA |
Bile acid preparations |
WHO ATC |
|
0-L |
A05AA01 |
chenodeoxycholic acid |
WHO ATC |
|
0-L |
A05AA02 |
ursodeoxycholic acid |
WHO ATC |
|
0-L |
A05AA03 |
cholic acid |
WHO ATC |
|
0-L |
A05AB |
Preparations for biliary tract therapy |
WHO ATC |
|
0-L |
A05AB01 |
nicotinyl methylamide |
WHO ATC |
|
0-L |
A05AX |
Other drugs for bile therapy |
WHO ATC |
|
0-L |
A05AX01 |
piprozolin |
WHO ATC |
|
0-L |
A05AX02 |
hymecromone |
WHO ATC |
|
0-L |
A05AX03 |
cyclobutyrol |
WHO ATC |
|
0-L |
A05B |
LIVER THERAPY, LIPOTROPICS |
WHO ATC |
|
0-L |
A05BA |
Liver therapy |
WHO ATC |
|
0-L |
A05BA01 |
arginine glutamate |
WHO ATC |
|
0-L |
A05BA03 |
silymarin |
WHO ATC |
|
0-L |
A05BA04 |
citiolone |
WHO ATC |
|
0-L |
A05BA05 |
epomediol |
WHO ATC |
|
0-L |
A05BA06 |
ornithine oxoglurate |
WHO ATC |
|
0-L |
A05BA07 |
tidiacic arginine |
WHO ATC |
|
0-L |
A05BA08 |
glycyrrhizic acid |
WHO ATC |
|
0-L |
A05C |
DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION |
WHO ATC |
|
0-L |
A06 |
LAXATIVES |
WHO ATC |
|
0-L |
A06A |
LAXATIVES |
WHO ATC |
|
0-L |
A06AA |
Softeners, emollients |
WHO ATC |
|
0-L |
A06AA01 |
liquid paraffin |
WHO ATC |
|
0-L |
A06AA02 |
docusate sodium |
WHO ATC |
|
0-L |
A06AA51 |
liquid paraffin, combinations |
WHO ATC |
|
0-L |
A06AB |
Contact laxatives |
WHO ATC |
|
0-L |
A06AB01 |
oxyphenisatine |
WHO ATC |
|
0-L |
A06AB02 |
bisacodyl |
WHO ATC |
|
0-L |
A06AB03 |
dantron |
WHO ATC |
|
0-L |
A06AB04 |
phenolphthalein |
WHO ATC |
|
0-L |
A06AB05 |
castor oil |
WHO ATC |
|
0-L |
A06AB06 |
senna glycosides |
WHO ATC |
|
0-L |
A06AB07 |
cascara |
WHO ATC |
|
0-L |
A06AB08 |
sodium picosulfate |
WHO ATC |
|
0-L |
A06AB09 |
bisoxatin |
WHO ATC |
|
0-L |
A06AB20 |
contact laxatives in combination |
WHO ATC |
|
0-L |
A06AB30 |
contact laxatives in combination with belladonna alkaloids |
WHO ATC |
|
0-L |
A06AB52 |
bisacodyl, combinations |
WHO ATC |
|
0-L |
A06AB53 |
dantron, combinations |
WHO ATC |
|
0-L |
A06AB56 |
senna glycosides, combinations |
WHO ATC |
|
0-L |
A06AB57 |
cascara, combinations |
WHO ATC |
|
0-L |
A06AB58 |
sodium picosulfate, combinations |
WHO ATC |
|
0-L |
A06AC |
Bulk producers |
WHO ATC |
|
0-L |
A06AC01 |
ispaghula (psylla seeds) |
WHO ATC |
|
0-L |
A06AC02 |
ethulose |
WHO ATC |
|
0-L |
A06AC03 |
sterculia |
WHO ATC |
|
0-L |
A06AC05 |
linseed |
WHO ATC |
|
0-L |
A06AC06 |
methylcellulose |
WHO ATC |
|
0-L |
A06AC07 |
triticum (wheat fibre) |
WHO ATC |
|
0-L |
A06AC08 |
polycarbophil calcium |
WHO ATC |
|
0-L |
A06AC51 |
ispaghula, combinations |
WHO ATC |
|
0-L |
A06AC53 |
sterculia, combinations |
WHO ATC |
|
0-L |
A06AC55 |
linseed, combinations |
WHO ATC |
|
0-L |
A06AD |
Osmotically acting laxatives |
WHO ATC |
|
0-L |
A06AD01 |
magnesium carbonate |
WHO ATC |
|
0-L |
A06AD02 |
magnesium oxide |
WHO ATC |
|
0-L |
A06AD03 |
magnesium peroxide |
WHO ATC |
|
0-L |
A06AD04 |
magnesium sulfate |
WHO ATC |
|
0-L |
A06AD10 |
mineral salts in combination |
WHO ATC |
|
0-L |
A06AD11 |
lactulose |
WHO ATC |
|
0-L |
A06AD12 |
lactitol |
WHO ATC |
|
0-L |
A06AD13 |
sodium sulfate |
WHO ATC |
|
0-L |
A06AD14 |
pentaerithrityl |
WHO ATC |
|
0-L |
A06AD15 |
macrogol |
WHO ATC |
|
0-L |
A06AD16 |
mannitol |
WHO ATC |
|
0-L |
A06AD17 |
sodium phosphate |
WHO ATC |
|
0-L |
A06AD18 |
sorbitol |
WHO ATC |
|
0-L |
A06AD19 |
magnesium citrate |
WHO ATC |
|
0-L |
A06AD21 |
sodium tartrate |
WHO ATC |
|
0-L |
A06AD61 |
lactulose, combinations |
WHO ATC |
|
0-L |
A06AD65 |
macrogol, combinations |
WHO ATC |
|
0-L |
A06AG |
Enemas |
WHO ATC |
|
0-L |
A06AG01 |
sodium phosphate |
WHO ATC |
|
0-L |
A06AG02 |
bisacodyl |
WHO ATC |
|
0-L |
A06AG03 |
dantron, incl. combinations |
WHO ATC |
|
0-L |
A06AG04 |
glycerol |
WHO ATC |
|
0-L |
A06AG06 |
oil |
WHO ATC |
|
0-L |
A06AG07 |
sorbitol |
WHO ATC |
|
0-L |
A06AG10 |
docusate sodium, incl. combinations |
WHO ATC |
|
0-L |
A06AG11 |
laurilsulfate, incl. combinations |
WHO ATC |
|
0-L |
A06AG20 |
combinations |
WHO ATC |
|
0-L |
A06AH |
Peripheral opioid receptor antagonists |
WHO ATC |
|
0-L |
A06AH01 |
methylnaltrexone bromide |
WHO ATC |
|
0-L |
A06AH02 |
alvimopan |
WHO ATC |
|
0-L |
A06AX |
Other laxatives |
WHO ATC |
|
0-L |
A06AX01 |
glycerol |
WHO ATC |
|
0-L |
A06AX02 |
carbon dioxide producing drugs |
WHO ATC |
|
0-L |
A06AX03 |
lubiprostone |
WHO ATC |
|
0-L |
A07 |
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVEAGENTS |
WHO ATC |
|
0-L |
A07A |
INTESTINAL ANTIINFECTIVES |
WHO ATC |
|
0-L |
A07AA |
Antibiotics |
WHO ATC |
|
0-L |
A07AA01 |
neomycin |
WHO ATC |
|
0-L |
A07AA02 |
nystatin |
WHO ATC |
|
0-L |
A07AA03 |
natamycin |
WHO ATC |
|
0-L |
A07AA04 |
streptomycin |
WHO ATC |
|
0-L |
A07AA05 |
polymyxin B |
WHO ATC |
|
0-L |
A07AA06 |
paromomycin |
WHO ATC |
|
0-L |
A07AA07 |
amphotericin B |
WHO ATC |
|
0-L |
A07AA08 |
kanamycin |
WHO ATC |
|
0-L |
A07AA09 |
vancomycin |
WHO ATC |
|
0-L |
A07AA10 |
colistin |
WHO ATC |
|
0-L |
A07AA11 |
rifaximin |
WHO ATC |
|
0-L |
A07AA51 |
neomycin, combinations |
WHO ATC |
|
0-L |
A07AA54 |
streptomycin, combinations |
WHO ATC |
|
0-L |
A07AB |
Sulfonamides |
WHO ATC |
|
0-L |
A07AB02 |
phthalylsulfathiazole |
WHO ATC |
|
0-L |
A07AB03 |
sulfaguanidine |
WHO ATC |
|
0-L |
A07AB04 |
succinylsulfathiazole |
WHO ATC |
|
0-L |
A07AC |
Imidazole derivatives |
WHO ATC |
|
0-L |
A07AC01 |
miconazole |
WHO ATC |
|
0-L |
A07AX |
Other intestinal antiinfectives |
WHO ATC |
|
0-L |
A07AX01 |
broxyquinoline |
WHO ATC |
|
0-L |
A07AX02 |
acetarsol |
WHO ATC |
|
0-L |
A07AX03 |
nifuroxazide |
WHO ATC |
|
0-L |
A07AX04 |
nifurzide |
WHO ATC |
|
0-L |
A07B |
INTESTINAL ADSORBENTS |
WHO ATC |
|
0-L |
A07BA |
Charcoal preparations |
WHO ATC |
|
0-L |
A07BA01 |
medicinal charcoal |
WHO ATC |
|
0-L |
A07BA51 |
medicinal charcoal, combinations |
WHO ATC |
|
0-L |
A07BB |
Bismuth preparations |
WHO ATC |
|
0-L |
A07BC |
Other intestinal adsorbents |
WHO ATC |
|
0-L |
A07BC01 |
pectin |
WHO ATC |
|
0-L |
A07BC02 |
kaolin |
WHO ATC |
|
0-L |
A07BC03 |
crospovidone |
WHO ATC |
|
0-L |
A07BC04 |
attapulgite |
WHO ATC |
|
0-L |
A07BC05 |
diosmectite |
WHO ATC |
|
0-L |
A07BC30 |
combinations |
WHO ATC |
|
0-L |
A07BC54 |
attapulgite, combinations |
WHO ATC |
|
0-L |
A07C |
ELECTROLYTES WITH CARBOHYDRATES |
WHO ATC |
|
0-L |
A07CA |
Oral rehydration salt formulations |
WHO ATC |
|
0-L |
A07D |
ANTIPROPULSIVES |
WHO ATC |
|
0-L |
A07DA |
Antipropulsives |
WHO ATC |
|
0-L |
A07DA01 |
diphenoxylate |
WHO ATC |
|
0-L |
A07DA02 |
opium |
WHO ATC |
|
0-L |
A07DA03 |
loperamide |
WHO ATC |
|
0-L |
A07DA04 |
difenoxin |
WHO ATC |
|
0-L |
A07DA05 |
loperamide oxide |
WHO ATC |
|
0-L |
A07DA52 |
morphine, combinations |
WHO ATC |
|
0-L |
A07DA53 |
loperamide, combinations |
WHO ATC |
|
0-L |
A07E |
INTESTINAL ANTIINFLAMMATORY AGENTS |
WHO ATC |
|
0-L |
A07EA |
Corticosteroids acting locally |
WHO ATC |
|
0-L |
A07EA01 |
prednisolone |
WHO ATC |
|
0-L |
A07EA02 |
hydrocortisone |
WHO ATC |
|
0-L |
A07EA03 |
prednisone |
WHO ATC |
|
0-L |
A07EA04 |
betamethasone |
WHO ATC |
|
0-L |
A07EA05 |
tixocortol |
WHO ATC |
|
0-L |
A07EA06 |
budesonide |
WHO ATC |
|
0-L |
A07EA07 |
beclometasone |
WHO ATC |
|
0-L |
A07EB |
Antiallergic agents, excl. corticosteroids |
WHO ATC |
|
0-L |
A07EB01 |
cromoglicic acid |
WHO ATC |
|
0-L |
A07EC |
Aminosalicylic acid and similar agents |
WHO ATC |
|
0-L |
A07EC01 |
sulfasalazine |
WHO ATC |
|
0-L |
A07EC02 |
mesalazine |
WHO ATC |
|
0-L |
A07EC03 |
olsalazine |
WHO ATC |
|
0-L |
A07EC04 |
balsalazide |
WHO ATC |
|
0-L |
A07F |
ANTIDIARRHEAL MICROORGANISMS |
WHO ATC |
|
0-L |
A07FA |
Antidiarrheal microorganisms |
WHO ATC |
|
0-L |
A07FA01 |
lactic acid producing organisms |
WHO ATC |
|
0-L |
A07FA02 |
saccharomyces boulardii |
WHO ATC |
|
0-L |
A07FA51 |
lactic acid producing organisms, combinations |
WHO ATC |
|
0-L |
A07X |
OTHER ANTIDIARRHEALS |
WHO ATC |
|
0-L |
A07XA |
Other antidiarrheals |
WHO ATC |
|
0-L |
A07XA01 |
albumin tannate |
WHO ATC |
|
0-L |
A07XA02 |
ceratonia |
WHO ATC |
|
0-L |
A07XA03 |
calcium compounds |
WHO ATC |
|
0-L |
A07XA04 |
racecadotril |
WHO ATC |
|
0-L |
A07XA51 |
albumin tannate, combinations |
WHO ATC |
|
0-L |
A08 |
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS |
WHO ATC |
|
0-L |
A08A |
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS |
WHO ATC |
|
0-L |
A08AA |
Centrally acting antiobesity products |
WHO ATC |
|
0-L |
A08AA01 |
phentermine |
WHO ATC |
|
0-L |
A08AA02 |
fenfluramine |
WHO ATC |
|
0-L |
A08AA03 |
amfepramone |
WHO ATC |
|
0-L |
A08AA04 |
dexfenfluramine |
WHO ATC |
|
0-L |
A08AA05 |
mazindol |
WHO ATC |
|
0-L |
A08AA06 |
etilamfetamine |
WHO ATC |
|
0-L |
A08AA07 |
cathine |
WHO ATC |
|
0-L |
A08AA08 |
clobenzorex |
WHO ATC |
|
0-L |
A08AA09 |
mefenorex |
WHO ATC |
|
0-L |
A08AA10 |
sibutramine |
WHO ATC |
|
0-L |
A08AA56 |
ephedrine, combinations |
WHO ATC |
|
0-L |
A08AB |
Peripherally acting antiobesity products |
WHO ATC |
|
0-L |
A08AB01 |
orlistat |
WHO ATC |
|
0-L |
A08AX |
Other antiobesity drugs |
WHO ATC |
|
0-L |
A08AX01 |
rimonabant |
WHO ATC |
|
0-L |
A09 |
DIGESTIVES, INCL. ENZYMES |
WHO ATC |
|
0-L |
A09A |
DIGESTIVES, INCL. ENZYMES |
WHO ATC |
|
0-L |
A09AA |
Enzyme preparations |
WHO ATC |
|
0-L |
A09AA01 |
diastase |
WHO ATC |
|
0-L |
A09AA02 |
multienzymes (lipase, protease etc.) |
WHO ATC |
|
0-L |
A09AA03 |
pepsin |
WHO ATC |
|
0-L |
A09AA04 |
tilactase |
WHO ATC |
|
0-L |
A09AB |
Acid preparations |
WHO ATC |
|
0-L |
A09AB01 |
glutamic acid hydrochloride |
WHO ATC |
|
0-L |
A09AB02 |
betaine hydrochloride |
WHO ATC |
|
0-L |
A09AB03 |
hydrochloric acid |
WHO ATC |
|
0-L |
A09AB04 |
citric acid |
WHO ATC |
|
0-L |
A09AC |
Enzyme and acid preparations, combinations |
WHO ATC |
|
0-L |
A09AC01 |
pepsin and acid preparations |
WHO ATC |
|
0-L |
A09AC02 |
multienzymes and acid preparations |
WHO ATC |
|
0-L |
A10 |
DRUGS USED IN DIABETES |
WHO ATC |
|
0-L |
A10A |
INSULINS AND ANALOGUES |
WHO ATC |
|
0-L |
A10AB |
Insulins and analogues for injection, fast-acting |
WHO ATC |
|
0-L |
A10AB01 |
insulin (human) |
WHO ATC |
|
0-L |
A10AB02 |
insulin (beef) |
WHO ATC |
|
0-L |
A10AB03 |
insulin (pork) |
WHO ATC |
|
0-L |
A10AB04 |
insulin lispro |
WHO ATC |
|
0-L |
A10AB05 |
insulin aspart |
WHO ATC |
|
0-L |
A10AB06 |
insulin glulisine |
WHO ATC |
|
0-L |
A10AB30 |
combinations |
WHO ATC |
|
0-L |
A10AC |
Insulins and analogues for injection, intermediate-acting |
WHO ATC |
|
0-L |
A10AC01 |
insulin (human) |
WHO ATC |
|
0-L |
A10AC02 |
insulin (beef) |
WHO ATC |
|
0-L |
A10AC03 |
insulin (pork) |
WHO ATC |
|
0-L |
A10AC04 |
insulin lispro |
WHO ATC |
|
0-L |
A10AC30 |
combinations |
WHO ATC |
|
0-L |
A10AD |
Insulins and analogues for injection, intermediate-acting combined with fast-acting |
WHO ATC |
|
0-L |
A10AD01 |
insulin (human) |
WHO ATC |
|
0-L |
A10AD02 |
insulin (beef) |
WHO ATC |
|
0-L |
A10AD03 |
insulin (pork) |
WHO ATC |
|
0-L |
A10AD04 |
Insulin lispro |
WHO ATC |
|
0-L |
A10AD05 |
insulin aspart |
WHO ATC |
|
0-L |
A10AD30 |
combinations |
WHO ATC |
|
0-L |
A10AE |
Insulins and analogues for injection, long-acting |
WHO ATC |
|
0-L |
A10AE01 |
insulin (human) |
WHO ATC |
|
0-L |
A10AE02 |
insulin (beef) |
WHO ATC |
|
0-L |
A10AE03 |
insulin (pork) |
WHO ATC |
|
0-L |
A10AE04 |
insulin glargine |
WHO ATC |
|
0-L |
A10AE05 |
insulin detemir |
WHO ATC |
|
0-L |
A10AE30 |
combinations |
WHO ATC |
|
0-L |
A10AF |
Insulins and analogues for inhalation |
WHO ATC |
|
0-L |
A10AF01 |
insulin (human) |
WHO ATC |
|
0-L |
A10B |
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
WHO ATC |
|
0-L |
A10BA |
Biguanides |
WHO ATC |
|
0-L |
A10BA01 |
phenformin |
WHO ATC |
|
0-L |
A10BA02 |
metformin |
WHO ATC |
|
0-L |
A10BA03 |
buformin |
WHO ATC |
|
0-L |
A10BB |
Sulfonamides, urea derivatives |
WHO ATC |
|
0-L |
A10BB01 |
glibenclamide |
WHO ATC |
|
0-L |
A10BB02 |
chlorpropamide |
WHO ATC |
|
0-L |
A10BB03 |
tolbutamide |
WHO ATC |
|
0-L |
A10BB04 |
glibornuride |
WHO ATC |
|
0-L |
A10BB05 |
tolazamide |
WHO ATC |
|
0-L |
A10BB06 |
carbutamide |
WHO ATC |
|
0-L |
A10BB07 |
glipizide |
WHO ATC |
|
0-L |
A10BB08 |
gliquidone |
WHO ATC |
|
0-L |
A10BB09 |
gliclazide |
WHO ATC |
|
0-L |
A10BB10 |
metahexamide |
WHO ATC |
|
0-L |
A10BB11 |
glisoxepide |
WHO ATC |
|
0-L |
A10BB12 |
glimepiride |
WHO ATC |
|
0-L |
A10BB31 |
acetohexamide |
WHO ATC |
|
0-L |
A10BC |
Sulfonamides (heterocyclic) |
WHO ATC |
|
0-L |
A10BC01 |
glymidine |
WHO ATC |
|
0-L |
A10BD |
Combinations of oral blood glucose lowering drugs |
WHO ATC |
|
0-L |
A10BD01 |
phenformin and sulfonamides |
WHO ATC |
|
0-L |
A10BD02 |
metformin and sulfonamides |
WHO ATC |
|
0-L |
A10BD03 |
metformin and rosiglitazone |
WHO ATC |
|
0-L |
A10BD04 |
glimepiride and rosiglitazone |
WHO ATC |
|
0-L |
A10BD05 |
metformin and pioglitazone |
WHO ATC |
|
0-L |
A10BD06 |
glimepiride and pioglitazone |
WHO ATC |
|
0-L |
A10BD07 |
metformin and sitagliptin |
WHO ATC |
|
0-L |
A10BD08 |
metformin and vildagliptin |
WHO ATC |
|
0-L |
A10BD09 |
pioglitazone and alogliptin |
WHO ATC |
|
0-L |
A10BF |
Alpha glucosidase inhibitors |
WHO ATC |
|
0-L |
A10BF01 |
acarbose |
WHO ATC |
|
0-L |
A10BF02 |
miglitol |
WHO ATC |
|
0-L |
A10BF03 |
voglibose |
WHO ATC |
|
0-L |
A10BG |
Thiazolidinediones |
WHO ATC |
|
0-L |
A10BG01 |
troglitazone |
WHO ATC |
|
0-L |
A10BG02 |
rosiglitazone |
WHO ATC |
|
0-L |
A10BG03 |
pioglitazone |
WHO ATC |
|
0-L |
A10BH |
Dipeptidyl peptidase 4 (DPP-4) inhibitors |
WHO ATC |
|
0-L |
A10BH01 |
sitagliptin |
WHO ATC |
|
0-L |
A10BH02 |
vildagliptin |
WHO ATC |
|
0-L |
A10BH03 |
saxagliptin |
WHO ATC |
|
0-L |
A10BH04 |
alogliptin |
WHO ATC |
|
0-L |
A10BX |
Other blood glucose lowering drugs, excl. insulins |
WHO ATC |
|
0-L |
A10BX01 |
guar gum |
WHO ATC |
|
0-L |
A10BX02 |
repaglinide |
WHO ATC |
|
0-L |
A10BX03 |
nateglinide |
WHO ATC |
|
0-L |
A10BX04 |
exenatide |
WHO ATC |
|
0-L |
A10BX05 |
pramlintide |
WHO ATC |
|
0-L |
A10BX06 |
benfluorex |
WHO ATC |
|
0-L |
A10BX07 |
liraglutide |
WHO ATC |
|
0-L |
A10BX08 |
mitiglinide |
WHO ATC |
|
0-L |
A10X |
OTHER DRUGS USED IN DIABETES |
WHO ATC |
|
0-L |
A10XA |
Aldose reductase inhibitors |
WHO ATC |
|
0-L |
A10XA01 |
tolrestat |
WHO ATC |
|
0-L |
A11 |
VITAMINS |
WHO ATC |
|
0-L |
A11A |
MULTIVITAMINS, COMBINATIONS |
WHO ATC |
|
0-L |
A11AA |
Multivitamins with minerals |
WHO ATC |
|
0-L |
A11AA01 |
multivitamins and iron |
WHO ATC |
|
0-L |
A11AA02 |
multivitamins and calcium |
WHO ATC |
|
0-L |
A11AA03 |
multivitamins and other minerals, incl. combinations |
WHO ATC |
|
0-L |
A11AA04 |
multivitamins and trace elements |
WHO ATC |
|
0-L |
A11AB |
Multivitamins, other combinations |
WHO ATC |
|
0-L |
A11B |
MULTIVITAMINS, PLAIN |
WHO ATC |
|
0-L |
A11BA |
Multivitamins, plain |
WHO ATC |
|
0-L |
A11C |
VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO |
WHO ATC |
|
0-L |
A11CA |
Vitamin A, plain |
WHO ATC |
|
0-L |
A11CA01 |
retinol (vit A) |
WHO ATC |
|
0-L |
A11CA02 |
betacarotene |
WHO ATC |
|
0-L |
A11CB |
Vitamin A and D in combination |
WHO ATC |
|
0-L |
A11CC |
Vitamin D and analogues |
WHO ATC |
|
0-L |
A11CC01 |
ergocalciferol |
WHO ATC |
|
0-L |
A11CC02 |
dihydrotachysterol |
WHO ATC |
|
0-L |
A11CC03 |
alfacalcidol |
WHO ATC |
|
0-L |
A11CC04 |
calcitriol |
WHO ATC |
|
0-L |
A11CC05 |
colecalciferol |
WHO ATC |
|
0-L |
A11CC06 |
calcifediol |
WHO ATC |
|
0-L |
A11CC20 |
combinations |
WHO ATC |
|
0-L |
A11D |
VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 |
WHO ATC |
|
0-L |
A11DA |
Vitamin B1, plain |
WHO ATC |
|
0-L |
A11DA01 |
thiamine (vit B1) |
WHO ATC |
|
0-L |
A11DA02 |
sulbutiamine |
WHO ATC |
|
0-L |
A11DA03 |
benfotiamine |
WHO ATC |
|
0-L |
A11DB |
Vitamin B1 in combination with vitamin B6 and/or vitamin B12 |
WHO ATC |
|
0-L |
A11E |
VITAMIN B-COMPLEX, INCL. COMBINATIONS |
WHO ATC |
|
0-L |
A11EA |
Vitamin B-complex, plain |
WHO ATC |
|
0-L |
A11EB |
Vitamin B-complex with vitamin C |
WHO ATC |
|
0-L |
A11EC |
Vitamin B-complex with minerals |
WHO ATC |
|
0-L |
A11ED |
Vitamin B-complex with anabolic steroids |
WHO ATC |
|
0-L |
A11EX |
Vitamin B-complex, other combinations |
WHO ATC |
|
0-L |
A11G |
ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS |
WHO ATC |
|
0-L |
A11GA |
Ascorbic acid (vitamin C), plain |
WHO ATC |
|
0-L |
A11GA01 |
ascorbic acid (vit C) |
WHO ATC |
|
0-L |
A11GB |
Ascorbic acid (vitamin C), combinations |
WHO ATC |
|
0-L |
A11GB01 |
ascorbic acid (vit C) and calcium |
WHO ATC |
|
0-L |
A11H |
OTHER PLAIN VITAMIN PREPARATIONS |
WHO ATC |
|
0-L |
A11HA |
Other plain vitamin preparations |
WHO ATC |
|
0-L |
A11HA01 |
nicotinamide |
WHO ATC |
|
0-L |
A11HA02 |
pyridoxine (vit B6) |
WHO ATC |
|
0-L |
A11HA03 |
tocopherol (vit E) |
WHO ATC |
|
0-L |
A11HA04 |
riboflavin (vit B2) |
WHO ATC |
|
0-L |
A11HA05 |
biotin |
WHO ATC |
|
0-L |
A11HA06 |
pyridoxal phosphate |
WHO ATC |
|
0-L |
A11HA07 |
inositol |
WHO ATC |
|
0-L |
A11HA08 |
tocofersolan |
WHO ATC |
|
0-L |
A11HA30 |
dexpanthenol |
WHO ATC |
|
0-L |
A11HA31 |
calcium pantothenate |
WHO ATC |
|
0-L |
A11HA32 |
pantethine |
WHO ATC |
|
0-L |
A11J |
OTHER VITAMIN PRODUCTS, COMBINATIONS |
WHO ATC |
|
0-L |
A11JA |
Combinations of vitamins |
WHO ATC |
|
0-L |
A11JB |
Vitamins with minerals |
WHO ATC |
|
0-L |
A11JC |
Vitamins, other combinations |
WHO ATC |
|
0-L |
A12 |
MINERAL SUPPLEMENTS |
WHO ATC |
|
0-L |
A12A |
CALCIUM |
WHO ATC |
|
0-L |
A12AA |
Calcium |
WHO ATC |
|
0-L |
A12AA01 |
calcium phosphate |
WHO ATC |
|
0-L |
A12AA02 |
calcium glubionate |
WHO ATC |
|
0-L |
A12AA03 |
calcium gluconate |
WHO ATC |
|
0-L |
A12AA04 |
calcium carbonate |
WHO ATC |
|
0-L |
A12AA05 |
calcium lactate |
WHO ATC |
|
0-L |
A12AA06 |
calcium lactate gluconate |
WHO ATC |
|
0-L |
A12AA07 |
calcium chloride |
WHO ATC |
|
0-L |
A12AA08 |
calcium glycerylphosphate |
WHO ATC |
|
0-L |
A12AA09 |
calcium citrate lysine complex |
WHO ATC |
|
0-L |
A12AA10 |
calcium glucoheptonate |
WHO ATC |
|
0-L |
A12AA11 |
calcium pangamate |
WHO ATC |
|
0-L |
A12AA12 |
calcium acetate anhydrous |
WHO ATC |
|
0-L |
A12AA20 |
calcium (different salts in combination) |
WHO ATC |
|
0-L |
A12AA30 |
calcium laevulate |
WHO ATC |
|
0-L |
A12AX |
Calcium, combinations with other drugs |
WHO ATC |
|
0-L |
A12B |
POTASSIUM |
WHO ATC |
|
0-L |
A12BA |
Potassium |
WHO ATC |
|
0-L |
A12BA01 |
potassium chloride |
WHO ATC |
|
0-L |
A12BA02 |
potassium citrate |
WHO ATC |
|
0-L |
A12BA03 |
potassium hydrogentartrate |
WHO ATC |
|
0-L |
A12BA04 |
potassium hydrogencarbonate |
WHO ATC |
|
0-L |
A12BA05 |
potassium gluconate |
WHO ATC |
|
0-L |
A12BA30 |
combinations |
WHO ATC |
|
0-L |
A12BA51 |
potassium chloride, combinations |
WHO ATC |
|
0-L |
A12C |
OTHER MINERAL SUPPLEMENTS |
WHO ATC |
|
0-L |
A12CA |
Sodium |
WHO ATC |
|
0-L |
A12CA01 |
sodium chloride |
WHO ATC |
|
0-L |
A12CA02 |
sodium sulfate |
WHO ATC |
|
0-L |
A12CB |
Zinc |
WHO ATC |
|
0-L |
A12CB01 |
zinc sulfate |
WHO ATC |
|
0-L |
A12CB02 |
zinc gluconate |
WHO ATC |
|
0-L |
A12CB03 |
zinc protein complex |
WHO ATC |
|
0-L |
A12CC |
Magnesium |
WHO ATC |
|
0-L |
A12CC01 |
magnesium chloride |
WHO ATC |
|
0-L |
A12CC02 |
magnesium sulfate |
WHO ATC |
|
0-L |
A12CC03 |
magnesium gluconate |
WHO ATC |
|
0-L |
A12CC04 |
magnesium citrate |
WHO ATC |
|
0-L |
A12CC05 |
magnesium aspartate |
WHO ATC |
|
0-L |
A12CC06 |
magnesium lactate |
WHO ATC |
|
0-L |
A12CC07 |
magnesium levulinate |
WHO ATC |
|
0-L |
A12CC08 |
magnesium pidolate |
WHO ATC |
|
0-L |
A12CC09 |
magnesium orotate |
WHO ATC |
|
0-L |
A12CC10 |
magnesium oxide |
WHO ATC |
|
0-L |
A12CC30 |
magnesium (different salts in combination) |
WHO ATC |
|
0-L |
A12CD |
Fluoride |
WHO ATC |
|
0-L |
A12CD01 |
sodium fluoride |
WHO ATC |
|
0-L |
A12CD02 |
sodium monofluorophosphate |
WHO ATC |
|
0-L |
A12CD51 |
fluoride, combinations |
WHO ATC |
|
0-L |
A12CE |
Selenium |
WHO ATC |
|
0-L |
A12CE01 |
sodium selenate |
WHO ATC |
|
0-L |
A12CE02 |
sodium selenite |
WHO ATC |
|
0-L |
A12CX |
Other mineral products |
WHO ATC |
|
0-L |
A13 |
TONICS |
WHO ATC |
|
0-L |
A13A |
TONICS |
WHO ATC |
|
0-L |
A14 |
ANABOLIC AGENTS FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
A14A |
ANABOLIC STEROIDS |
WHO ATC |
|
0-L |
A14AA |
Androstan derivatives |
WHO ATC |
|
0-L |
A14AA01 |
androstanolone |
WHO ATC |
|
0-L |
A14AA02 |
stanozolol |
WHO ATC |
|
0-L |
A14AA03 |
metandienone |
WHO ATC |
|
0-L |
A14AA04 |
metenolone |
WHO ATC |
|
0-L |
A14AA05 |
oxymetholone |
WHO ATC |
|
0-L |
A14AA06 |
quinbolone |
WHO ATC |
|
0-L |
A14AA07 |
prasterone |
WHO ATC |
|
0-L |
A14AA08 |
oxandrolone |
WHO ATC |
|
0-L |
A14AA09 |
norethandrolone |
WHO ATC |
|
0-L |
A14AB |
Estren derivatives |
WHO ATC |
|
0-L |
A14AB01 |
nandrolone |
WHO ATC |
|
0-L |
A14AB02 |
ethylestrenol |
WHO ATC |
|
0-L |
A14AB03 |
oxabolone cipionate |
WHO ATC |
|
0-L |
A14B |
OTHER ANABOLIC AGENTS |
WHO ATC |
|
0-L |
A15 |
APPETITE STIMULANTS |
WHO ATC |
|
0-L |
A16 |
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS |
WHO ATC |
|
0-L |
A16A |
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS |
WHO ATC |
|
0-L |
A16AA |
Amino acids and derivatives |
WHO ATC |
|
0-L |
A16AA01 |
levocarnitine |
WHO ATC |
|
0-L |
A16AA02 |
ademetionine |
WHO ATC |
|
0-L |
A16AA03 |
glutamine |
WHO ATC |
|
0-L |
A16AA04 |
mercaptamine |
WHO ATC |
|
0-L |
A16AA05 |
carglumic acid |
WHO ATC |
|
0-L |
A16AA06 |
betaine |
WHO ATC |
|
0-L |
A16AB |
Enzymes |
WHO ATC |
|
0-L |
A16AB01 |
alglucerase |
WHO ATC |
|
0-L |
A16AB02 |
imiglucerase |
WHO ATC |
|
0-L |
A16AB03 |
agalsidase alfa |
WHO ATC |
|
0-L |
A16AB04 |
agalsidase beta |
WHO ATC |
|
0-L |
A16AB05 |
laronidase |
WHO ATC |
|
0-L |
A16AB06 |
sacrosidase |
WHO ATC |
|
0-L |
A16AB07 |
alglucosidase alfa |
WHO ATC |
|
0-L |
A16AB08 |
galsulfase |
WHO ATC |
|
0-L |
A16AB09 |
idursulfase |
WHO ATC |
|
0-L |
A16AX |
Various alimentary tract and metabolism products |
WHO ATC |
|
0-L |
A16AX01 |
tioctic acid |
WHO ATC |
|
0-L |
A16AX02 |
anethole trithione |
WHO ATC |
|
0-L |
A16AX03 |
sodium phenylbutyrate |
WHO ATC |
|
0-L |
A16AX04 |
nitisinone |
WHO ATC |
|
0-L |
A16AX05 |
zinc acetate |
WHO ATC |
|
0-L |
A16AX06 |
miglustat |
WHO ATC |
|
0-L |
A16AX07 |
sapropterin |
WHO ATC |
|
0-L |
B |
BLOOD AND BLOOD FORMING ORGANS |
WHO ATC |
|
0-L |
B01 |
ANTITHROMBOTIC AGENTS |
WHO ATC |
|
0-L |
B01A |
ANTITHROMBOTIC AGENTS |
WHO ATC |
|
0-L |
B01AA |
Vitamin K antagonists |
WHO ATC |
|
0-L |
B01AA01 |
dicoumarol |
WHO ATC |
|
0-L |
B01AA02 |
phenindione |
WHO ATC |
|
0-L |
B01AA03 |
warfarin |
WHO ATC |
|
0-L |
B01AA04 |
phenprocoumon |
WHO ATC |
|
0-L |
B01AA07 |
acenocoumarol |
WHO ATC |
|
0-L |
B01AA08 |
ethyl biscoumacetate |
WHO ATC |
|
0-L |
B01AA09 |
clorindione |
WHO ATC |
|
0-L |
B01AA10 |
diphenadione |
WHO ATC |
|
0-L |
B01AA11 |
tioclomarol |
WHO ATC |
|
0-L |
B01AB |
Heparin group |
WHO ATC |
|
0-L |
B01AB01 |
heparin |
WHO ATC |
|
0-L |
B01AB02 |
antithrombin III |
WHO ATC |
|
0-L |
B01AB04 |
dalteparin |
WHO ATC |
|
0-L |
B01AB05 |
enoxaparin |
WHO ATC |
|
0-L |
B01AB06 |
nadroparin |
WHO ATC |
|
0-L |
B01AB07 |
parnaparin |
WHO ATC |
|
0-L |
B01AB08 |
reviparin |
WHO ATC |
|
0-L |
B01AB09 |
danaparoid |
WHO ATC |
|
0-L |
B01AB10 |
tinzaparin |
WHO ATC |
|
0-L |
B01AB11 |
sulodexide |
WHO ATC |
|
0-L |
B01AB12 |
bemiparin |
WHO ATC |
|
0-L |
B01AB51 |
heparin, combinations |
WHO ATC |
|
0-L |
B01AC |
Platelet aggregation inhibitors excl. heparin |
WHO ATC |
|
0-L |
B01AC01 |
ditazole |
WHO ATC |
|
0-L |
B01AC02 |
cloricromen |
WHO ATC |
|
0-L |
B01AC03 |
picotamide |
WHO ATC |
|
0-L |
B01AC04 |
clopidogrel |
WHO ATC |
|
0-L |
B01AC05 |
ticlopidine |
WHO ATC |
|
0-L |
B01AC06 |
acetylsalicylic acid |
WHO ATC |
|
0-L |
B01AC07 |
dipyridamole |
WHO ATC |
|
0-L |
B01AC08 |
carbasalate calcium |
WHO ATC |
|
0-L |
B01AC09 |
epoprostenol |
WHO ATC |
|
0-L |
B01AC10 |
indobufen |
WHO ATC |
|
0-L |
B01AC11 |
iloprost |
WHO ATC |
|
0-L |
B01AC13 |
abciximab |
WHO ATC |
|
0-L |
B01AC15 |
aloxiprin |
WHO ATC |
|
0-L |
B01AC16 |
eptifibatide |
WHO ATC |
|
0-L |
B01AC17 |
tirofiban |
WHO ATC |
|
0-L |
B01AC18 |
triflusal |
WHO ATC |
|
0-L |
B01AC19 |
beraprost |
WHO ATC |
|
0-L |
B01AC21 |
treprostinil |
WHO ATC |
|
0-L |
B01AC22 |
prasugrel |
WHO ATC |
|
0-L |
B01AC30 |
combinations |
WHO ATC |
|
0-L |
B01AD |
Enzymes |
WHO ATC |
|
0-L |
B01AD01 |
streptokinase |
WHO ATC |
|
0-L |
B01AD02 |
alteplase |
WHO ATC |
|
0-L |
B01AD03 |
anistreplase |
WHO ATC |
|
0-L |
B01AD04 |
urokinase |
WHO ATC |
|
0-L |
B01AD05 |
fibrinolysin |
WHO ATC |
|
0-L |
B01AD06 |
brinase |
WHO ATC |
|
0-L |
B01AD07 |
reteplase |
WHO ATC |
|
0-L |
B01AD08 |
saruplase |
WHO ATC |
|
0-L |
B01AD09 |
ancrod |
WHO ATC |
|
0-L |
B01AD10 |
drotrecogin alfa (activated) |
WHO ATC |
|
0-L |
B01AD11 |
tenecteplase |
WHO ATC |
|
0-L |
B01AD12 |
protein C |
WHO ATC |
|
0-L |
B01AE |
Direct thrombin inhibitors |
WHO ATC |
|
0-L |
B01AE01 |
desirudin |
WHO ATC |
|
0-L |
B01AE02 |
lepirudin |
WHO ATC |
|
0-L |
B01AE03 |
argatroban |
WHO ATC |
|
0-L |
B01AE04 |
melagatran |
WHO ATC |
|
0-L |
B01AE05 |
ximelagatran |
WHO ATC |
|
0-L |
B01AE06 |
bivalirudin |
WHO ATC |
|
0-L |
B01AE07 |
dabigatran etexilate |
WHO ATC |
|
0-L |
B01AX |
Other antithrombotic agents |
WHO ATC |
|
0-L |
B01AX01 |
defibrotide |
WHO ATC |
|
0-L |
B01AX04 |
dermatan sulfate |
WHO ATC |
|
0-L |
B01AX05 |
fondaparinux |
WHO ATC |
|
0-L |
B01AX06 |
rivaroxaban |
WHO ATC |
|
0-L |
B02 |
ANTIHEMORRHAGICS |
WHO ATC |
|
0-L |
B02A |
ANTIFIBRINOLYTICS |
WHO ATC |
|
0-L |
B02AA |
Amino acids |
WHO ATC |
|
0-L |
B02AA01 |
aminocaproic acid |
WHO ATC |
|
0-L |
B02AA02 |
tranexamic acid |
WHO ATC |
|
0-L |
B02AA03 |
aminomethylbenzoic acid |
WHO ATC |
|
0-L |
B02AB |
Proteinase inhibitors |
WHO ATC |
|
0-L |
B02AB01 |
aprotinin |
WHO ATC |
|
0-L |
B02AB02 |
alfa1 antitrypsin |
WHO ATC |
|
0-L |
B02AB03 |
c1-inhibitor |
WHO ATC |
|
0-L |
B02AB04 |
camostat |
WHO ATC |
|
0-L |
B02B |
VITAMIN K AND OTHER HEMOSTATICS |
WHO ATC |
|
0-L |
B02BA |
Vitamin K |
WHO ATC |
|
0-L |
B02BA01 |
phytomenadione |
WHO ATC |
|
0-L |
B02BA02 |
menadione |
WHO ATC |
|
0-L |
B02BB |
Fibrinogen |
WHO ATC |
|
0-L |
B02BB01 |
human fibrinogen |
WHO ATC |
|
0-L |
B02BC |
Local hemostatics |
WHO ATC |
|
0-L |
B02BC01 |
absorbable gelatin sponge |
WHO ATC |
|
0-L |
B02BC02 |
oxidized cellulose |
WHO ATC |
|
0-L |
B02BC03 |
tetragalacturonic acid hydroxymethylester |
WHO ATC |
|
0-L |
B02BC05 |
adrenalone |
WHO ATC |
|
0-L |
B02BC06 |
thrombin |
WHO ATC |
|
0-L |
B02BC07 |
collagen |
WHO ATC |
|
0-L |
B02BC08 |
calcium alginate |
WHO ATC |
|
0-L |
B02BC09 |
epinephrine |
WHO ATC |
|
0-L |
B02BC10 |
fibrinogen, human |
WHO ATC |
|
0-L |
B02BC30 |
combinations |
WHO ATC |
|
0-L |
B02BD |
Blood coagulation factors |
WHO ATC |
|
0-L |
B02BD01 |
coagulation factor IX, II, VII and X in combination |
WHO ATC |
|
0-L |
B02BD02 |
coagulation factor VIII |
WHO ATC |
|
0-L |
B02BD03 |
factor VIII inhibitor bypassing activity |
WHO ATC |
|
0-L |
B02BD04 |
coagulation factor IX |
WHO ATC |
|
0-L |
B02BD05 |
coagulation factor VII |
WHO ATC |
|
0-L |
B02BD06 |
von Willebrand factor and coagulation factor VIII in combination |
WHO ATC |
|
0-L |
B02BD07 |
coagulation factor XIII |
WHO ATC |
|
0-L |
B02BD08 |
eptacog alfa (activated) |
WHO ATC |
|
0-L |
B02BD09 |
nonacog alfa |
WHO ATC |
|
0-L |
B02BD30 |
thrombin |
WHO ATC |
|
0-L |
B02BX |
Other systemic hemostatics |
WHO ATC |
|
0-L |
B02BX01 |
etamsylate |
WHO ATC |
|
0-L |
B02BX02 |
carbazochrome |
WHO ATC |
|
0-L |
B02BX03 |
batroxobin |
WHO ATC |
|
0-L |
B02BX04 |
romiplostim |
WHO ATC |
|
0-L |
B02BX05 |
eltrombopag |
WHO ATC |
|
0-L |
B03 |
ANTIANEMIC PREPARATIONS |
WHO ATC |
|
0-L |
B03A |
IRON PREPARATIONS |
WHO ATC |
|
0-L |
B03AA |
Iron bivalent, oral preparations |
WHO ATC |
|
0-L |
B03AA01 |
ferrous glycine sulfate |
WHO ATC |
|
0-L |
B03AA02 |
ferrous fumarate |
WHO ATC |
|
0-L |
B03AA03 |
ferrous gluconate |
WHO ATC |
|
0-L |
B03AA04 |
ferrous carbonate |
WHO ATC |
|
0-L |
B03AA05 |
ferrous chloride |
WHO ATC |
|
0-L |
B03AA06 |
ferrous succinate |
WHO ATC |
|
0-L |
B03AA07 |
ferrous sulfate |
WHO ATC |
|
0-L |
B03AA08 |
ferrous tartrate |
WHO ATC |
|
0-L |
B03AA09 |
ferrous aspartate |
WHO ATC |
|
0-L |
B03AA10 |
ferrous ascorbate |
WHO ATC |
|
0-L |
B03AA11 |
ferrous iodine |
WHO ATC |
|
0-L |
B03AB |
Iron trivalent, oral preparations |
WHO ATC |
|
0-L |
B03AB01 |
ferric sodium citrate |
WHO ATC |
|
0-L |
B03AB02 |
saccharated iron oxide |
WHO ATC |
|
0-L |
B03AB03 |
sodium feredetate |
WHO ATC |
|
0-L |
B03AB04 |
ferric hydroxide |
WHO ATC |
|
0-L |
B03AB05 |
dextriferron |
WHO ATC |
|
0-L |
B03AB06 |
ferric citrate |
WHO ATC |
|
0-L |
B03AB07 |
chondroitin sulfate-iron complex |
WHO ATC |
|
0-L |
B03AB08 |
ferric acetyl transferrin |
WHO ATC |
|
0-L |
B03AB09 |
ferric proteinsuccinylate |
WHO ATC |
|
0-L |
B03AC |
Iron trivalent, parenteral preparations |
WHO ATC |
|
0-L |
B03AC01 |
dextriferron |
WHO ATC |
|
0-L |
B03AC02 |
saccharated iron oxide |
WHO ATC |
|
0-L |
B03AC03 |
iron-sorbitol-citric acid complex |
WHO ATC |
|
0-L |
B03AC05 |
ferric sorbitol gluconic acid complex |
WHO ATC |
|
0-L |
B03AC06 |
ferric oxide dextran complex |
WHO ATC |
|
0-L |
B03AC07 |
ferric sodium gluconate complex |
WHO ATC |
|
0-L |
B03AD |
Iron in combination with folic acid |
WHO ATC |
|
0-L |
B03AD01 |
ferrous amino acid complex |
WHO ATC |
|
0-L |
B03AD02 |
ferrous fumarate |
WHO ATC |
|
0-L |
B03AD03 |
ferrous sulfate |
WHO ATC |
|
0-L |
B03AD04 |
dextriferron |
WHO ATC |
|
0-L |
B03AE |
Iron in other combinations |
WHO ATC |
|
0-L |
B03AE01 |
iron, vitamin B12 and folic acid |
WHO ATC |
|
0-L |
B03AE02 |
iron, multivitamins and folic acid |
WHO ATC |
|
0-L |
B03AE03 |
iron and multivitamins |
WHO ATC |
|
0-L |
B03AE04 |
iron, multivitamins and minerals |
WHO ATC |
|
0-L |
B03AE10 |
various combinations |
WHO ATC |
|
0-L |
B03B |
VITAMIN B12 AND FOLIC ACID |
WHO ATC |
|
0-L |
B03BA |
Vitamin B12 (cyanocobalamin and analogues) |
WHO ATC |
|
0-L |
B03BA01 |
cyanocobalamin |
WHO ATC |
|
0-L |
B03BA02 |
cyanocobalamin tannin complex |
WHO ATC |
|
0-L |
B03BA03 |
hydroxocobalamin |
WHO ATC |
|
0-L |
B03BA04 |
cobamamide |
WHO ATC |
|
0-L |
B03BA05 |
mecobalamin |
WHO ATC |
|
0-L |
B03BA51 |
cyanocobalamin, combinations |
WHO ATC |
|
0-L |
B03BA53 |
hydroxocobalamin, combinations |
WHO ATC |
|
0-L |
B03BB |
Folic acid and derivatives |
WHO ATC |
|
0-L |
B03BB01 |
folic acid |
WHO ATC |
|
0-L |
B03BB51 |
folic acid, combinations |
WHO ATC |
|
0-L |
B03X |
OTHER ANTIANEMIC PREPARATIONS |
WHO ATC |
|
0-L |
B03XA |
Other antianemic preparations |
WHO ATC |
|
0-L |
B03XA01 |
erythropoietin |
WHO ATC |
|
0-L |
B03XA02 |
darbepoetin alfa |
WHO ATC |
|
0-L |
B03XA03 |
methoxy polyethylene glycol-epoetin beta |
WHO ATC |
|
0-L |
B05 |
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS |
WHO ATC |
|
0-L |
B05A |
BLOOD AND RELATED PRODUCTS |
WHO ATC |
|
0-L |
B05AA |
Blood substitutes and plasma protein fractions |
WHO ATC |
|
0-L |
B05AA01 |
albumin |
WHO ATC |
|
0-L |
B05AA02 |
other plasma protein fractions |
WHO ATC |
|
0-L |
B05AA03 |
fluorocarbon blood substitutes |
WHO ATC |
|
0-L |
B05AA05 |
dextran |
WHO ATC |
|
0-L |
B05AA06 |
gelatin agents |
WHO ATC |
|
0-L |
B05AA07 |
hydroxyethylstarch |
WHO ATC |
|
0-L |
B05AA08 |
hemoglobin crosfumaril |
WHO ATC |
|
0-L |
B05AA09 |
hemoglobin raffimer |
WHO ATC |
|
0-L |
B05AA10 |
hemoglobin glutamer (bovine) |
WHO ATC |
|
0-L |
B05AX |
Other blood products |
WHO ATC |
|
0-L |
B05AX01 |
erythrocytes |
WHO ATC |
|
0-L |
B05AX02 |
thrombocytes |
WHO ATC |
|
0-L |
B05AX03 |
blood plasma |
WHO ATC |
|
0-L |
B05AX04 |
stem cells from umbilical cord blood |
WHO ATC |
|
0-L |
B05B |
I.V. SOLUTIONS |
WHO ATC |
|
0-L |
B05BA |
Solutions for parenteral nutrition |
WHO ATC |
|
0-L |
B05BA01 |
amino acids |
WHO ATC |
|
0-L |
B05BA02 |
fat emulsions |
WHO ATC |
|
0-L |
B05BA03 |
carbohydrates |
WHO ATC |
|
0-L |
B05BA04 |
protein hydrolysates |
WHO ATC |
|
0-L |
B05BA10 |
combinations |
WHO ATC |
|
0-L |
B05BB |
Solutions affecting the electrolyte balance |
WHO ATC |
|
0-L |
B05BB01 |
electrolytes |
WHO ATC |
|
0-L |
B05BB02 |
electrolytes with carbohydrates |
WHO ATC |
|
0-L |
B05BB03 |
trometamol |
WHO ATC |
|
0-L |
B05BC |
Solutions producing osmotic diuresis |
WHO ATC |
|
0-L |
B05BC01 |
mannitol |
WHO ATC |
|
0-L |
B05BC02 |
carbamide |
WHO ATC |
|
0-L |
B05C |
IRRIGATING SOLUTIONS |
WHO ATC |
|
0-L |
B05CA |
Antiinfectives |
WHO ATC |
|
0-L |
B05CA01 |
cetylpyridinium |
WHO ATC |
|
0-L |
B05CA02 |
chlorhexidine |
WHO ATC |
|
0-L |
B05CA03 |
nitrofural |
WHO ATC |
|
0-L |
B05CA04 |
sulfamethizole |
WHO ATC |
|
0-L |
B05CA05 |
taurolidine |
WHO ATC |
|
0-L |
B05CA06 |
mandelic acid |
WHO ATC |
|
0-L |
B05CA07 |
noxytiolin |
WHO ATC |
|
0-L |
B05CA08 |
ethacridine lactate |
WHO ATC |
|
0-L |
B05CA09 |
neomycin |
WHO ATC |
|
0-L |
B05CA10 |
combinations |
WHO ATC |
|
0-L |
B05CB |
Salt solutions |
WHO ATC |
|
0-L |
B05CB01 |
sodium chloride |
WHO ATC |
|
0-L |
B05CB02 |
sodium citrate |
WHO ATC |
|
0-L |
B05CB03 |
magnesium citrate |
WHO ATC |
|
0-L |
B05CB04 |
sodium bicarbonate |
WHO ATC |
|
0-L |
B05CB10 |
combinations |
WHO ATC |
|
0-L |
B05CX |
Other irrigating solutions |
WHO ATC |
|
0-L |
B05CX01 |
glucose |
WHO ATC |
|
0-L |
B05CX02 |
sorbitol |
WHO ATC |
|
0-L |
B05CX03 |
glycine |
WHO ATC |
|
0-L |
B05CX04 |
mannitol |
WHO ATC |
|
0-L |
B05CX10 |
combinations |
WHO ATC |
|
0-L |
B05D |
PERITONEAL DIALYTICS |
WHO ATC |
|
0-L |
B05DA |
Isotonic solutions |
WHO ATC |
|
0-L |
B05DB |
Hypertonic solutions |
WHO ATC |
|
0-L |
B05X |
I.V. SOLUTION ADDITIVES |
WHO ATC |
|
0-L |
B05XA |
Electrolyte solutions |
WHO ATC |
|
0-L |
B05XA01 |
potassium chloride |
WHO ATC |
|
0-L |
B05XA02 |
sodium bicarbonate |
WHO ATC |
|
0-L |
B05XA03 |
sodium chloride |
WHO ATC |
|
0-L |
B05XA04 |
ammonium chloride |
WHO ATC |
|
0-L |
B05XA05 |
magnesium sulfate |
WHO ATC |
|
0-L |
B05XA06 |
potassium phosphate, incl. comb. with other potassium salts |
WHO ATC |
|
0-L |
B05XA07 |
calcium chloride |
WHO ATC |
|
0-L |
B05XA08 |
sodium acetate |
WHO ATC |
|
0-L |
B05XA09 |
sodium phosphate |
WHO ATC |
|
0-L |
B05XA10 |
magnesium phosphate |
WHO ATC |
|
0-L |
B05XA11 |
magnesium chloride |
WHO ATC |
|
0-L |
B05XA12 |
zinc chloride |
WHO ATC |
|
0-L |
B05XA13 |
hydrochloric acid |
WHO ATC |
|
0-L |
B05XA14 |
sodium glycerophosphate |
WHO ATC |
|
0-L |
B05XA15 |
potassium lactate |
WHO ATC |
|
0-L |
B05XA16 |
cardioplegia solutions |
WHO ATC |
|
0-L |
B05XA17 |
potassium acetate |
WHO ATC |
|
0-L |
B05XA30 |
combinations of electrolytes |
WHO ATC |
|
0-L |
B05XA31 |
electrolytes in combination with other drugs |
WHO ATC |
|
0-L |
B05XB |
Amino acids |
WHO ATC |
|
0-L |
B05XB01 |
arginine hydrochloride |
WHO ATC |
|
0-L |
B05XB02 |
alanyl glutamine |
WHO ATC |
|
0-L |
B05XB03 |
lysine |
WHO ATC |
|
0-L |
B05XC |
Vitamins |
WHO ATC |
|
0-L |
B05XX |
Other i.v. solution additives |
WHO ATC |
|
0-L |
B05XX02 |
trometamol |
WHO ATC |
|
0-L |
B05Z |
HEMODIALYTICS AND HEMOFILTRATES |
WHO ATC |
|
0-L |
B05ZA |
Hemodialytics, concentrates |
WHO ATC |
|
0-L |
B05ZB |
Hemofiltrates |
WHO ATC |
|
0-L |
B06 |
OTHER HEMATOLOGICAL AGENTS |
WHO ATC |
|
0-L |
B06A |
OTHER HEMATOLOGICAL AGENTS |
WHO ATC |
|
0-L |
B06AA |
Enzymes |
WHO ATC |
|
0-L |
B06AA02 |
fibrinolysin and desoxyribonuclease |
WHO ATC |
|
0-L |
B06AA03 |
hyaluronidase |
WHO ATC |
|
0-L |
B06AA04 |
chymotrypsin |
WHO ATC |
|
0-L |
B06AA07 |
trypsin |
WHO ATC |
|
0-L |
B06AA10 |
desoxyribonuclease |
WHO ATC |
|
0-L |
B06AA11 |
bromelains |
WHO ATC |
|
0-L |
B06AA55 |
streptokinase, combinations |
WHO ATC |
|
0-L |
B06AB |
Other hem products |
WHO ATC |
|
0-L |
B06AB01 |
hematin |
WHO ATC |
|
0-L |
C |
CARDIOVASCULAR SYSTEM |
WHO ATC |
|
0-L |
C01 |
CARDIAC THERAPY |
WHO ATC |
|
0-L |
C01A |
CARDIAC GLYCOSIDES |
WHO ATC |
|
0-L |
C01AA |
Digitalis glycosides |
WHO ATC |
|
0-L |
C01AA01 |
acetyldigitoxin |
WHO ATC |
|
0-L |
C01AA02 |
acetyldigoxin |
WHO ATC |
|
0-L |
C01AA03 |
digitalis leaves |
WHO ATC |
|
0-L |
C01AA04 |
digitoxin |
WHO ATC |
|
0-L |
C01AA05 |
digoxin |
WHO ATC |
|
0-L |
C01AA06 |
lanatoside C |
WHO ATC |
|
0-L |
C01AA07 |
deslanoside |
WHO ATC |
|
0-L |
C01AA08 |
metildigoxin |
WHO ATC |
|
0-L |
C01AA09 |
gitoformate |
WHO ATC |
|
0-L |
C01AA52 |
acetyldigoxin, combinations |
WHO ATC |
|
0-L |
C01AB |
Scilla glycosides |
WHO ATC |
|
0-L |
C01AB01 |
proscillaridin |
WHO ATC |
|
0-L |
C01AB51 |
proscillaridin, combinations |
WHO ATC |
|
0-L |
C01AC |
Strophantus glycosides |
WHO ATC |
|
0-L |
C01AC01 |
g-strophanthin |
WHO ATC |
|
0-L |
C01AC03 |
cymarin |
WHO ATC |
|
0-L |
C01AX |
Other cardiac glycosides |
WHO ATC |
|
0-L |
C01AX02 |
peruvoside |
WHO ATC |
|
0-L |
C01B |
ANTIARRHYTHMICS, CLASS I AND III |
WHO ATC |
|
0-L |
C01BA |
Antiarrhythmics, class Ia |
WHO ATC |
|
0-L |
C01BA01 |
quinidine |
WHO ATC |
|
0-L |
C01BA02 |
procainamide |
WHO ATC |
|
0-L |
C01BA03 |
disopyramide |
WHO ATC |
|
0-L |
C01BA04 |
sparteine |
WHO ATC |
|
0-L |
C01BA05 |
ajmaline |
WHO ATC |
|
0-L |
C01BA08 |
prajmaline |
WHO ATC |
|
0-L |
C01BA12 |
lorajmine |
WHO ATC |
|
0-L |
C01BA51 |
quinidine, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
C01BA71 |
quinidine, combinations with psycholeptics |
WHO ATC |
|
0-L |
C01BB |
Antiarrhythmics, class Ib |
WHO ATC |
|
0-L |
C01BB01 |
lidocaine |
WHO ATC |
|
0-L |
C01BB02 |
mexiletine |
WHO ATC |
|
0-L |
C01BB03 |
tocainide |
WHO ATC |
|
0-L |
C01BB04 |
aprindine |
WHO ATC |
|
0-L |
C01BC |
Antiarrhythmics, class Ic |
WHO ATC |
|
0-L |
C01BC03 |
propafenone |
WHO ATC |
|
0-L |
C01BC04 |
flecainide |
WHO ATC |
|
0-L |
C01BC07 |
lorcainide |
WHO ATC |
|
0-L |
C01BC08 |
encainide |
WHO ATC |
|
0-L |
C01BD |
Antiarrhythmics, class III |
WHO ATC |
|
0-L |
C01BD01 |
amiodarone |
WHO ATC |
|
0-L |
C01BD02 |
bretylium tosilate |
WHO ATC |
|
0-L |
C01BD03 |
bunaftine |
WHO ATC |
|
0-L |
C01BD04 |
dofetilide |
WHO ATC |
|
0-L |
C01BD05 |
ibutilide |
WHO ATC |
|
0-L |
C01BD06 |
tedisamil |
WHO ATC |
|
0-L |
C01BG |
Other class I antiarrhythmics |
WHO ATC |
|
0-L |
C01BG01 |
moracizine |
WHO ATC |
|
0-L |
C01BG07 |
cibenzoline |
WHO ATC |
|
0-L |
C01C |
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES |
WHO ATC |
|
0-L |
C01CA |
Adrenergic and dopaminergic agents |
WHO ATC |
|
0-L |
C01CA01 |
etilefrine |
WHO ATC |
|
0-L |
C01CA02 |
isoprenaline |
WHO ATC |
|
0-L |
C01CA03 |
norepinephrine |
WHO ATC |
|
0-L |
C01CA04 |
dopamine |
WHO ATC |
|
0-L |
C01CA05 |
norfenefrine |
WHO ATC |
|
0-L |
C01CA06 |
phenylephrine |
WHO ATC |
|
0-L |
C01CA07 |
dobutamine |
WHO ATC |
|
0-L |
C01CA08 |
oxedrine |
WHO ATC |
|
0-L |
C01CA09 |
metaraminol |
WHO ATC |
|
0-L |
C01CA10 |
methoxamine |
WHO ATC |
|
0-L |
C01CA11 |
mephentermine |
WHO ATC |
|
0-L |
C01CA12 |
dimetofrine |
WHO ATC |
|
0-L |
C01CA13 |
prenalterol |
WHO ATC |
|
0-L |
C01CA14 |
dopexamine |
WHO ATC |
|
0-L |
C01CA15 |
gepefrine |
WHO ATC |
|
0-L |
C01CA16 |
ibopamine |
WHO ATC |
|
0-L |
C01CA17 |
midodrine |
WHO ATC |
|
0-L |
C01CA18 |
octopamine |
WHO ATC |
|
0-L |
C01CA19 |
fenoldopam |
WHO ATC |
|
0-L |
C01CA21 |
cafedrine |
WHO ATC |
|
0-L |
C01CA22 |
arbutamine |
WHO ATC |
|
0-L |
C01CA23 |
theodrenaline |
WHO ATC |
|
0-L |
C01CA24 |
epinephrine |
WHO ATC |
|
0-L |
C01CA30 |
combinations |
WHO ATC |
|
0-L |
C01CA51 |
etilefrine, combinations |
WHO ATC |
|
0-L |
C01CE |
Phosphodiesterase inhibitors |
WHO ATC |
|
0-L |
C01CE01 |
amrinone |
WHO ATC |
|
0-L |
C01CE02 |
milrinone |
WHO ATC |
|
0-L |
C01CE03 |
enoximone |
WHO ATC |
|
0-L |
C01CE04 |
bucladesine |
WHO ATC |
|
0-L |
C01CX |
Other cardiac stimulants |
WHO ATC |
|
0-L |
C01CX06 |
angiotensinamide |
WHO ATC |
|
0-L |
C01CX07 |
xamoterol |
WHO ATC |
|
0-L |
C01CX08 |
levosimendan |
WHO ATC |
|
0-L |
C01D |
VASODILATORS USED IN CARDIAC DISEASES |
WHO ATC |
|
0-L |
C01DA |
Organic nitrates |
WHO ATC |
|
0-L |
C01DA02 |
glyceryl trinitrate |
WHO ATC |
|
0-L |
C01DA04 |
methylpropylpropanediol dinitrate |
WHO ATC |
|
0-L |
C01DA05 |
pentaerithrityl tetranitrate |
WHO ATC |
|
0-L |
C01DA07 |
propatylnitrate |
WHO ATC |
|
0-L |
C01DA08 |
isosorbide dinitrate |
WHO ATC |
|
0-L |
C01DA09 |
trolnitrate |
WHO ATC |
|
0-L |
C01DA13 |
eritrityl tetranitrate |
WHO ATC |
|
0-L |
C01DA14 |
isosorbide mononitrate |
WHO ATC |
|
0-L |
C01DA20 |
organic nitrates in combination |
WHO ATC |
|
0-L |
C01DA38 |
tenitramine |
WHO ATC |
|
0-L |
C01DA52 |
glyceryl trinitrate, combinations |
WHO ATC |
|
0-L |
C01DA54 |
methylpropylpropanediol dinitrate, combinations |
WHO ATC |
|
0-L |
C01DA55 |
pentaerithrityl tetranitrate, combinations |
WHO ATC |
|
0-L |
C01DA57 |
propatylnitrate, combinations |
WHO ATC |
|
0-L |
C01DA58 |
isosorbide dinitrate, combinations |
WHO ATC |
|
0-L |
C01DA59 |
trolnitrate, combinations |
WHO ATC |
|
0-L |
C01DA63 |
eritrityl tetranitrate, combinations |
WHO ATC |
|
0-L |
C01DA70 |
organic nitrates in combination with psycholeptics |
WHO ATC |
|
0-L |
C01DB |
Quinolone vasodilators |
WHO ATC |
|
0-L |
C01DB01 |
flosequinan |
WHO ATC |
|
0-L |
C01DX |
Other vasodilators used in cardiac diseases |
WHO ATC |
|
0-L |
C01DX01 |
itramin tosilate |
WHO ATC |
|
0-L |
C01DX02 |
prenylamine |
WHO ATC |
|
0-L |
C01DX03 |
oxyfedrine |
WHO ATC |
|
0-L |
C01DX04 |
benziodarone |
WHO ATC |
|
0-L |
C01DX05 |
carbocromen |
WHO ATC |
|
0-L |
C01DX06 |
hexobendine |
WHO ATC |
|
0-L |
C01DX07 |
etafenone |
WHO ATC |
|
0-L |
C01DX08 |
heptaminol |
WHO ATC |
|
0-L |
C01DX09 |
imolamine |
WHO ATC |
|
0-L |
C01DX10 |
dilazep |
WHO ATC |
|
0-L |
C01DX11 |
trapidil |
WHO ATC |
|
0-L |
C01DX12 |
molsidomine |
WHO ATC |
|
0-L |
C01DX13 |
efloxate |
WHO ATC |
|
0-L |
C01DX14 |
cinepazet |
WHO ATC |
|
0-L |
C01DX15 |
cloridarol |
WHO ATC |
|
0-L |
C01DX16 |
nicorandil |
WHO ATC |
|
0-L |
C01DX18 |
linsidomine |
WHO ATC |
|
0-L |
C01DX19 |
nesiritide |
WHO ATC |
|
0-L |
C01DX51 |
itramin tosilate, combinations |
WHO ATC |
|
0-L |
C01DX52 |
prenylamine, combinations |
WHO ATC |
|
0-L |
C01DX53 |
oxyfedrine, combinations |
WHO ATC |
|
0-L |
C01DX54 |
benziodarone, combinations |
WHO ATC |
|
0-L |
C01E |
OTHER CARDIAC PREPARATIONS |
WHO ATC |
|
0-L |
C01EA |
Prostaglandins |
WHO ATC |
|
0-L |
C01EA01 |
alprostadil |
WHO ATC |
|
0-L |
C01EB |
Other cardiac preparations |
WHO ATC |
|
0-L |
C01EB02 |
camphora |
WHO ATC |
|
0-L |
C01EB03 |
indometacin |
WHO ATC |
|
0-L |
C01EB04 |
crataegus glycosides |
WHO ATC |
|
0-L |
C01EB05 |
creatinolfosfate |
WHO ATC |
|
0-L |
C01EB06 |
fosfocreatine |
WHO ATC |
|
0-L |
C01EB07 |
fructose 1,6-diphosphate |
WHO ATC |
|
0-L |
C01EB09 |
ubidecarenone |
WHO ATC |
|
0-L |
C01EB10 |
adenosine |
WHO ATC |
|
0-L |
C01EB11 |
tiracizine |
WHO ATC |
|
0-L |
C01EB13 |
acadesine |
WHO ATC |
|
0-L |
C01EB15 |
trimetazidine |
WHO ATC |
|
0-L |
C01EB16 |
ibuprofen |
WHO ATC |
|
0-L |
C01EB17 |
ivabradine |
WHO ATC |
|
0-L |
C01EB18 |
ranolazine |
WHO ATC |
|
0-L |
C01EB19 |
icatibant |
WHO ATC |
|
0-L |
C01EB21 |
regadenoson |
WHO ATC |
|
0-L |
C01EX |
Other cardiac combination products |
WHO ATC |
|
0-L |
C02 |
ANTIHYPERTENSIVES |
WHO ATC |
|
0-L |
C02A |
ANTIADRENERGIC AGENTS, CENTRALLY ACTING |
WHO ATC |
|
0-L |
C02AA |
Rauwolfia alkaloids |
WHO ATC |
|
0-L |
C02AA01 |
rescinnamine |
WHO ATC |
|
0-L |
C02AA02 |
reserpine |
WHO ATC |
|
0-L |
C02AA03 |
combinations of rauwolfia alkaloids |
WHO ATC |
|
0-L |
C02AA04 |
rauwolfia alkaloids, whole root |
WHO ATC |
|
0-L |
C02AA05 |
deserpidine |
WHO ATC |
|
0-L |
C02AA06 |
methoserpidine |
WHO ATC |
|
0-L |
C02AA07 |
bietaserpine |
WHO ATC |
|
0-L |
C02AA52 |
reserpine, combinations |
WHO ATC |
|
0-L |
C02AA53 |
combinations of rauwolfia alkoloids, combinations |
WHO ATC |
|
0-L |
C02AA57 |
bietaserpine, combinations |
WHO ATC |
|
0-L |
C02AB |
Methyldopa |
WHO ATC |
|
0-L |
C02AB01 |
methyldopa (levorotatory) |
WHO ATC |
|
0-L |
C02AB02 |
methyldopa (racemic) |
WHO ATC |
|
0-L |
C02AC |
Imidazoline receptor agonists |
WHO ATC |
|
0-L |
C02AC01 |
clonidine |
WHO ATC |
|
0-L |
C02AC02 |
guanfacine |
WHO ATC |
|
0-L |
C02AC04 |
tolonidine |
WHO ATC |
|
0-L |
C02AC05 |
moxonidine |
WHO ATC |
|
0-L |
C02AC06 |
rilmenidine |
WHO ATC |
|
0-L |
C02B |
ANTIADRENERGIC AGENTS, GANGLION-BLOCKING |
WHO ATC |
|
0-L |
C02BA |
Sulfonium derivatives |
WHO ATC |
|
0-L |
C02BA01 |
trimetaphan |
WHO ATC |
|
0-L |
C02BB |
Secondary and tertiary amines |
WHO ATC |
|
0-L |
C02BB01 |
mecamylamine |
WHO ATC |
|
0-L |
C02BC |
Bisquaternary ammonium compounds |
WHO ATC |
|
0-L |
C02C |
ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING |
WHO ATC |
|
0-L |
C02CA |
Alpha-adrenoreceptor antagonists |
WHO ATC |
|
0-L |
C02CA01 |
prazosin |
WHO ATC |
|
0-L |
C02CA02 |
indoramin |
WHO ATC |
|
0-L |
C02CA03 |
trimazosin |
WHO ATC |
|
0-L |
C02CA04 |
doxazosin |
WHO ATC |
|
0-L |
C02CA06 |
urapidil |
WHO ATC |
|
0-L |
C02CC |
Guanidine derivatives |
WHO ATC |
|
0-L |
C02CC01 |
betanidine |
WHO ATC |
|
0-L |
C02CC02 |
guanethidine |
WHO ATC |
|
0-L |
C02CC03 |
guanoxan |
WHO ATC |
|
0-L |
C02CC04 |
debrisoquine |
WHO ATC |
|
0-L |
C02CC05 |
guanoclor |
WHO ATC |
|
0-L |
C02CC06 |
guanazodine |
WHO ATC |
|
0-L |
C02CC07 |
guanoxabenz |
WHO ATC |
|
0-L |
C02D |
ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON |
WHO ATC |
|
0-L |
C02DA |
Thiazide derivatives |
WHO ATC |
|
0-L |
C02DA01 |
diazoxide |
WHO ATC |
|
0-L |
C02DB |
Hydrazinophthalazine derivatives |
WHO ATC |
|
0-L |
C02DB01 |
dihydralazine |
WHO ATC |
|
0-L |
C02DB02 |
hydralazine |
WHO ATC |
|
0-L |
C02DB03 |
endralazine |
WHO ATC |
|
0-L |
C02DB04 |
cadralazine |
WHO ATC |
|
0-L |
C02DC |
Pyrimidine derivatives |
WHO ATC |
|
0-L |
C02DC01 |
minoxidil |
WHO ATC |
|
0-L |
C02DD |
Nitroferricyanide derivatives |
WHO ATC |
|
0-L |
C02DD01 |
nitroprusside |
WHO ATC |
|
0-L |
C02DG |
Guanidine derivatives |
WHO ATC |
|
0-L |
C02DG01 |
pinacidil |
WHO ATC |
|
0-L |
C02K |
OTHER ANTIHYPERTENSIVES |
WHO ATC |
|
0-L |
C02KA |
Alkaloids, excl. rauwolfia |
WHO ATC |
|
0-L |
C02KA01 |
veratrum |
WHO ATC |
|
0-L |
C02KB |
Tyrosine hydroxylase inhibitors |
WHO ATC |
|
0-L |
C02KB01 |
metirosine |
WHO ATC |
|
0-L |
C02KC |
MAO inhibitors |
WHO ATC |
|
0-L |
C02KC01 |
pargyline |
WHO ATC |
|
0-L |
C02KD |
Serotonin antagonists |
WHO ATC |
|
0-L |
C02KD01 |
ketanserin |
WHO ATC |
|
0-L |
C02KX |
Other antihypertensives |
WHO ATC |
|
0-L |
C02KX01 |
bosentan |
WHO ATC |
|
0-L |
C02KX02 |
ambrisentan |
WHO ATC |
|
0-L |
C02KX03 |
sitaxentan |
WHO ATC |
|
0-L |
C02L |
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION |
WHO ATC |
|
0-L |
C02LA |
Rauwolfia alkaloids and diuretics in combination |
WHO ATC |
|
0-L |
C02LA01 |
reserpine and diuretics |
WHO ATC |
|
0-L |
C02LA02 |
rescinnamine and diuretics |
WHO ATC |
|
0-L |
C02LA03 |
deserpidine and diuretics |
WHO ATC |
|
0-L |
C02LA04 |
methoserpidine and diuretics |
WHO ATC |
|
0-L |
C02LA07 |
bietaserpine and diuretics |
WHO ATC |
|
0-L |
C02LA08 |
rauwolfia alkaloids, whole root and diuretics |
WHO ATC |
|
0-L |
C02LA09 |
syrosingopine and diuretics |
WHO ATC |
|
0-L |
C02LA50 |
comb. of rauwolfia alkaloids and diuretics incl. other combinations |
WHO ATC |
|
0-L |
C02LA51 |
reserpine and diuretics, combinations with other drugs |
WHO ATC |
|
0-L |
C02LA52 |
rescinnamine and diuretics, combinations with other drugs |
WHO ATC |
|
0-L |
C02LA71 |
reserpine and diuretics, combinations with psycholeptics |
WHO ATC |
|
0-L |
C02LB |
Methyldopa and diuretics in combination |
WHO ATC |
|
0-L |
C02LB01 |
methyldopa (levorotatory) and diuretics |
WHO ATC |
|
0-L |
C02LC |
Imidazoline receptor agonists in combination with diuretics |
WHO ATC |
|
0-L |
C02LC01 |
clonidine and diuretics |
WHO ATC |
|
0-L |
C02LC05 |
moxonidine and diuretics |
WHO ATC |
|
0-L |
C02LC51 |
clonidine and diuretics, combinations with other drugs |
WHO ATC |
|
0-L |
C02LE |
Alpha-adrenoreceptor antagonists and diuretics |
WHO ATC |
|
0-L |
C02LE01 |
prazosin and diuretics |
WHO ATC |
|
0-L |
C02LF |
Guanidine derivatives and diuretics |
WHO ATC |
|
0-L |
C02LF01 |
guanethidine and diuretics |
WHO ATC |
|
0-L |
C02LG |
Hydrazinophthalazine derivatives and diuretics |
WHO ATC |
|
0-L |
C02LG01 |
dihydralazine and diuretics |
WHO ATC |
|
0-L |
C02LG02 |
hydralazine and diuretics |
WHO ATC |
|
0-L |
C02LG03 |
picodralazine and diuretics |
WHO ATC |
|
0-L |
C02LG51 |
dihydralazine and diuretics, combinations with other drugs |
WHO ATC |
|
0-L |
C02LG73 |
picodralazine and diuretics, combinations with psycholeptics |
WHO ATC |
|
0-L |
C02LK |
Alkaloids, excl. rauwolfia, in combination with diuretics |
WHO ATC |
|
0-L |
C02LK01 |
veratrum and diuretics |
WHO ATC |
|
0-L |
C02LL |
MAO inhibitors and diuretics |
WHO ATC |
|
0-L |
C02LL01 |
pargyline and diuretics |
WHO ATC |
|
0-L |
C02LN |
Serotonin antagonists and diuretics |
WHO ATC |
|
0-L |
C02LX |
Other antihypertensives and diuretics |
WHO ATC |
|
0-L |
C02LX01 |
pinacidil and diuretics |
WHO ATC |
|
0-L |
C02N |
COMBINATIONS OF ANTIHYPERTENSIVES IN ATC-GR. C02 |
WHO ATC |
|
0-L |
C03 |
DIURETICS |
WHO ATC |
|
0-L |
C03A |
LOW-CEILING DIURETICS, THIAZIDES |
WHO ATC |
|
0-L |
C03AA |
Thiazides, plain |
WHO ATC |
|
0-L |
C03AA01 |
bendroflumethiazide |
WHO ATC |
|
0-L |
C03AA02 |
hydroflumethiazide |
WHO ATC |
|
0-L |
C03AA03 |
hydrochlorothiazide |
WHO ATC |
|
0-L |
C03AA04 |
chlorothiazide |
WHO ATC |
|
0-L |
C03AA05 |
polythiazide |
WHO ATC |
|
0-L |
C03AA06 |
trichlormethiazide |
WHO ATC |
|
0-L |
C03AA07 |
cyclopenthiazide |
WHO ATC |
|
0-L |
C03AA08 |
methyclothiazide |
WHO ATC |
|
0-L |
C03AA09 |
cyclothiazide |
WHO ATC |
|
0-L |
C03AA13 |
mebutizide |
WHO ATC |
|
0-L |
C03AB |
Thiazides and potassium in combination |
WHO ATC |
|
0-L |
C03AB01 |
bendroflumethiazide and potassium |
WHO ATC |
|
0-L |
C03AB02 |
hydroflumethiazide and potassium |
WHO ATC |
|
0-L |
C03AB03 |
hydrochlorothiazide and potassium |
WHO ATC |
|
0-L |
C03AB04 |
chlorothiazide and potassium |
WHO ATC |
|
0-L |
C03AB05 |
polythiazide and potassium |
WHO ATC |
|
0-L |
C03AB06 |
trichlormethiazide and potassium |
WHO ATC |
|
0-L |
C03AB07 |
cyclopenthiazide and potassium |
WHO ATC |
|
0-L |
C03AB08 |
methyclothiazide and potassium |
WHO ATC |
|
0-L |
C03AB09 |
cyclothiazide and potassium |
WHO ATC |
|
0-L |
C03AH |
Thiazides, combinations with psycholeptics and/or analgesics |
WHO ATC |
|
0-L |
C03AH01 |
chlorothiazide, combinations |
WHO ATC |
|
0-L |
C03AH02 |
hydroflumethiazide, combinations |
WHO ATC |
|
0-L |
C03AX |
Thiazides, combinations with other drugs |
WHO ATC |
|
0-L |
C03AX01 |
hydrochlorothiazide, combinations |
WHO ATC |
|
0-L |
C03B |
LOW-CEILING DIURETICS, EXCL. THIAZIDES |
WHO ATC |
|
0-L |
C03BA |
Sulfonamides, plain |
WHO ATC |
|
0-L |
C03BA02 |
quinethazone |
WHO ATC |
|
0-L |
C03BA03 |
clopamide |
WHO ATC |
|
0-L |
C03BA04 |
chlortalidone |
WHO ATC |
|
0-L |
C03BA05 |
mefruside |
WHO ATC |
|
0-L |
C03BA07 |
clofenamide |
WHO ATC |
|
0-L |
C03BA08 |
metolazone |
WHO ATC |
|
0-L |
C03BA09 |
meticrane |
WHO ATC |
|
0-L |
C03BA10 |
xipamide |
WHO ATC |
|
0-L |
C03BA11 |
indapamide |
WHO ATC |
|
0-L |
C03BA12 |
clorexolone |
WHO ATC |
|
0-L |
C03BA13 |
fenquizone |
WHO ATC |
|
0-L |
C03BA82 |
clorexolone, comb. with psycholeptics |
WHO ATC |
|
0-L |
C03BB |
Sulfonamides and potassium in combination |
WHO ATC |
|
0-L |
C03BB02 |
quinethazone and potassium |
WHO ATC |
|
0-L |
C03BB03 |
clopamide and potassium |
WHO ATC |
|
0-L |
C03BB04 |
chlortalidone and potassium |
WHO ATC |
|
0-L |
C03BB05 |
mefruside and potassium |
WHO ATC |
|
0-L |
C03BB07 |
clofenamide and potassium |
WHO ATC |
|
0-L |
C03BC |
Mercurial diuretics |
WHO ATC |
|
0-L |
C03BC01 |
mersalyl |
WHO ATC |
|
0-L |
C03BD |
Xanthine derivatives |
WHO ATC |
|
0-L |
C03BD01 |
theobromine |
WHO ATC |
|
0-L |
C03BK |
Sulfonamides, combinations with other drugs |
WHO ATC |
|
0-L |
C03BX |
Other low-ceiling diuretics |
WHO ATC |
|
0-L |
C03BX03 |
cicletanine |
WHO ATC |
|
0-L |
C03C |
HIGH-CEILING DIURETICS |
WHO ATC |
|
0-L |
C03CA |
Sulfonamides, plain |
WHO ATC |
|
0-L |
C03CA01 |
furosemide |
WHO ATC |
|
0-L |
C03CA02 |
bumetanide |
WHO ATC |
|
0-L |
C03CA03 |
piretanide |
WHO ATC |
|
0-L |
C03CA04 |
torasemide |
WHO ATC |
|
0-L |
C03CB |
Sulfonamides and potassium in combination |
WHO ATC |
|
0-L |
C03CB01 |
furosemide and potassium |
WHO ATC |
|
0-L |
C03CB02 |
bumetanide and potassium |
WHO ATC |
|
0-L |
C03CC |
Aryloxyacetic acid derivatives |
WHO ATC |
|
0-L |
C03CC01 |
etacrynic acid |
WHO ATC |
|
0-L |
C03CC02 |
tienilic acid |
WHO ATC |
|
0-L |
C03CD |
Pyrazolone derivatives |
WHO ATC |
|
0-L |
C03CD01 |
muzolimine |
WHO ATC |
|
0-L |
C03CX |
Other high-ceiling diuretics |
WHO ATC |
|
0-L |
C03CX01 |
etozolin |
WHO ATC |
|
0-L |
C03D |
POTASSIUM-SPARING AGENTS |
WHO ATC |
|
0-L |
C03DA |
Aldosterone antagonists |
WHO ATC |
|
0-L |
C03DA01 |
spironolactone |
WHO ATC |
|
0-L |
C03DA02 |
potassium canrenoate |
WHO ATC |
|
0-L |
C03DA03 |
canrenone |
WHO ATC |
|
0-L |
C03DA04 |
eplerenone |
WHO ATC |
|
0-L |
C03DB |
Other potassium-sparing agents |
WHO ATC |
|
0-L |
C03DB01 |
amiloride |
WHO ATC |
|
0-L |
C03DB02 |
triamterene |
WHO ATC |
|
0-L |
C03E |
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION |
WHO ATC |
|
0-L |
C03EA |
Low-ceiling diuretics and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA01 |
hydrochlorothiazide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA02 |
trichlormethiazide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA03 |
epitizide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA04 |
altizide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA05 |
mebutizide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA06 |
chlortalidone and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA07 |
cyclopenthiazide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA12 |
metolazone and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA13 |
bendroflumethiazide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA14 |
butizide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EB |
High-ceiling diuretics and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EB01 |
furosemide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EB02 |
bumetanide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03X |
OTHER DIURETICS |
WHO ATC |
|
0-L |
C03XA |
Vasopressin antagonists |
WHO ATC |
|
0-L |
C03XA01 |
tolvaptan |
WHO ATC |
|
0-L |
C03XA02 |
conivaptan |
WHO ATC |
|
0-L |
C04 |
PERIPHERAL VASODILATORS |
WHO ATC |
|
0-L |
C04A |
PERIPHERAL VASODILATORS |
WHO ATC |
|
0-L |
C04AA |
2-amino-1-phenylethanol derivatives |
WHO ATC |
|
0-L |
C04AA01 |
isoxsuprine |
WHO ATC |
|
0-L |
C04AA02 |
buphenine |
WHO ATC |
|
0-L |
C04AA31 |
bamethan |
WHO ATC |
|
0-L |
C04AB |
Imidazoline derivatives |
WHO ATC |
|
0-L |
C04AB01 |
phentolamine |
WHO ATC |
|
0-L |
C04AB02 |
tolazoline |
WHO ATC |
|
0-L |
C04AC |
Nicotinic acid and derivatives |
WHO ATC |
|
0-L |
C04AC01 |
nicotinic acid |
WHO ATC |
|
0-L |
C04AC02 |
nicotinyl alcohol (pyridylcarbinol) |
WHO ATC |
|
0-L |
C04AC03 |
inositol nicotinate |
WHO ATC |
|
0-L |
C04AC07 |
ciclonicate |
WHO ATC |
|
0-L |
C04AD |
Purine derivatives |
WHO ATC |
|
0-L |
C04AD01 |
pentifylline |
WHO ATC |
|
0-L |
C04AD02 |
xantinol nicotinate |
WHO ATC |
|
0-L |
C04AD03 |
pentoxifylline |
WHO ATC |
|
0-L |
C04AD04 |
etofylline nicotinate |
WHO ATC |
|
0-L |
C04AE |
Ergot alkaloids |
WHO ATC |
|
0-L |
C04AE01 |
ergoloid mesylates |
WHO ATC |
|
0-L |
C04AE02 |
nicergoline |
WHO ATC |
|
0-L |
C04AE04 |
dihydroergocristine |
WHO ATC |
|
0-L |
C04AE51 |
ergoloid mesylates, combinations |
WHO ATC |
|
0-L |
C04AE54 |
dihydroergocristine, combinations |
WHO ATC |
|
0-L |
C04AF |
Enzymes |
WHO ATC |
|
0-L |
C04AF01 |
kallidinogenase |
WHO ATC |
|
0-L |
C04AX |
Other peripheral vasodilators |
WHO ATC |
|
0-L |
C04AX01 |
cyclandelate |
WHO ATC |
|
0-L |
C04AX02 |
phenoxybenzamine |
WHO ATC |
|
0-L |
C04AX07 |
vincamine |
WHO ATC |
|
0-L |
C04AX10 |
moxisylyte |
WHO ATC |
|
0-L |
C04AX11 |
bencyclane |
WHO ATC |
|
0-L |
C04AX17 |
vinburnine |
WHO ATC |
|
0-L |
C04AX19 |
suloctidil |
WHO ATC |
|
0-L |
C04AX20 |
buflomedil |
WHO ATC |
|
0-L |
C04AX21 |
naftidrofuryl |
WHO ATC |
|
0-L |
C04AX23 |
butalamine |
WHO ATC |
|
0-L |
C04AX24 |
visnadine |
WHO ATC |
|
0-L |
C04AX26 |
cetiedil |
WHO ATC |
|
0-L |
C04AX27 |
cinepazide |
WHO ATC |
|
0-L |
C04AX28 |
ifenprodil |
WHO ATC |
|
0-L |
C04AX30 |
azapetine |
WHO ATC |
|
0-L |
C04AX32 |
fasudil |
WHO ATC |
|
0-L |
C05 |
VASOPROTECTIVES |
WHO ATC |
|
0-L |
C05A |
AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANALFISSURES FOR TOPICAL USE |
WHO ATC |
|
0-L |
C05AA |
Corticosteroids |
WHO ATC |
|
0-L |
C05AA01 |
hydrocortisone |
WHO ATC |
|
0-L |
C05AA04 |
prednisolone |
WHO ATC |
|
0-L |
C05AA05 |
betamethasone |
WHO ATC |
|
0-L |
C05AA06 |
fluorometholone |
WHO ATC |
|
0-L |
C05AA08 |
fluocortolone |
WHO ATC |
|
0-L |
C05AA09 |
dexamethasone |
WHO ATC |
|
0-L |
C05AA10 |
fluocinolone acetonide |
WHO ATC |
|
0-L |
C05AA11 |
fluocinonide |
WHO ATC |
|
0-L |
C05AB |
Antibiotics |
WHO ATC |
|
0-L |
C05AD |
Local anesthetics |
WHO ATC |
|
0-L |
C05AD01 |
lidocaine |
WHO ATC |
|
0-L |
C05AD02 |
tetracaine |
WHO ATC |
|
0-L |
C05AD03 |
benzocaine |
WHO ATC |
|
0-L |
C05AD04 |
cinchocaine |
WHO ATC |
|
0-L |
C05AD05 |
procaine |
WHO ATC |
|
0-L |
C05AD06 |
oxetacaine |
WHO ATC |
|
0-L |
C05AD07 |
pramocaine |
WHO ATC |
|
0-L |
C05AE |
Muscle relaxants |
WHO ATC |
|
0-L |
C05AE01 |
glyceryl trinitrate |
WHO ATC |
|
0-L |
C05AE02 |
isosorbide dinitrate |
WHO ATC |
|
0-L |
C05AX |
Other agents for treatment of hemorrhoids and anal fissures for topical use |
WHO ATC |
|
0-L |
C05AX01 |
aluminium preparations |
WHO ATC |
|
0-L |
C05AX02 |
bismuth preparations, combinations |
WHO ATC |
|
0-L |
C05AX03 |
other preparations, combinations |
WHO ATC |
|
0-L |
C05AX04 |
zinc preparations |
WHO ATC |
|
0-L |
C05AX05 |
tribenoside |
WHO ATC |
|
0-L |
C05B |
ANTIVARICOSE THERAPY |
WHO ATC |
|
0-L |
C05BA |
Heparins or heparinoids for topical use |
WHO ATC |
|
0-L |
C05BA01 |
organo-heparinoid |
WHO ATC |
|
0-L |
C05BA02 |
sodium apolate |
WHO ATC |
|
0-L |
C05BA03 |
heparin |
WHO ATC |
|
0-L |
C05BA04 |
pentosan polysulfate sodium |
WHO ATC |
|
0-L |
C05BA51 |
heparinoid, combinations |
WHO ATC |
|
0-L |
C05BA53 |
heparin, combinations |
WHO ATC |
|
0-L |
C05BB |
Sclerosing agents for local injection |
WHO ATC |
|
0-L |
C05BB01 |
monoethanolamine oleate |
WHO ATC |
|
0-L |
C05BB02 |
polidocanol |
WHO ATC |
|
0-L |
C05BB03 |
invert sugar |
WHO ATC |
|
0-L |
C05BB04 |
sodium tetradecyl sulfate |
WHO ATC |
|
0-L |
C05BB05 |
phenol |
WHO ATC |
|
0-L |
C05BB56 |
glucose, combinations |
WHO ATC |
|
0-L |
C05BX |
Other sclerosing agents |
WHO ATC |
|
0-L |
C05BX01 |
calcium dobesilate |
WHO ATC |
|
0-L |
C05BX51 |
calcium dobesilate, combinations |
WHO ATC |
|
0-L |
C05C |
CAPILLARY STABILIZING AGENTS |
WHO ATC |
|
0-L |
C05CA |
Bioflavonoids |
WHO ATC |
|
0-L |
C05CA01 |
rutoside |
WHO ATC |
|
0-L |
C05CA02 |
monoxerutin |
WHO ATC |
|
0-L |
C05CA03 |
diosmin |
WHO ATC |
|
0-L |
C05CA04 |
troxerutin |
WHO ATC |
|
0-L |
C05CA05 |
hidrosmin |
WHO ATC |
|
0-L |
C05CA51 |
rutoside, combinations |
WHO ATC |
|
0-L |
C05CA53 |
diosmin, combinations |
WHO ATC |
|
0-L |
C05CA54 |
troxerutin, combinations |
WHO ATC |
|
0-L |
C05CX |
Other capillary stabilizing agents |
WHO ATC |
|
0-L |
C05CX01 |
tribenoside |
WHO ATC |
|
0-L |
C07 |
BETA BLOCKING AGENTS |
WHO ATC |
|
0-L |
C07A |
BETA BLOCKING AGENTS |
WHO ATC |
|
0-L |
C07AA |
Beta blocking agents, non-selective |
WHO ATC |
|
0-L |
C07AA01 |
alprenolol |
WHO ATC |
|
0-L |
C07AA02 |
oxprenolol |
WHO ATC |
|
0-L |
C07AA03 |
pindolol |
WHO ATC |
|
0-L |
C07AA05 |
propranolol |
WHO ATC |
|
0-L |
C07AA06 |
timolol |
WHO ATC |
|
0-L |
C07AA07 |
sotalol |
WHO ATC |
|
0-L |
C07AA12 |
nadolol |
WHO ATC |
|
0-L |
C07AA14 |
mepindolol |
WHO ATC |
|
0-L |
C07AA15 |
carteolol |
WHO ATC |
|
0-L |
C07AA16 |
tertatolol |
WHO ATC |
|
0-L |
C07AA17 |
bopindolol |
WHO ATC |
|
0-L |
C07AA19 |
bupranolol |
WHO ATC |
|
0-L |
C07AA23 |
penbutolol |
WHO ATC |
|
0-L |
C07AA27 |
cloranolol |
WHO ATC |
|
0-L |
C07AA57 |
sotalol, combinations |
WHO ATC |
|
0-L |
C07AB |
Beta blocking agents, selective |
WHO ATC |
|
0-L |
C07AB01 |
practolol |
WHO ATC |
|
0-L |
C07AB02 |
metoprolol |
WHO ATC |
|
0-L |
C07AB03 |
atenolol |
WHO ATC |
|
0-L |
C07AB04 |
acebutolol |
WHO ATC |
|
0-L |
C07AB05 |
betaxolol |
WHO ATC |
|
0-L |
C07AB06 |
bevantolol |
WHO ATC |
|
0-L |
C07AB07 |
bisoprolol |
WHO ATC |
|
0-L |
C07AB08 |
celiprolol |
WHO ATC |
|
0-L |
C07AB09 |
esmolol |
WHO ATC |
|
0-L |
C07AB10 |
epanolol |
WHO ATC |
|
0-L |
C07AB11 |
s-atenolol |
WHO ATC |
|
0-L |
C07AB12 |
nebivolol |
WHO ATC |
|
0-L |
C07AB13 |
talinolol |
WHO ATC |
|
0-L |
C07AB52 |
metoprolol, combinations |
WHO ATC |
|
0-L |
C07AB57 |
bisoprolol, combinations |
WHO ATC |
|
0-L |
C07AG |
Alpha and beta blocking agents |
WHO ATC |
|
0-L |
C07AG01 |
labetalol |
WHO ATC |
|
0-L |
C07AG02 |
carvedilol |
WHO ATC |
|
0-L |
C07B |
BETA BLOCKING AGENTS AND THIAZIDES |
WHO ATC |
|
0-L |
C07BA |
Beta blocking agents, non-selective, and thiazides |
WHO ATC |
|
0-L |
C07BA02 |
oxprenolol and thiazides |
WHO ATC |
|
0-L |
C07BA05 |
propranolol and thiazides |
WHO ATC |
|
0-L |
C07BA06 |
timolol and thiazides |
WHO ATC |
|
0-L |
C07BA07 |
sotalol and thiazides |
WHO ATC |
|
0-L |
C07BA12 |
nadolol and thiazides |
WHO ATC |
|
0-L |
C07BA68 |
metipranolol and thiazides, combinations |
WHO ATC |
|
0-L |
C07BB |
Beta blocking agents, selective, and thiazides |
WHO ATC |
|
0-L |
C07BB02 |
metoprolol and thiazides |
WHO ATC |
|
0-L |
C07BB03 |
atenolol and thiazides |
WHO ATC |
|
0-L |
C07BB04 |
acebutolol and thiazides |
WHO ATC |
|
0-L |
C07BB06 |
bevantolol and thiazides |
WHO ATC |
|
0-L |
C07BB07 |
bisoprolol and thiazides |
WHO ATC |
|
0-L |
C07BB52 |
metoprolol and thiazides, combinations |
WHO ATC |
|
0-L |
C07BG |
Alpha and beta blocking agents and thiazides |
WHO ATC |
|
0-L |
C07BG01 |
labetalol and thiazides |
WHO ATC |
|
0-L |
C07C |
BETA BLOCKING AGENTS AND OTHER DIURETICS |
WHO ATC |
|
0-L |
C07CA |
Beta blocking agents, non-selective, and other diuretics |
WHO ATC |
|
0-L |
C07CA02 |
oxprenolol and other diuretics |
WHO ATC |
|
0-L |
C07CA03 |
pindolol and other diuretics |
WHO ATC |
|
0-L |
C07CA17 |
bopindolol and other diuretics |
WHO ATC |
|
0-L |
C07CA23 |
penbutolol and other diuretics |
WHO ATC |
|
0-L |
C07CB |
Beta blocking agents, selective, and other diuretics |
WHO ATC |
|
0-L |
C07CB02 |
metoprolol and other diuretics |
WHO ATC |
|
0-L |
C07CB03 |
atenolol and other diuretics |
WHO ATC |
|
0-L |
C07CB53 |
atenolol and other diuretics, combinations |
WHO ATC |
|
0-L |
C07CG |
Alpha and beta blocking agents and other diuretics |
WHO ATC |
|
0-L |
C07CG01 |
labetalol and other diuretics |
WHO ATC |
|
0-L |
C07D |
BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS |
WHO ATC |
|
0-L |
C07DA |
Beta blocking agents, non-selective, thiazides and other diuretics |
WHO ATC |
|
0-L |
C07DA06 |
timolol, thiazides and other diuretics |
WHO ATC |
|
0-L |
C07DB |
Beta blocking agents, selective, thiazides and other diuretics |
WHO ATC |
|
0-L |
C07DB01 |
atenolol, thiazides and other diuretics |
WHO ATC |
|
0-L |
C07E |
BETA BLOCKING AGENTS AND VASODILATORS |
WHO ATC |
|
0-L |
C07EA |
Beta blocking agents, non-selective, and vasodilators |
WHO ATC |
|
0-L |
C07EB |
Beta blocking agents, selective, and vasodilators |
WHO ATC |
|
0-L |
C07F |
BETA BLOCKING AGENTS AND OTHER ANTIHYPERTENSIVES |
WHO ATC |
|
0-L |
C07FA |
Beta blocking agents, non-selective, and other antihypertensives |
WHO ATC |
|
0-L |
C07FA05 |
propranolol and other antihypertensives |
WHO ATC |
|
0-L |
C07FB |
Beta blocking agents, selective, and other antihypertensives |
WHO ATC |
|
0-L |
C07FB02 |
metoprolol and other antihypertensives |
WHO ATC |
|
0-L |
C07FB03 |
atenolol and other antihypertensives |
WHO ATC |
|
0-L |
C08 |
CALCIUM CHANNEL BLOCKERS |
WHO ATC |
|
0-L |
C08C |
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS |
WHO ATC |
|
0-L |
C08CA |
Dihydropyridine derivatives |
WHO ATC |
|
0-L |
C08CA01 |
amlodipine |
WHO ATC |
|
0-L |
C08CA02 |
felodipine |
WHO ATC |
|
0-L |
C08CA03 |
isradipine |
WHO ATC |
|
0-L |
C08CA04 |
nicardipine |
WHO ATC |
|
0-L |
C08CA05 |
nifedipine |
WHO ATC |
|
0-L |
C08CA06 |
nimodipine |
WHO ATC |
|
0-L |
C08CA07 |
nisoldipine |
WHO ATC |
|
0-L |
C08CA08 |
nitrendipine |
WHO ATC |
|
0-L |
C08CA09 |
lacidipine |
WHO ATC |
|
0-L |
C08CA10 |
nilvadipine |
WHO ATC |
|
0-L |
C08CA11 |
manidipine |
WHO ATC |
|
0-L |
C08CA12 |
barnidipine |
WHO ATC |
|
0-L |
C08CA13 |
lercanidipine |
WHO ATC |
|
0-L |
C08CA14 |
cilnidipine |
WHO ATC |
|
0-L |
C08CA15 |
benidipine |
WHO ATC |
|
0-L |
C08CA55 |
nifedipine, combinations |
WHO ATC |
|
0-L |
C08CX |
Other selective calcium channel blockers with mainly vascular effects |
WHO ATC |
|
0-L |
C08CX01 |
mibefradil |
WHO ATC |
|
0-L |
C08D |
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS |
WHO ATC |
|
0-L |
C08DA |
Phenylalkylamine derivatives |
WHO ATC |
|
0-L |
C08DA01 |
verapamil |
WHO ATC |
|
0-L |
C08DA02 |
gallopamil |
WHO ATC |
|
0-L |
C08DA51 |
verapamil, combinations |
WHO ATC |
|
0-L |
C08DB |
Benzothiazepine derivatives |
WHO ATC |
|
0-L |
C08DB01 |
diltiazem |
WHO ATC |
|
0-L |
C08E |
NON-SELECTIVE CALCIUM CHANNEL BLOCKERS |
WHO ATC |
|
0-L |
C08EA |
Phenylalkylamine derivatives |
WHO ATC |
|
0-L |
C08EA01 |
fendiline |
WHO ATC |
|
0-L |
C08EA02 |
bepridil |
WHO ATC |
|
0-L |
C08EX |
Other non-selective calcium channel blockers |
WHO ATC |
|
0-L |
C08EX01 |
lidoflazine |
WHO ATC |
|
0-L |
C08EX02 |
perhexiline |
WHO ATC |
|
0-L |
C08G |
CALCIUM CHANNEL BLOCKERS AND DIURETICS |
WHO ATC |
|
0-L |
C08GA |
Calcium channel blockers and diuretics |
WHO ATC |
|
0-L |
C08GA01 |
nifedipine and diuretics |
WHO ATC |
|
0-L |
C09 |
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM |
WHO ATC |
|
0-L |
C09A |
ACE INHIBITORS, PLAIN |
WHO ATC |
|
0-L |
C09AA |
ACE inhibitors, plain |
WHO ATC |
|
0-L |
C09AA01 |
captopril |
WHO ATC |
|
0-L |
C09AA02 |
enalapril |
WHO ATC |
|
0-L |
C09AA03 |
lisinopril |
WHO ATC |
|
0-L |
C09AA04 |
perindopril |
WHO ATC |
|
0-L |
C09AA05 |
ramipril |
WHO ATC |
|
0-L |
C09AA06 |
quinapril |
WHO ATC |
|
0-L |
C09AA07 |
benazepril |
WHO ATC |
|
0-L |
C09AA08 |
cilazapril |
WHO ATC |
|
0-L |
C09AA09 |
fosinopril |
WHO ATC |
|
0-L |
C09AA10 |
trandolapril |
WHO ATC |
|
0-L |
C09AA11 |
spirapril |
WHO ATC |
|
0-L |
C09AA12 |
delapril |
WHO ATC |
|
0-L |
C09AA13 |
moexipril |
WHO ATC |
|
0-L |
C09AA14 |
temocapril |
WHO ATC |
|
0-L |
C09AA15 |
zofenopril |
WHO ATC |
|
0-L |
C09AA16 |
imidapril |
WHO ATC |
|
0-L |
C09B |
ACE INHIBITORS, COMBINATIONS |
WHO ATC |
|
0-L |
C09BA |
ACE inhibitors and diuretics |
WHO ATC |
|
0-L |
C09BA01 |
captopril and diuretics |
WHO ATC |
|
0-L |
C09BA02 |
enalapril and diuretics |
WHO ATC |
|
0-L |
C09BA03 |
lisinopril and diuretics |
WHO ATC |
|
0-L |
C09BA04 |
perindopril and diuretics |
WHO ATC |
|
0-L |
C09BA05 |
ramipril and diuretics |
WHO ATC |
|
0-L |
C09BA06 |
quinapril and diuretics |
WHO ATC |
|
0-L |
C09BA07 |
benazepril and diuretics |
WHO ATC |
|
0-L |
C09BA08 |
cilazapril and diuretics |
WHO ATC |
|
0-L |
C09BA09 |
fosinopril and diuretics |
WHO ATC |
|
0-L |
C09BA12 |
delapril and diuretics |
WHO ATC |
|
0-L |
C09BA13 |
moexipril and diuretics |
WHO ATC |
|
0-L |
C09BA15 |
zofenopril and diuretics |
WHO ATC |
|
0-L |
C09BB |
ACE inhibitors and calcium channel blockers |
WHO ATC |
|
0-L |
C09BB02 |
enalapril and lercanidipine |
WHO ATC |
|
0-L |
C09BB03 |
lisinopril and amlodipine |
WHO ATC |
|
0-L |
C09BB04 |
perindopril and amlodipine |
WHO ATC |
|
0-L |
C09BB05 |
ramipril and felodipine |
WHO ATC |
|
0-L |
C09BB10 |
trandolapril and verapamil |
WHO ATC |
|
0-L |
C09BB12 |
delapril and manidipine |
WHO ATC |
|
0-L |
C09C |
ANGIOTENSIN II ANTAGONISTS, PLAIN |
WHO ATC |
|
0-L |
C09CA |
Angiotensin II antagonists, plain |
WHO ATC |
|
0-L |
C09CA01 |
losartan |
WHO ATC |
|
0-L |
C09CA02 |
eprosartan |
WHO ATC |
|
0-L |
C09CA03 |
valsartan |
WHO ATC |
|
0-L |
C09CA04 |
irbesartan |
WHO ATC |
|
0-L |
C09CA05 |
tasosartan |
WHO ATC |
|
0-L |
C09CA06 |
candesartan |
WHO ATC |
|
0-L |
C09CA07 |
telmisartan |
WHO ATC |
|
0-L |
C09CA08 |
olmesartan medoxomil |
WHO ATC |
|
0-L |
C09D |
ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
WHO ATC |
|
0-L |
C09DA |
Angiotensin II antagonists and diuretics |
WHO ATC |
|
0-L |
C09DA01 |
losartan and diuretics |
WHO ATC |
|
0-L |
C09DA02 |
eprosartan and diuretics |
WHO ATC |
|
0-L |
C09DA03 |
valsartan and diuretics |
WHO ATC |
|
0-L |
C09DA04 |
irbesartan and diuretics |
WHO ATC |
|
0-L |
C09DA06 |
candesartan and diuretics |
WHO ATC |
|
0-L |
C09DA07 |
telmisartan and diuretics |
WHO ATC |
|
0-L |
C09DA08 |
olmesartan medoxomil and diuretics |
WHO ATC |
|
0-L |
C09DB |
Angiotensin II antagonists and calcium channel blockers |
WHO ATC |
|
0-L |
C09DB01 |
valsartan and amlodipine |
WHO ATC |
|
0-L |
C09DB02 |
olmesartan medoxomil and amlodipine |
WHO ATC |
|
0-L |
C09DB04 |
telmisartan and amlodipine |
WHO ATC |
|
0-L |
C09DX |
Angiotensin II antagonists, other combinations |
WHO ATC |
|
0-L |
C09DX01 |
valsartan, amlodipine and hydrochlorothiazide |
WHO ATC |
|
0-L |
C09DX02 |
valsartan and aliskiren |
WHO ATC |
|
0-L |
C09X |
OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM |
WHO ATC |
|
0-L |
C09XA |
Renin-inhibitors |
WHO ATC |
|
0-L |
C09XA01 |
remikiren |
WHO ATC |
|
0-L |
C09XA02 |
aliskiren |
WHO ATC |
|
0-L |
C09XA52 |
aliskiren and hydrochlorothiazide |
WHO ATC |
|
0-L |
C10 |
LIPID MODIFYING AGENTS |
WHO ATC |
|
0-L |
C10A |
LIPID MODIFYING AGENTS, PLAIN |
WHO ATC |
|
0-L |
C10AA |
HMG CoA reductase inhibitors |
WHO ATC |
|
0-L |
C10AA01 |
simvastatin |
WHO ATC |
|
0-L |
C10AA02 |
lovastatin |
WHO ATC |
|
0-L |
C10AA03 |
pravastatin |
WHO ATC |
|
0-L |
C10AA04 |
fluvastatin |
WHO ATC |
|
0-L |
C10AA05 |
atorvastatin |
WHO ATC |
|
0-L |
C10AA06 |
cerivastatin |
WHO ATC |
|
0-L |
C10AA07 |
rosuvastatin |
WHO ATC |
|
0-L |
C10AA08 |
pitavastatin |
WHO ATC |
|
0-L |
C10AB |
Fibrates |
WHO ATC |
|
0-L |
C10AB01 |
clofibrate |
WHO ATC |
|
0-L |
C10AB02 |
bezafibrate |
WHO ATC |
|
0-L |
C10AB03 |
aluminium clofibrate |
WHO ATC |
|
0-L |
C10AB04 |
gemfibrozil |
WHO ATC |
|
0-L |
C10AB05 |
fenofibrate |
WHO ATC |
|
0-L |
C10AB06 |
simfibrate |
WHO ATC |
|
0-L |
C10AB07 |
ronifibrate |
WHO ATC |
|
0-L |
C10AB08 |
ciprofibrate |
WHO ATC |
|
0-L |
C10AB09 |
etofibrate |
WHO ATC |
|
0-L |
C10AB10 |
clofibride |
WHO ATC |
|
0-L |
C10AC |
Bile acid sequestrants |
WHO ATC |
|
0-L |
C10AC01 |
colestyramine |
WHO ATC |
|
0-L |
C10AC02 |
colestipol |
WHO ATC |
|
0-L |
C10AC03 |
colextran |
WHO ATC |
|
0-L |
C10AC04 |
colesevelam |
WHO ATC |
|
0-L |
C10AD |
Nicotinic acid and derivatives |
WHO ATC |
|
0-L |
C10AD01 |
niceritrol |
WHO ATC |
|
0-L |
C10AD02 |
nicotinic acid |
WHO ATC |
|
0-L |
C10AD03 |
nicofuranose |
WHO ATC |
|
0-L |
C10AD04 |
aluminium nicotinate |
WHO ATC |
|
0-L |
C10AD05 |
nicotinyl alcohol (pyridylcarbinol) |
WHO ATC |
|
0-L |
C10AD06 |
acipimox |
WHO ATC |
|
0-L |
C10AD52 |
nicotinic acid, combinations |
WHO ATC |
|
0-L |
C10AX |
Other lipid modifying agents |
WHO ATC |
|
0-L |
C10AX01 |
dextrothyroxine |
WHO ATC |
|
0-L |
C10AX02 |
probucol |
WHO ATC |
|
0-L |
C10AX03 |
tiadenol |
WHO ATC |
|
0-L |
C10AX05 |
meglutol |
WHO ATC |
|
0-L |
C10AX06 |
omega-3-triglycerides incl. other esters and acids |
WHO ATC |
|
0-L |
C10AX07 |
magnesium pyridoxal 5-phosphate glutamate |
WHO ATC |
|
0-L |
C10AX08 |
policosanol |
WHO ATC |
|
0-L |
C10AX09 |
ezetimibe |
WHO ATC |
|
0-L |
C10AX10 |
alipogene tiparvovec |
WHO ATC |
|
0-L |
C10B |
LIPID MODIFYING AGENTS, COMBINATIONS |
WHO ATC |
|
0-L |
C10BA |
HMG CoA reductase inhibitors in combination with other lipid modifying agents |
WHO ATC |
|
0-L |
C10BA01 |
lovastatin and nicotinic acid |
WHO ATC |
|
0-L |
C10BA02 |
simvastatin and ezetimibe |
WHO ATC |
|
0-L |
C10BA03 |
pravastatin and fenofibrate |
WHO ATC |
|
0-L |
C10BX |
HMG CoA reductase inhibitors, other combinations |
WHO ATC |
|
0-L |
C10BX01 |
simvastatin and acetylsalicylic acid |
WHO ATC |
|
0-L |
C10BX02 |
pravastatin and acetylsalicylic acid |
WHO ATC |
|
0-L |
C10BX03 |
atorvastatin and amlodipine |
WHO ATC |
|
0-L |
D |
DERMATOLOGICALS |
WHO ATC |
|
0-L |
D01 |
ANTIFUNGALS FOR DERMATOLOGICAL USE |
WHO ATC |
|
0-L |
D01A |
ANTIFUNGALS FOR TOPICAL USE |
WHO ATC |
|
0-L |
D01AA |
Antibiotics |
WHO ATC |
|
0-L |
D01AA01 |
nystatin |
WHO ATC |
|
0-L |
D01AA02 |
natamycin |
WHO ATC |
|
0-L |
D01AA03 |
hachimycin |
WHO ATC |
|
0-L |
D01AA04 |
pecilocin |
WHO ATC |
|
0-L |
D01AA06 |
mepartricin |
WHO ATC |
|
0-L |
D01AA07 |
pyrrolnitrin |
WHO ATC |
|
0-L |
D01AA08 |
griseofulvin |
WHO ATC |
|
0-L |
D01AA20 |
combinations |
WHO ATC |
|
0-L |
D01AC |
Imidazole and triazole derivatives |
WHO ATC |
|
0-L |
D01AC01 |
clotrimazole |
WHO ATC |
|
0-L |
D01AC02 |
miconazole |
WHO ATC |
|
0-L |
D01AC03 |
econazole |
WHO ATC |
|
0-L |
D01AC04 |
chlormidazole |
WHO ATC |
|
0-L |
D01AC05 |
isoconazole |
WHO ATC |
|
0-L |
D01AC06 |
tiabendazole |
WHO ATC |
|
0-L |
D01AC07 |
tioconazole |
WHO ATC |
|
0-L |
D01AC08 |
ketoconazole |
WHO ATC |
|
0-L |
D01AC09 |
sulconazole |
WHO ATC |
|
0-L |
D01AC10 |
bifonazole |
WHO ATC |
|
0-L |
D01AC11 |
oxiconazole |
WHO ATC |
|
0-L |
D01AC12 |
fenticonazole |
WHO ATC |
|
0-L |
D01AC13 |
omoconazole |
WHO ATC |
|
0-L |
D01AC14 |
sertaconazole |
WHO ATC |
|
0-L |
D01AC15 |
fluconazole |
WHO ATC |
|
0-L |
D01AC16 |
flutrimazole |
WHO ATC |
|
0-L |
D01AC20 |
combinations |
WHO ATC |
|
0-L |
D01AC52 |
miconazole, combinations |
WHO ATC |
|
0-L |
D01AC60 |
bifonazole, combinations |
WHO ATC |
|
0-L |
D01AE |
Other antifungals for topical use |
WHO ATC |
|
0-L |
D01AE01 |
bromochlorosalicylanilide |
WHO ATC |
|
0-L |
D01AE02 |
methylrosaniline |
WHO ATC |
|
0-L |
D01AE03 |
tribromometacresol |
WHO ATC |
|
0-L |
D01AE04 |
undecylenic acid |
WHO ATC |
|
0-L |
D01AE05 |
polynoxylin |
WHO ATC |
|
0-L |
D01AE06 |
2-(4-chlorphenoxy)-ethanol |
WHO ATC |
|
0-L |
D01AE07 |
chlorphenesin |
WHO ATC |
|
0-L |
D01AE08 |
ticlatone |
WHO ATC |
|
0-L |
D01AE09 |
sulbentine |
WHO ATC |
|
0-L |
D01AE10 |
ethyl hydroxybenzoate |
WHO ATC |
|
0-L |
D01AE11 |
haloprogin |
WHO ATC |
|
0-L |
D01AE12 |
salicylic acid |
WHO ATC |
|
0-L |
D01AE13 |
selenium sulfide |
WHO ATC |
|
0-L |
D01AE14 |
ciclopirox |
WHO ATC |
|
0-L |
D01AE15 |
terbinafine |
WHO ATC |
|
0-L |
D01AE16 |
amorolfine |
WHO ATC |
|
0-L |
D01AE17 |
dimazole |
WHO ATC |
|
0-L |
D01AE18 |
tolnaftate |
WHO ATC |
|
0-L |
D01AE19 |
tolciclate |
WHO ATC |
|
0-L |
D01AE20 |
combinations |
WHO ATC |
|
0-L |
D01AE21 |
flucytosine |
WHO ATC |
|
0-L |
D01AE22 |
naftifine |
WHO ATC |
|
0-L |
D01AE23 |
butenafine |
WHO ATC |
|
0-L |
D01AE54 |
undecylenic acid, combinations |
WHO ATC |
|
0-L |
D01B |
ANTIFUNGALS FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
D01BA |
Antifungals for systemic use |
WHO ATC |
|
0-L |
D01BA01 |
griseofulvin |
WHO ATC |
|
0-L |
D01BA02 |
terbinafine |
WHO ATC |
|
0-L |
D02 |
EMOLLIENTS AND PROTECTIVES |
WHO ATC |
|
0-L |
D02A |
EMOLLIENTS AND PROTECTIVES |
WHO ATC |
|
0-L |
D02AA |
Silicone products |
WHO ATC |
|
0-L |
D02AB |
Zinc products |
WHO ATC |
|
0-L |
D02AC |
Soft paraffin and fat products |
WHO ATC |
|
0-L |
D02AD |
Liquid plasters |
WHO ATC |
|
0-L |
D02AE |
Carbamide products |
WHO ATC |
|
0-L |
D02AE01 |
carbamide |
WHO ATC |
|
0-L |
D02AE51 |
carbamide, combinations |
WHO ATC |
|
0-L |
D02AF |
Salicylic acid preparations |
WHO ATC |
|
0-L |
D02AX |
Other emollients and protectives |
WHO ATC |
|
0-L |
D02B |
PROTECTIVES AGAINST UV-RADIATION |
WHO ATC |
|
0-L |
D02BA |
Protectives against UV-radiation for topical use |
WHO ATC |
|
0-L |
D02BA01 |
aminobenzoic acid |
WHO ATC |
|
0-L |
D02BA02 |
octinoxate |
WHO ATC |
|
0-L |
D02BB |
Protectives against UV-radiation for systemic use |
WHO ATC |
|
0-L |
D02BB01 |
betacarotene |
WHO ATC |
|
0-L |
D03 |
PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS |
WHO ATC |
|
0-L |
D03A |
CICATRIZANTS |
WHO ATC |
|
0-L |
D03AA |
Cod-liver oil ointments |
WHO ATC |
|
0-L |
D03AX |
Other cicatrizants |
WHO ATC |
|
0-L |
D03AX01 |
cadexomer iodine |
WHO ATC |
|
0-L |
D03AX02 |
dextranomer |
WHO ATC |
|
0-L |
D03AX03 |
dexpanthenol |
WHO ATC |
|
0-L |
D03AX04 |
calcium pantothenate |
WHO ATC |
|
0-L |
D03AX05 |
hyaluronic acid |
WHO ATC |
|
0-L |
D03AX06 |
becaplermin |
WHO ATC |
|
0-L |
D03AX09 |
crilanomer |
WHO ATC |
|
0-L |
D03AX10 |
enoxolone |
WHO ATC |
|
0-L |
D03B |
ENZYMES |
WHO ATC |
|
0-L |
D03BA |
Proteolytic enzymes |
WHO ATC |
|
0-L |
D03BA01 |
trypsin |
WHO ATC |
|
0-L |
D03BA02 |
collagenase |
WHO ATC |
|
0-L |
D03BA52 |
collagenase, combinations |
WHO ATC |
|
0-L |
D04 |
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. |
WHO ATC |
|
0-L |
D04A |
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. |
WHO ATC |
|
0-L |
D04AA |
Antihistamines for topical use |
WHO ATC |
|
0-L |
D04AA01 |
thonzylamine |
WHO ATC |
|
0-L |
D04AA02 |
mepyramine |
WHO ATC |
|
0-L |
D04AA03 |
thenalidine |
WHO ATC |
|
0-L |
D04AA04 |
tripelennamine |
WHO ATC |
|
0-L |
D04AA09 |
chloropyramine |
WHO ATC |
|
0-L |
D04AA10 |
promethazine |
WHO ATC |
|
0-L |
D04AA12 |
tolpropamine |
WHO ATC |
|
0-L |
D04AA13 |
dimetindene |
WHO ATC |
|
0-L |
D04AA14 |
clemastine |
WHO ATC |
|
0-L |
D04AA15 |
bamipine |
WHO ATC |
|
0-L |
D04AA22 |
isothipendyl |
WHO ATC |
|
0-L |
D04AA32 |
diphenhydramine |
WHO ATC |
|
0-L |
D04AA33 |
diphenhydramine methylbromide |
WHO ATC |
|
0-L |
D04AA34 |
chlorphenoxamine |
WHO ATC |
|
0-L |
D04AB |
Anesthetics for topical use |
WHO ATC |
|
0-L |
D04AB01 |
lidocaine |
WHO ATC |
|
0-L |
D04AB02 |
cinchocaine |
WHO ATC |
|
0-L |
D04AB03 |
oxybuprocaine |
WHO ATC |
|
0-L |
D04AB04 |
benzocaine |
WHO ATC |
|
0-L |
D04AB05 |
quinisocaine |
WHO ATC |
|
0-L |
D04AB06 |
tetracaine |
WHO ATC |
|
0-L |
D04AB07 |
pramocaine |
WHO ATC |
|
0-L |
D04AX |
Other antipruritics |
WHO ATC |
|
0-L |
D05 |
ANTIPSORIATICS |
WHO ATC |
|
0-L |
D05A |
ANTIPSORIATICS FOR TOPICAL USE |
WHO ATC |
|
0-L |
D05AA |
Tars |
WHO ATC |
|
0-L |
D05AC |
Antracen derivatives |
WHO ATC |
|
0-L |
D05AC01 |
dithranol |
WHO ATC |
|
0-L |
D05AC51 |
dithranol, combinations |
WHO ATC |
|
0-L |
D05AD |
Psoralens for topical use |
WHO ATC |
|
0-L |
D05AD01 |
trioxysalen |
WHO ATC |
|
0-L |
D05AD02 |
methoxsalen |
WHO ATC |
|
0-L |
D05AX |
Other antipsoriatics for topical use |
WHO ATC |
|
0-L |
D05AX01 |
fumaric acid |
WHO ATC |
|
0-L |
D05AX02 |
calcipotriol |
WHO ATC |
|
0-L |
D05AX03 |
calcitriol |
WHO ATC |
|
0-L |
D05AX04 |
tacalcitol |
WHO ATC |
|
0-L |
D05AX05 |
tazarotene |
WHO ATC |
|
0-L |
D05AX52 |
calcipotriol, combinations |
WHO ATC |
|
0-L |
D05B |
ANTIPSORIATICS FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
D05BA |
Psoralens for systemic use |
WHO ATC |
|
0-L |
D05BA01 |
trioxysalen |
WHO ATC |
|
0-L |
D05BA02 |
methoxsalen |
WHO ATC |
|
0-L |
D05BA03 |
bergapten |
WHO ATC |
|
0-L |
D05BB |
Retinoids for treatment of psoriasis |
WHO ATC |
|
0-L |
D05BB01 |
etretinate |
WHO ATC |
|
0-L |
D05BB02 |
acitretin |
WHO ATC |
|
0-L |
D05BX |
Other antipsoriatics for systemic use |
WHO ATC |
|
0-L |
D05BX51 |
fumaric acid derivatives, combinations |
WHO ATC |
|
0-L |
D06 |
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE |
WHO ATC |
|
0-L |
D06A |
ANTIBIOTICS FOR TOPICAL USE |
WHO ATC |
|
0-L |
D06AA |
Tetracycline and derivatives |
WHO ATC |
|
0-L |
D06AA01 |
demeclocycline |
WHO ATC |
|
0-L |
D06AA02 |
chlortetracycline |
WHO ATC |
|
0-L |
D06AA03 |
oxytetracycline |
WHO ATC |
|
0-L |
D06AA04 |
tetracycline |
WHO ATC |
|
0-L |
D06AX |
Other antibiotics for topical use |
WHO ATC |
|
0-L |
D06AX01 |
fusidic acid |
WHO ATC |
|
0-L |
D06AX02 |
chloramphenicol |
WHO ATC |
|
0-L |
D06AX04 |
neomycin |
WHO ATC |
|
0-L |
D06AX05 |
bacitracin |
WHO ATC |
|
0-L |
D06AX07 |
gentamicin |
WHO ATC |
|
0-L |
D06AX08 |
tyrothricin |
WHO ATC |
|
0-L |
D06AX09 |
mupirocin |
WHO ATC |
|
0-L |
D06AX10 |
virginiamycin |
WHO ATC |
|
0-L |
D06AX11 |
rifaximin |
WHO ATC |
|
0-L |
D06AX12 |
amikacin |
WHO ATC |
|
0-L |
D06AX13 |
retapamulin |
WHO ATC |
|
0-L |
D06B |
CHEMOTHERAPEUTICS FOR TOPICAL USE |
WHO ATC |
|
0-L |
D06BA |
Sulfonamides |
WHO ATC |
|
0-L |
D06BA01 |
silver sulfadiazine |
WHO ATC |
|
0-L |
D06BA02 |
sulfathiazole |
WHO ATC |
|
0-L |
D06BA03 |
mafenide |
WHO ATC |
|
0-L |
D06BA04 |
sulfamethizole |
WHO ATC |
|
0-L |
D06BA05 |
sulfanilamide |
WHO ATC |
|
0-L |
D06BA06 |
sulfamerazine |
WHO ATC |
|
0-L |
D06BA51 |
silver sulfadiazine, combinations |
WHO ATC |
|
0-L |
D06BB |
Antivirals |
WHO ATC |
|
0-L |
D06BB01 |
idoxuridine |
WHO ATC |
|
0-L |
D06BB02 |
tromantadine |
WHO ATC |
|
0-L |
D06BB03 |
aciclovir |
WHO ATC |
|
0-L |
D06BB04 |
podophyllotoxin |
WHO ATC |
|
0-L |
D06BB05 |
inosine |
WHO ATC |
|
0-L |
D06BB06 |
penciclovir |
WHO ATC |
|
0-L |
D06BB07 |
lysozyme |
WHO ATC |
|
0-L |
D06BB08 |
ibacitabine |
WHO ATC |
|
0-L |
D06BB09 |
edoxudine |
WHO ATC |
|
0-L |
D06BB10 |
imiquimod |
WHO ATC |
|
0-L |
D06BB11 |
docosanol |
WHO ATC |
|
0-L |
D06BB53 |
aciclovir, combinations |
WHO ATC |
|
0-L |
D06BX |
Other chemotherapeutics |
WHO ATC |
|
0-L |
D06BX01 |
metronidazole |
WHO ATC |
|
0-L |
D06C |
ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS |
WHO ATC |
|
0-L |
D07 |
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS |
WHO ATC |
|
0-L |
D07A |
CORTICOSTEROIDS, PLAIN |
WHO ATC |
|
0-L |
D07AA |
Corticosteroids, weak (group I) |
WHO ATC |
|
0-L |
D07AA01 |
methylprednisolone |
WHO ATC |
|
0-L |
D07AA02 |
hydrocortisone |
WHO ATC |
|
0-L |
D07AA03 |
prednisolone |
WHO ATC |
|
0-L |
D07AB |
Corticosteroids, moderately potent (group II) |
WHO ATC |
|
0-L |
D07AB01 |
clobetasone |
WHO ATC |
|
0-L |
D07AB02 |
hydrocortisone butyrate |
WHO ATC |
|
0-L |
D07AB03 |
flumetasone |
WHO ATC |
|
0-L |
D07AB04 |
fluocortin |
WHO ATC |
|
0-L |
D07AB05 |
fluperolone |
WHO ATC |
|
0-L |
D07AB06 |
fluorometholone |
WHO ATC |
|
0-L |
D07AB07 |
fluprednidene |
WHO ATC |
|
0-L |
D07AB08 |
desonide |
WHO ATC |
|
0-L |
D07AB09 |
triamcinolone |
WHO ATC |
|
0-L |
D07AB10 |
alclometasone |
WHO ATC |
|
0-L |
D07AB11 |
hydrocortisone buteprate |
WHO ATC |
|
0-L |
D07AB19 |
dexamethasone |
WHO ATC |
|
0-L |
D07AB21 |
clocortolone |
WHO ATC |
|
0-L |
D07AB30 |
combinations of corticosteroids |
WHO ATC |
|
0-L |
D07AC |
Corticosteroids, potent (group III) |
WHO ATC |
|
0-L |
D07AC01 |
betamethasone |
WHO ATC |
|
0-L |
D07AC02 |
fluclorolone |
WHO ATC |
|
0-L |
D07AC03 |
desoximetasone |
WHO ATC |
|
0-L |
D07AC04 |
fluocinolone acetonide |
WHO ATC |
|
0-L |
D07AC05 |
fluocortolone |
WHO ATC |
|
0-L |
D07AC06 |
diflucortolone |
WHO ATC |
|
0-L |
D07AC07 |
fludroxycortide |
WHO ATC |
|
0-L |
D07AC08 |
fluocinonide |
WHO ATC |
|
0-L |
D07AC09 |
budesonide |
WHO ATC |
|
0-L |
D07AC10 |
diflorasone |
WHO ATC |
|
0-L |
D07AC11 |
amcinonide |
WHO ATC |
|
0-L |
D07AC12 |
halometasone |
WHO ATC |
|
0-L |
D07AC13 |
mometasone |
WHO ATC |
|
0-L |
D07AC14 |
methylprednisolone aceponate |
WHO ATC |
|
0-L |
D07AC15 |
beclometasone |
WHO ATC |
|
0-L |
D07AC16 |
hydrocortisone aceponate |
WHO ATC |
|
0-L |
D07AC17 |
fluticasone |
WHO ATC |
|
0-L |
D07AC18 |
prednicarbate |
WHO ATC |
|
0-L |
D07AC19 |
difluprednate |
WHO ATC |
|
0-L |
D07AC21 |
ulobetasol |
WHO ATC |
|
0-L |
D07AD |
Corticosteroids, very potent (group IV) |
WHO ATC |
|
0-L |
D07AD01 |
clobetasol |
WHO ATC |
|
0-L |
D07AD02 |
halcinonide |
WHO ATC |
|
0-L |
D07B |
CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS |
WHO ATC |
|
0-L |
D07BA |
Corticosteroids, weak, combinations with antiseptics |
WHO ATC |
|
0-L |
D07BA01 |
prednisolone and antiseptics |
WHO ATC |
|
0-L |
D07BA04 |
hydrocortisone and antiseptics |
WHO ATC |
|
0-L |
D07BB |
Corticosteroids, moderately potent, combinations with antiseptics |
WHO ATC |
|
0-L |
D07BB01 |
flumetasone and antiseptics |
WHO ATC |
|
0-L |
D07BB02 |
desonide and antiseptics |
WHO ATC |
|
0-L |
D07BB03 |
triamcinolone and antiseptics |
WHO ATC |
|
0-L |
D07BB04 |
hydrocortisone butyrate and antiseptics |
WHO ATC |
|
0-L |
D07BC |
Corticosteroids, potent, combinations with antiseptics |
WHO ATC |
|
0-L |
D07BC01 |
betamethasone and antiseptics |
WHO ATC |
|
0-L |
D07BC02 |
fluocinolone acetonide and antiseptics |
WHO ATC |
|
0-L |
D07BC03 |
fluocortolone and antiseptics |
WHO ATC |
|
0-L |
D07BC04 |
diflucortolone and antiseptics |
WHO ATC |
|
0-L |
D07BD |
Corticosteroids, very potent, combinations with antiseptics |
WHO ATC |
|
0-L |
D07C |
CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS |
WHO ATC |
|
0-L |
D07CA |
Corticosteroids, weak, combinations with antibiotics |
WHO ATC |
|
0-L |
D07CA01 |
hydrocortisone and antibiotics |
WHO ATC |
|
0-L |
D07CA02 |
methylprednisolone and antibiotics |
WHO ATC |
|
0-L |
D07CA03 |
prednisolone and antibiotics |
WHO ATC |
|
0-L |
D07CB |
Corticosteroids, moderately potent, combinations with antibiotics |
WHO ATC |
|
0-L |
D07CB01 |
triamcinolone and antibiotics |
WHO ATC |
|
0-L |
D07CB02 |
fluprednidene and antibiotics |
WHO ATC |
|
0-L |
D07CB03 |
fluorometholone and antibiotics |
WHO ATC |
|
0-L |
D07CB04 |
dexamethasone and antibiotics |
WHO ATC |
|
0-L |
D07CB05 |
flumetasone and antibiotics |
WHO ATC |
|
0-L |
D07CC |
Corticosteroids, potent, combinations with antibiotics |
WHO ATC |
|
0-L |
D07CC01 |
betamethasone and antibiotics |
WHO ATC |
|
0-L |
D07CC02 |
fluocinolone acetonide and antibiotics |
WHO ATC |
|
0-L |
D07CC03 |
fludroxycortide and antibiotics |
WHO ATC |
|
0-L |
D07CC04 |
beclometasone and antibiotics |
WHO ATC |
|
0-L |
D07CC05 |
fluocinonide and antibiotics |
WHO ATC |
|
0-L |
D07CC06 |
fluocortolone and antibiotics |
WHO ATC |
|
0-L |
D07CD |
Corticosteroids, very potent, combinations with antibiotics |
WHO ATC |
|
0-L |
D07CD01 |
clobetasol and antibiotics |
WHO ATC |
|
0-L |
D07X |
CORTICOSTEROIDS, OTHER COMBINATIONS |
WHO ATC |
|
0-L |
D07XA |
Corticosteroids, weak, other combinations |
WHO ATC |
|
0-L |
D07XA01 |
hydrocortisone |
WHO ATC |
|
0-L |
D07XA02 |
prednisolone |
WHO ATC |
|
0-L |
D07XB |
Corticosteroids, moderately potent, other combinations |
WHO ATC |
|
0-L |
D07XB01 |
flumetasone |
WHO ATC |
|
0-L |
D07XB02 |
triamcinolone |
WHO ATC |
|
0-L |
D07XB03 |
fluprednidene |
WHO ATC |
|
0-L |
D07XB04 |
fluorometholone |
WHO ATC |
|
0-L |
D07XB05 |
dexamethasone |
WHO ATC |
|
0-L |
D07XB30 |
combinations of corticosteroids |
WHO ATC |
|
0-L |
D07XC |
Corticosteroids, potent, other combinations |
WHO ATC |
|
0-L |
D07XC01 |
betamethasone |
WHO ATC |
|
0-L |
D07XC02 |
desoximetasone |
WHO ATC |
|
0-L |
D07XC03 |
mometasone |
WHO ATC |
|
0-L |
D07XC04 |
diflucortolone |
WHO ATC |
|
0-L |
D07XD |
Corticosteroids, very potent, other combinations |
WHO ATC |
|
0-L |
D08 |
ANTISEPTICS AND DISINFECTANTS |
WHO ATC |
|
0-L |
D08A |
ANTISEPTICS AND DISINFECTANTS |
WHO ATC |
|
0-L |
D08AA |
Acridine derivatives |
WHO ATC |
|
0-L |
D08AA01 |
ethacridine lactate |
WHO ATC |
|
0-L |
D08AA02 |
aminoacridine |
WHO ATC |
|
0-L |
D08AA03 |
euflavine |
WHO ATC |
|
0-L |
D08AB |
Aluminium agents |
WHO ATC |
|
0-L |
D08AC |
Biguanides and amidines |
WHO ATC |
|
0-L |
D08AC01 |
dibrompropamidine |
WHO ATC |
|
0-L |
D08AC02 |
chlorhexidine |
WHO ATC |
|
0-L |
D08AC03 |
propamidine |
WHO ATC |
|
0-L |
D08AC04 |
hexamidine |
WHO ATC |
|
0-L |
D08AC05 |
polihexanide |
WHO ATC |
|
0-L |
D08AC52 |
chlorhexidine, combinations |
WHO ATC |
|
0-L |
D08AD |
Boric acid products |
WHO ATC |
|
0-L |
D08AE |
Phenol and derivatives |
WHO ATC |
|
0-L |
D08AE01 |
hexachlorophene |
WHO ATC |
|
0-L |
D08AE02 |
policresulen |
WHO ATC |
|
0-L |
D08AE03 |
phenol |
WHO ATC |
|
0-L |
D08AE04 |
triclosan |
WHO ATC |
|
0-L |
D08AE05 |
chloroxylenol |
WHO ATC |
|
0-L |
D08AE06 |
biphenylol |
WHO ATC |
|
0-L |
D08AF |
Nitrofuran derivatives |
WHO ATC |
|
0-L |
D08AF01 |
nitrofural |
WHO ATC |
|
0-L |
D08AG |
Iodine products |
WHO ATC |
|
0-L |
D08AG01 |
iodine/octylphenoxypolyglycolether |
WHO ATC |
|
0-L |
D08AG02 |
povidone-iodine |
WHO ATC |
|
0-L |
D08AG03 |
iodine |
WHO ATC |
|
0-L |
D08AG04 |
diiodohydroxypropane |
WHO ATC |
|
0-L |
D08AH |
Quinoline derivatives |
WHO ATC |
|
0-L |
D08AH01 |
dequalinium |
WHO ATC |
|
0-L |
D08AH02 |
chlorquinaldol |
WHO ATC |
|
0-L |
D08AH03 |
oxyquinoline |
WHO ATC |
|
0-L |
D08AH30 |
clioquinol |
WHO ATC |
|
0-L |
D08AJ |
Quaternary ammonium compounds |
WHO ATC |
|
0-L |
D08AJ01 |
benzalkonium |
WHO ATC |
|
0-L |
D08AJ02 |
cetrimonium |
WHO ATC |
|
0-L |
D08AJ03 |
cetylpyridinium |
WHO ATC |
|
0-L |
D08AJ04 |
cetrimide |
WHO ATC |
|
0-L |
D08AJ05 |
benzoxonium chloride |
WHO ATC |
|
0-L |
D08AJ06 |
didecyldimethylammonium chloride |
WHO ATC |
|
0-L |
D08AJ08 |
benzethonium chloride |
WHO ATC |
|
0-L |
D08AJ57 |
octenidine, combinations |
WHO ATC |
|
0-L |
D08AJ58 |
benzethonium chloride, combinations |
WHO ATC |
|
0-L |
D08AJ59 |
dodeclonium bromide, combinations |
WHO ATC |
|
0-L |
D08AK |
Mercurial products |
WHO ATC |
|
0-L |
D08AK01 |
mercuric amidochloride |
WHO ATC |
|
0-L |
D08AK02 |
phenylmercuric borate |
WHO ATC |
|
0-L |
D08AK03 |
mercuric chloride |
WHO ATC |
|
0-L |
D08AK04 |
mercurochrome |
WHO ATC |
|
0-L |
D08AK05 |
mercury, metallic |
WHO ATC |
|
0-L |
D08AK06 |
thiomersal |
WHO ATC |
|
0-L |
D08AK30 |
mercuric iodide |
WHO ATC |
|
0-L |
D08AL |
Silver compounds |
WHO ATC |
|
0-L |
D08AL01 |
silver nitrate |
WHO ATC |
|
0-L |
D08AL30 |
silver |
WHO ATC |
|
0-L |
D08AX |
Other antiseptics and disinfectants |
WHO ATC |
|
0-L |
D08AX01 |
hydrogen peroxide |
WHO ATC |
|
0-L |
D08AX02 |
eosin |
WHO ATC |
|
0-L |
D08AX03 |
propanol |
WHO ATC |
|
0-L |
D08AX04 |
tosylchloramide sodium |
WHO ATC |
|
0-L |
D08AX05 |
isopropanol |
WHO ATC |
|
0-L |
D08AX06 |
potassium permanganate |
WHO ATC |
|
0-L |
D08AX07 |
sodium hypochlorite |
WHO ATC |
|
0-L |
D08AX08 |
ethanol |
WHO ATC |
|
0-L |
D08AX53 |
propanol, combinations |
WHO ATC |
|
0-L |
D09 |
MEDICATED DRESSINGS |
WHO ATC |
|
0-L |
D09A |
MEDICATED DRESSINGS |
WHO ATC |
|
0-L |
D09AA |
Medicated dressings with antiinfectives |
WHO ATC |
|
0-L |
D09AA01 |
framycetin |
WHO ATC |
|
0-L |
D09AA02 |
fusidic acid |
WHO ATC |
|
0-L |
D09AA03 |
nitrofural |
WHO ATC |
|
0-L |
D09AA04 |
phenylmercuric nitrate |
WHO ATC |
|
0-L |
D09AA05 |
benzododecinium |
WHO ATC |
|
0-L |
D09AA06 |
triclosan |
WHO ATC |
|
0-L |
D09AA07 |
cetylpyridinium |
WHO ATC |
|
0-L |
D09AA08 |
aluminium chlorohydrate |
WHO ATC |
|
0-L |
D09AA09 |
povidone-iodine |
WHO ATC |
|
0-L |
D09AA10 |
clioquinol |
WHO ATC |
|
0-L |
D09AA11 |
benzalkonium |
WHO ATC |
|
0-L |
D09AA12 |
chlorhexidine |
WHO ATC |
|
0-L |
D09AA13 |
iodoform |
WHO ATC |
|
0-L |
D09AB |
Zinc bandages |
WHO ATC |
|
0-L |
D09AB01 |
zinc bandage without supplements |
WHO ATC |
|
0-L |
D09AB02 |
zinc bandage with supplements |
WHO ATC |
|
0-L |
D09AX |
Soft paraffin dressings |
WHO ATC |
|
0-L |
D10 |
ANTI-ACNE PREPARATIONS |
WHO ATC |
|
0-L |
D10A |
ANTI-ACNE PREPARATIONS FOR TOPICAL USE |
WHO ATC |
|
0-L |
D10AA |
Corticosteroids, combinations for treatment of acne |
WHO ATC |
|
0-L |
D10AA01 |
fluorometholone |
WHO ATC |
|
0-L |
D10AA02 |
methylprednisolone |
WHO ATC |
|
0-L |
D10AA03 |
dexamethasone |
WHO ATC |
|
0-L |
D10AB |
Preparations containing sulfur |
WHO ATC |
|
0-L |
D10AB01 |
bithionol |
WHO ATC |
|
0-L |
D10AB02 |
sulfur |
WHO ATC |
|
0-L |
D10AB03 |
tioxolone |
WHO ATC |
|
0-L |
D10AB05 |
mesulfen |
WHO ATC |
|
0-L |
D10AD |
Retinoids for topical use in acne |
WHO ATC |
|
0-L |
D10AD01 |
tretinoin |
WHO ATC |
|
0-L |
D10AD02 |
retinol |
WHO ATC |
|
0-L |
D10AD03 |
adapalene |
WHO ATC |
|
0-L |
D10AD04 |
isotretinoin |
WHO ATC |
|
0-L |
D10AD05 |
motretinide |
WHO ATC |
|
0-L |
D10AD51 |
tretinoin, combinations |
WHO ATC |
|
0-L |
D10AD53 |
adapalene, combinations |
WHO ATC |
|
0-L |
D10AD54 |
isotretinoin, combinations |
WHO ATC |
|
0-L |
D10AE |
Peroxides |
WHO ATC |
|
0-L |
D10AE01 |
benzoyl peroxide |
WHO ATC |
|
0-L |
D10AE51 |
benzoyl peroxide, combinations |
WHO ATC |
|
0-L |
D10AF |
Antiinfectives for treatment of acne |
WHO ATC |
|
0-L |
D10AF01 |
clindamycin |
WHO ATC |
|
0-L |
D10AF02 |
erythromycin |
WHO ATC |
|
0-L |
D10AF03 |
chloramphenicol |
WHO ATC |
|
0-L |
D10AF04 |
meclocycline |
WHO ATC |
|
0-L |
D10AF51 |
clindamycin, combinations |
WHO ATC |
|
0-L |
D10AF52 |
erythromycin, combinations |
WHO ATC |
|
0-L |
D10AX |
Other anti-acne preparations for topical use |
WHO ATC |
|
0-L |
D10AX01 |
aluminium chloride |
WHO ATC |
|
0-L |
D10AX02 |
resorcinol |
WHO ATC |
|
0-L |
D10AX03 |
azelaic acid |
WHO ATC |
|
0-L |
D10AX04 |
aluminium oxide |
WHO ATC |
|
0-L |
D10AX05 |
dapsone |
WHO ATC |
|
0-L |
D10AX30 |
various combinations |
WHO ATC |
|
0-L |
D10B |
ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
D10BA |
Retinoids for treatment of acne |
WHO ATC |
|
0-L |
D10BA01 |
isotretinoin |
WHO ATC |
|
0-L |
D10BX |
Other anti-acne preparations for systemic use |
WHO ATC |
|
0-L |
D10BX01 |
ichtasol |
WHO ATC |
|
0-L |
D11 |
OTHER DERMATOLOGICAL PREPARATIONS |
WHO ATC |
|
0-L |
D11A |
OTHER DERMATOLOGICAL PREPARATIONS |
WHO ATC |
|
0-L |
D11AA |
Antihidrotics |
WHO ATC |
|
0-L |
D11AC |
Medicated shampoos |
WHO ATC |
|
0-L |
D11AC01 |
cetrimide |
WHO ATC |
|
0-L |
D11AC02 |
cadmium compounds |
WHO ATC |
|
0-L |
D11AC03 |
selenium compounds |
WHO ATC |
|
0-L |
D11AC06 |
povidone-iodine |
WHO ATC |
|
0-L |
D11AC08 |
sulfur compounds |
WHO ATC |
|
0-L |
D11AC09 |
xenysalate |
WHO ATC |
|
0-L |
D11AC30 |
others |
WHO ATC |
|
0-L |
D11AE |
Androgens for topical use |
WHO ATC |
|
0-L |
D11AE01 |
metandienone |
WHO ATC |
|
0-L |
D11AF |
Wart and anti-corn preparations |
WHO ATC |
|
0-L |
D11AH |
Agents for atopic dermatitis, excluding corticosteroids |
WHO ATC |
|
0-L |
D11AH01 |
tacrolimus |
WHO ATC |
|
0-L |
D11AH02 |
pimecrolimus |
WHO ATC |
|
0-L |
D11AH03 |
cromoglicic acid |
WHO ATC |
|
0-L |
D11AX |
Other dermatologicals |
WHO ATC |
|
0-L |
D11AX01 |
minoxidil |
WHO ATC |
|
0-L |
D11AX02 |
gamolenic acid |
WHO ATC |
|
0-L |
D11AX03 |
calcium gluconate |
WHO ATC |
|
0-L |
D11AX04 |
lithium succinate |
WHO ATC |
|
0-L |
D11AX05 |
magnesium sulfate |
WHO ATC |
|
0-L |
D11AX06 |
mequinol |
WHO ATC |
|
0-L |
D11AX08 |
tiratricol |
WHO ATC |
|
0-L |
D11AX09 |
oxaceprol |
WHO ATC |
|
0-L |
D11AX10 |
finasteride |
WHO ATC |
|
0-L |
D11AX11 |
hydroquinone |
WHO ATC |
|
0-L |
D11AX12 |
pyrithione zinc |
WHO ATC |
|
0-L |
D11AX13 |
monobenzone |
WHO ATC |
|
0-L |
D11AX16 |
eflornithine |
WHO ATC |
|
0-L |
D11AX18 |
diclofenac |
WHO ATC |
|
0-L |
D11AX19 |
alitretinoin |
WHO ATC |
|
0-L |
D11AX52 |
gamolenic acid, combinations |
WHO ATC |
|
0-L |
D11AX57 |
collagen, combinations |
WHO ATC |
|
0-L |
G |
GENITO URINARY SYSTEM AND SEX HORMONES |
WHO ATC |
|
0-L |
G01 |
GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS |
WHO ATC |
|
0-L |
G01A |
ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONSWITH CORTICOSTEROIDS |
WHO ATC |
|
0-L |
G01AA |
Antibiotics |
WHO ATC |
|
0-L |
G01AA01 |
nystatin |
WHO ATC |
|
0-L |
G01AA02 |
natamycin |
WHO ATC |
|
0-L |
G01AA03 |
amphotericin B |
WHO ATC |
|
0-L |
G01AA04 |
candicidin |
WHO ATC |
|
0-L |
G01AA05 |
chloramphenicol |
WHO ATC |
|
0-L |
G01AA06 |
hachimycin |
WHO ATC |
|
0-L |
G01AA07 |
oxytetracycline |
WHO ATC |
|
0-L |
G01AA08 |
carfecillin |
WHO ATC |
|
0-L |
G01AA09 |
mepartricin |
WHO ATC |
|
0-L |
G01AA10 |
clindamycin |
WHO ATC |
|
0-L |
G01AA11 |
pentamycin |
WHO ATC |
|
0-L |
G01AA51 |
nystatin, combinations |
WHO ATC |
|
0-L |
G01AB |
Arsenic compounds |
WHO ATC |
|
0-L |
G01AB01 |
acetarsol |
WHO ATC |
|
0-L |
G01AC |
Quinoline derivatives |
WHO ATC |
|
0-L |
G01AC01 |
diiodohydroxyquinoline |
WHO ATC |
|
0-L |
G01AC02 |
clioquinol |
WHO ATC |
|
0-L |
G01AC03 |
chlorquinaldol |
WHO ATC |
|
0-L |
G01AC05 |
dequalinium |
WHO ATC |
|
0-L |
G01AC06 |
broxyquinoline |
WHO ATC |
|
0-L |
G01AC30 |
oxyquinoline |
WHO ATC |
|
0-L |
G01AD |
Organic acids |
WHO ATC |
|
0-L |
G01AD01 |
lactic acid |
WHO ATC |
|
0-L |
G01AD02 |
acetic acid |
WHO ATC |
|
0-L |
G01AD03 |
ascorbic acid |
WHO ATC |
|
0-L |
G01AE |
Sulfonamides |
WHO ATC |
|
0-L |
G01AE01 |
sulfatolamide |
WHO ATC |
|
0-L |
G01AE10 |
combinations of sulfonamides |
WHO ATC |
|
0-L |
G01AF |
Imidazole derivatives |
WHO ATC |
|
0-L |
G01AF01 |
metronidazole |
WHO ATC |
|
0-L |
G01AF02 |
clotrimazole |
WHO ATC |
|
0-L |
G01AF04 |
miconazole |
WHO ATC |
|
0-L |
G01AF05 |
econazole |
WHO ATC |
|
0-L |
G01AF06 |
ornidazole |
WHO ATC |
|
0-L |
G01AF07 |
isoconazole |
WHO ATC |
|
0-L |
G01AF08 |
tioconazole |
WHO ATC |
|
0-L |
G01AF11 |
ketoconazole |
WHO ATC |
|
0-L |
G01AF12 |
fenticonazole |
WHO ATC |
|
0-L |
G01AF13 |
azanidazole |
WHO ATC |
|
0-L |
G01AF14 |
propenidazole |
WHO ATC |
|
0-L |
G01AF15 |
butoconazole |
WHO ATC |
|
0-L |
G01AF16 |
omoconazole |
WHO ATC |
|
0-L |
G01AF17 |
oxiconazole |
WHO ATC |
|
0-L |
G01AF18 |
flutrimazole |
WHO ATC |
|
0-L |
G01AF20 |
combinations of imidazole derivatives |
WHO ATC |
|
0-L |
G01AG |
Triazole derivatives |
WHO ATC |
|
0-L |
G01AG02 |
terconazole |
WHO ATC |
|
0-L |
G01AX |
Other antiinfectives and antiseptics |
WHO ATC |
|
0-L |
G01AX01 |
clodantoin |
WHO ATC |
|
0-L |
G01AX02 |
inosine |
WHO ATC |
|
0-L |
G01AX03 |
policresulen |
WHO ATC |
|
0-L |
G01AX05 |
nifuratel |
WHO ATC |
|
0-L |
G01AX06 |
furazolidone |
WHO ATC |
|
0-L |
G01AX09 |
methylrosaniline |
WHO ATC |
|
0-L |
G01AX11 |
povidone-iodine |
WHO ATC |
|
0-L |
G01AX12 |
ciclopirox |
WHO ATC |
|
0-L |
G01AX13 |
protiofate |
WHO ATC |
|
0-L |
G01AX14 |
lactobacillus fermentum |
WHO ATC |
|
0-L |
G01AX15 |
copper usnate |
WHO ATC |
|
0-L |
G01AX66 |
octenidine, combinations |
WHO ATC |
|
0-L |
G01B |
ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS |
WHO ATC |
|
0-L |
G01BA |
Antibiotics and corticosteroids |
WHO ATC |
|
0-L |
G01BC |
Quinoline derivatives and corticosteroids |
WHO ATC |
|
0-L |
G01BD |
Antiseptics and corticosteroids |
WHO ATC |
|
0-L |
G01BE |
Sulfonamides and corticosteroids |
WHO ATC |
|
0-L |
G01BF |
Imidazole derivatives and corticosteroids |
WHO ATC |
|
0-L |
G02 |
OTHER GYNECOLOGICALS |
WHO ATC |
|
0-L |
G02A |
OXYTOCICS |
WHO ATC |
|
0-L |
G02AB |
Ergot alkaloids |
WHO ATC |
|
0-L |
G02AB01 |
methylergometrine |
WHO ATC |
|
0-L |
G02AB02 |
ergot alkaloids |
WHO ATC |
|
0-L |
G02AB03 |
ergometrine |
WHO ATC |
|
0-L |
G02AC |
Ergot alkaloids and oxytocin incl. analogues, in combination |
WHO ATC |
|
0-L |
G02AC01 |
methylergometrine and oxytocin |
WHO ATC |
|
0-L |
G02AD |
Prostaglandins |
WHO ATC |
|
0-L |
G02AD01 |
dinoprost |
WHO ATC |
|
0-L |
G02AD02 |
dinoprostone |
WHO ATC |
|
0-L |
G02AD03 |
gemeprost |
WHO ATC |
|
0-L |
G02AD04 |
carboprost |
WHO ATC |
|
0-L |
G02AD05 |
sulprostone |
WHO ATC |
|
0-L |
G02AD06 |
misoprostol |
WHO ATC |
|
0-L |
G02AX |
Other oxytocics |
WHO ATC |
|
0-L |
G02B |
CONTRACEPTIVES FOR TOPICAL USE |
WHO ATC |
|
0-L |
G02BA |
Intrauterine contraceptives |
WHO ATC |
|
0-L |
G02BA01 |
plastic IUD |
WHO ATC |
|
0-L |
G02BA02 |
plastic IUD with copper |
WHO ATC |
|
0-L |
G02BA03 |
plastic IUD with progestogen |
WHO ATC |
|
0-L |
G02BB |
Intravaginal contraceptives |
WHO ATC |
|
0-L |
G02BB01 |
vaginal ring with progestogen and estrogen |
WHO ATC |
|
0-L |
G02C |
OTHER GYNECOLOGICALS |
WHO ATC |
|
0-L |
G02CA |
Sympathomimetics, labour repressants |
WHO ATC |
|
0-L |
G02CA01 |
ritodrine |
WHO ATC |
|
0-L |
G02CA02 |
buphenine |
WHO ATC |
|
0-L |
G02CA03 |
fenoterol |
WHO ATC |
|
0-L |
G02CB |
Prolactine inhibitors |
WHO ATC |
|
0-L |
G02CB01 |
bromocriptine |
WHO ATC |
|
0-L |
G02CB02 |
lisuride |
WHO ATC |
|
0-L |
G02CB03 |
cabergoline |
WHO ATC |
|
0-L |
G02CB04 |
quinagolide |
WHO ATC |
|
0-L |
G02CB05 |
metergoline |
WHO ATC |
|
0-L |
G02CB06 |
terguride |
WHO ATC |
|
0-L |
G02CC |
Antiinflammatory products for vaginal administration |
WHO ATC |
|
0-L |
G02CC01 |
ibuprofen |
WHO ATC |
|
0-L |
G02CC02 |
naproxen |
WHO ATC |
|
0-L |
G02CC03 |
benzydamine |
WHO ATC |
|
0-L |
G02CC04 |
flunoxaprofen |
WHO ATC |
|
0-L |
G02CX |
Other gynecologicals |
WHO ATC |
|
0-L |
G02CX01 |
atosiban |
WHO ATC |
|
0-L |
G03 |
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM |
WHO ATC |
|
0-L |
G03A |
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
G03AA |
Progestogens and estrogens, fixed combinations |
WHO ATC |
|
0-L |
G03AA01 |
etynodiol and estrogen |
WHO ATC |
|
0-L |
G03AA02 |
quingestanol and estrogen |
WHO ATC |
|
0-L |
G03AA03 |
lynestrenol and estrogen |
WHO ATC |
|
0-L |
G03AA04 |
megestrol and estrogen |
WHO ATC |
|
0-L |
G03AA05 |
norethisterone and estrogen |
WHO ATC |
|
0-L |
G03AA06 |
norgestrel and estrogen |
WHO ATC |
|
0-L |
G03AA07 |
levonorgestrel and estrogen |
WHO ATC |
|
0-L |
G03AA08 |
medroxyprogesterone and estrogen |
WHO ATC |
|
0-L |
G03AA09 |
desogestrel and estrogen |
WHO ATC |
|
0-L |
G03AA10 |
gestodene and estrogen |
WHO ATC |
|
0-L |
G03AA11 |
norgestimate and estrogen |
WHO ATC |
|
0-L |
G03AA12 |
drospirenone and estrogen |
WHO ATC |
|
0-L |
G03AA13 |
norelgestromin and estrogen |
WHO ATC |
|
0-L |
G03AA14 |
nomegestrol and estrogen |
WHO ATC |
|
0-L |
G03AB |
Progestogens and estrogens, sequential preparations |
WHO ATC |
|
0-L |
G03AB01 |
megestrol and estrogen |
WHO ATC |
|
0-L |
G03AB02 |
lynestrenol and estrogen |
WHO ATC |
|
0-L |
G03AB03 |
levonorgestrel and estrogen |
WHO ATC |
|
0-L |
G03AB04 |
norethisterone and estrogen |
WHO ATC |
|
0-L |
G03AB05 |
desogestrel and estrogen |
WHO ATC |
|
0-L |
G03AB06 |
gestodene and estrogen |
WHO ATC |
|
0-L |
G03AB07 |
chlormadinone and estrogen |
WHO ATC |
|
0-L |
G03AC |
Progestogens |
WHO ATC |
|
0-L |
G03AC01 |
norethisterone |
WHO ATC |
|
0-L |
G03AC02 |
lynestrenol |
WHO ATC |
|
0-L |
G03AC03 |
levonorgestrel |
WHO ATC |
|
0-L |
G03AC04 |
quingestanol |
WHO ATC |
|
0-L |
G03AC05 |
megestrol |
WHO ATC |
|
0-L |
G03AC06 |
medroxyprogesterone |
WHO ATC |
|
0-L |
G03AC07 |
norgestrienone |
WHO ATC |
|
0-L |
G03AC08 |
etonogestrel |
WHO ATC |
|
0-L |
G03AC09 |
desogestrel |
WHO ATC |
|
0-L |
G03B |
ANDROGENS |
WHO ATC |
|
0-L |
G03BA |
3-oxoandrosten (4) derivatives |
WHO ATC |
|
0-L |
G03BA01 |
fluoxymesterone |
WHO ATC |
|
0-L |
G03BA02 |
methyltestosterone |
WHO ATC |
|
0-L |
G03BA03 |
testosterone |
WHO ATC |
|
0-L |
G03BB |
5-androstanon (3) derivatives |
WHO ATC |
|
0-L |
G03BB01 |
mesterolone |
WHO ATC |
|
0-L |
G03BB02 |
androstanolone |
WHO ATC |
|
0-L |
G03C |
ESTROGENS |
WHO ATC |
|
0-L |
G03CA |
Natural and semisynthetic estrogens, plain |
WHO ATC |
|
0-L |
G03CA01 |
ethinylestradiol |
WHO ATC |
|
0-L |
G03CA03 |
estradiol |
WHO ATC |
|
0-L |
G03CA04 |
estriol |
WHO ATC |
|
0-L |
G03CA06 |
chlorotrianisene |
WHO ATC |
|
0-L |
G03CA07 |
estrone |
WHO ATC |
|
0-L |
G03CA09 |
promestriene |
WHO ATC |
|
0-L |
G03CA53 |
estradiol, combinations |
WHO ATC |
|
0-L |
G03CA57 |
conjugated estrogens |
WHO ATC |
|
0-L |
G03CB |
Synthetic estrogens, plain |
WHO ATC |
|
0-L |
G03CB01 |
dienestrol |
WHO ATC |
|
0-L |
G03CB02 |
diethylstilbestrol |
WHO ATC |
|
0-L |
G03CB03 |
methallenestril |
WHO ATC |
|
0-L |
G03CB04 |
moxestrol |
WHO ATC |
|
0-L |
G03CC |
Estrogens, combinations with other drugs |
WHO ATC |
|
0-L |
G03CC02 |
dienestrol |
WHO ATC |
|
0-L |
G03CC03 |
methallenestril |
WHO ATC |
|
0-L |
G03CC04 |
estrone |
WHO ATC |
|
0-L |
G03CC05 |
diethylstilbestrol |
WHO ATC |
|
0-L |
G03CC06 |
estriol |
WHO ATC |
|
0-L |
G03CX |
Other estrogens |
WHO ATC |
|
0-L |
G03CX01 |
tibolone |
WHO ATC |
|
0-L |
G03D |
PROGESTOGENS |
WHO ATC |
|
0-L |
G03DA |
Pregnen (4) derivatives |
WHO ATC |
|
0-L |
G03DA01 |
gestonorone |
WHO ATC |
|
0-L |
G03DA02 |
medroxyprogesterone |
WHO ATC |
|
0-L |
G03DA03 |
hydroxyprogesterone |
WHO ATC |
|
0-L |
G03DA04 |
progesterone |
WHO ATC |
|
0-L |
G03DB |
Pregnadien derivatives |
WHO ATC |
|
0-L |
G03DB01 |
dydrogesterone |
WHO ATC |
|
0-L |
G03DB02 |
megestrol |
WHO ATC |
|
0-L |
G03DB03 |
medrogestone |
WHO ATC |
|
0-L |
G03DB04 |
nomegestrol |
WHO ATC |
|
0-L |
G03DB05 |
demegestone |
WHO ATC |
|
0-L |
G03DB06 |
chlormadinone |
WHO ATC |
|
0-L |
G03DB07 |
promegestone |
WHO ATC |
|
0-L |
G03DC |
Estren derivatives |
WHO ATC |
|
0-L |
G03DC01 |
allylestrenol |
WHO ATC |
|
0-L |
G03DC02 |
norethisterone |
WHO ATC |
|
0-L |
G03DC03 |
lynestrenol |
WHO ATC |
|
0-L |
G03DC04 |
ethisterone |
WHO ATC |
|
0-L |
G03DC06 |
etynodiol |
WHO ATC |
|
0-L |
G03DC31 |
methylestrenolone |
WHO ATC |
|
0-L |
G03E |
ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION |
WHO ATC |
|
0-L |
G03EA |
Androgens and estrogens |
WHO ATC |
|
0-L |
G03EA01 |
methyltestosterone and estrogen |
WHO ATC |
|
0-L |
G03EA02 |
testosterone and estrogen |
WHO ATC |
|
0-L |
G03EA03 |
prasterone and estrogen |
WHO ATC |
|
0-L |
G03EB |
Androgen, progestogen and estrogen in combination |
WHO ATC |
|
0-L |
G03EK |
Androgens and female sex hormones in combination with other drugs |
WHO ATC |
|
0-L |
G03EK01 |
methyltestosterone |
WHO ATC |
|
0-L |
G03F |
PROGESTOGENS AND ESTROGENS IN COMBINATION |
WHO ATC |
|
0-L |
G03FA |
Progestogens and estrogens, fixed combinations |
WHO ATC |
|
0-L |
G03FA01 |
norethisterone and estrogen |
WHO ATC |
|
0-L |
G03FA02 |
hydroxyprogesterone and estrogen |
WHO ATC |
|
0-L |
G03FA03 |
ethisterone and estrogen |
WHO ATC |
|
0-L |
G03FA04 |
progesterone and estrogen |
WHO ATC |
|
0-L |
G03FA05 |
methylnortestosterone and estrogen |
WHO ATC |
|
0-L |
G03FA06 |
etynodiol and estrogen |
WHO ATC |
|
0-L |
G03FA07 |
lynestrenol and estrogen |
WHO ATC |
|
0-L |
G03FA08 |
megestrol and estrogen |
WHO ATC |
|
0-L |
G03FA09 |
noretynodrel and estrogen |
WHO ATC |
|
0-L |
G03FA10 |
norgestrel and estrogen |
WHO ATC |
|
0-L |
G03FA11 |
levonorgestrel and estrogen |
WHO ATC |
|
0-L |
G03FA12 |
medroxyprogesterone and estrogen |
WHO ATC |
|
0-L |
G03FA13 |
norgestimate and estrogen |
WHO ATC |
|
0-L |
G03FA14 |
dydrogesterone and estrogen |
WHO ATC |
|
0-L |
G03FA15 |
dienogest and estrogen |
WHO ATC |
|
0-L |
G03FA16 |
trimegestone and estrogen |
WHO ATC |
|
0-L |
G03FA17 |
drospirenone and estrogen |
WHO ATC |
|
0-L |
G03FB |
Progestogens and estrogens, sequential preparations |
WHO ATC |
|
0-L |
G03FB01 |
norgestrel and estrogen |
WHO ATC |
|
0-L |
G03FB02 |
lynestrenol and estrogen |
WHO ATC |
|
0-L |
G03FB03 |
chlormadinone and estrogen |
WHO ATC |
|
0-L |
G03FB04 |
megestrol and estrogen |
WHO ATC |
|
0-L |
G03FB05 |
norethisterone and estrogen |
WHO ATC |
|
0-L |
G03FB06 |
medroxyprogesterone and estrogen |
WHO ATC |
|
0-L |
G03FB07 |
medrogestone and estrogen |
WHO ATC |
|
0-L |
G03FB08 |
dydrogesterone and estrogen |
WHO ATC |
|
0-L |
G03FB09 |
levonorgestrel and estrogen |
WHO ATC |
|
0-L |
G03FB10 |
desogestrel and estrogen |
WHO ATC |
|
0-L |
G03FB11 |
trimegestone and estrogen |
WHO ATC |
|
0-L |
G03G |
GONADOTROPINS AND OTHER OVULATION STIMULANTS |
WHO ATC |
|
0-L |
G03GA |
Gonadotropins |
WHO ATC |
|
0-L |
G03GA01 |
chorionic gonadotrophin |
WHO ATC |
|
0-L |
G03GA02 |
human menopausal gonadotrophin |
WHO ATC |
|
0-L |
G03GA03 |
serum gonadotrophin |
WHO ATC |
|
0-L |
G03GA04 |
urofollitropin |
WHO ATC |
|
0-L |
G03GA05 |
follitropin alfa |
WHO ATC |
|
0-L |
G03GA06 |
follitropin beta |
WHO ATC |
|
0-L |
G03GA07 |
lutropin alfa |
WHO ATC |
|
0-L |
G03GA08 |
choriogonadotropin alfa |
WHO ATC |
|
0-L |
G03GA09 |
corifollitropin alfa |
WHO ATC |
|
0-L |
G03GA30 |
combinations |
WHO ATC |
|
0-L |
G03GB |
Ovulation stimulants, synthetic |
WHO ATC |
|
0-L |
G03GB01 |
cyclofenil |
WHO ATC |
|
0-L |
G03GB02 |
clomifene |
WHO ATC |
|
0-L |
G03GB03 |
epimestrol |
WHO ATC |
|
0-L |
G03H |
ANTIANDROGENS |
WHO ATC |
|
0-L |
G03HA |
Antiandrogens, plain |
WHO ATC |
|
0-L |
G03HA01 |
cyproterone |
WHO ATC |
|
0-L |
G03HB |
Antiandrogens and estrogens |
WHO ATC |
|
0-L |
G03HB01 |
cyproterone and estrogen |
WHO ATC |
|
0-L |
G03X |
OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM |
WHO ATC |
|
0-L |
G03XA |
Antigonadotropins and similar agents |
WHO ATC |
|
0-L |
G03XA01 |
danazol |
WHO ATC |
|
0-L |
G03XA02 |
gestrinone |
WHO ATC |
|
0-L |
G03XB |
Antiprogestogens |
WHO ATC |
|
0-L |
G03XB01 |
mifepristone |
WHO ATC |
|
0-L |
G03XC |
Selective estrogen receptor modulators |
WHO ATC |
|
0-L |
G03XC01 |
raloxifene |
WHO ATC |
|
0-L |
G03XC02 |
bazedoxifene |
WHO ATC |
|
0-L |
G04 |
UROLOGICALS |
WHO ATC |
|
0-L |
G04B |
OTHER UROLOGICALS, INCL. ANTISPASMODICS |
WHO ATC |
|
0-L |
G04BA |
Acidifiers |
WHO ATC |
|
0-L |
G04BA01 |
ammonium chloride |
WHO ATC |
|
0-L |
G04BA03 |
calcium chloride |
WHO ATC |
|
0-L |
G04BC |
Urinary concrement solvents |
WHO ATC |
|
0-L |
G04BD |
Urinary antispasmodics |
WHO ATC |
|
0-L |
G04BD01 |
emepronium |
WHO ATC |
|
0-L |
G04BD02 |
flavoxate |
WHO ATC |
|
0-L |
G04BD03 |
meladrazine |
WHO ATC |
|
0-L |
G04BD04 |
oxybutynin |
WHO ATC |
|
0-L |
G04BD05 |
terodiline |
WHO ATC |
|
0-L |
G04BD06 |
propiverine |
WHO ATC |
|
0-L |
G04BD07 |
tolterodine |
WHO ATC |
|
0-L |
G04BD08 |
solifenacin |
WHO ATC |
|
0-L |
G04BD09 |
trospium |
WHO ATC |
|
0-L |
G04BD10 |
darifenacin |
WHO ATC |
|
0-L |
G04BD11 |
fesoterodine |
WHO ATC |
|
0-L |
G04BE |
Drugs used in erectile dysfunction |
WHO ATC |
|
0-L |
G04BE01 |
alprostadil |
WHO ATC |
|
0-L |
G04BE02 |
papaverine |
WHO ATC |
|
0-L |
G04BE03 |
sildenafil |
WHO ATC |
|
0-L |
G04BE04 |
yohimbine |
WHO ATC |
|
0-L |
G04BE05 |
phentolamine |
WHO ATC |
|
0-L |
G04BE06 |
moxisylyte |
WHO ATC |
|
0-L |
G04BE07 |
apomorphine |
WHO ATC |
|
0-L |
G04BE08 |
tadalafil |
WHO ATC |
|
0-L |
G04BE09 |
vardenafil |
WHO ATC |
|
0-L |
G04BE30 |
combinations |
WHO ATC |
|
0-L |
G04BE52 |
papaverine, combinations |
WHO ATC |
|
0-L |
G04BX |
Other urologicals |
WHO ATC |
|
0-L |
G04BX01 |
magnesium hydroxide |
WHO ATC |
|
0-L |
G04BX03 |
acetohydroxamic acid |
WHO ATC |
|
0-L |
G04BX06 |
phenazopyridine |
WHO ATC |
|
0-L |
G04BX10 |
succinimide |
WHO ATC |
|
0-L |
G04BX11 |
collagen |
WHO ATC |
|
0-L |
G04BX12 |
phenyl salicylate |
WHO ATC |
|
0-L |
G04BX13 |
dimethyl sulfoxide |
WHO ATC |
|
0-L |
G04BX14 |
dapoxetine |
WHO ATC |
|
0-L |
G04C |
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY |
WHO ATC |
|
0-L |
G04CA |
Alpha-adrenoreceptor antagonists |
WHO ATC |
|
0-L |
G04CA01 |
alfuzosin |
WHO ATC |
|
0-L |
G04CA02 |
tamsulosin |
WHO ATC |
|
0-L |
G04CA03 |
terazosin |
WHO ATC |
|
0-L |
G04CA04 |
silodosin |
WHO ATC |
|
0-L |
G04CA51 |
alfuzosin and finasteride |
WHO ATC |
|
0-L |
G04CA52 |
tamsulosin and dutasteride |
WHO ATC |
|
0-L |
G04CB |
Testosterone-5-alpha reductase inhibitors |
WHO ATC |
|
0-L |
G04CB01 |
finasteride |
WHO ATC |
|
0-L |
G04CB02 |
dutasteride |
WHO ATC |
|
0-L |
G04CX |
Other drugs used in benign prostatic hypertrophy |
WHO ATC |
|
0-L |
G04CX01 |
pygeum africanum |
WHO ATC |
|
0-L |
G04CX02 |
serenoa repens |
WHO ATC |
|
0-L |
G04CX03 |
mepartricin |
WHO ATC |
|
0-L |
H |
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS |
WHO ATC |
|
0-L |
H01 |
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES |
WHO ATC |
|
0-L |
H01A |
ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES |
WHO ATC |
|
0-L |
H01AA |
ACTH |
WHO ATC |
|
0-L |
H01AA01 |
corticotropin |
WHO ATC |
|
0-L |
H01AA02 |
tetracosactide |
WHO ATC |
|
0-L |
H01AB |
Thyrotropin |
WHO ATC |
|
0-L |
H01AB01 |
thyrotropin |
WHO ATC |
|
0-L |
H01AC |
Somatropin and somatropin agonists |
WHO ATC |
|
0-L |
H01AC01 |
somatropin |
WHO ATC |
|
0-L |
H01AC02 |
somatrem |
WHO ATC |
|
0-L |
H01AC03 |
mecasermin |
WHO ATC |
|
0-L |
H01AC04 |
sermorelin |
WHO ATC |
|
0-L |
H01AC05 |
mecasermin rinfabate |
WHO ATC |
|
0-L |
H01AX |
Other anterior pituitary lobe hormones and analogues |
WHO ATC |
|
0-L |
H01AX01 |
pegvisomant |
WHO ATC |
|
0-L |
H01B |
POSTERIOR PITUITARY LOBE HORMONES |
WHO ATC |
|
0-L |
H01BA |
Vasopressin and analogues |
WHO ATC |
|
0-L |
H01BA01 |
vasopressin |
WHO ATC |
|
0-L |
H01BA02 |
desmopressin |
WHO ATC |
|
0-L |
H01BA03 |
lypressin |
WHO ATC |
|
0-L |
H01BA04 |
terlipressin |
WHO ATC |
|
0-L |
H01BA05 |
ornipressin |
WHO ATC |
|
0-L |
H01BA06 |
argipressin |
WHO ATC |
|
0-L |
H01BB |
Oxytocin and analogues |
WHO ATC |
|
0-L |
H01BB01 |
demoxytocin |
WHO ATC |
|
0-L |
H01BB02 |
oxytocin |
WHO ATC |
|
0-L |
H01BB03 |
carbetocin |
WHO ATC |
|
0-L |
H01C |
HYPOTHALAMIC HORMONES |
WHO ATC |
|
0-L |
H01CA |
Gonadotropin-releasing hormones |
WHO ATC |
|
0-L |
H01CA01 |
gonadorelin |
WHO ATC |
|
0-L |
H01CA02 |
nafarelin |
WHO ATC |
|
0-L |
H01CA03 |
histrelin |
WHO ATC |
|
0-L |
H01CB |
Antigrowth hormones |
WHO ATC |
|
0-L |
H01CB01 |
somatostatin |
WHO ATC |
|
0-L |
H01CB02 |
octreotide |
WHO ATC |
|
0-L |
H01CB03 |
lanreotide |
WHO ATC |
|
0-L |
H01CB04 |
vapreotide |
WHO ATC |
|
0-L |
H01CC |
Anti-gonadotropin-releasing hormones |
WHO ATC |
|
0-L |
H01CC01 |
ganirelix |
WHO ATC |
|
0-L |
H01CC02 |
cetrorelix |
WHO ATC |
|
0-L |
H02 |
CORTICOSTEROIDS FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
H02A |
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN |
WHO ATC |
|
0-L |
H02AA |
Mineralocorticoids |
WHO ATC |
|
0-L |
H02AA01 |
aldosterone |
WHO ATC |
|
0-L |
H02AA02 |
fludrocortisone |
WHO ATC |
|
0-L |
H02AA03 |
desoxycortone |
WHO ATC |
|
0-L |
H02AB |
Glucocorticoids |
WHO ATC |
|
0-L |
H02AB01 |
betamethasone |
WHO ATC |
|
0-L |
H02AB02 |
dexamethasone |
WHO ATC |
|
0-L |
H02AB03 |
fluocortolone |
WHO ATC |
|
0-L |
H02AB04 |
methylprednisolone |
WHO ATC |
|
0-L |
H02AB05 |
paramethasone |
WHO ATC |
|
0-L |
H02AB06 |
prednisolone |
WHO ATC |
|
0-L |
H02AB07 |
prednisone |
WHO ATC |
|
0-L |
H02AB08 |
triamcinolone |
WHO ATC |
|
0-L |
H02AB09 |
hydrocortisone |
WHO ATC |
|
0-L |
H02AB10 |
cortisone |
WHO ATC |
|
0-L |
H02AB11 |
prednylidene |
WHO ATC |
|
0-L |
H02AB12 |
rimexolone |
WHO ATC |
|
0-L |
H02AB13 |
deflazacort |
WHO ATC |
|
0-L |
H02AB14 |
cloprednol |
WHO ATC |
|
0-L |
H02AB15 |
meprednisone |
WHO ATC |
|
0-L |
H02AB17 |
cortivazol |
WHO ATC |
|
0-L |
H02B |
CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS |
WHO ATC |
|
0-L |
H02BX |
Corticosteroids for systemic use, combinations |
WHO ATC |
|
0-L |
H02BX01 |
methylprednisolone, combinations |
WHO ATC |
|
0-L |
H02C |
ANTIADRENAL PREPARATIONS |
WHO ATC |
|
0-L |
H02CA |
Anticorticosteroids |
WHO ATC |
|
0-L |
H02CA01 |
trilostane |
WHO ATC |
|
0-L |
H03 |
THYROID THERAPY |
WHO ATC |
|
0-L |
H03A |
THYROID PREPARATIONS |
WHO ATC |
|
0-L |
H03AA |
Thyroid hormones |
WHO ATC |
|
0-L |
H03AA01 |
levothyroxine sodium |
WHO ATC |
|
0-L |
H03AA02 |
liothyronine sodium |
WHO ATC |
|
0-L |
H03AA03 |
combinations of levothyroxine and liothyronine |
WHO ATC |
|
0-L |
H03AA04 |
tiratricol |
WHO ATC |
|
0-L |
H03AA05 |
thyroid gland preparations |
WHO ATC |
|
0-L |
H03B |
ANTITHYROID PREPARATIONS |
WHO ATC |
|
0-L |
H03BA |
Thiouracils |
WHO ATC |
|
0-L |
H03BA01 |
methylthiouracil |
WHO ATC |
|
0-L |
H03BA02 |
propylthiouracil |
WHO ATC |
|
0-L |
H03BA03 |
benzylthiouracil |
WHO ATC |
|
0-L |
H03BB |
Sulfur-containing imidazole derivatives |
WHO ATC |
|
0-L |
H03BB01 |
carbimazole |
WHO ATC |
|
0-L |
H03BB02 |
thiamazole |
WHO ATC |
|
0-L |
H03BB52 |
thiamazole, combinations |
WHO ATC |
|
0-L |
H03BC |
Perchlorates |
WHO ATC |
|
0-L |
H03BC01 |
potassium perchlorate |
WHO ATC |
|
0-L |
H03BX |
Other antithyroid preparations |
WHO ATC |
|
0-L |
H03BX01 |
diiodotyrosine |
WHO ATC |
|
0-L |
H03BX02 |
dibromotyrosine |
WHO ATC |
|
0-L |
H03C |
IODINE THERAPY |
WHO ATC |
|
0-L |
H03CA |
Iodine therapy |
WHO ATC |
|
0-L |
H04 |
PANCREATIC HORMONES |
WHO ATC |
|
0-L |
H04A |
GLYCOGENOLYTIC HORMONES |
WHO ATC |
|
0-L |
H04AA |
Glycogenolytic hormones |
WHO ATC |
|
0-L |
H04AA01 |
glucagon |
WHO ATC |
|
0-L |
H05 |
CALCIUM HOMEOSTASIS |
WHO ATC |
|
0-L |
H05A |
PARATHYROID HORMONES AND ANALOGUES |
WHO ATC |
|
0-L |
H05AA |
Parathyroid hormones and analogues |
WHO ATC |
|
0-L |
H05AA01 |
parathyroid gland extract |
WHO ATC |
|
0-L |
H05AA02 |
teriparatide |
WHO ATC |
|
0-L |
H05AA03 |
parathyroid hormone |
WHO ATC |
|
0-L |
H05B |
ANTI-PARATHYROID AGENTS |
WHO ATC |
|
0-L |
H05BA |
Calcitonin preparations |
WHO ATC |
|
0-L |
H05BA01 |
calcitonin (salmon synthetic) |
WHO ATC |
|
0-L |
H05BA02 |
calcitonin (pork natural) |
WHO ATC |
|
0-L |
H05BA03 |
calcitonin (human synthetic) |
WHO ATC |
|
0-L |
H05BA04 |
elcatonin |
WHO ATC |
|
0-L |
H05BX |
Other anti-parathyroid agents |
WHO ATC |
|
0-L |
H05BX01 |
cinacalcet |
WHO ATC |
|
0-L |
H05BX02 |
paricalcitol |
WHO ATC |
|
0-L |
H05BX03 |
doxercalciferol |
WHO ATC |
|
0-L |
J |
ANTIINFECTIVES FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
J01 |
ANTIBACTERIALS FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
J01A |
TETRACYCLINES |
WHO ATC |
|
0-L |
J01AA |
Tetracyclines |
WHO ATC |
|
0-L |
J01AA01 |
demeclocycline |
WHO ATC |
|
0-L |
J01AA02 |
doxycycline |
WHO ATC |
|
0-L |
J01AA03 |
chlortetracycline |
WHO ATC |
|
0-L |
J01AA04 |
lymecycline |
WHO ATC |
|
0-L |
J01AA05 |
metacycline |
WHO ATC |
|
0-L |
J01AA06 |
oxytetracycline |
WHO ATC |
|
0-L |
J01AA07 |
tetracycline |
WHO ATC |
|
0-L |
J01AA08 |
minocycline |
WHO ATC |
|
0-L |
J01AA09 |
rolitetracycline |
WHO ATC |
|
0-L |
J01AA10 |
penimepicycline |
WHO ATC |
|
0-L |
J01AA11 |
clomocycline |
WHO ATC |
|
0-L |
J01AA12 |
tigecycline |
WHO ATC |
|
0-L |
J01AA20 |
combinations of tetracyclines |
WHO ATC |
|
0-L |
J01AA56 |
oxytetracycline, combinations |
WHO ATC |
|
0-L |
J01B |
AMPHENICOLS |
WHO ATC |
|
0-L |
J01BA |
Amphenicols |
WHO ATC |
|
0-L |
J01BA01 |
chloramphenicol |
WHO ATC |
|
0-L |
J01BA02 |
thiamphenicol |
WHO ATC |
|
0-L |
J01BA52 |
thiamphenicol, combinations |
WHO ATC |
|
0-L |
J01C |
BETA-LACTAM ANTIBACTERIALS, PENICILLINS |
WHO ATC |
|
0-L |
J01CA |
Penicillins with extended spectrum |
WHO ATC |
|
0-L |
J01CA01 |
ampicillin |
WHO ATC |
|
0-L |
J01CA02 |
pivampicillin |
WHO ATC |
|
0-L |
J01CA03 |
carbenicillin |
WHO ATC |
|
0-L |
J01CA04 |
amoxicillin |
WHO ATC |
|
0-L |
J01CA05 |
carindacillin |
WHO ATC |
|
0-L |
J01CA06 |
bacampicillin |
WHO ATC |
|
0-L |
J01CA07 |
epicillin |
WHO ATC |
|
0-L |
J01CA08 |
pivmecillinam |
WHO ATC |
|
0-L |
J01CA09 |
azlocillin |
WHO ATC |
|
0-L |
J01CA10 |
mezlocillin |
WHO ATC |
|
0-L |
J01CA11 |
mecillinam |
WHO ATC |
|
0-L |
J01CA12 |
piperacillin |
WHO ATC |
|
0-L |
J01CA13 |
ticarcillin |
WHO ATC |
|
0-L |
J01CA14 |
metampicillin |
WHO ATC |
|
0-L |
J01CA15 |
talampicillin |
WHO ATC |
|
0-L |
J01CA16 |
sulbenicillin |
WHO ATC |
|
0-L |
J01CA17 |
temocillin |
WHO ATC |
|
0-L |
J01CA18 |
hetacillin |
WHO ATC |
|
0-L |
J01CA20 |
combinations |
WHO ATC |
|
0-L |
J01CA51 |
ampicillin, combinations |
WHO ATC |
|
0-L |
J01CE |
Beta-lactamase sensitive penicillins |
WHO ATC |
|
0-L |
J01CE01 |
benzylpenicillin |
WHO ATC |
|
0-L |
J01CE02 |
phenoxymethylpenicillin |
WHO ATC |
|
0-L |
J01CE03 |
propicillin |
WHO ATC |
|
0-L |
J01CE04 |
azidocillin |
WHO ATC |
|
0-L |
J01CE05 |
pheneticillin |
WHO ATC |
|
0-L |
J01CE06 |
penamecillin |
WHO ATC |
|
0-L |
J01CE07 |
clometocillin |
WHO ATC |
|
0-L |
J01CE08 |
benzathine benzylpenicillin |
WHO ATC |
|
0-L |
J01CE09 |
procaine benzylpenicillin |
WHO ATC |
|
0-L |
J01CE10 |
benzathine phenoxymethylpenicillin |
WHO ATC |
|
0-L |
J01CE30 |
combinations |
WHO ATC |
|
0-L |
J01CF |
Beta-lactamase resistant penicillins |
WHO ATC |
|
0-L |
J01CF01 |
dicloxacillin |
WHO ATC |
|
0-L |
J01CF02 |
cloxacillin |
WHO ATC |
|
0-L |
J01CF03 |
meticillin |
WHO ATC |
|
0-L |
J01CF04 |
oxacillin |
WHO ATC |
|
0-L |
J01CF05 |
flucloxacillin |
WHO ATC |
|
0-L |
J01CG |
Beta-lactamase inhibitors |
WHO ATC |
|
0-L |
J01CG01 |
sulbactam |
WHO ATC |
|
0-L |
J01CG02 |
tazobactam |
WHO ATC |
|
0-L |
J01CR |
Combinations of penicillins, incl. beta-lactamase inhibitors |
WHO ATC |
|
0-L |
J01CR01 |
ampicillin and enzyme inhibitor |
WHO ATC |
|
0-L |
J01CR02 |
amoxicillin and enzyme inhibitor |
WHO ATC |
|
0-L |
J01CR03 |
ticarcillin and enzyme inhibitor |
WHO ATC |
|
0-L |
J01CR04 |
sultamicillin |
WHO ATC |
|
0-L |
J01CR05 |
piperacillin and enzyme inhibitor |
WHO ATC |
|
0-L |
J01CR50 |
combinations of penicillins |
WHO ATC |
|
0-L |
J01D |
OTHER BETA-LACTAM ANTIBACTERIALS |
WHO ATC |
|
0-L |
J01DB |
First-generation cephalosporins |
WHO ATC |
|
0-L |
J01DB01 |
cefalexin |
WHO ATC |
|
0-L |
J01DB02 |
cefaloridine |
WHO ATC |
|
0-L |
J01DB03 |
cefalotin |
WHO ATC |
|
0-L |
J01DB04 |
cefazolin |
WHO ATC |
|
0-L |
J01DB05 |
cefadroxil |
WHO ATC |
|
0-L |
J01DB06 |
cefazedone |
WHO ATC |
|
0-L |
J01DB07 |
cefatrizine |
WHO ATC |
|
0-L |
J01DB08 |
cefapirin |
WHO ATC |
|
0-L |
J01DB09 |
cefradine |
WHO ATC |
|
0-L |
J01DB10 |
cefacetrile |
WHO ATC |
|
0-L |
J01DB11 |
cefroxadine |
WHO ATC |
|
0-L |
J01DB12 |
ceftezole |
WHO ATC |
|
0-L |
J01DC |
Second-generation cephalosporins |
WHO ATC |
|
0-L |
J01DC01 |
cefoxitin |
WHO ATC |
|
0-L |
J01DC02 |
cefuroxime |
WHO ATC |
|
0-L |
J01DC03 |
cefamandole |
WHO ATC |
|
0-L |
J01DC04 |
cefaclor |
WHO ATC |
|
0-L |
J01DC05 |
cefotetan |
WHO ATC |
|
0-L |
J01DC06 |
cefonicid |
WHO ATC |
|
0-L |
J01DC07 |
cefotiam |
WHO ATC |
|
0-L |
J01DC08 |
loracarbef |
WHO ATC |
|
0-L |
J01DC09 |
cefmetazole |
WHO ATC |
|
0-L |
J01DC10 |
cefprozil |
WHO ATC |
|
0-L |
J01DC11 |
ceforanide |
WHO ATC |
|
0-L |
J01DD |
Third-generation cephalosporins |
WHO ATC |
|
0-L |
J01DD01 |
cefotaxime |
WHO ATC |
|
0-L |
J01DD02 |
ceftazidime |
WHO ATC |
|
0-L |
J01DD03 |
cefsulodin |
WHO ATC |
|
0-L |
J01DD04 |
ceftriaxone |
WHO ATC |
|
0-L |
J01DD05 |
cefmenoxime |
WHO ATC |
|
0-L |
J01DD06 |
latamoxef |
WHO ATC |
|
0-L |
J01DD07 |
ceftizoxime |
WHO ATC |
|
0-L |
J01DD08 |
cefixime |
WHO ATC |
|
0-L |
J01DD09 |
cefodizime |
WHO ATC |
|
0-L |
J01DD10 |
cefetamet |
WHO ATC |
|
0-L |
J01DD11 |
cefpiramide |
WHO ATC |
|
0-L |
J01DD12 |
cefoperazone |
WHO ATC |
|
0-L |
J01DD13 |
cefpodoxime |
WHO ATC |
|
0-L |
J01DD14 |
ceftibuten |
WHO ATC |
|
0-L |
J01DD15 |
cefdinir |
WHO ATC |
|
0-L |
J01DD16 |
cefditoren |
WHO ATC |
|
0-L |
J01DD17 |
cefcapene |
WHO ATC |
|
0-L |
J01DD54 |
ceftriaxone, combinations |
WHO ATC |
|
0-L |
J01DD62 |
cefoperazone, combinations |
WHO ATC |
|
0-L |
J01DE |
Fourth-generation cephalosporins |
WHO ATC |
|
0-L |
J01DE01 |
cefepime |
WHO ATC |
|
0-L |
J01DE02 |
cefpirome |
WHO ATC |
|
0-L |
J01DE03 |
cefozopran |
WHO ATC |
|
0-L |
J01DF |
Monobactams |
WHO ATC |
|
0-L |
J01DF01 |
aztreonam |
WHO ATC |
|
0-L |
J01DH |
Carbapenems |
WHO ATC |
|
0-L |
J01DH02 |
meropenem |
WHO ATC |
|
0-L |
J01DH03 |
ertapenem |
WHO ATC |
|
0-L |
J01DH04 |
doripenem |
WHO ATC |
|
0-L |
J01DH05 |
biapenem |
WHO ATC |
|
0-L |
J01DH51 |
imipenem and enzyme inhibitor |
WHO ATC |
|
0-L |
J01DH55 |
panipenem and betamipron |
WHO ATC |
|
0-L |
J01DI |
Other cephalosporins |
WHO ATC |
|
0-L |
J01DI01 |
ceftobiprole medocaril |
WHO ATC |
|
0-L |
J01E |
SULFONAMIDES AND TRIMETHOPRIM |
WHO ATC |
|
0-L |
J01EA |
Trimethoprim and derivatives |
WHO ATC |
|
0-L |
J01EA01 |
trimethoprim |
WHO ATC |
|
0-L |
J01EA02 |
brodimoprim |
WHO ATC |
|
0-L |
J01EA03 |
iclaprim |
WHO ATC |
|
0-L |
J01EB |
Short-acting sulfonamides |
WHO ATC |
|
0-L |
J01EB01 |
sulfaisodimidine |
WHO ATC |
|
0-L |
J01EB02 |
sulfamethizole |
WHO ATC |
|
0-L |
J01EB03 |
sulfadimidine |
WHO ATC |
|
0-L |
J01EB04 |
sulfapyridine |
WHO ATC |
|
0-L |
J01EB05 |
sulfafurazole |
WHO ATC |
|
0-L |
J01EB06 |
sulfanilamide |
WHO ATC |
|
0-L |
J01EB07 |
sulfathiazole |
WHO ATC |
|
0-L |
J01EB08 |
sulfathiourea |
WHO ATC |
|
0-L |
J01EB20 |
combinations |
WHO ATC |
|
0-L |
J01EC |
Intermediate-acting sulfonamides |
WHO ATC |
|
0-L |
J01EC01 |
sulfamethoxazole |
WHO ATC |
|
0-L |
J01EC02 |
sulfadiazine |
WHO ATC |
|
0-L |
J01EC03 |
sulfamoxole |
WHO ATC |
|
0-L |
J01EC20 |
combinations |
WHO ATC |
|
0-L |
J01ED |
Long-acting sulfonamides |
WHO ATC |
|
0-L |
J01ED01 |
sulfadimethoxine |
WHO ATC |
|
0-L |
J01ED02 |
sulfalene |
WHO ATC |
|
0-L |
J01ED03 |
sulfametomidine |
WHO ATC |
|
0-L |
J01ED04 |
sulfametoxydiazine |
WHO ATC |
|
0-L |
J01ED05 |
sulfamethoxypyridazine |
WHO ATC |
|
0-L |
J01ED06 |
sulfaperin |
WHO ATC |
|
0-L |
J01ED07 |
sulfamerazine |
WHO ATC |
|
0-L |
J01ED08 |
sulfaphenazole |
WHO ATC |
|
0-L |
J01ED09 |
sulfamazone |
WHO ATC |
|
0-L |
J01ED20 |
combinations |
WHO ATC |
|
0-L |
J01EE |
Combinations of sulfonamides and trimethoprim, incl. derivatives |
WHO ATC |
|
0-L |
J01EE01 |
sulfamethoxazole and trimethoprim |
WHO ATC |
|
0-L |
J01EE02 |
sulfadiazine and trimethoprim |
WHO ATC |
|
0-L |
J01EE03 |
sulfametrole and trimethoprim |
WHO ATC |
|
0-L |
J01EE04 |
sulfamoxole and trimethoprim |
WHO ATC |
|
0-L |
J01EE05 |
sulfadimidine and trimethoprim |
WHO ATC |
|
0-L |
J01EE06 |
sulfadiazine and tetroxoprim |
WHO ATC |
|
0-L |
J01EE07 |
sulfamerazine and trimethoprim |
WHO ATC |
|
0-L |
J01F |
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS |
WHO ATC |
|
0-L |
J01FA |
Macrolides |
WHO ATC |
|
0-L |
J01FA01 |
erythromycin |
WHO ATC |
|
0-L |
J01FA02 |
spiramycin |
WHO ATC |
|
0-L |
J01FA03 |
midecamycin |
WHO ATC |
|
0-L |
J01FA05 |
oleandomycin |
WHO ATC |
|
0-L |
J01FA06 |
roxithromycin |
WHO ATC |
|
0-L |
J01FA07 |
josamycin |
WHO ATC |
|
0-L |
J01FA08 |
troleandomycin |
WHO ATC |
|
0-L |
J01FA09 |
clarithromycin |
WHO ATC |
|
0-L |
J01FA10 |
azithromycin |
WHO ATC |
|
0-L |
J01FA11 |
miocamycin |
WHO ATC |
|
0-L |
J01FA12 |
rokitamycin |
WHO ATC |
|
0-L |
J01FA13 |
dirithromycin |
WHO ATC |
|
0-L |
J01FA14 |
flurithromycin |
WHO ATC |
|
0-L |
J01FA15 |
telithromycin |
WHO ATC |
|
0-L |
J01FF |
Lincosamides |
WHO ATC |
|
0-L |
J01FF01 |
clindamycin |
WHO ATC |
|
0-L |
J01FF02 |
lincomycin |
WHO ATC |
|
0-L |
J01FG |
Streptogramins |
WHO ATC |
|
0-L |
J01FG01 |
pristinamycin |
WHO ATC |
|
0-L |
J01FG02 |
quinupristin/dalfopristin |
WHO ATC |
|
0-L |
J01G |
AMINOGLYCOSIDE ANTIBACTERIALS |
WHO ATC |
|
0-L |
J01GA |
Streptomycins |
WHO ATC |
|
0-L |
J01GA01 |
streptomycin |
WHO ATC |
|
0-L |
J01GA02 |
streptoduocin |
WHO ATC |
|
0-L |
J01GB |
Other aminoglycosides |
WHO ATC |
|
0-L |
J01GB01 |
tobramycin |
WHO ATC |
|
0-L |
J01GB03 |
gentamicin |
WHO ATC |
|
0-L |
J01GB04 |
kanamycin |
WHO ATC |
|
0-L |
J01GB05 |
neomycin |
WHO ATC |
|
0-L |
J01GB06 |
amikacin |
WHO ATC |
|
0-L |
J01GB07 |
netilmicin |
WHO ATC |
|
0-L |
J01GB08 |
sisomicin |
WHO ATC |
|
0-L |
J01GB09 |
dibekacin |
WHO ATC |
|
0-L |
J01GB10 |
ribostamycin |
WHO ATC |
|
0-L |
J01GB11 |
isepamicin |
WHO ATC |
|
0-L |
J01GB12 |
arbekacin |
WHO ATC |
|
0-L |
J01M |
QUINOLONE ANTIBACTERIALS |
WHO ATC |
|
0-L |
J01MA |
Fluoroquinolones |
WHO ATC |
|
0-L |
J01MA01 |
ofloxacin |
WHO ATC |
|
0-L |
J01MA02 |
ciprofloxacin |
WHO ATC |
|
0-L |
J01MA03 |
pefloxacin |
WHO ATC |
|
0-L |
J01MA04 |
enoxacin |
WHO ATC |
|
0-L |
J01MA05 |
temafloxacin |
WHO ATC |
|
0-L |
J01MA06 |
norfloxacin |
WHO ATC |
|
0-L |
J01MA07 |
lomefloxacin |
WHO ATC |
|
0-L |
J01MA08 |
fleroxacin |
WHO ATC |
|
0-L |
J01MA09 |
sparfloxacin |
WHO ATC |
|
0-L |
J01MA10 |
rufloxacin |
WHO ATC |
|
0-L |
J01MA11 |
grepafloxacin |
WHO ATC |
|
0-L |
J01MA12 |
levofloxacin |
WHO ATC |
|
0-L |
J01MA13 |
trovafloxacin |
WHO ATC |
|
0-L |
J01MA14 |
moxifloxacin |
WHO ATC |
|
0-L |
J01MA15 |
gemifloxacin |
WHO ATC |
|
0-L |
J01MA16 |
gatifloxacin |
WHO ATC |
|
0-L |
J01MA17 |
prulifloxacin |
WHO ATC |
|
0-L |
J01MA18 |
pazufloxacin |
WHO ATC |
|
0-L |
J01MA19 |
garenoxacin |
WHO ATC |
|
0-L |
J01MB |
Other quinolones |
WHO ATC |
|
0-L |
J01MB01 |
rosoxacin |
WHO ATC |
|
0-L |
J01MB02 |
nalidixic acid |
WHO ATC |
|
0-L |
J01MB03 |
piromidic acid |
WHO ATC |
|
0-L |
J01MB04 |
pipemidic acid |
WHO ATC |
|
0-L |
J01MB05 |
oxolinic acid |
WHO ATC |
|
0-L |
J01MB06 |
cinoxacin |
WHO ATC |
|
0-L |
J01MB07 |
flumequine |
WHO ATC |
|
0-L |
J01R |
COMBINATIONS OF ANTIBACTERIALS |
WHO ATC |
|
0-L |
J01RA |
Combinations of antibacterials |
WHO ATC |
|
0-L |
J01RA01 |
penicillins, combinations with other antibacterials |
WHO ATC |
|
0-L |
J01RA02 |
sulfonamides, combinations with other antibacterials (excl. trimethoprim) |
WHO ATC |
|
0-L |
J01RA03 |
cefuroxime, combinations with other antibacterials |
WHO ATC |
|
0-L |
J01RA04 |
spiramycin, combinations with other antibacterials |
WHO ATC |
|
0-L |
J01X |
OTHER ANTIBACTERIALS |
WHO ATC |
|
0-L |
J01XA |
Glycopeptide antibacterials |
WHO ATC |
|
0-L |
J01XA01 |
vancomycin |
WHO ATC |
|
0-L |
J01XA02 |
teicoplanin |
WHO ATC |
|
0-L |
J01XA03 |
telavancin |
WHO ATC |
|
0-L |
J01XA04 |
dalbavancin |
WHO ATC |
|
0-L |
J01XA05 |
oritavancin |
WHO ATC |
|
0-L |
J01XB |
Polymyxins |
WHO ATC |
|
0-L |
J01XB01 |
colistin |
WHO ATC |
|
0-L |
J01XB02 |
polymyxin B |
WHO ATC |
|
0-L |
J01XC |
Steroid antibacterials |
WHO ATC |
|
0-L |
J01XC01 |
fusidic acid |
WHO ATC |
|
0-L |
J01XD |
Imidazole derivatives |
WHO ATC |
|
0-L |
J01XD01 |
metronidazole |
WHO ATC |
|
0-L |
J01XD02 |
tinidazole |
WHO ATC |
|
0-L |
J01XD03 |
ornidazole |
WHO ATC |
|
0-L |
J01XE |
Nitrofuran derivatives |
WHO ATC |
|
0-L |
J01XE01 |
nitrofurantoin |
WHO ATC |
|
0-L |
J01XE02 |
nifurtoinol |
WHO ATC |
|
0-L |
J01XX |
Other antibacterials |
WHO ATC |
|
0-L |
J01XX01 |
fosfomycin |
WHO ATC |
|
0-L |
J01XX02 |
xibornol |
WHO ATC |
|
0-L |
J01XX03 |
clofoctol |
WHO ATC |
|
0-L |
J01XX04 |
spectinomycin |
WHO ATC |
|
0-L |
J01XX05 |
methenamine |
WHO ATC |
|
0-L |
J01XX06 |
mandelic acid |
WHO ATC |
|
0-L |
J01XX07 |
nitroxoline |
WHO ATC |
|
0-L |
J01XX08 |
linezolid |
WHO ATC |
|
0-L |
J01XX09 |
daptomycin |
WHO ATC |
|
0-L |
J01XX10 |
bacitracin |
WHO ATC |
|
0-L |
J02 |
ANTIMYCOTICS FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
J02A |
ANTIMYCOTICS FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
J02AA |
Antibiotics |
WHO ATC |
|
0-L |
J02AA01 |
amphotericin B |
WHO ATC |
|
0-L |
J02AA02 |
hachimycin |
WHO ATC |
|
0-L |
J02AB |
Imidazole derivatives |
WHO ATC |
|
0-L |
J02AB01 |
miconazole |
WHO ATC |
|
0-L |
J02AB02 |
ketoconazole |
WHO ATC |
|
0-L |
J02AC |
Triazole derivatives |
WHO ATC |
|
0-L |
J02AC01 |
fluconazole |
WHO ATC |
|
0-L |
J02AC02 |
itraconazole |
WHO ATC |
|
0-L |
J02AC03 |
voriconazole |
WHO ATC |
|
0-L |
J02AC04 |
posaconazole |
WHO ATC |
|
0-L |
J02AX |
Other antimycotics for systemic use |
WHO ATC |
|
0-L |
J02AX01 |
flucytosine |
WHO ATC |
|
0-L |
J02AX04 |
caspofungin |
WHO ATC |
|
0-L |
J02AX05 |
micafungin |
WHO ATC |
|
0-L |
J02AX06 |
anidulafungin |
WHO ATC |
|
0-L |
J04 |
ANTIMYCOBACTERIALS |
WHO ATC |
|
0-L |
J04A |
DRUGS FOR TREATMENT OF TUBERCULOSIS |
WHO ATC |
|
0-L |
J04AA |
Aminosalicylic acid and derivatives |
WHO ATC |
|
0-L |
J04AA01 |
aminosalicylic acid |
WHO ATC |
|
0-L |
J04AA02 |
sodium aminosalicylate |
WHO ATC |
|
0-L |
J04AA03 |
calcium aminosalicylate |
WHO ATC |
|
0-L |
J04AB |
Antibiotics |
WHO ATC |
|
0-L |
J04AB01 |
cycloserine |
WHO ATC |
|
0-L |
J04AB02 |
rifampicin |
WHO ATC |
|
0-L |
J04AB03 |
rifamycin |
WHO ATC |
|
0-L |
J04AB04 |
rifabutin |
WHO ATC |
|
0-L |
J04AB05 |
rifapentine |
WHO ATC |
|
0-L |
J04AB30 |
capreomycin |
WHO ATC |
|
0-L |
J04AC |
Hydrazides |
WHO ATC |
|
0-L |
J04AC01 |
isoniazid |
WHO ATC |
|
0-L |
J04AC51 |
isoniazid, combinations |
WHO ATC |
|
0-L |
J04AD |
Thiocarbamide derivatives |
WHO ATC |
|
0-L |
J04AD01 |
protionamide |
WHO ATC |
|
0-L |
J04AD02 |
tiocarlide |
WHO ATC |
|
0-L |
J04AD03 |
ethionamide |
WHO ATC |
|
0-L |
J04AK |
Other drugs for treatment of tuberculosis |
WHO ATC |
|
0-L |
J04AK01 |
pyrazinamide |
WHO ATC |
|
0-L |
J04AK02 |
ethambutol |
WHO ATC |
|
0-L |
J04AK03 |
terizidone |
WHO ATC |
|
0-L |
J04AK04 |
morinamide |
WHO ATC |
|
0-L |
J04AM |
Combinations of drugs for treatment of tuberculosis |
WHO ATC |
|
0-L |
J04AM01 |
streptomycin and isoniazid |
WHO ATC |
|
0-L |
J04AM02 |
rifampicin and isoniazid |
WHO ATC |
|
0-L |
J04AM03 |
ethambutol and isoniazid |
WHO ATC |
|
0-L |
J04AM04 |
thioacetazone and isoniazid |
WHO ATC |
|
0-L |
J04AM05 |
rifampicin, pyrazinamide and isoniazid |
WHO ATC |
|
0-L |
J04AM06 |
rifampicin, pyrazinamide, ethambutol and isoniazid |
WHO ATC |
|
0-L |
J04B |
DRUGS FOR TREATMENT OF LEPRA |
WHO ATC |
|
0-L |
J04BA |
Drugs for treatment of lepra |
WHO ATC |
|
0-L |
J04BA01 |
clofazimine |
WHO ATC |
|
0-L |
J04BA02 |
dapsone |
WHO ATC |
|
0-L |
J04BA03 |
aldesulfone sodium |
WHO ATC |
|
0-L |
J05 |
ANTIVIRALS FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
J05A |
DIRECT ACTING ANTIVIRALS |
WHO ATC |
|
0-L |
J05AA |
Thiosemicarbazones |
WHO ATC |
|
0-L |
J05AA01 |
metisazone |
WHO ATC |
|
0-L |
J05AB |
Nucleosides and nucleotides excl. reverse transcriptase inhibitors |
WHO ATC |
|
0-L |
J05AB01 |
aciclovir |
WHO ATC |
|
0-L |
J05AB02 |
idoxuridine |
WHO ATC |
|
0-L |
J05AB03 |
vidarabine |
WHO ATC |
|
0-L |
J05AB04 |
ribavirin |
WHO ATC |
|
0-L |
J05AB06 |
ganciclovir |
WHO ATC |
|
0-L |
J05AB09 |
famciclovir |
WHO ATC |
|
0-L |
J05AB11 |
valaciclovir |
WHO ATC |
|
0-L |
J05AB12 |
cidofovir |
WHO ATC |
|
0-L |
J05AB13 |
penciclovir |
WHO ATC |
|
0-L |
J05AB14 |
valganciclovir |
WHO ATC |
|
0-L |
J05AB15 |
brivudine |
WHO ATC |
|
0-L |
J05AC |
Cyclic amines |
WHO ATC |
|
0-L |
J05AC02 |
rimantadine |
WHO ATC |
|
0-L |
J05AC03 |
tromantadine |
WHO ATC |
|
0-L |
J05AD |
Phosphonic acid derivatives |
WHO ATC |
|
0-L |
J05AD01 |
foscarnet |
WHO ATC |
|
0-L |
J05AD02 |
fosfonet |
WHO ATC |
|
0-L |
J05AE |
Protease inhibitors |
WHO ATC |
|
0-L |
J05AE01 |
saquinavir |
WHO ATC |
|
0-L |
J05AE02 |
indinavir |
WHO ATC |
|
0-L |
J05AE03 |
ritonavir |
WHO ATC |
|
0-L |
J05AE04 |
nelfinavir |
WHO ATC |
|
0-L |
J05AE05 |
amprenavir |
WHO ATC |
|
0-L |
J05AE06 |
lopinavir |
WHO ATC |
|
0-L |
J05AE07 |
fosamprenavir |
WHO ATC |
|
0-L |
J05AE08 |
atazanavir |
WHO ATC |
|
0-L |
J05AE09 |
tipranavir |
WHO ATC |
|
0-L |
J05AE10 |
darunavir |
WHO ATC |
|
0-L |
J05AF |
Nucleoside and nucleotide reverse transcriptase inhibitors |
WHO ATC |
|
0-L |
J05AF01 |
zidovudine |
WHO ATC |
|
0-L |
J05AF02 |
didanosine |
WHO ATC |
|
0-L |
J05AF03 |
zalcitabine |
WHO ATC |
|
0-L |
J05AF04 |
stavudine |
WHO ATC |
|
0-L |
J05AF05 |
lamivudine |
WHO ATC |
|
0-L |
J05AF06 |
abacavir |
WHO ATC |
|
0-L |
J05AF07 |
tenofovir disoproxil |
WHO ATC |
|
0-L |
J05AF08 |
adefovir dipivoxil |
WHO ATC |
|
0-L |
J05AF09 |
emtricitabine |
WHO ATC |
|
0-L |
J05AF10 |
entecavir |
WHO ATC |
|
0-L |
J05AF11 |
telbivudine |
WHO ATC |
|
0-L |
J05AF12 |
clevudine |
WHO ATC |
|
0-L |
J05AG |
Non-nucleoside reverse transcriptase inhibitors |
WHO ATC |
|
0-L |
J05AG01 |
nevirapine |
WHO ATC |
|
0-L |
J05AG02 |
delavirdine |
WHO ATC |
|
0-L |
J05AG03 |
efavirenz |
WHO ATC |
|
0-L |
J05AG04 |
etravirine |
WHO ATC |
|
0-L |
J05AH |
Neuraminidase inhibitors |
WHO ATC |
|
0-L |
J05AH01 |
zanamivir |
WHO ATC |
|
0-L |
J05AH02 |
oseltamivir |
WHO ATC |
|
0-L |
J05AR |
Antivirals for treatment of HIV infections, combinations |
WHO ATC |
|
0-L |
J05AR01 |
zidovudine and lamivudine |
WHO ATC |
|
0-L |
J05AR02 |
lamivudine and abacavir |
WHO ATC |
|
0-L |
J05AR03 |
tenofovir disoproxil and emtricitabine |
WHO ATC |
|
0-L |
J05AR04 |
zidovudine, lamivudine and abacavir |
WHO ATC |
|
0-L |
J05AR05 |
zidovudine, lamivudine and nevirapine |
WHO ATC |
|
0-L |
J05AR06 |
emtricitabine, tenofovir disoproxil and efavirenz |
WHO ATC |
|
0-L |
J05AR07 |
stavudine, lamivudine and nevirapine |
WHO ATC |
|
0-L |
J05AX |
Other antivirals |
WHO ATC |
|
0-L |
J05AX01 |
moroxydine |
WHO ATC |
|
0-L |
J05AX02 |
lysozyme |
WHO ATC |
|
0-L |
J05AX05 |
inosine pranobex |
WHO ATC |
|
0-L |
J05AX06 |
pleconaril |
WHO ATC |
|
0-L |
J05AX07 |
enfuvirtide |
WHO ATC |
|
0-L |
J05AX08 |
raltegravir |
WHO ATC |
|
0-L |
J05AX09 |
maraviroc |
WHO ATC |
|
0-L |
J05AX10 |
maribavir |
WHO ATC |
|
0-L |
J06 |
IMMUNE SERA AND IMMUNOGLOBULINS |
WHO ATC |
|
0-L |
J06A |
IMMUNE SERA |
WHO ATC |
|
0-L |
J06AA |
Immune sera |
WHO ATC |
|
0-L |
J06AA01 |
diphtheria antitoxin |
WHO ATC |
|
0-L |
J06AA02 |
tetanus antitoxin |
WHO ATC |
|
0-L |
J06AA03 |
snake venom antiserum |
WHO ATC |
|
0-L |
J06AA04 |
botulinum antitoxin |
WHO ATC |
|
0-L |
J06AA05 |
gas-gangrene sera |
WHO ATC |
|
0-L |
J06AA06 |
rabies serum |
WHO ATC |
|
0-L |
J06B |
IMMUNOGLOBULINS |
WHO ATC |
|
0-L |
J06BA |
Immunoglobulins, normal human |
WHO ATC |
|
0-L |
J06BA01 |
immunoglobulins, normal human, for extravascular adm. |
WHO ATC |
|
0-L |
J06BA02 |
immunoglobulins, normal human, for intravascular adm. |
WHO ATC |
|
0-L |
J06BB |
Specific immunoglobulins |
WHO ATC |
|
0-L |
J06BB01 |
anti-D (rh) immunoglobulin |
WHO ATC |
|
0-L |
J06BB02 |
tetanus immunoglobulin |
WHO ATC |
|
0-L |
J06BB03 |
varicella/zoster immunoglobulin |
WHO ATC |
|
0-L |
J06BB04 |
hepatitis B immunoglobulin |
WHO ATC |
|
0-L |
J06BB05 |
rabies immunoglobulin |
WHO ATC |
|
0-L |
J06BB06 |
rubella immunoglobulin |
WHO ATC |
|
0-L |
J06BB07 |
vaccinia immunoglobulin |
WHO ATC |
|
0-L |
J06BB08 |
staphylococcus immunoglobulin |
WHO ATC |
|
0-L |
J06BB09 |
cytomegalovirus immunoglobulin |
WHO ATC |
|
0-L |
J06BB10 |
diphtheria immunoglobulin |
WHO ATC |
|
0-L |
J06BB11 |
hepatitis A immunoglobulin |
WHO ATC |
|
0-L |
J06BB12 |
encephalitis, tick borne immunoglobulin |
WHO ATC |
|
0-L |
J06BB13 |
pertussis immunoglobulin |
WHO ATC |
|
0-L |
J06BB14 |
measles immunoglobulin |
WHO ATC |
|
0-L |
J06BB15 |
mumps immunoglobulin |
WHO ATC |
|
0-L |
J06BB16 |
palivizumab |
WHO ATC |
|
0-L |
J06BB30 |
combinations |
WHO ATC |
|
0-L |
J06BC |
Other immunoglobulins |
WHO ATC |
|
0-L |
J06BC01 |
nebacumab |
WHO ATC |
|
0-L |
J07 |
VACCINES |
WHO ATC |
|
0-L |
J07A |
BACTERIAL VACCINES |
WHO ATC |
|
0-L |
J07AC |
Anthrax vaccines |
WHO ATC |
|
0-L |
J07AC01 |
anthrax antigen |
WHO ATC |
|
0-L |
J07AD |
Brucellosis vaccines |
WHO ATC |
|
0-L |
J07AD01 |
brucella antigen |
WHO ATC |
|
0-L |
J07AE |
Cholera vaccines |
WHO ATC |
|
0-L |
J07AE01 |
cholera, inactivated, whole cell |
WHO ATC |
|
0-L |
J07AE02 |
cholera, live attenuated |
WHO ATC |
|
0-L |
J07AE51 |
cholera, combinations with typhoid vaccine, inactivated, whole cell |
WHO ATC |
|
0-L |
J07AF |
Diphtheria vaccines |
WHO ATC |
|
0-L |
J07AF01 |
diphtheria toxoid |
WHO ATC |
|
0-L |
J07AG |
Hemophilus influenzae B vaccines |
WHO ATC |
|
0-L |
J07AG01 |
hemophilus influenzae B, purified antigen conjugated |
WHO ATC |
|
0-L |
J07AG51 |
hemophilus influenzae B, combinations with toxoids |
WHO ATC |
|
0-L |
J07AG52 |
hemophilus influenzae B, combinations with pertussis and toxoids |
WHO ATC |
|
0-L |
J07AG53 |
hemophilus influenzae B, combinations with meningococcus C, conjugated |
WHO ATC |
|
0-L |
J07AH |
Meningococcal vaccines |
WHO ATC |
|
0-L |
J07AH01 |
meningococcus A, purified polysaccharides antigen |
WHO ATC |
|
0-L |
J07AH02 |
other meningococcal monovalent purified polysaccharides antigen |
WHO ATC |
|
0-L |
J07AH03 |
meningococcus, bivalent purified polysaccharides antigen |
WHO ATC |
|
0-L |
J07AH04 |
meningococcus, tetravalent purified polysaccharides antigen |
WHO ATC |
|
0-L |
J07AH05 |
other meningococcal polyvalent purified polysaccharides antigen |
WHO ATC |
|
0-L |
J07AH06 |
meningococcus B, outer membrane vesicle vaccine |
WHO ATC |
|
0-L |
J07AH07 |
meningococcus C, purified polysaccharides antigen conjugated |
WHO ATC |
|
0-L |
J07AH08 |
meningococcus, tetravalent purified polysaccharides antigen conjugated |
WHO ATC |
|
0-L |
J07AJ |
Pertussis vaccines |
WHO ATC |
|
0-L |
J07AJ01 |
pertussis, inactivated, whole cell |
WHO ATC |
|
0-L |
J07AJ02 |
pertussis, purified antigen |
WHO ATC |
|
0-L |
J07AJ51 |
pertussis, inactivated, whole cell, combinations with toxoids |
WHO ATC |
|
0-L |
J07AJ52 |
pertussis, purified antigen, combinations with toxoids |
WHO ATC |
|
0-L |
J07AK |
Plague vaccines |
WHO ATC |
|
0-L |
J07AK01 |
plague, inactivated, whole cell |
WHO ATC |
|
0-L |
J07AL |
Pneumococcal vaccines |
WHO ATC |
|
0-L |
J07AL01 |
pneumococcus, purified polysaccharides antigen |
WHO ATC |
|
0-L |
J07AL02 |
pneumococcus, purified polysaccharides antigen conjugated |
WHO ATC |
|
0-L |
J07AL52 |
pneumococcus purified polysaccharides antigen and Haemophilus influenzae, conjugated |
WHO ATC |
|
0-L |
J07AM |
Tetanus vaccines |
WHO ATC |
|
0-L |
J07AM01 |
tetanus toxoid |
WHO ATC |
|
0-L |
J07AM51 |
tetanus toxoid, combinations with diphtheria toxoid |
WHO ATC |
|
0-L |
J07AM52 |
tetanus toxoid, combinations with tetanus immunoglobulin |
WHO ATC |
|
0-L |
J07AN |
Tuberculosis vaccines |
WHO ATC |
|
0-L |
J07AN01 |
tuberculosis, live attenuated |
WHO ATC |
|
0-L |
J07AP |
Typhoid vaccines |
WHO ATC |
|
0-L |
J07AP01 |
typhoid, oral, live attenuated |
WHO ATC |
|
0-L |
J07AP02 |
typhoid, inactivated, whole cell |
WHO ATC |
|
0-L |
J07AP03 |
typhoid, purified polysaccharide antigen |
WHO ATC |
|
0-L |
J07AP10 |
typhoid, combinations with paratyphi types |
WHO ATC |
|
0-L |
J07AR |
Typhus (exanthematicus) vaccines |
WHO ATC |
|
0-L |
J07AR01 |
typhus exanthematicus, inactivated, whole cell |
WHO ATC |
|
0-L |
J07AX |
Other bacterial vaccines |
WHO ATC |
|
0-L |
J07B |
VIRAL VACCINES |
WHO ATC |
|
0-L |
J07BA |
Encephalitis vaccines |
WHO ATC |
|
0-L |
J07BA01 |
encephalitis, tick borne, inactivated, whole virus |
WHO ATC |
|
0-L |
J07BA02 |
encephalitis, Japanese, inactivated, whole virus |
WHO ATC |
|
0-L |
J07BB |
Influenza vaccines |
WHO ATC |
|
0-L |
J07BB01 |
influenza, inactivated, whole virus |
WHO ATC |
|
0-L |
J07BB02 |
influenza, inactivated, split virus or surface antigen |
WHO ATC |
|
0-L |
J07BB03 |
influenza, live attenuated |
WHO ATC |
|
0-L |
J07BC |
Hepatitis vaccines |
WHO ATC |
|
0-L |
J07BC01 |
hepatitis B, purified antigen |
WHO ATC |
|
0-L |
J07BC02 |
hepatitis A, inactivated, whole virus |
WHO ATC |
|
0-L |
J07BC20 |
combinations |
WHO ATC |
|
0-L |
J07BD |
Measles vaccines |
WHO ATC |
|
0-L |
J07BD01 |
measles, live attenuated |
WHO ATC |
|
0-L |
J07BD51 |
measles, combinations with mumps, live attenuated |
WHO ATC |
|
0-L |
J07BD52 |
measles, combinations with mumps and rubella, live attenuated |
WHO ATC |
|
0-L |
J07BD53 |
measles, combinations with rubella, live attenuated |
WHO ATC |
|
0-L |
J07BD54 |
measles, combinations with mumps, rubella and varicella, live attenuated |
WHO ATC |
|
0-L |
J07BE |
Mumps vaccines |
WHO ATC |
|
0-L |
J07BE01 |
mumps, live attenuated |
WHO ATC |
|
0-L |
J07BF |
Poliomyelitis vaccines |
WHO ATC |
|
0-L |
J07BF01 |
poliomyelitis oral, monovalent live attenuated |
WHO ATC |
|
0-L |
J07BF02 |
poliomyelitis oral, trivalent, live attenuated |
WHO ATC |
|
0-L |
J07BF03 |
poliomyelitis, trivalent, inactivated, whole virus |
WHO ATC |
|
0-L |
J07BG |
Rabies vaccines |
WHO ATC |
|
0-L |
J07BG01 |
rabies, inactivated, whole virus |
WHO ATC |
|
0-L |
J07BH |
Rota virus diarrhea vaccines |
WHO ATC |
|
0-L |
J07BH01 |
rota virus, live attenuated |
WHO ATC |
|
0-L |
J07BH02 |
rota virus, pentavalent, live, reassorted |
WHO ATC |
|
0-L |
J07BJ |
Rubella vaccines |
WHO ATC |
|
0-L |
J07BJ01 |
rubella, live attenuated |
WHO ATC |
|
0-L |
J07BJ51 |
rubella, combinations with mumps, live attenuated |
WHO ATC |
|
0-L |
J07BK |
Varicella zoster vaccines |
WHO ATC |
|
0-L |
J07BK01 |
varicella, live attenuated |
WHO ATC |
|
0-L |
J07BK02 |
zoster, live attenuated |
WHO ATC |
|
0-L |
J07BL |
Yellow fever vaccines |
WHO ATC |
|
0-L |
J07BL01 |
yellow fever, live attenuated |
WHO ATC |
|
0-L |
J07BM |
Papillomavirus vaccines |
WHO ATC |
|
0-L |
J07BM01 |
papillomavirus (human types 6, 11, 16, 18) |
WHO ATC |
|
0-L |
J07BM02 |
papillomavirus (human types 16, 18) |
WHO ATC |
|
0-L |
J07BX |
Other viral vaccines |
WHO ATC |
|
0-L |
J07C |
BACTERIAL AND VIRAL VACCINES, COMBINED |
WHO ATC |
|
0-L |
J07CA |
Bacterial and viral vaccines, combined |
WHO ATC |
|
0-L |
J07CA01 |
diphtheria-poliomyelitis-tetanus |
WHO ATC |
|
0-L |
J07CA02 |
diphtheria-pertussis-poliomyelitis-tetanus |
WHO ATC |
|
0-L |
J07CA03 |
diphtheria-rubella-tetanus |
WHO ATC |
|
0-L |
J07CA04 |
hemophilus influenzae B and poliomyelitis |
WHO ATC |
|
0-L |
J07CA05 |
diphtheria-hepatitis B-pertussis-tetanus |
WHO ATC |
|
0-L |
J07CA06 |
diphtheria-Hemophilus influenzae B-pertussis-poliomyelitis-tetanus |
WHO ATC |
|
0-L |
J07CA07 |
diphtheria-hepatitis B-tetanus |
WHO ATC |
|
0-L |
J07CA08 |
hemophilus influenzae B and hepatitis B |
WHO ATC |
|
0-L |
J07CA09 |
diphtheria-Hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B |
WHO ATC |
|
0-L |
J07CA10 |
typhoid-hepatitis A |
WHO ATC |
|
0-L |
J07CA11 |
diphtheria-Hemophilus influenzae B-pertussis-tetanus-hepatitis B |
WHO ATC |
|
0-L |
J07CA12 |
diphtheria-pertussis-poliomyelitis-tetanus-hepatitis B |
WHO ATC |
|
0-L |
J07CA13 |
diphtheria-hemophilus influenzae B-pertussis-tetanus-hepatitis B-meningococcus A +
C
|
WHO ATC |
|
0-L |
J07X |
OTHER VACCINES |
WHO ATC |
|
0-L |
L |
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS |
WHO ATC |
|
0-L |
L01 |
ANTINEOPLASTIC AGENTS |
WHO ATC |
|
0-L |
L01A |
ALKYLATING AGENTS |
WHO ATC |
|
0-L |
L01AA |
Nitrogen mustard analogues |
WHO ATC |
|
0-L |
L01AA01 |
cyclophosphamide |
WHO ATC |
|
0-L |
L01AA02 |
chlorambucil |
WHO ATC |
|
0-L |
L01AA03 |
melphalan |
WHO ATC |
|
0-L |
L01AA05 |
chlormethine |
WHO ATC |
|
0-L |
L01AA06 |
ifosfamide |
WHO ATC |
|
0-L |
L01AA07 |
trofosfamide |
WHO ATC |
|
0-L |
L01AA08 |
prednimustine |
WHO ATC |
|
0-L |
L01AA09 |
bendamustine |
WHO ATC |
|
0-L |
L01AB |
Alkyl sulfonates |
WHO ATC |
|
0-L |
L01AB01 |
busulfan |
WHO ATC |
|
0-L |
L01AB02 |
treosulfan |
WHO ATC |
|
0-L |
L01AB03 |
mannosulfan |
WHO ATC |
|
0-L |
L01AC |
Ethylene imines |
WHO ATC |
|
0-L |
L01AC01 |
thiotepa |
WHO ATC |
|
0-L |
L01AC02 |
triaziquone |
WHO ATC |
|
0-L |
L01AC03 |
carboquone |
WHO ATC |
|
0-L |
L01AD |
Nitrosoureas |
WHO ATC |
|
0-L |
L01AD01 |
carmustine |
WHO ATC |
|
0-L |
L01AD02 |
lomustine |
WHO ATC |
|
0-L |
L01AD03 |
semustine |
WHO ATC |
|
0-L |
L01AD04 |
streptozocin |
WHO ATC |
|
0-L |
L01AD05 |
fotemustine |
WHO ATC |
|
0-L |
L01AD06 |
nimustine |
WHO ATC |
|
0-L |
L01AD07 |
ranimustine |
WHO ATC |
|
0-L |
L01AG |
Epoxides |
WHO ATC |
|
0-L |
L01AG01 |
etoglucid |
WHO ATC |
|
0-L |
L01AX |
Other alkylating agents |
WHO ATC |
|
0-L |
L01AX01 |
mitobronitol |
WHO ATC |
|
0-L |
L01AX02 |
pipobroman |
WHO ATC |
|
0-L |
L01AX03 |
temozolomide |
WHO ATC |
|
0-L |
L01AX04 |
dacarbazine |
WHO ATC |
|
0-L |
L01B |
ANTIMETABOLITES |
WHO ATC |
|
0-L |
L01BA |
Folic acid analogues |
WHO ATC |
|
0-L |
L01BA01 |
methotrexate |
WHO ATC |
|
0-L |
L01BA03 |
raltitrexed |
WHO ATC |
|
0-L |
L01BA04 |
pemetrexed |
WHO ATC |
|
0-L |
L01BA05 |
pralatrexate |
WHO ATC |
|
0-L |
L01BB |
Purine analogues |
WHO ATC |
|
0-L |
L01BB02 |
mercaptopurine |
WHO ATC |
|
0-L |
L01BB03 |
tioguanine |
WHO ATC |
|
0-L |
L01BB04 |
cladribine |
WHO ATC |
|
0-L |
L01BB05 |
fludarabine |
WHO ATC |
|
0-L |
L01BB06 |
clofarabine |
WHO ATC |
|
0-L |
L01BB07 |
nelarabine |
WHO ATC |
|
0-L |
L01BC |
Pyrimidine analogues |
WHO ATC |
|
0-L |
L01BC01 |
cytarabine |
WHO ATC |
|
0-L |
L01BC02 |
fluorouracil |
WHO ATC |
|
0-L |
L01BC03 |
tegafur |
WHO ATC |
|
0-L |
L01BC04 |
carmofur |
WHO ATC |
|
0-L |
L01BC05 |
gemcitabine |
WHO ATC |
|
0-L |
L01BC06 |
capecitabine |
WHO ATC |
|
0-L |
L01BC07 |
azacitidine |
WHO ATC |
|
0-L |
L01BC08 |
decitabine |
WHO ATC |
|
0-L |
L01BC52 |
fluorouracil, combinations |
WHO ATC |
|
0-L |
L01BC53 |
tegafur, combinations |
WHO ATC |
|
0-L |
L01C |
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS |
WHO ATC |
|
0-L |
L01CA |
Vinca alkaloids and analogues |
WHO ATC |
|
0-L |
L01CA01 |
vinblastine |
WHO ATC |
|
0-L |
L01CA02 |
vincristine |
WHO ATC |
|
0-L |
L01CA03 |
vindesine |
WHO ATC |
|
0-L |
L01CA04 |
vinorelbine |
WHO ATC |
|
0-L |
L01CA05 |
vinflunine |
WHO ATC |
|
0-L |
L01CB |
Podophyllotoxin derivatives |
WHO ATC |
|
0-L |
L01CB01 |
etoposide |
WHO ATC |
|
0-L |
L01CB02 |
teniposide |
WHO ATC |
|
0-L |
L01CC |
Colchicine derivatives |
WHO ATC |
|
0-L |
L01CC01 |
demecolcine |
WHO ATC |
|
0-L |
L01CD |
Taxanes |
WHO ATC |
|
0-L |
L01CD01 |
paclitaxel |
WHO ATC |
|
0-L |
L01CD02 |
docetaxel |
WHO ATC |
|
0-L |
L01CD03 |
paclitaxel poliglumex |
WHO ATC |
|
0-L |
L01CX |
Other plant alkaloids and natural products |
WHO ATC |
|
0-L |
L01CX01 |
trabectedin |
WHO ATC |
|
0-L |
L01D |
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES |
WHO ATC |
|
0-L |
L01DA |
Actinomycines |
WHO ATC |
|
0-L |
L01DA01 |
dactinomycin |
WHO ATC |
|
0-L |
L01DB |
Anthracyclines and related substances |
WHO ATC |
|
0-L |
L01DB01 |
doxorubicin |
WHO ATC |
|
0-L |
L01DB02 |
daunorubicin |
WHO ATC |
|
0-L |
L01DB03 |
epirubicin |
WHO ATC |
|
0-L |
L01DB04 |
aclarubicin |
WHO ATC |
|
0-L |
L01DB05 |
zorubicin |
WHO ATC |
|
0-L |
L01DB06 |
idarubicin |
WHO ATC |
|
0-L |
L01DB07 |
mitoxantrone |
WHO ATC |
|
0-L |
L01DB08 |
pirarubicin |
WHO ATC |
|
0-L |
L01DB09 |
valrubicin |
WHO ATC |
|
0-L |
L01DC |
Other cytotoxic antibiotics |
WHO ATC |
|
0-L |
L01DC01 |
bleomycin |
WHO ATC |
|
0-L |
L01DC02 |
plicamycin |
WHO ATC |
|
0-L |
L01DC03 |
mitomycin |
WHO ATC |
|
0-L |
L01DC04 |
ixabepilone |
WHO ATC |
|
0-L |
L01X |
OTHER ANTINEOPLASTIC AGENTS |
WHO ATC |
|
0-L |
L01XA |
Platinum compounds |
WHO ATC |
|
0-L |
L01XA01 |
cisplatin |
WHO ATC |
|
0-L |
L01XA02 |
carboplatin |
WHO ATC |
|
0-L |
L01XA03 |
oxaliplatin |
WHO ATC |
|
0-L |
L01XA04 |
satraplatin |
WHO ATC |
|
0-L |
L01XB |
Methylhydrazines |
WHO ATC |
|
0-L |
L01XB01 |
procarbazine |
WHO ATC |
|
0-L |
L01XC |
Monoclonal antibodies |
WHO ATC |
|
0-L |
L01XC01 |
edrecolomab |
WHO ATC |
|
0-L |
L01XC02 |
rituximab |
WHO ATC |
|
0-L |
L01XC03 |
trastuzumab |
WHO ATC |
|
0-L |
L01XC04 |
alemtuzumab |
WHO ATC |
|
0-L |
L01XC05 |
gemtuzumab |
WHO ATC |
|
0-L |
L01XC06 |
cetuximab |
WHO ATC |
|
0-L |
L01XC07 |
bevacizumab |
WHO ATC |
|
0-L |
L01XC08 |
panitumumab |
WHO ATC |
|
0-L |
L01XC09 |
catumaxomab |
WHO ATC |
|
0-L |
L01XC10 |
ofatumumab |
WHO ATC |
|
0-L |
L01XD |
Sensitizers used in photodynamic/radiation therapy |
WHO ATC |
|
0-L |
L01XD01 |
porfimer sodium |
WHO ATC |
|
0-L |
L01XD03 |
methyl aminolevulinate |
WHO ATC |
|
0-L |
L01XD04 |
aminolevulinic acid |
WHO ATC |
|
0-L |
L01XD05 |
temoporfin |
WHO ATC |
|
0-L |
L01XD06 |
efaproxiral |
WHO ATC |
|
0-L |
L01XE |
Protein kinase inhibitors |
WHO ATC |
|
0-L |
L01XE01 |
imatinib |
WHO ATC |
|
0-L |
L01XE02 |
gefitinib |
WHO ATC |
|
0-L |
L01XE03 |
erlotinib |
WHO ATC |
|
0-L |
L01XE04 |
sunitinib |
WHO ATC |
|
0-L |
L01XE05 |
sorafenib |
WHO ATC |
|
0-L |
L01XE06 |
dasatinib |
WHO ATC |
|
0-L |
L01XE07 |
lapatinib |
WHO ATC |
|
0-L |
L01XE08 |
nilotinib |
WHO ATC |
|
0-L |
L01XE09 |
temsirolimus |
WHO ATC |
|
0-L |
L01XE10 |
everolimus |
WHO ATC |
|
0-L |
L01XE11 |
pazopanib |
WHO ATC |
|
0-L |
L01XX |
Other antineoplastic agents |
WHO ATC |
|
0-L |
L01XX01 |
amsacrine |
WHO ATC |
|
0-L |
L01XX02 |
asparaginase |
WHO ATC |
|
0-L |
L01XX03 |
altretamine |
WHO ATC |
|
0-L |
L01XX05 |
hydroxycarbamide |
WHO ATC |
|
0-L |
L01XX07 |
lonidamine |
WHO ATC |
|
0-L |
L01XX08 |
pentostatin |
WHO ATC |
|
0-L |
L01XX09 |
miltefosine |
WHO ATC |
|
0-L |
L01XX10 |
masoprocol |
WHO ATC |
|
0-L |
L01XX11 |
estramustine |
WHO ATC |
|
0-L |
L01XX14 |
tretinoin |
WHO ATC |
|
0-L |
L01XX16 |
mitoguazone |
WHO ATC |
|
0-L |
L01XX17 |
topotecan |
WHO ATC |
|
0-L |
L01XX18 |
tiazofurine |
WHO ATC |
|
0-L |
L01XX19 |
irinotecan |
WHO ATC |
|
0-L |
L01XX22 |
alitretinoin |
WHO ATC |
|
0-L |
L01XX23 |
mitotane |
WHO ATC |
|
0-L |
L01XX24 |
pegaspargase |
WHO ATC |
|
0-L |
L01XX25 |
bexarotene |
WHO ATC |
|
0-L |
L01XX27 |
arsenic trioxide |
WHO ATC |
|
0-L |
L01XX29 |
denileukin diftitox |
WHO ATC |
|
0-L |
L01XX32 |
bortezomib |
WHO ATC |
|
0-L |
L01XX33 |
celecoxib |
WHO ATC |
|
0-L |
L01XX35 |
anagrelide |
WHO ATC |
|
0-L |
L01XX36 |
oblimersen |
WHO ATC |
|
0-L |
L01XX37 |
sitimagene ceradenovec |
WHO ATC |
|
0-L |
L01XX38 |
vorinostat |
WHO ATC |
|
0-L |
L01XX39 |
romidepsin |
WHO ATC |
|
0-L |
L01XY |
Combinations of antineoplastic agents |
WHO ATC |
|
0-L |
L02 |
ENDOCRINE THERAPY |
WHO ATC |
|
0-L |
L02A |
HORMONES AND RELATED AGENTS |
WHO ATC |
|
0-L |
L02AA |
Estrogens |
WHO ATC |
|
0-L |
L02AA01 |
diethylstilbestrol |
WHO ATC |
|
0-L |
L02AA02 |
polyestradiol phosphate |
WHO ATC |
|
0-L |
L02AA03 |
ethinylestradiol |
WHO ATC |
|
0-L |
L02AA04 |
fosfestrol |
WHO ATC |
|
0-L |
L02AB |
Progestogens |
WHO ATC |
|
0-L |
L02AB01 |
megestrol |
WHO ATC |
|
0-L |
L02AB02 |
medroxyprogesterone |
WHO ATC |
|
0-L |
L02AB03 |
gestonorone |
WHO ATC |
|
0-L |
L02AE |
Gonadotropin releasing hormone analogues |
WHO ATC |
|
0-L |
L02AE01 |
buserelin |
WHO ATC |
|
0-L |
L02AE02 |
leuprorelin |
WHO ATC |
|
0-L |
L02AE03 |
goserelin |
WHO ATC |
|
0-L |
L02AE04 |
triptorelin |
WHO ATC |
|
0-L |
L02AX |
Other hormones |
WHO ATC |
|
0-L |
L02B |
HORMONE ANTAGONISTS AND RELATED AGENTS |
WHO ATC |
|
0-L |
L02BA |
Anti-estrogens |
WHO ATC |
|
0-L |
L02BA01 |
tamoxifen |
WHO ATC |
|
0-L |
L02BA02 |
toremifene |
WHO ATC |
|
0-L |
L02BA03 |
fulvestrant |
WHO ATC |
|
0-L |
L02BB |
Anti-androgens |
WHO ATC |
|
0-L |
L02BB01 |
flutamide |
WHO ATC |
|
0-L |
L02BB02 |
nilutamide |
WHO ATC |
|
0-L |
L02BB03 |
bicalutamide |
WHO ATC |
|
0-L |
L02BG |
Enzyme inhibitors |
WHO ATC |
|
0-L |
L02BG01 |
aminoglutethimide |
WHO ATC |
|
0-L |
L02BG02 |
formestane |
WHO ATC |
|
0-L |
L02BG03 |
anastrozole |
WHO ATC |
|
0-L |
L02BG04 |
letrozole |
WHO ATC |
|
0-L |
L02BG05 |
vorozole |
WHO ATC |
|
0-L |
L02BG06 |
exemestane |
WHO ATC |
|
0-L |
L02BX |
Other hormone antagonists and related agents |
WHO ATC |
|
0-L |
L02BX01 |
abarelix |
WHO ATC |
|
0-L |
L02BX02 |
degarelix |
WHO ATC |
|
0-L |
L03 |
IMMUNOSTIMULANTS |
WHO ATC |
|
0-L |
L03A |
IMMUNOSTIMULANTS |
WHO ATC |
|
0-L |
L03AA |
Colony stimulating factors |
WHO ATC |
|
0-L |
L03AA02 |
filgrastim |
WHO ATC |
|
0-L |
L03AA03 |
molgramostim |
WHO ATC |
|
0-L |
L03AA09 |
sargramostim |
WHO ATC |
|
0-L |
L03AA10 |
lenograstim |
WHO ATC |
|
0-L |
L03AA12 |
ancestim |
WHO ATC |
|
0-L |
L03AA13 |
pegfilgrastim |
WHO ATC |
|
0-L |
L03AB |
Interferons |
WHO ATC |
|
0-L |
L03AB01 |
interferon alfa natural |
WHO ATC |
|
0-L |
L03AB02 |
interferon beta natural |
WHO ATC |
|
0-L |
L03AB03 |
interferon gamma |
WHO ATC |
|
0-L |
L03AB04 |
interferon alfa-2a |
WHO ATC |
|
0-L |
L03AB05 |
interferon alfa-2b |
WHO ATC |
|
0-L |
L03AB06 |
interferon alfa-n1 |
WHO ATC |
|
0-L |
L03AB07 |
interferon beta-1a |
WHO ATC |
|
0-L |
L03AB08 |
interferon beta-1b |
WHO ATC |
|
0-L |
L03AB09 |
interferon alfacon-1 |
WHO ATC |
|
0-L |
L03AB10 |
peginterferon alfa-2b |
WHO ATC |
|
0-L |
L03AB11 |
peginterferon alfa-2a |
WHO ATC |
|
0-L |
L03AB60 |
peginterferon alfa-2b, combinations |
WHO ATC |
|
0-L |
L03AB61 |
peginterferon alfa-2a, combinations |
WHO ATC |
|
0-L |
L03AC |
Interleukins |
WHO ATC |
|
0-L |
L03AC01 |
aldesleukin |
WHO ATC |
|
0-L |
L03AC02 |
oprelvekin |
WHO ATC |
|
0-L |
L03AX |
Other immunostimulants |
WHO ATC |
|
0-L |
L03AX01 |
lentinan |
WHO ATC |
|
0-L |
L03AX02 |
roquinimex |
WHO ATC |
|
0-L |
L03AX03 |
BCG vaccine |
WHO ATC |
|
0-L |
L03AX04 |
pegademase |
WHO ATC |
|
0-L |
L03AX05 |
pidotimod |
WHO ATC |
|
0-L |
L03AX07 |
poly I:C |
WHO ATC |
|
0-L |
L03AX08 |
poly ICLC |
WHO ATC |
|
0-L |
L03AX09 |
thymopentin |
WHO ATC |
|
0-L |
L03AX10 |
immunocyanin |
WHO ATC |
|
0-L |
L03AX11 |
tasonermin |
WHO ATC |
|
0-L |
L03AX12 |
melanoma vaccine |
WHO ATC |
|
0-L |
L03AX13 |
glatiramer acetate |
WHO ATC |
|
0-L |
L03AX14 |
histamine dihydrochloride |
WHO ATC |
|
0-L |
L03AX15 |
mifamurtide |
WHO ATC |
|
0-L |
L03AX16 |
plerixafor |
WHO ATC |
|
0-L |
L04 |
IMMUNOSUPPRESSANTS |
WHO ATC |
|
0-L |
L04A |
IMMUNOSUPPRESSANTS |
WHO ATC |
|
0-L |
L04AA |
Selective immunosuppressants |
WHO ATC |
|
0-L |
L04AA02 |
muromonab-CD3 |
WHO ATC |
|
0-L |
L04AA03 |
antilymphocyte immunoglobulin (horse) |
WHO ATC |
|
0-L |
L04AA04 |
antithymocyte immunoglobulin (rabbit) |
WHO ATC |
|
0-L |
L04AA06 |
mycophenolic acid |
WHO ATC |
|
0-L |
L04AA10 |
sirolimus |
WHO ATC |
|
0-L |
L04AA13 |
leflunomide |
WHO ATC |
|
0-L |
L04AA15 |
alefacept |
WHO ATC |
|
0-L |
L04AA18 |
everolimus |
WHO ATC |
|
0-L |
L04AA19 |
gusperimus |
WHO ATC |
|
0-L |
L04AA21 |
efalizumab |
WHO ATC |
|
0-L |
L04AA22 |
abetimus |
WHO ATC |
|
0-L |
L04AA23 |
natalizumab |
WHO ATC |
|
0-L |
L04AA24 |
abatacept |
WHO ATC |
|
0-L |
L04AA25 |
eculizumab |
WHO ATC |
|
0-L |
L04AB |
Tumor necrosis factor alpha (TNF-α) inhibitors |
WHO ATC |
|
0-L |
L04AB01 |
etanercept |
WHO ATC |
|
0-L |
L04AB02 |
infliximab |
WHO ATC |
|
0-L |
L04AB03 |
afelimomab |
WHO ATC |
|
0-L |
L04AB04 |
adalimumab |
WHO ATC |
|
0-L |
L04AB05 |
certolizumab pegol |
WHO ATC |
|
0-L |
L04AB06 |
golimumab |
WHO ATC |
|
0-L |
L04AC |
Interleukin inhibitors |
WHO ATC |
|
0-L |
L04AC01 |
daclizumab |
WHO ATC |
|
0-L |
L04AC02 |
basiliximab |
WHO ATC |
|
0-L |
L04AC03 |
anakinra |
WHO ATC |
|
0-L |
L04AC04 |
rilonacept |
WHO ATC |
|
0-L |
L04AC05 |
ustekinumab |
WHO ATC |
|
0-L |
L04AC06 |
mepolizumab |
WHO ATC |
|
0-L |
L04AC07 |
tocilizumab |
WHO ATC |
|
0-L |
L04AC08 |
canakinumab |
WHO ATC |
|
0-L |
L04AD |
Calcineurin inhibitors |
WHO ATC |
|
0-L |
L04AD01 |
ciclosporin |
WHO ATC |
|
0-L |
L04AD02 |
tacrolimus |
WHO ATC |
|
0-L |
L04AX |
Other immunosuppressants |
WHO ATC |
|
0-L |
L04AX01 |
azathioprine |
WHO ATC |
|
0-L |
L04AX02 |
thalidomide |
WHO ATC |
|
0-L |
L04AX03 |
methotrexate |
WHO ATC |
|
0-L |
L04AX04 |
lenalidomide |
WHO ATC |
|
0-L |
M |
MUSCULO-SKELETAL SYSTEM |
WHO ATC |
|
0-L |
M01 |
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS |
WHO ATC |
|
0-L |
M01A |
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS |
WHO ATC |
|
0-L |
M01AA |
Butylpyrazolidines |
WHO ATC |
|
0-L |
M01AA01 |
phenylbutazone |
WHO ATC |
|
0-L |
M01AA02 |
mofebutazone |
WHO ATC |
|
0-L |
M01AA03 |
oxyphenbutazone |
WHO ATC |
|
0-L |
M01AA05 |
clofezone |
WHO ATC |
|
0-L |
M01AA06 |
kebuzone |
WHO ATC |
|
0-L |
M01AB |
Acetic acid derivatives and related substances |
WHO ATC |
|
0-L |
M01AB01 |
indometacin |
WHO ATC |
|
0-L |
M01AB02 |
sulindac |
WHO ATC |
|
0-L |
M01AB03 |
tolmetin |
WHO ATC |
|
0-L |
M01AB04 |
zomepirac |
WHO ATC |
|
0-L |
M01AB05 |
diclofenac |
WHO ATC |
|
0-L |
M01AB06 |
alclofenac |
WHO ATC |
|
0-L |
M01AB07 |
bumadizone |
WHO ATC |
|
0-L |
M01AB08 |
etodolac |
WHO ATC |
|
0-L |
M01AB09 |
lonazolac |
WHO ATC |
|
0-L |
M01AB10 |
fentiazac |
WHO ATC |
|
0-L |
M01AB11 |
acemetacin |
WHO ATC |
|
0-L |
M01AB12 |
difenpiramide |
WHO ATC |
|
0-L |
M01AB13 |
oxametacin |
WHO ATC |
|
0-L |
M01AB14 |
proglumetacin |
WHO ATC |
|
0-L |
M01AB15 |
ketorolac |
WHO ATC |
|
0-L |
M01AB16 |
aceclofenac |
WHO ATC |
|
0-L |
M01AB17 |
bufexamac |
WHO ATC |
|
0-L |
M01AB51 |
indometacin, combinations |
WHO ATC |
|
0-L |
M01AB55 |
diclofenac, combinations |
WHO ATC |
|
0-L |
M01AC |
Oxicams |
WHO ATC |
|
0-L |
M01AC01 |
piroxicam |
WHO ATC |
|
0-L |
M01AC02 |
tenoxicam |
WHO ATC |
|
0-L |
M01AC04 |
droxicam |
WHO ATC |
|
0-L |
M01AC05 |
lornoxicam |
WHO ATC |
|
0-L |
M01AC06 |
meloxicam |
WHO ATC |
|
0-L |
M01AE |
Propionic acid derivatives |
WHO ATC |
|
0-L |
M01AE01 |
ibuprofen |
WHO ATC |
|
0-L |
M01AE02 |
naproxen |
WHO ATC |
|
0-L |
M01AE03 |
ketoprofen |
WHO ATC |
|
0-L |
M01AE04 |
fenoprofen |
WHO ATC |
|
0-L |
M01AE05 |
fenbufen |
WHO ATC |
|
0-L |
M01AE06 |
benoxaprofen |
WHO ATC |
|
0-L |
M01AE07 |
suprofen |
WHO ATC |
|
0-L |
M01AE08 |
pirprofen |
WHO ATC |
|
0-L |
M01AE09 |
flurbiprofen |
WHO ATC |
|
0-L |
M01AE10 |
indoprofen |
WHO ATC |
|
0-L |
M01AE11 |
tiaprofenic acid |
WHO ATC |
|
0-L |
M01AE12 |
oxaprozin |
WHO ATC |
|
0-L |
M01AE13 |
ibuproxam |
WHO ATC |
|
0-L |
M01AE14 |
dexibuprofen |
WHO ATC |
|
0-L |
M01AE15 |
flunoxaprofen |
WHO ATC |
|
0-L |
M01AE16 |
alminoprofen |
WHO ATC |
|
0-L |
M01AE17 |
dexketoprofen |
WHO ATC |
|
0-L |
M01AE51 |
ibuprofen, combinations |
WHO ATC |
|
0-L |
M01AE53 |
ketoprofen, combinations |
WHO ATC |
|
0-L |
M01AG |
Fenamates |
WHO ATC |
|
0-L |
M01AG01 |
mefenamic acid |
WHO ATC |
|
0-L |
M01AG02 |
tolfenamic acid |
WHO ATC |
|
0-L |
M01AG03 |
flufenamic acid |
WHO ATC |
|
0-L |
M01AG04 |
meclofenamic acid |
WHO ATC |
|
0-L |
M01AH |
Coxibs |
WHO ATC |
|
0-L |
M01AH01 |
celecoxib |
WHO ATC |
|
0-L |
M01AH02 |
rofecoxib |
WHO ATC |
|
0-L |
M01AH03 |
valdecoxib |
WHO ATC |
|
0-L |
M01AH04 |
parecoxib |
WHO ATC |
|
0-L |
M01AH05 |
etoricoxib |
WHO ATC |
|
0-L |
M01AH06 |
lumiracoxib |
WHO ATC |
|
0-L |
M01AX |
Other antiinflammatory and antirheumatic agents, non-steroids |
WHO ATC |
|
0-L |
M01AX01 |
nabumetone |
WHO ATC |
|
0-L |
M01AX02 |
niflumic acid |
WHO ATC |
|
0-L |
M01AX04 |
azapropazone |
WHO ATC |
|
0-L |
M01AX05 |
glucosamine |
WHO ATC |
|
0-L |
M01AX07 |
benzydamine |
WHO ATC |
|
0-L |
M01AX12 |
glucosaminoglycan polysulfate |
WHO ATC |
|
0-L |
M01AX13 |
proquazone |
WHO ATC |
|
0-L |
M01AX14 |
orgotein |
WHO ATC |
|
0-L |
M01AX17 |
nimesulide |
WHO ATC |
|
0-L |
M01AX18 |
feprazone |
WHO ATC |
|
0-L |
M01AX21 |
diacerein |
WHO ATC |
|
0-L |
M01AX22 |
morniflumate |
WHO ATC |
|
0-L |
M01AX23 |
tenidap |
WHO ATC |
|
0-L |
M01AX24 |
oxaceprol |
WHO ATC |
|
0-L |
M01AX25 |
chondroitin sulfate |
WHO ATC |
|
0-L |
M01AX68 |
feprazone, combinations |
WHO ATC |
|
0-L |
M01B |
ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION |
WHO ATC |
|
0-L |
M01BA |
Antiinflammatory/antirheumatic agents in combination with corticosteroids |
WHO ATC |
|
0-L |
M01BA01 |
phenylbutazone and corticosteroids |
WHO ATC |
|
0-L |
M01BA02 |
dipyrocetyl and corticosteroids |
WHO ATC |
|
0-L |
M01BA03 |
acetylsalicylic acid and corticosteroids |
WHO ATC |
|
0-L |
M01BX |
Other antiinflammatory/antirheumatic agents in combination with other drugs |
WHO ATC |
|
0-L |
M01C |
SPECIFIC ANTIRHEUMATIC AGENTS |
WHO ATC |
|
0-L |
M01CA |
Quinolines |
WHO ATC |
|
0-L |
M01CA03 |
oxycinchophen |
WHO ATC |
|
0-L |
M01CB |
Gold preparations |
WHO ATC |
|
0-L |
M01CB01 |
sodium aurothiomalate |
WHO ATC |
|
0-L |
M01CB02 |
sodium aurotiosulfate |
WHO ATC |
|
0-L |
M01CB03 |
auranofin |
WHO ATC |
|
0-L |
M01CB04 |
aurothioglucose |
WHO ATC |
|
0-L |
M01CB05 |
aurotioprol |
WHO ATC |
|
0-L |
M01CC |
Penicillamine and similar agents |
WHO ATC |
|
0-L |
M01CC01 |
penicillamine |
WHO ATC |
|
0-L |
M01CC02 |
bucillamine |
WHO ATC |
|
0-L |
M01CX |
Other specific antirheumatic agents |
WHO ATC |
|
0-L |
M02 |
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN |
WHO ATC |
|
0-L |
M02A |
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN |
WHO ATC |
|
0-L |
M02AA |
Antiinflammatory preparations, non-steroids for topical use |
WHO ATC |
|
0-L |
M02AA01 |
phenylbutazone |
WHO ATC |
|
0-L |
M02AA02 |
mofebutazone |
WHO ATC |
|
0-L |
M02AA03 |
clofezone |
WHO ATC |
|
0-L |
M02AA04 |
oxyphenbutazone |
WHO ATC |
|
0-L |
M02AA05 |
benzydamine |
WHO ATC |
|
0-L |
M02AA06 |
etofenamate |
WHO ATC |
|
0-L |
M02AA07 |
piroxicam |
WHO ATC |
|
0-L |
M02AA08 |
felbinac |
WHO ATC |
|
0-L |
M02AA09 |
bufexamac |
WHO ATC |
|
0-L |
M02AA10 |
ketoprofen |
WHO ATC |
|
0-L |
M02AA11 |
bendazac |
WHO ATC |
|
0-L |
M02AA12 |
naproxen |
WHO ATC |
|
0-L |
M02AA13 |
ibuprofen |
WHO ATC |
|
0-L |
M02AA14 |
fentiazac |
WHO ATC |
|
0-L |
M02AA15 |
diclofenac |
WHO ATC |
|
0-L |
M02AA16 |
feprazone |
WHO ATC |
|
0-L |
M02AA17 |
niflumic acid |
WHO ATC |
|
0-L |
M02AA18 |
meclofenamic acid |
WHO ATC |
|
0-L |
M02AA19 |
flurbiprofen |
WHO ATC |
|
0-L |
M02AA21 |
tolmetin |
WHO ATC |
|
0-L |
M02AA22 |
suxibuzone |
WHO ATC |
|
0-L |
M02AA23 |
indometacin |
WHO ATC |
|
0-L |
M02AA24 |
nifenazone |
WHO ATC |
|
0-L |
M02AA25 |
aceclofenac |
WHO ATC |
|
0-L |
M02AB |
Capsaicin and similar agents |
WHO ATC |
|
0-L |
M02AB01 |
capsaicin |
WHO ATC |
|
0-L |
M02AB02 |
zucapsaicin |
WHO ATC |
|
0-L |
M02AC |
Preparations with salicylic acid derivatives |
WHO ATC |
|
0-L |
M02AX |
Other topical products for joint and muscular pain |
WHO ATC |
|
0-L |
M02AX02 |
tolazoline |
WHO ATC |
|
0-L |
M02AX03 |
dimethyl sulfoxide |
WHO ATC |
|
0-L |
M02AX10 |
various |
WHO ATC |
|
0-L |
M03 |
MUSCLE RELAXANTS |
WHO ATC |
|
0-L |
M03A |
MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS |
WHO ATC |
|
0-L |
M03AA |
Curare alkaloids |
WHO ATC |
|
0-L |
M03AA01 |
alcuronium |
WHO ATC |
|
0-L |
M03AA02 |
tubocurarine |
WHO ATC |
|
0-L |
M03AA04 |
dimethyltubocurarine |
WHO ATC |
|
0-L |
M03AB |
Choline derivatives |
WHO ATC |
|
0-L |
M03AB01 |
suxamethonium |
WHO ATC |
|
0-L |
M03AC |
Other quaternary ammonium compounds |
WHO ATC |
|
0-L |
M03AC01 |
pancuronium |
WHO ATC |
|
0-L |
M03AC02 |
gallamine |
WHO ATC |
|
0-L |
M03AC03 |
vecuronium |
WHO ATC |
|
0-L |
M03AC04 |
atracurium |
WHO ATC |
|
0-L |
M03AC05 |
hexafluronium |
WHO ATC |
|
0-L |
M03AC06 |
pipecuronium bromide |
WHO ATC |
|
0-L |
M03AC07 |
doxacurium chloride |
WHO ATC |
|
0-L |
M03AC08 |
fazadinium bromide |
WHO ATC |
|
0-L |
M03AC09 |
rocuronium bromide |
WHO ATC |
|
0-L |
M03AC10 |
mivacurium chloride |
WHO ATC |
|
0-L |
M03AC11 |
cisatracurium |
WHO ATC |
|
0-L |
M03AX |
Other muscle relaxants, peripherally acting agents |
WHO ATC |
|
0-L |
M03AX01 |
botulinum toxin |
WHO ATC |
|
0-L |
M03B |
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS |
WHO ATC |
|
0-L |
M03BA |
Carbamic acid esters |
WHO ATC |
|
0-L |
M03BA01 |
phenprobamate |
WHO ATC |
|
0-L |
M03BA02 |
carisoprodol |
WHO ATC |
|
0-L |
M03BA03 |
methocarbamol |
WHO ATC |
|
0-L |
M03BA04 |
styramate |
WHO ATC |
|
0-L |
M03BA05 |
febarbamate |
WHO ATC |
|
0-L |
M03BA51 |
phenprobamate, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
M03BA52 |
carisoprodol, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
M03BA53 |
methocarbamol, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
M03BA71 |
phenprobamate, combinations with psycholeptics |
WHO ATC |
|
0-L |
M03BA72 |
carisoprodol, combinations with psycholeptics |
WHO ATC |
|
0-L |
M03BA73 |
methocarbamol, combinations with psycholeptics |
WHO ATC |
|
0-L |
M03BB |
Oxazol, thiazine, and triazine derivatives |
WHO ATC |
|
0-L |
M03BB02 |
chlormezanone |
WHO ATC |
|
0-L |
M03BB03 |
chlorzoxazone |
WHO ATC |
|
0-L |
M03BB52 |
chlormezanone, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
M03BB53 |
chlorzoxazone, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
M03BB72 |
chlormezanone, combinations with psycholeptics |
WHO ATC |
|
0-L |
M03BB73 |
chlorzoxazone, combinations with psycholeptics |
WHO ATC |
|
0-L |
M03BC |
Ethers, chemically close to antihistamines |
WHO ATC |
|
0-L |
M03BC01 |
orphenadrine (citrate) |
WHO ATC |
|
0-L |
M03BC51 |
orphenadrine, combinations |
WHO ATC |
|
0-L |
M03BX |
Other centrally acting agents |
WHO ATC |
|
0-L |
M03BX01 |
baclofen |
WHO ATC |
|
0-L |
M03BX02 |
tizanidine |
WHO ATC |
|
0-L |
M03BX03 |
pridinol |
WHO ATC |
|
0-L |
M03BX04 |
tolperisone |
WHO ATC |
|
0-L |
M03BX05 |
thiocolchicoside |
WHO ATC |
|
0-L |
M03BX06 |
mephenesin |
WHO ATC |
|
0-L |
M03BX07 |
tetrazepam |
WHO ATC |
|
0-L |
M03BX08 |
cyclobenzaprine |
WHO ATC |
|
0-L |
M03BX09 |
eperisone |
WHO ATC |
|
0-L |
M03BX30 |
fenyramidol |
WHO ATC |
|
0-L |
M03C |
MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS |
WHO ATC |
|
0-L |
M03CA |
Dantrolene and derivatives |
WHO ATC |
|
0-L |
M03CA01 |
dantrolene |
WHO ATC |
|
0-L |
M04 |
ANTIGOUT PREPARATIONS |
WHO ATC |
|
0-L |
M04A |
ANTIGOUT PREPARATIONS |
WHO ATC |
|
0-L |
M04AA |
Preparations inhibiting uric acid production |
WHO ATC |
|
0-L |
M04AA01 |
allopurinol |
WHO ATC |
|
0-L |
M04AA02 |
tisopurine |
WHO ATC |
|
0-L |
M04AA03 |
febuxostat |
WHO ATC |
|
0-L |
M04AA51 |
allopurinol, combinations |
WHO ATC |
|
0-L |
M04AB |
Preparations increasing uric acid excretion |
WHO ATC |
|
0-L |
M04AB01 |
probenecid |
WHO ATC |
|
0-L |
M04AB02 |
sulfinpyrazone |
WHO ATC |
|
0-L |
M04AB03 |
benzbromarone |
WHO ATC |
|
0-L |
M04AB04 |
isobromindione |
WHO ATC |
|
0-L |
M04AC |
Preparations with no effect on uric acid metabolism |
WHO ATC |
|
0-L |
M04AC01 |
colchicine |
WHO ATC |
|
0-L |
M04AC02 |
cinchophen |
WHO ATC |
|
0-L |
M04AX |
Other antigout preparations |
WHO ATC |
|
0-L |
M04AX01 |
urate oxidase |
WHO ATC |
|
0-L |
M04AX02 |
pegloticase |
WHO ATC |
|
0-L |
M05 |
DRUGS FOR TREATMENT OF BONE DISEASES |
WHO ATC |
|
0-L |
M05B |
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION |
WHO ATC |
|
0-L |
M05BA |
Bisphosphonates |
WHO ATC |
|
0-L |
M05BA01 |
etidronic acid |
WHO ATC |
|
0-L |
M05BA02 |
clodronic acid |
WHO ATC |
|
0-L |
M05BA03 |
pamidronic acid |
WHO ATC |
|
0-L |
M05BA04 |
alendronic acid |
WHO ATC |
|
0-L |
M05BA05 |
tiludronic acid |
WHO ATC |
|
0-L |
M05BA06 |
ibandronic acid |
WHO ATC |
|
0-L |
M05BA07 |
risedronic acid |
WHO ATC |
|
0-L |
M05BA08 |
zoledronic acid |
WHO ATC |
|
0-L |
M05BB |
Bisphosphonates, combinations |
WHO ATC |
|
0-L |
M05BB01 |
etidronic acid and calcium, sequential |
WHO ATC |
|
0-L |
M05BB02 |
risedronic acid and calcium, sequential |
WHO ATC |
|
0-L |
M05BB03 |
alendronic acid and colecalciferol |
WHO ATC |
|
0-L |
M05BB04 |
risedronic acid, calcium and colecalciferol, sequential |
WHO ATC |
|
0-L |
M05BC |
Bone morphogenetic proteins |
WHO ATC |
|
0-L |
M05BC01 |
dibotermin alfa |
WHO ATC |
|
0-L |
M05BC02 |
eptotermin alfa |
WHO ATC |
|
0-L |
M05BX |
Other drugs affecting bone structure and mineralization |
WHO ATC |
|
0-L |
M05BX01 |
ipriflavone |
WHO ATC |
|
0-L |
M05BX02 |
aluminium chlorohydrate |
WHO ATC |
|
0-L |
M05BX03 |
strontium ranelate |
WHO ATC |
|
0-L |
M05BX04 |
denosumab |
WHO ATC |
|
0-L |
M09 |
OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM |
WHO ATC |
|
0-L |
M09A |
OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM |
WHO ATC |
|
0-L |
M09AA |
Quinine and derivatives |
WHO ATC |
|
0-L |
M09AA01 |
hydroquinine |
WHO ATC |
|
0-L |
M09AA72 |
quinine, combinations with psycholeptics |
WHO ATC |
|
0-L |
M09AB |
Enzymes |
WHO ATC |
|
0-L |
M09AB01 |
chymopapain |
WHO ATC |
|
0-L |
M09AB52 |
trypsin, combinations |
WHO ATC |
|
0-L |
M09AX |
Other drugs for disorders of the musculo-skeletal system |
WHO ATC |
|
0-L |
M09AX01 |
hyaluronic acid |
WHO ATC |
|
0-L |
N |
NERVOUS SYSTEM |
WHO ATC |
|
0-L |
N01 |
ANESTHETICS |
WHO ATC |
|
0-L |
N01A |
ANESTHETICS, GENERAL |
WHO ATC |
|
0-L |
N01AA |
Ethers |
WHO ATC |
|
0-L |
N01AA01 |
diethyl ether |
WHO ATC |
|
0-L |
N01AA02 |
vinyl ether |
WHO ATC |
|
0-L |
N01AB |
Halogenated hydrocarbons |
WHO ATC |
|
0-L |
N01AB01 |
halothane |
WHO ATC |
|
0-L |
N01AB02 |
chloroform |
WHO ATC |
|
0-L |
N01AB04 |
enflurane |
WHO ATC |
|
0-L |
N01AB05 |
trichloroethylene |
WHO ATC |
|
0-L |
N01AB06 |
isoflurane |
WHO ATC |
|
0-L |
N01AB07 |
desflurane |
WHO ATC |
|
0-L |
N01AB08 |
sevoflurane |
WHO ATC |
|
0-L |
N01AF |
Barbiturates, plain |
WHO ATC |
|
0-L |
N01AF01 |
methohexital |
WHO ATC |
|
0-L |
N01AF02 |
hexobarbital |
WHO ATC |
|
0-L |
N01AF03 |
thiopental |
WHO ATC |
|
0-L |
N01AG |
Barbiturates in combination with other drugs |
WHO ATC |
|
0-L |
N01AG01 |
narcobarbital |
WHO ATC |
|
0-L |
N01AH |
Opioid anesthetics |
WHO ATC |
|
0-L |
N01AH01 |
fentanyl |
WHO ATC |
|
0-L |
N01AH02 |
alfentanil |
WHO ATC |
|
0-L |
N01AH03 |
sufentanil |
WHO ATC |
|
0-L |
N01AH04 |
phenoperidine |
WHO ATC |
|
0-L |
N01AH05 |
anileridine |
WHO ATC |
|
0-L |
N01AH06 |
remifentanil |
WHO ATC |
|
0-L |
N01AH51 |
fentanyl, combinations |
WHO ATC |
|
0-L |
N01AX |
Other general anesthetics |
WHO ATC |
|
0-L |
N01AX01 |
droperidol |
WHO ATC |
|
0-L |
N01AX03 |
ketamine |
WHO ATC |
|
0-L |
N01AX04 |
propanidid |
WHO ATC |
|
0-L |
N01AX05 |
alfaxalone |
WHO ATC |
|
0-L |
N01AX07 |
etomidate |
WHO ATC |
|
0-L |
N01AX10 |
propofol |
WHO ATC |
|
0-L |
N01AX11 |
sodium oxybate |
WHO ATC |
|
0-L |
N01AX13 |
nitrous oxide |
WHO ATC |
|
0-L |
N01AX14 |
esketamine |
WHO ATC |
|
0-L |
N01AX15 |
xenon |
WHO ATC |
|
0-L |
N01AX63 |
nitrous oxide, combinations |
WHO ATC |
|
0-L |
N01B |
ANESTHETICS, LOCAL |
WHO ATC |
|
0-L |
N01BA |
Esters of aminobenzoic acid |
WHO ATC |
|
0-L |
N01BA01 |
metabutethamine |
WHO ATC |
|
0-L |
N01BA02 |
procaine |
WHO ATC |
|
0-L |
N01BA03 |
tetracaine |
WHO ATC |
|
0-L |
N01BA04 |
chloroprocaine |
WHO ATC |
|
0-L |
N01BA05 |
benzocaine |
WHO ATC |
|
0-L |
N01BA52 |
procaine, combinations |
WHO ATC |
|
0-L |
N01BB |
Amides |
WHO ATC |
|
0-L |
N01BB01 |
bupivacaine |
WHO ATC |
|
0-L |
N01BB02 |
lidocaine |
WHO ATC |
|
0-L |
N01BB03 |
mepivacaine |
WHO ATC |
|
0-L |
N01BB04 |
prilocaine |
WHO ATC |
|
0-L |
N01BB05 |
butanilicaine |
WHO ATC |
|
0-L |
N01BB06 |
cinchocaine |
WHO ATC |
|
0-L |
N01BB07 |
etidocaine |
WHO ATC |
|
0-L |
N01BB08 |
articaine |
WHO ATC |
|
0-L |
N01BB09 |
ropivacaine |
WHO ATC |
|
0-L |
N01BB10 |
levobupivacaine |
WHO ATC |
|
0-L |
N01BB20 |
combinations |
WHO ATC |
|
0-L |
N01BB51 |
bupivacaine, combinations |
WHO ATC |
|
0-L |
N01BB52 |
lidocaine, combinations |
WHO ATC |
|
0-L |
N01BB53 |
mepivacaine, combinations |
WHO ATC |
|
0-L |
N01BB54 |
prilocaine, combinations |
WHO ATC |
|
0-L |
N01BB57 |
etidocaine, combinations |
WHO ATC |
|
0-L |
N01BB58 |
articaine, combinations |
WHO ATC |
|
0-L |
N01BC |
Esters of benzoic acid |
WHO ATC |
|
0-L |
N01BC01 |
cocaine |
WHO ATC |
|
0-L |
N01BX |
Other local anesthetics |
WHO ATC |
|
0-L |
N01BX01 |
ethyl chloride |
WHO ATC |
|
0-L |
N01BX02 |
dyclonine |
WHO ATC |
|
0-L |
N01BX03 |
phenol |
WHO ATC |
|
0-L |
N01BX04 |
capsaicin |
WHO ATC |
|
0-L |
N02 |
ANALGESICS |
WHO ATC |
|
0-L |
N02A |
OPIOIDS |
WHO ATC |
|
0-L |
N02AA |
Natural opium alkaloids |
WHO ATC |
|
0-L |
N02AA01 |
morphine |
WHO ATC |
|
0-L |
N02AA02 |
opium |
WHO ATC |
|
0-L |
N02AA03 |
hydromorphone |
WHO ATC |
|
0-L |
N02AA04 |
nicomorphine |
WHO ATC |
|
0-L |
N02AA05 |
oxycodone |
WHO ATC |
|
0-L |
N02AA08 |
dihydrocodeine |
WHO ATC |
|
0-L |
N02AA09 |
diamorphine |
WHO ATC |
|
0-L |
N02AA10 |
papaveretum |
WHO ATC |
|
0-L |
N02AA51 |
morphine, combinations |
WHO ATC |
|
0-L |
N02AA55 |
oxycodone, combinations |
WHO ATC |
|
0-L |
N02AA58 |
dihydrocodeine, combinations |
WHO ATC |
|
0-L |
N02AA59 |
codeine, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
N02AA79 |
codeine, combinations with psycholeptics |
WHO ATC |
|
0-L |
N02AB |
Phenylpiperidine derivatives |
WHO ATC |
|
0-L |
N02AB01 |
ketobemidone |
WHO ATC |
|
0-L |
N02AB02 |
pethidine |
WHO ATC |
|
0-L |
N02AB03 |
fentanyl |
WHO ATC |
|
0-L |
N02AB52 |
pethidine, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
N02AB72 |
pethidine, combinations with psycholeptics |
WHO ATC |
|
0-L |
N02AC |
Diphenylpropylamine derivatives |
WHO ATC |
|
0-L |
N02AC01 |
dextromoramide |
WHO ATC |
|
0-L |
N02AC03 |
piritramide |
WHO ATC |
|
0-L |
N02AC04 |
dextropropoxyphene |
WHO ATC |
|
0-L |
N02AC05 |
bezitramide |
WHO ATC |
|
0-L |
N02AC52 |
methadone, comb. excl. psycholeptics |
WHO ATC |
|
0-L |
N02AC54 |
dextropropoxyphene, comb. excl. psycholeptics |
WHO ATC |
|
0-L |
N02AC74 |
dextropropoxyphene, comb. with psycholeptics |
WHO ATC |
|
0-L |
N02AD |
Benzomorphan derivatives |
WHO ATC |
|
0-L |
N02AD01 |
pentazocine |
WHO ATC |
|
0-L |
N02AD02 |
phenazocine |
WHO ATC |
|
0-L |
N02AE |
Oripavine derivatives |
WHO ATC |
|
0-L |
N02AE01 |
buprenorphine |
WHO ATC |
|
0-L |
N02AF |
Morphinan derivatives |
WHO ATC |
|
0-L |
N02AF01 |
butorphanol |
WHO ATC |
|
0-L |
N02AF02 |
nalbuphine |
WHO ATC |
|
0-L |
N02AG |
Opioids in combination with antispasmodics |
WHO ATC |
|
0-L |
N02AG01 |
morphine and antispasmodics |
WHO ATC |
|
0-L |
N02AG02 |
ketobemidone and antispasmodics |
WHO ATC |
|
0-L |
N02AG03 |
pethidine and antispasmodics |
WHO ATC |
|
0-L |
N02AG04 |
hydromorphone and antispasmodics |
WHO ATC |
|
0-L |
N02AX |
Other opioids |
WHO ATC |
|
0-L |
N02AX01 |
tilidine |
WHO ATC |
|
0-L |
N02AX02 |
tramadol |
WHO ATC |
|
0-L |
N02AX03 |
dezocine |
WHO ATC |
|
0-L |
N02AX05 |
meptazinol |
WHO ATC |
|
0-L |
N02AX06 |
tapentadol |
WHO ATC |
|
0-L |
N02AX52 |
tramadol, combinations |
WHO ATC |
|
0-L |
N02B |
OTHER ANALGESICS AND ANTIPYRETICS |
WHO ATC |
|
0-L |
N02BA |
Salicylic acid and derivatives |
WHO ATC |
|
0-L |
N02BA01 |
acetylsalicylic acid |
WHO ATC |
|
0-L |
N02BA02 |
aloxiprin |
WHO ATC |
|
0-L |
N02BA03 |
choline salicylate |
WHO ATC |
|
0-L |
N02BA04 |
sodium salicylate |
WHO ATC |
|
0-L |
N02BA05 |
salicylamide |
WHO ATC |
|
0-L |
N02BA06 |
salsalate |
WHO ATC |
|
0-L |
N02BA07 |
ethenzamide |
WHO ATC |
|
0-L |
N02BA08 |
morpholine salicylate |
WHO ATC |
|
0-L |
N02BA09 |
dipyrocetyl |
WHO ATC |
|
0-L |
N02BA10 |
benorilate |
WHO ATC |
|
0-L |
N02BA11 |
diflunisal |
WHO ATC |
|
0-L |
N02BA12 |
potassium salicylate |
WHO ATC |
|
0-L |
N02BA14 |
guacetisal |
WHO ATC |
|
0-L |
N02BA15 |
carbasalate calcium |
WHO ATC |
|
0-L |
N02BA16 |
imidazole salicylate |
WHO ATC |
|
0-L |
N02BA51 |
acetylsalicylic acid, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
N02BA55 |
salicylamide, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
N02BA57 |
ethenzamide, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
N02BA59 |
dipyrocetyl, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
N02BA65 |
carbasalate calcium combinations excl. psycholeptics |
WHO ATC |
|
0-L |
N02BA71 |
acetylsalicylic acid, combinations with psycholeptics |
WHO ATC |
|
0-L |
N02BA75 |
salicylamide, combinations with psycholeptics |
WHO ATC |
|
0-L |
N02BA77 |
ethenzamide, combinations with psycholeptics |
WHO ATC |
|
0-L |
N02BA79 |
dipyrocetyl, combinations with psycholeptics |
WHO ATC |
|
0-L |
N02BB |
Pyrazolones |
WHO ATC |
|
0-L |
N02BB01 |
phenazone |
WHO ATC |
|
0-L |
N02BB02 |
metamizole sodium |
WHO ATC |
|
0-L |
N02BB03 |
aminophenazone |
WHO ATC |
|
0-L |
N02BB04 |
propyphenazone |
WHO ATC |
|
0-L |
N02BB05 |
nifenazone |
WHO ATC |
|
0-L |
N02BB51 |
phenazone, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
N02BB52 |
metamizole sodium, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
N02BB53 |
aminophenazone, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
N02BB54 |
propyphenazone, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
N02BB71 |
phenazone, combinations with psycholeptics |
WHO ATC |
|
0-L |
N02BB72 |
metamizole sodium, combinations with psycholeptics |
WHO ATC |
|
0-L |
N02BB73 |
aminophenazone, combinations with psycholeptics |
WHO ATC |
|
0-L |
N02BB74 |
propyphenazone, combinations with psycholeptics |
WHO ATC |
|
0-L |
N02BE |
Anilides |
WHO ATC |
|
0-L |
N02BE01 |
paracetamol |
WHO ATC |
|
0-L |
N02BE03 |
phenacetin |
WHO ATC |
|
0-L |
N02BE04 |
bucetin |
WHO ATC |
|
0-L |
N02BE05 |
propacetamol |
WHO ATC |
|
0-L |
N02BE51 |
paracetamol, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
N02BE53 |
phenacetin, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
N02BE54 |
bucetin, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
N02BE71 |
paracetamol, combinations with psycholeptics |
WHO ATC |
|
0-L |
N02BE73 |
phenacetin, combinations with psycholeptics |
WHO ATC |
|
0-L |
N02BE74 |
bucetin, combinations with psycholeptics |
WHO ATC |
|
0-L |
N02BG |
Other analgesics and antipyretics |
WHO ATC |
|
0-L |
N02BG02 |
rimazolium |
WHO ATC |
|
0-L |
N02BG03 |
glafenine |
WHO ATC |
|
0-L |
N02BG04 |
floctafenine |
WHO ATC |
|
0-L |
N02BG05 |
viminol |
WHO ATC |
|
0-L |
N02BG06 |
nefopam |
WHO ATC |
|
0-L |
N02BG07 |
flupirtine |
WHO ATC |
|
0-L |
N02BG08 |
ziconotide |
WHO ATC |
|
0-L |
N02BG09 |
methoxyflurane |
WHO ATC |
|
0-L |
N02BG10 |
nabiximols |
WHO ATC |
|
0-L |
N02C |
ANTIMIGRAINE PREPARATIONS |
WHO ATC |
|
0-L |
N02CA |
Ergot alkaloids |
WHO ATC |
|
0-L |
N02CA01 |
dihydroergotamine |
WHO ATC |
|
0-L |
N02CA02 |
ergotamine |
WHO ATC |
|
0-L |
N02CA04 |
methysergide |
WHO ATC |
|
0-L |
N02CA07 |
lisuride |
WHO ATC |
|
0-L |
N02CA51 |
dihydroergotamine, combinations |
WHO ATC |
|
0-L |
N02CA52 |
ergotamine, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
N02CA72 |
ergotamine, combinations with psycholeptics |
WHO ATC |
|
0-L |
N02CB |
Corticosteroid derivatives |
WHO ATC |
|
0-L |
N02CB01 |
flumedroxone |
WHO ATC |
|
0-L |
N02CC |
Selective serotonin (5HT1) agonists |
WHO ATC |
|
0-L |
N02CC01 |
sumatriptan |
WHO ATC |
|
0-L |
N02CC02 |
naratriptan |
WHO ATC |
|
0-L |
N02CC03 |
zolmitriptan |
WHO ATC |
|
0-L |
N02CC04 |
rizatriptan |
WHO ATC |
|
0-L |
N02CC05 |
almotriptan |
WHO ATC |
|
0-L |
N02CC06 |
eletriptan |
WHO ATC |
|
0-L |
N02CC07 |
frovatriptan |
WHO ATC |
|
0-L |
N02CX |
Other antimigraine preparations |
WHO ATC |
|
0-L |
N02CX01 |
pizotifen |
WHO ATC |
|
0-L |
N02CX02 |
clonidine |
WHO ATC |
|
0-L |
N02CX03 |
iprazochrome |
WHO ATC |
|
0-L |
N02CX05 |
dimetotiazine |
WHO ATC |
|
0-L |
N02CX06 |
oxetorone |
WHO ATC |
|
0-L |
N03 |
ANTIEPILEPTICS |
WHO ATC |
|
0-L |
N03A |
ANTIEPILEPTICS |
WHO ATC |
|
0-L |
N03AA |
Barbiturates and derivatives |
WHO ATC |
|
0-L |
N03AA01 |
methylphenobarbital |
WHO ATC |
|
0-L |
N03AA02 |
phenobarbital |
WHO ATC |
|
0-L |
N03AA03 |
primidone |
WHO ATC |
|
0-L |
N03AA04 |
barbexaclone |
WHO ATC |
|
0-L |
N03AA30 |
metharbital |
WHO ATC |
|
0-L |
N03AB |
Hydantoin derivatives |
WHO ATC |
|
0-L |
N03AB01 |
ethotoin |
WHO ATC |
|
0-L |
N03AB02 |
phenytoin |
WHO ATC |
|
0-L |
N03AB03 |
amino(diphenylhydantoin) valeric acid |
WHO ATC |
|
0-L |
N03AB04 |
mephenytoin |
WHO ATC |
|
0-L |
N03AB05 |
fosphenytoin |
WHO ATC |
|
0-L |
N03AB52 |
phenytoin, combinations |
WHO ATC |
|
0-L |
N03AB54 |
mephenytoin, combinations |
WHO ATC |
|
0-L |
N03AC |
Oxazolidine derivatives |
WHO ATC |
|
0-L |
N03AC01 |
paramethadione |
WHO ATC |
|
0-L |
N03AC02 |
trimethadione |
WHO ATC |
|
0-L |
N03AC03 |
ethadione |
WHO ATC |
|
0-L |
N03AD |
Succinimide derivatives |
WHO ATC |
|
0-L |
N03AD01 |
ethosuximide |
WHO ATC |
|
0-L |
N03AD02 |
phensuximide |
WHO ATC |
|
0-L |
N03AD03 |
mesuximide |
WHO ATC |
|
0-L |
N03AD51 |
ethosuximide, combinations |
WHO ATC |
|
0-L |
N03AE |
Benzodiazepine derivatives |
WHO ATC |
|
0-L |
N03AE01 |
clonazepam |
WHO ATC |
|
0-L |
N03AF |
Carboxamide derivatives |
WHO ATC |
|
0-L |
N03AF01 |
carbamazepine |
WHO ATC |
|
0-L |
N03AF02 |
oxcarbazepine |
WHO ATC |
|
0-L |
N03AF03 |
rufinamide |
WHO ATC |
|
0-L |
N03AF04 |
eslicarbazepine |
WHO ATC |
|
0-L |
N03AG |
Fatty acid derivatives |
WHO ATC |
|
0-L |
N03AG01 |
valproic acid |
WHO ATC |
|
0-L |
N03AG02 |
valpromide |
WHO ATC |
|
0-L |
N03AG03 |
aminobutyric acid |
WHO ATC |
|
0-L |
N03AG04 |
vigabatrin |
WHO ATC |
|
0-L |
N03AG05 |
progabide |
WHO ATC |
|
0-L |
N03AG06 |
tiagabine |
WHO ATC |
|
0-L |
N03AX |
Other antiepileptics |
WHO ATC |
|
0-L |
N03AX03 |
sultiame |
WHO ATC |
|
0-L |
N03AX07 |
phenacemide |
WHO ATC |
|
0-L |
N03AX09 |
lamotrigine |
WHO ATC |
|
0-L |
N03AX10 |
felbamate |
WHO ATC |
|
0-L |
N03AX11 |
topiramate |
WHO ATC |
|
0-L |
N03AX12 |
gabapentin |
WHO ATC |
|
0-L |
N03AX13 |
pheneturide |
WHO ATC |
|
0-L |
N03AX14 |
levetiracetam |
WHO ATC |
|
0-L |
N03AX15 |
zonisamide |
WHO ATC |
|
0-L |
N03AX16 |
pregabalin |
WHO ATC |
|
0-L |
N03AX17 |
stiripentol |
WHO ATC |
|
0-L |
N03AX18 |
lacosamide |
WHO ATC |
|
0-L |
N03AX19 |
carisbamate |
WHO ATC |
|
0-L |
N03AX30 |
beclamide |
WHO ATC |
|
0-L |
N04 |
ANTI-PARKINSON DRUGS |
WHO ATC |
|
0-L |
N04A |
ANTICHOLINERGIC AGENTS |
WHO ATC |
|
0-L |
N04AA |
Tertiary amines |
WHO ATC |
|
0-L |
N04AA01 |
trihexyphenidyl |
WHO ATC |
|
0-L |
N04AA02 |
biperiden |
WHO ATC |
|
0-L |
N04AA03 |
metixene |
WHO ATC |
|
0-L |
N04AA04 |
procyclidine |
WHO ATC |
|
0-L |
N04AA05 |
profenamine |
WHO ATC |
|
0-L |
N04AA08 |
dexetimide |
WHO ATC |
|
0-L |
N04AA09 |
phenglutarimide |
WHO ATC |
|
0-L |
N04AA10 |
mazaticol |
WHO ATC |
|
0-L |
N04AA11 |
bornaprine |
WHO ATC |
|
0-L |
N04AA12 |
tropatepine |
WHO ATC |
|
0-L |
N04AB |
Ethers chemically close to antihistamines |
WHO ATC |
|
0-L |
N04AB01 |
etanautine |
WHO ATC |
|
0-L |
N04AB02 |
orphenadrine (chloride) |
WHO ATC |
|
0-L |
N04AC |
Ethers of tropine or tropine derivatives |
WHO ATC |
|
0-L |
N04AC01 |
benzatropine |
WHO ATC |
|
0-L |
N04AC30 |
etybenzatropine |
WHO ATC |
|
0-L |
N04B |
DOPAMINERGIC AGENTS |
WHO ATC |
|
0-L |
N04BA |
Dopa and dopa derivatives |
WHO ATC |
|
0-L |
N04BA01 |
levodopa |
WHO ATC |
|
0-L |
N04BA02 |
levodopa and decarboxylase inhibitor |
WHO ATC |
|
0-L |
N04BA03 |
levodopa, decarboxylase inhibitor and COMT inhibitor |
WHO ATC |
|
0-L |
N04BA04 |
melevodopa |
WHO ATC |
|
0-L |
N04BA05 |
melevodopa and decarboxylase inhibitor |
WHO ATC |
|
0-L |
N04BA06 |
etilevodopa and decarboxylase inhibitor |
WHO ATC |
|
0-L |
N04BB |
Adamantane derivatives |
WHO ATC |
|
0-L |
N04BB01 |
amantadine |
WHO ATC |
|
0-L |
N04BC |
Dopamine agonists |
WHO ATC |
|
0-L |
N04BC01 |
bromocriptine |
WHO ATC |
|
0-L |
N04BC02 |
pergolide |
WHO ATC |
|
0-L |
N04BC03 |
dihydroergocryptine mesylate |
WHO ATC |
|
0-L |
N04BC04 |
ropinirole |
WHO ATC |
|
0-L |
N04BC05 |
pramipexole |
WHO ATC |
|
0-L |
N04BC06 |
cabergoline |
WHO ATC |
|
0-L |
N04BC07 |
apomorphine |
WHO ATC |
|
0-L |
N04BC08 |
piribedil |
WHO ATC |
|
0-L |
N04BC09 |
rotigotine |
WHO ATC |
|
0-L |
N04BD |
Monoamine oxidase B inhibitors |
WHO ATC |
|
0-L |
N04BD01 |
selegiline |
WHO ATC |
|
0-L |
N04BD02 |
rasagiline |
WHO ATC |
|
0-L |
N04BX |
Other dopaminergic agents |
WHO ATC |
|
0-L |
N04BX01 |
tolcapone |
WHO ATC |
|
0-L |
N04BX02 |
entacapone |
WHO ATC |
|
0-L |
N04BX03 |
budipine |
WHO ATC |
|
0-L |
N05 |
PSYCHOLEPTICS |
WHO ATC |
|
0-L |
N05A |
ANTIPSYCHOTICS |
WHO ATC |
|
0-L |
N05AA |
Phenothiazines with aliphatic side-chain |
WHO ATC |
|
0-L |
N05AA01 |
chlorpromazine |
WHO ATC |
|
0-L |
N05AA02 |
levomepromazine |
WHO ATC |
|
0-L |
N05AA03 |
promazine |
WHO ATC |
|
0-L |
N05AA04 |
acepromazine |
WHO ATC |
|
0-L |
N05AA05 |
triflupromazine |
WHO ATC |
|
0-L |
N05AA06 |
cyamemazine |
WHO ATC |
|
0-L |
N05AA07 |
chlorproethazine |
WHO ATC |
|
0-L |
N05AB |
Phenothiazines with piperazine structure |
WHO ATC |
|
0-L |
N05AB01 |
dixyrazine |
WHO ATC |
|
0-L |
N05AB02 |
fluphenazine |
WHO ATC |
|
0-L |
N05AB03 |
perphenazine |
WHO ATC |
|
0-L |
N05AB04 |
prochlorperazine |
WHO ATC |
|
0-L |
N05AB05 |
thiopropazate |
WHO ATC |
|
0-L |
N05AB06 |
trifluoperazine |
WHO ATC |
|
0-L |
N05AB07 |
acetophenazine |
WHO ATC |
|
0-L |
N05AB08 |
thioproperazine |
WHO ATC |
|
0-L |
N05AB09 |
butaperazine |
WHO ATC |
|
0-L |
N05AB10 |
perazine |
WHO ATC |
|
0-L |
N05AC |
Phenothiazines with piperidine structure |
WHO ATC |
|
0-L |
N05AC01 |
periciazine |
WHO ATC |
|
0-L |
N05AC02 |
thioridazine |
WHO ATC |
|
0-L |
N05AC03 |
mesoridazine |
WHO ATC |
|
0-L |
N05AC04 |
pipotiazine |
WHO ATC |
|
0-L |
N05AD |
Butyrophenone derivatives |
WHO ATC |
|
0-L |
N05AD01 |
haloperidol |
WHO ATC |
|
0-L |
N05AD02 |
trifluperidol |
WHO ATC |
|
0-L |
N05AD03 |
melperone |
WHO ATC |
|
0-L |
N05AD04 |
moperone |
WHO ATC |
|
0-L |
N05AD05 |
pipamperone |
WHO ATC |
|
0-L |
N05AD06 |
bromperidol |
WHO ATC |
|
0-L |
N05AD07 |
benperidol |
WHO ATC |
|
0-L |
N05AD08 |
droperidol |
WHO ATC |
|
0-L |
N05AD09 |
fluanisone |
WHO ATC |
|
0-L |
N05AE |
Indole derivatives |
WHO ATC |
|
0-L |
N05AE01 |
oxypertine |
WHO ATC |
|
0-L |
N05AE02 |
molindone |
WHO ATC |
|
0-L |
N05AE03 |
sertindole |
WHO ATC |
|
0-L |
N05AE04 |
ziprasidone |
WHO ATC |
|
0-L |
N05AF |
Thioxanthene derivatives |
WHO ATC |
|
0-L |
N05AF01 |
flupentixol |
WHO ATC |
|
0-L |
N05AF02 |
clopenthixol |
WHO ATC |
|
0-L |
N05AF03 |
chlorprothixene |
WHO ATC |
|
0-L |
N05AF04 |
tiotixene |
WHO ATC |
|
0-L |
N05AF05 |
zuclopenthixol |
WHO ATC |
|
0-L |
N05AG |
Diphenylbutylpiperidine derivatives |
WHO ATC |
|
0-L |
N05AG01 |
fluspirilene |
WHO ATC |
|
0-L |
N05AG02 |
pimozide |
WHO ATC |
|
0-L |
N05AG03 |
penfluridol |
WHO ATC |
|
0-L |
N05AH |
Diazepines, oxazepines, thiazepines and oxepines |
WHO ATC |
|
0-L |
N05AH01 |
loxapine |
WHO ATC |
|
0-L |
N05AH02 |
clozapine |
WHO ATC |
|
0-L |
N05AH03 |
olanzapine |
WHO ATC |
|
0-L |
N05AH04 |
quetiapine |
WHO ATC |
|
0-L |
N05AH05 |
asenapine |
WHO ATC |
|
0-L |
N05AH06 |
clotiapine |
WHO ATC |
|
0-L |
N05AL |
Benzamides |
WHO ATC |
|
0-L |
N05AL01 |
sulpiride |
WHO ATC |
|
0-L |
N05AL02 |
sultopride |
WHO ATC |
|
0-L |
N05AL03 |
tiapride |
WHO ATC |
|
0-L |
N05AL04 |
remoxipride |
WHO ATC |
|
0-L |
N05AL05 |
amisulpride |
WHO ATC |
|
0-L |
N05AL06 |
veralipride |
WHO ATC |
|
0-L |
N05AL07 |
levosulpiride |
WHO ATC |
|
0-L |
N05AN |
Lithium |
WHO ATC |
|
0-L |
N05AN01 |
lithium |
WHO ATC |
|
0-L |
N05AX |
Other antipsychotics |
WHO ATC |
|
0-L |
N05AX07 |
prothipendyl |
WHO ATC |
|
0-L |
N05AX08 |
risperidone |
WHO ATC |
|
0-L |
N05AX10 |
mosapramine |
WHO ATC |
|
0-L |
N05AX11 |
zotepine |
WHO ATC |
|
0-L |
N05AX12 |
aripiprazole |
WHO ATC |
|
0-L |
N05AX13 |
paliperidone |
WHO ATC |
|
0-L |
N05B |
ANXIOLYTICS |
WHO ATC |
|
0-L |
N05BA |
Benzodiazepine derivatives |
WHO ATC |
|
0-L |
N05BA01 |
diazepam |
WHO ATC |
|
0-L |
N05BA02 |
chlordiazepoxide |
WHO ATC |
|
0-L |
N05BA03 |
medazepam |
WHO ATC |
|
0-L |
N05BA04 |
oxazepam |
WHO ATC |
|
0-L |
N05BA05 |
potassium clorazepate |
WHO ATC |
|
0-L |
N05BA06 |
lorazepam |
WHO ATC |
|
0-L |
N05BA07 |
adinazolam |
WHO ATC |
|
0-L |
N05BA08 |
bromazepam |
WHO ATC |
|
0-L |
N05BA09 |
clobazam |
WHO ATC |
|
0-L |
N05BA10 |
ketazolam |
WHO ATC |
|
0-L |
N05BA11 |
prazepam |
WHO ATC |
|
0-L |
N05BA12 |
alprazolam |
WHO ATC |
|
0-L |
N05BA13 |
halazepam |
WHO ATC |
|
0-L |
N05BA14 |
pinazepam |
WHO ATC |
|
0-L |
N05BA15 |
camazepam |
WHO ATC |
|
0-L |
N05BA16 |
nordazepam |
WHO ATC |
|
0-L |
N05BA17 |
fludiazepam |
WHO ATC |
|
0-L |
N05BA18 |
ethyl loflazepate |
WHO ATC |
|
0-L |
N05BA19 |
etizolam |
WHO ATC |
|
0-L |
N05BA21 |
clotiazepam |
WHO ATC |
|
0-L |
N05BA22 |
cloxazolam |
WHO ATC |
|
0-L |
N05BA23 |
tofisopam |
WHO ATC |
|
0-L |
N05BA56 |
lorazepam, combinations |
WHO ATC |
|
0-L |
N05BB |
Diphenylmethane derivatives |
WHO ATC |
|
0-L |
N05BB01 |
hydroxyzine |
WHO ATC |
|
0-L |
N05BB02 |
captodiame |
WHO ATC |
|
0-L |
N05BB51 |
hydroxyzine, combinations |
WHO ATC |
|
0-L |
N05BC |
Carbamates |
WHO ATC |
|
0-L |
N05BC01 |
meprobamate |
WHO ATC |
|
0-L |
N05BC03 |
emylcamate |
WHO ATC |
|
0-L |
N05BC04 |
mebutamate |
WHO ATC |
|
0-L |
N05BC51 |
meprobamate, combinations |
WHO ATC |
|
0-L |
N05BD |
Dibenzo-bicyclo-octadiene derivatives |
WHO ATC |
|
0-L |
N05BD01 |
benzoctamine |
WHO ATC |
|
0-L |
N05BE |
Azaspirodecanedione derivatives |
WHO ATC |
|
0-L |
N05BE01 |
buspirone |
WHO ATC |
|
0-L |
N05BX |
Other anxiolytics |
WHO ATC |
|
0-L |
N05BX01 |
mephenoxalone |
WHO ATC |
|
0-L |
N05BX02 |
gedocarnil |
WHO ATC |
|
0-L |
N05BX03 |
etifoxine |
WHO ATC |
|
0-L |
N05C |
HYPNOTICS AND SEDATIVES |
WHO ATC |
|
0-L |
N05CA |
Barbiturates, plain |
WHO ATC |
|
0-L |
N05CA01 |
pentobarbital |
WHO ATC |
|
0-L |
N05CA02 |
amobarbital |
WHO ATC |
|
0-L |
N05CA03 |
butobarbital |
WHO ATC |
|
0-L |
N05CA04 |
barbital |
WHO ATC |
|
0-L |
N05CA05 |
aprobarbital |
WHO ATC |
|
0-L |
N05CA06 |
secobarbital |
WHO ATC |
|
0-L |
N05CA07 |
talbutal |
WHO ATC |
|
0-L |
N05CA08 |
vinylbital |
WHO ATC |
|
0-L |
N05CA09 |
vinbarbital |
WHO ATC |
|
0-L |
N05CA10 |
cyclobarbital |
WHO ATC |
|
0-L |
N05CA11 |
heptabarbital |
WHO ATC |
|
0-L |
N05CA12 |
reposal |
WHO ATC |
|
0-L |
N05CA15 |
methohexital |
WHO ATC |
|
0-L |
N05CA16 |
hexobarbital |
WHO ATC |
|
0-L |
N05CA19 |
thiopental |
WHO ATC |
|
0-L |
N05CA20 |
etallobarbital |
WHO ATC |
|
0-L |
N05CA21 |
allobarbital |
WHO ATC |
|
0-L |
N05CA22 |
proxibarbal |
WHO ATC |
|
0-L |
N05CB |
Barbiturates, combinations |
WHO ATC |
|
0-L |
N05CB01 |
combinations of barbiturates |
WHO ATC |
|
0-L |
N05CB02 |
barbiturates in combination with other drugs |
WHO ATC |
|
0-L |
N05CC |
Aldehydes and derivatives |
WHO ATC |
|
0-L |
N05CC01 |
chloral hydrate |
WHO ATC |
|
0-L |
N05CC02 |
chloralodol |
WHO ATC |
|
0-L |
N05CC03 |
acetylglycinamide chloral hydrate |
WHO ATC |
|
0-L |
N05CC04 |
dichloralphenazone |
WHO ATC |
|
0-L |
N05CC05 |
paraldehyde |
WHO ATC |
|
0-L |
N05CD |
Benzodiazepine derivatives |
WHO ATC |
|
0-L |
N05CD01 |
flurazepam |
WHO ATC |
|
0-L |
N05CD02 |
nitrazepam |
WHO ATC |
|
0-L |
N05CD03 |
flunitrazepam |
WHO ATC |
|
0-L |
N05CD04 |
estazolam |
WHO ATC |
|
0-L |
N05CD05 |
triazolam |
WHO ATC |
|
0-L |
N05CD06 |
lormetazepam |
WHO ATC |
|
0-L |
N05CD07 |
temazepam |
WHO ATC |
|
0-L |
N05CD08 |
midazolam |
WHO ATC |
|
0-L |
N05CD09 |
brotizolam |
WHO ATC |
|
0-L |
N05CD10 |
quazepam |
WHO ATC |
|
0-L |
N05CD11 |
loprazolam |
WHO ATC |
|
0-L |
N05CD12 |
doxefazepam |
WHO ATC |
|
0-L |
N05CD13 |
cinolazepam |
WHO ATC |
|
0-L |
N05CE |
Piperidinedione derivatives |
WHO ATC |
|
0-L |
N05CE01 |
glutethimide |
WHO ATC |
|
0-L |
N05CE02 |
methyprylon |
WHO ATC |
|
0-L |
N05CE03 |
pyrithyldione |
WHO ATC |
|
0-L |
N05CF |
Benzodiazepine related drugs |
WHO ATC |
|
0-L |
N05CF01 |
zopiclone |
WHO ATC |
|
0-L |
N05CF02 |
zolpidem |
WHO ATC |
|
0-L |
N05CF03 |
zaleplon |
WHO ATC |
|
0-L |
N05CF04 |
eszopiclone |
WHO ATC |
|
0-L |
N05CH |
Melatonin receptor agonists |
WHO ATC |
|
0-L |
N05CH01 |
melatonin |
WHO ATC |
|
0-L |
N05CH02 |
ramelteon |
WHO ATC |
|
0-L |
N05CM |
Other hypnotics and sedatives |
WHO ATC |
|
0-L |
N05CM01 |
methaqualone |
WHO ATC |
|
0-L |
N05CM02 |
clomethiazole |
WHO ATC |
|
0-L |
N05CM03 |
bromisoval |
WHO ATC |
|
0-L |
N05CM04 |
carbromal |
WHO ATC |
|
0-L |
N05CM05 |
scopolamine |
WHO ATC |
|
0-L |
N05CM06 |
propiomazine |
WHO ATC |
|
0-L |
N05CM07 |
triclofos |
WHO ATC |
|
0-L |
N05CM08 |
ethchlorvynol |
WHO ATC |
|
0-L |
N05CM09 |
valerian |
WHO ATC |
|
0-L |
N05CM10 |
hexapropymate |
WHO ATC |
|
0-L |
N05CM11 |
bromides |
WHO ATC |
|
0-L |
N05CM12 |
apronal |
WHO ATC |
|
0-L |
N05CM13 |
valnoctamide |
WHO ATC |
|
0-L |
N05CM15 |
methylpentynol |
WHO ATC |
|
0-L |
N05CM16 |
niaprazine |
WHO ATC |
|
0-L |
N05CM18 |
dexmedetomidine |
WHO ATC |
|
0-L |
N05CX |
Hypnotics and sedatives in combination, excl. barbiturates |
WHO ATC |
|
0-L |
N05CX01 |
meprobamate, combinations |
WHO ATC |
|
0-L |
N05CX02 |
methaqualone, combinations |
WHO ATC |
|
0-L |
N05CX03 |
methylpentynol, combinations |
WHO ATC |
|
0-L |
N05CX04 |
clomethiazole, combinations |
WHO ATC |
|
0-L |
N05CX05 |
emepronium, combinations |
WHO ATC |
|
0-L |
N05CX06 |
dipiperonylaminoethanol, combinations |
WHO ATC |
|
0-L |
N06 |
PSYCHOANALEPTICS |
WHO ATC |
|
0-L |
N06A |
ANTIDEPRESSANTS |
WHO ATC |
|
0-L |
N06AA |
Non-selective monoamine reuptake inhibitors |
WHO ATC |
|
0-L |
N06AA01 |
desipramine |
WHO ATC |
|
0-L |
N06AA02 |
imipramine |
WHO ATC |
|
0-L |
N06AA03 |
imipramine oxide |
WHO ATC |
|
0-L |
N06AA04 |
clomipramine |
WHO ATC |
|
0-L |
N06AA05 |
opipramol |
WHO ATC |
|
0-L |
N06AA06 |
trimipramine |
WHO ATC |
|
0-L |
N06AA07 |
lofepramine |
WHO ATC |
|
0-L |
N06AA08 |
dibenzepin |
WHO ATC |
|
0-L |
N06AA09 |
amitriptyline |
WHO ATC |
|
0-L |
N06AA10 |
nortriptyline |
WHO ATC |
|
0-L |
N06AA11 |
protriptyline |
WHO ATC |
|
0-L |
N06AA12 |
doxepin |
WHO ATC |
|
0-L |
N06AA13 |
iprindole |
WHO ATC |
|
0-L |
N06AA14 |
melitracen |
WHO ATC |
|
0-L |
N06AA15 |
butriptyline |
WHO ATC |
|
0-L |
N06AA16 |
dosulepin |
WHO ATC |
|
0-L |
N06AA17 |
amoxapine |
WHO ATC |
|
0-L |
N06AA18 |
dimetacrine |
WHO ATC |
|
0-L |
N06AA19 |
amineptine |
WHO ATC |
|
0-L |
N06AA21 |
maprotiline |
WHO ATC |
|
0-L |
N06AA23 |
quinupramine |
WHO ATC |
|
0-L |
N06AB |
Selective serotonin reuptake inhibitors |
WHO ATC |
|
0-L |
N06AB02 |
zimeldine |
WHO ATC |
|
0-L |
N06AB03 |
fluoxetine |
WHO ATC |
|
0-L |
N06AB04 |
citalopram |
WHO ATC |
|
0-L |
N06AB05 |
paroxetine |
WHO ATC |
|
0-L |
N06AB06 |
sertraline |
WHO ATC |
|
0-L |
N06AB07 |
alaproclate |
WHO ATC |
|
0-L |
N06AB08 |
fluvoxamine |
WHO ATC |
|
0-L |
N06AB09 |
etoperidone |
WHO ATC |
|
0-L |
N06AB10 |
escitalopram |
WHO ATC |
|
0-L |
N06AF |
Monoamine oxidase inhibitors, non-selective |
WHO ATC |
|
0-L |
N06AF01 |
isocarboxazid |
WHO ATC |
|
0-L |
N06AF02 |
nialamide |
WHO ATC |
|
0-L |
N06AF03 |
phenelzine |
WHO ATC |
|
0-L |
N06AF04 |
tranylcypromine |
WHO ATC |
|
0-L |
N06AF05 |
iproniazide |
WHO ATC |
|
0-L |
N06AF06 |
iproclozide |
WHO ATC |
|
0-L |
N06AG |
Monoamine oxidase A inhibitors |
WHO ATC |
|
0-L |
N06AG02 |
moclobemide |
WHO ATC |
|
0-L |
N06AG03 |
toloxatone |
WHO ATC |
|
0-L |
N06AX |
Other antidepressants |
WHO ATC |
|
0-L |
N06AX01 |
oxitriptan |
WHO ATC |
|
0-L |
N06AX02 |
tryptophan |
WHO ATC |
|
0-L |
N06AX03 |
mianserin |
WHO ATC |
|
0-L |
N06AX04 |
nomifensine |
WHO ATC |
|
0-L |
N06AX05 |
trazodone |
WHO ATC |
|
0-L |
N06AX06 |
nefazodone |
WHO ATC |
|
0-L |
N06AX07 |
minaprine |
WHO ATC |
|
0-L |
N06AX08 |
bifemelane |
WHO ATC |
|
0-L |
N06AX09 |
viloxazine |
WHO ATC |
|
0-L |
N06AX10 |
oxaflozane |
WHO ATC |
|
0-L |
N06AX11 |
mirtazapine |
WHO ATC |
|
0-L |
N06AX12 |
bupropion |
WHO ATC |
|
0-L |
N06AX13 |
medifoxamine |
WHO ATC |
|
0-L |
N06AX14 |
tianeptine |
WHO ATC |
|
0-L |
N06AX15 |
pivagabine |
WHO ATC |
|
0-L |
N06AX16 |
venlafaxine |
WHO ATC |
|
0-L |
N06AX17 |
milnacipran |
WHO ATC |
|
0-L |
N06AX18 |
reboxetine |
WHO ATC |
|
0-L |
N06AX19 |
gepirone |
WHO ATC |
|
0-L |
N06AX21 |
duloxetine |
WHO ATC |
|
0-L |
N06AX22 |
agomelatine |
WHO ATC |
|
0-L |
N06AX23 |
desvenlafaxine |
WHO ATC |
|
0-L |
N06B |
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS |
WHO ATC |
|
0-L |
N06BA |
Centrally acting sympathomimetics |
WHO ATC |
|
0-L |
N06BA01 |
amfetamine |
WHO ATC |
|
0-L |
N06BA02 |
dexamfetamine |
WHO ATC |
|
0-L |
N06BA03 |
metamfetamine |
WHO ATC |
|
0-L |
N06BA04 |
methylphenidate |
WHO ATC |
|
0-L |
N06BA05 |
pemoline |
WHO ATC |
|
0-L |
N06BA06 |
fencamfamin |
WHO ATC |
|
0-L |
N06BA07 |
modafinil |
WHO ATC |
|
0-L |
N06BA08 |
fenozolone |
WHO ATC |
|
0-L |
N06BA09 |
atomoxetine |
WHO ATC |
|
0-L |
N06BA10 |
fenetylline |
WHO ATC |
|
0-L |
N06BA11 |
dexmethylphenidate |
WHO ATC |
|
0-L |
N06BC |
Xanthine derivatives |
WHO ATC |
|
0-L |
N06BC01 |
caffeine |
WHO ATC |
|
0-L |
N06BC02 |
propentofylline |
WHO ATC |
|
0-L |
N06BX |
Other psychostimulants and nootropics |
WHO ATC |
|
0-L |
N06BX01 |
meclofenoxate |
WHO ATC |
|
0-L |
N06BX02 |
pyritinol |
WHO ATC |
|
0-L |
N06BX03 |
piracetam |
WHO ATC |
|
0-L |
N06BX04 |
deanol |
WHO ATC |
|
0-L |
N06BX05 |
fipexide |
WHO ATC |
|
0-L |
N06BX06 |
citicoline |
WHO ATC |
|
0-L |
N06BX07 |
oxiracetam |
WHO ATC |
|
0-L |
N06BX08 |
pirisudanol |
WHO ATC |
|
0-L |
N06BX09 |
linopirdine |
WHO ATC |
|
0-L |
N06BX10 |
nizofenone |
WHO ATC |
|
0-L |
N06BX11 |
aniracetam |
WHO ATC |
|
0-L |
N06BX12 |
acetylcarnitine |
WHO ATC |
|
0-L |
N06BX13 |
idebenone |
WHO ATC |
|
0-L |
N06BX14 |
prolintane |
WHO ATC |
|
0-L |
N06BX15 |
pipradrol |
WHO ATC |
|
0-L |
N06BX16 |
pramiracetam |
WHO ATC |
|
0-L |
N06BX17 |
adrafinil |
WHO ATC |
|
0-L |
N06BX18 |
vinpocetine |
WHO ATC |
|
0-L |
N06C |
PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION |
WHO ATC |
|
0-L |
N06CA |
Antidepressants in combination with psycholeptics |
WHO ATC |
|
0-L |
N06CA01 |
amitriptyline and psycholeptics |
WHO ATC |
|
0-L |
N06CA02 |
melitracen and psycholeptics |
WHO ATC |
|
0-L |
N06CB |
Psychostimulants in combination with psycholeptics |
WHO ATC |
|
0-L |
N06D |
ANTI-DEMENTIA DRUGS |
WHO ATC |
|
0-L |
N06DA |
Anticholinesterases |
WHO ATC |
|
0-L |
N06DA01 |
tacrine |
WHO ATC |
|
0-L |
N06DA02 |
donepezil |
WHO ATC |
|
0-L |
N06DA03 |
rivastigmine |
WHO ATC |
|
0-L |
N06DA04 |
galantamine |
WHO ATC |
|
0-L |
N06DX |
Other anti-dementia drugs |
WHO ATC |
|
0-L |
N06DX01 |
memantine |
WHO ATC |
|
0-L |
N06DX02 |
ginkgo biloba |
WHO ATC |
|
0-L |
N07 |
OTHER NERVOUS SYSTEM DRUGS |
WHO ATC |
|
0-L |
N07A |
PARASYMPATHOMIMETICS |
WHO ATC |
|
0-L |
N07AA |
Anticholinesterases |
WHO ATC |
|
0-L |
N07AA01 |
neostigmine |
WHO ATC |
|
0-L |
N07AA02 |
pyridostigmine |
WHO ATC |
|
0-L |
N07AA03 |
distigmine |
WHO ATC |
|
0-L |
N07AA30 |
ambenonium |
WHO ATC |
|
0-L |
N07AA51 |
neostigmine, combinations |
WHO ATC |
|
0-L |
N07AB |
Choline esters |
WHO ATC |
|
0-L |
N07AB01 |
carbachol |
WHO ATC |
|
0-L |
N07AB02 |
bethanechol |
WHO ATC |
|
0-L |
N07AX |
Other parasympathomimetics |
WHO ATC |
|
0-L |
N07AX01 |
pilocarpine |
WHO ATC |
|
0-L |
N07AX02 |
choline alfoscerate |
WHO ATC |
|
0-L |
N07AX03 |
cevimeline |
WHO ATC |
|
0-L |
N07B |
DRUGS USED IN ADDICTIVE DISORDERS |
WHO ATC |
|
0-L |
N07BA |
Drugs used in nicotine dependence |
WHO ATC |
|
0-L |
N07BA01 |
nicotine |
WHO ATC |
|
0-L |
N07BA03 |
varenicline |
WHO ATC |
|
0-L |
N07BB |
Drugs used in alcohol dependence |
WHO ATC |
|
0-L |
N07BB01 |
disulfiram |
WHO ATC |
|
0-L |
N07BB02 |
calcium carbimide |
WHO ATC |
|
0-L |
N07BB03 |
acamprosate |
WHO ATC |
|
0-L |
N07BB04 |
naltrexone |
WHO ATC |
|
0-L |
N07BC |
Drugs used in opioid dependence |
WHO ATC |
|
0-L |
N07BC01 |
buprenorphine |
WHO ATC |
|
0-L |
N07BC02 |
methadone |
WHO ATC |
|
0-L |
N07BC03 |
levacetylmethadol |
WHO ATC |
|
0-L |
N07BC04 |
lofexidine |
WHO ATC |
|
0-L |
N07BC51 |
buprenorphine, combinations |
WHO ATC |
|
0-L |
N07C |
ANTIVERTIGO PREPARATIONS |
WHO ATC |
|
0-L |
N07CA |
Antivertigo preparations |
WHO ATC |
|
0-L |
N07CA01 |
betahistine |
WHO ATC |
|
0-L |
N07CA02 |
cinnarizine |
WHO ATC |
|
0-L |
N07CA03 |
flunarizine |
WHO ATC |
|
0-L |
N07CA04 |
acetylleucine |
WHO ATC |
|
0-L |
N07CA52 |
cinnarizine, combinations |
WHO ATC |
|
0-L |
N07X |
OTHER NERVOUS SYSTEM DRUGS |
WHO ATC |
|
0-L |
N07XA |
Gangliosides and ganglioside derivatives |
WHO ATC |
|
0-L |
N07XX |
Other nervous system drugs |
WHO ATC |
|
0-L |
N07XX01 |
tirilazad |
WHO ATC |
|
0-L |
N07XX02 |
riluzole |
WHO ATC |
|
0-L |
N07XX03 |
xaliproden |
WHO ATC |
|
0-L |
N07XX04 |
sodium oxybate |
WHO ATC |
|
0-L |
N07XX05 |
amifampridine |
WHO ATC |
|
0-L |
N07XX06 |
tetrabenazine |
WHO ATC |
|
0-L |
P |
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS |
WHO ATC |
|
0-L |
P01 |
ANTIPROTOZOALS |
WHO ATC |
|
0-L |
P01A |
AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES |
WHO ATC |
|
0-L |
P01AA |
Hydroxyquinoline derivatives |
WHO ATC |
|
0-L |
P01AA01 |
broxyquinoline |
WHO ATC |
|
0-L |
P01AA02 |
clioquinol |
WHO ATC |
|
0-L |
P01AA04 |
chlorquinaldol |
WHO ATC |
|
0-L |
P01AA05 |
tilbroquinol |
WHO ATC |
|
0-L |
P01AA52 |
clioquinol, combinations |
WHO ATC |
|
0-L |
P01AB |
Nitroimidazole derivatives |
WHO ATC |
|
0-L |
P01AB01 |
metronidazole |
WHO ATC |
|
0-L |
P01AB02 |
tinidazole |
WHO ATC |
|
0-L |
P01AB03 |
ornidazole |
WHO ATC |
|
0-L |
P01AB04 |
azanidazole |
WHO ATC |
|
0-L |
P01AB05 |
propenidazole |
WHO ATC |
|
0-L |
P01AB06 |
nimorazole |
WHO ATC |
|
0-L |
P01AB07 |
secnidazole |
WHO ATC |
|
0-L |
P01AC |
Dichloroacetamide derivatives |
WHO ATC |
|
0-L |
P01AC01 |
diloxanide |
WHO ATC |
|
0-L |
P01AC02 |
clefamide |
WHO ATC |
|
0-L |
P01AC03 |
etofamide |
WHO ATC |
|
0-L |
P01AC04 |
teclozan |
WHO ATC |
|
0-L |
P01AR |
Arsenic compounds |
WHO ATC |
|
0-L |
P01AR01 |
arsthinol |
WHO ATC |
|
0-L |
P01AR02 |
difetarsone |
WHO ATC |
|
0-L |
P01AR03 |
glycobiarsol |
WHO ATC |
|
0-L |
P01AR53 |
glycobiarsol, combinations |
WHO ATC |
|
0-L |
P01AX |
Other agents against amoebiasis and other protozoal diseases |
WHO ATC |
|
0-L |
P01AX01 |
chiniofon |
WHO ATC |
|
0-L |
P01AX02 |
emetine |
WHO ATC |
|
0-L |
P01AX04 |
phanquinone |
WHO ATC |
|
0-L |
P01AX05 |
mepacrine |
WHO ATC |
|
0-L |
P01AX06 |
atovaquone |
WHO ATC |
|
0-L |
P01AX07 |
trimetrexate |
WHO ATC |
|
0-L |
P01AX08 |
tenonitrozole |
WHO ATC |
|
0-L |
P01AX09 |
dihydroemetine |
WHO ATC |
|
0-L |
P01AX10 |
fumagillin |
WHO ATC |
|
0-L |
P01AX11 |
nitazoxanide |
WHO ATC |
|
0-L |
P01AX52 |
emetine, combinations |
WHO ATC |
|
0-L |
P01B |
ANTIMALARIALS |
WHO ATC |
|
0-L |
P01BA |
Aminoquinolines |
WHO ATC |
|
0-L |
P01BA01 |
chloroquine |
WHO ATC |
|
0-L |
P01BA02 |
hydroxychloroquine |
WHO ATC |
|
0-L |
P01BA03 |
primaquine |
WHO ATC |
|
0-L |
P01BA06 |
amodiaquine |
WHO ATC |
|
0-L |
P01BB |
Biguanides |
WHO ATC |
|
0-L |
P01BB01 |
proguanil |
WHO ATC |
|
0-L |
P01BB02 |
cycloguanil embonate |
WHO ATC |
|
0-L |
P01BB51 |
proguanil, combinations |
WHO ATC |
|
0-L |
P01BC |
Methanolquinolines |
WHO ATC |
|
0-L |
P01BC01 |
quinine |
WHO ATC |
|
0-L |
P01BC02 |
mefloquine |
WHO ATC |
|
0-L |
P01BD |
Diaminopyrimidines |
WHO ATC |
|
0-L |
P01BD01 |
pyrimethamine |
WHO ATC |
|
0-L |
P01BD51 |
pyrimethamine, combinations |
WHO ATC |
|
0-L |
P01BE |
Artemisinin and derivatives |
WHO ATC |
|
0-L |
P01BE01 |
artemisinin |
WHO ATC |
|
0-L |
P01BE02 |
artemether |
WHO ATC |
|
0-L |
P01BE03 |
artesunate |
WHO ATC |
|
0-L |
P01BE04 |
artemotil |
WHO ATC |
|
0-L |
P01BE05 |
artenimol |
WHO ATC |
|
0-L |
P01BE52 |
artemether, combinations |
WHO ATC |
|
0-L |
P01BX |
Other antimalarials |
WHO ATC |
|
0-L |
P01BX01 |
halofantrine |
WHO ATC |
|
0-L |
P01C |
AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS |
WHO ATC |
|
0-L |
P01CA |
Nitroimidazole derivatives |
WHO ATC |
|
0-L |
P01CA02 |
benznidazole |
WHO ATC |
|
0-L |
P01CB |
Antimony compounds |
WHO ATC |
|
0-L |
P01CB01 |
meglumine antimonate |
WHO ATC |
|
0-L |
P01CB02 |
sodium stibogluconate |
WHO ATC |
|
0-L |
P01CC |
Nitrofuran derivatives |
WHO ATC |
|
0-L |
P01CC01 |
nifurtimox |
WHO ATC |
|
0-L |
P01CC02 |
nitrofural |
WHO ATC |
|
0-L |
P01CD |
Arsenic compounds |
WHO ATC |
|
0-L |
P01CD01 |
melarsoprol |
WHO ATC |
|
0-L |
P01CD02 |
acetarsol |
WHO ATC |
|
0-L |
P01CX |
Other agents against leishmaniasis and trypanosomiasis |
WHO ATC |
|
0-L |
P01CX01 |
pentamidine isethionate |
WHO ATC |
|
0-L |
P01CX02 |
suramin sodium |
WHO ATC |
|
0-L |
P01CX03 |
eflornithine |
WHO ATC |
|
0-L |
P02 |
ANTHELMINTICS |
WHO ATC |
|
0-L |
P02B |
ANTITREMATODALS |
WHO ATC |
|
0-L |
P02BA |
Quinoline derivatives and related substances |
WHO ATC |
|
0-L |
P02BA01 |
praziquantel |
WHO ATC |
|
0-L |
P02BA02 |
oxamniquine |
WHO ATC |
|
0-L |
P02BB |
Organophosphorous compounds |
WHO ATC |
|
0-L |
P02BB01 |
metrifonate |
WHO ATC |
|
0-L |
P02BX |
Other antitrematodal agents |
WHO ATC |
|
0-L |
P02BX01 |
bithionol |
WHO ATC |
|
0-L |
P02BX02 |
niridazole |
WHO ATC |
|
0-L |
P02BX03 |
stibophen |
WHO ATC |
|
0-L |
P02BX04 |
triclabendazole |
WHO ATC |
|
0-L |
P02C |
ANTINEMATODAL AGENTS |
WHO ATC |
|
0-L |
P02CA |
Benzimidazole derivatives |
WHO ATC |
|
0-L |
P02CA01 |
mebendazole |
WHO ATC |
|
0-L |
P02CA02 |
tiabendazole |
WHO ATC |
|
0-L |
P02CA03 |
albendazole |
WHO ATC |
|
0-L |
P02CA04 |
ciclobendazole |
WHO ATC |
|
0-L |
P02CA05 |
flubendazole |
WHO ATC |
|
0-L |
P02CA06 |
fenbendazole |
WHO ATC |
|
0-L |
P02CA51 |
mebendazole, combinations |
WHO ATC |
|
0-L |
P02CB |
Piperazine and derivatives |
WHO ATC |
|
0-L |
P02CB01 |
piperazine |
WHO ATC |
|
0-L |
P02CB02 |
diethylcarbamazine |
WHO ATC |
|
0-L |
P02CC |
Tetrahydropyrimidine derivatives |
WHO ATC |
|
0-L |
P02CC01 |
pyrantel |
WHO ATC |
|
0-L |
P02CC02 |
oxantel |
WHO ATC |
|
0-L |
P02CE |
Imidazothiazole derivatives |
WHO ATC |
|
0-L |
P02CE01 |
levamisole |
WHO ATC |
|
0-L |
P02CF |
Avermectines |
WHO ATC |
|
0-L |
P02CF01 |
ivermectin |
WHO ATC |
|
0-L |
P02CX |
Other antinematodals |
WHO ATC |
|
0-L |
P02CX01 |
pyrvinium |
WHO ATC |
|
0-L |
P02CX02 |
bephenium |
WHO ATC |
|
0-L |
P02D |
ANTICESTODALS |
WHO ATC |
|
0-L |
P02DA |
Salicylic acid derivatives |
WHO ATC |
|
0-L |
P02DA01 |
niclosamide |
WHO ATC |
|
0-L |
P02DX |
Other anticestodals |
WHO ATC |
|
0-L |
P02DX01 |
desaspidin |
WHO ATC |
|
0-L |
P02DX02 |
dichlorophen |
WHO ATC |
|
0-L |
P03 |
ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS |
WHO ATC |
|
0-L |
P03A |
ECTOPARASITICIDES, INCL. SCABICIDES |
WHO ATC |
|
0-L |
P03AA |
Sulfur containing products |
WHO ATC |
|
0-L |
P03AA01 |
dixanthogen |
WHO ATC |
|
0-L |
P03AA02 |
potassium polysulfide |
WHO ATC |
|
0-L |
P03AA03 |
mesulfen |
WHO ATC |
|
0-L |
P03AA04 |
disulfiram |
WHO ATC |
|
0-L |
P03AA05 |
thiram |
WHO ATC |
|
0-L |
P03AA54 |
disulfiram, combinations |
WHO ATC |
|
0-L |
P03AB |
Chlorine containing products |
WHO ATC |
|
0-L |
P03AB01 |
clofenotane |
WHO ATC |
|
0-L |
P03AB02 |
lindane |
WHO ATC |
|
0-L |
P03AB51 |
clofenotane, combinations |
WHO ATC |
|
0-L |
P03AC |
Pyrethrines, incl. synthetic compounds |
WHO ATC |
|
0-L |
P03AC01 |
pyrethrum |
WHO ATC |
|
0-L |
P03AC02 |
bioallethrin |
WHO ATC |
|
0-L |
P03AC03 |
phenothrin |
WHO ATC |
|
0-L |
P03AC04 |
permethrin |
WHO ATC |
|
0-L |
P03AC51 |
pyrethrum, combinations |
WHO ATC |
|
0-L |
P03AC52 |
bioallethrin, combinations |
WHO ATC |
|
0-L |
P03AC53 |
phenothrin, combinations |
WHO ATC |
|
0-L |
P03AC54 |
permethrin, combinations |
WHO ATC |
|
0-L |
P03AX |
Other ectoparasiticides, incl. scabicides |
WHO ATC |
|
0-L |
P03AX01 |
benzyl benzoate |
WHO ATC |
|
0-L |
P03AX02 |
copper oleinate |
WHO ATC |
|
0-L |
P03AX03 |
malathion |
WHO ATC |
|
0-L |
P03AX04 |
quassia |
WHO ATC |
|
0-L |
P03B |
INSECTICIDES AND REPELLENTS |
WHO ATC |
|
0-L |
P03BA |
Pyrethrines |
WHO ATC |
|
0-L |
P03BA01 |
cyfluthrin |
WHO ATC |
|
0-L |
P03BA02 |
cypermethrin |
WHO ATC |
|
0-L |
P03BA03 |
decamethrin |
WHO ATC |
|
0-L |
P03BA04 |
tetramethrin |
WHO ATC |
|
0-L |
P03BX |
Other insecticides and repellents |
WHO ATC |
|
0-L |
P03BX01 |
diethyltoluamide |
WHO ATC |
|
0-L |
P03BX02 |
dimethylphthalate |
WHO ATC |
|
0-L |
P03BX03 |
dibutylphthalate |
WHO ATC |
|
0-L |
P03BX04 |
dibutylsuccinate |
WHO ATC |
|
0-L |
P03BX05 |
dimethylcarbate |
WHO ATC |
|
0-L |
P03BX06 |
etohexadiol |
WHO ATC |
|
0-L |
R |
RESPIRATORY SYSTEM |
WHO ATC |
|
0-L |
R01 |
NASAL PREPARATIONS |
WHO ATC |
|
0-L |
R01A |
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE |
WHO ATC |
|
0-L |
R01AA |
Sympathomimetics, plain |
WHO ATC |
|
0-L |
R01AA02 |
cyclopentamine |
WHO ATC |
|
0-L |
R01AA03 |
ephedrine |
WHO ATC |
|
0-L |
R01AA04 |
phenylephrine |
WHO ATC |
|
0-L |
R01AA05 |
oxymetazoline |
WHO ATC |
|
0-L |
R01AA06 |
tetryzoline |
WHO ATC |
|
0-L |
R01AA07 |
xylometazoline |
WHO ATC |
|
0-L |
R01AA08 |
naphazoline |
WHO ATC |
|
0-L |
R01AA09 |
tramazoline |
WHO ATC |
|
0-L |
R01AA10 |
metizoline |
WHO ATC |
|
0-L |
R01AA11 |
tuaminoheptane |
WHO ATC |
|
0-L |
R01AA12 |
fenoxazoline |
WHO ATC |
|
0-L |
R01AA13 |
tymazoline |
WHO ATC |
|
0-L |
R01AA14 |
epinephrine |
WHO ATC |
|
0-L |
R01AB |
Sympathomimetics, combinations excl. corticosteroids |
WHO ATC |
|
0-L |
R01AB01 |
phenylephrine |
WHO ATC |
|
0-L |
R01AB02 |
naphazoline |
WHO ATC |
|
0-L |
R01AB03 |
tetryzoline |
WHO ATC |
|
0-L |
R01AB05 |
ephedrine |
WHO ATC |
|
0-L |
R01AB06 |
xylometazoline |
WHO ATC |
|
0-L |
R01AB07 |
oxymetazoline |
WHO ATC |
|
0-L |
R01AB08 |
tuaminoheptane |
WHO ATC |
|
0-L |
R01AC |
Antiallergic agents, excl. corticosteroids |
WHO ATC |
|
0-L |
R01AC01 |
cromoglicic acid |
WHO ATC |
|
0-L |
R01AC02 |
levocabastine |
WHO ATC |
|
0-L |
R01AC03 |
azelastine |
WHO ATC |
|
0-L |
R01AC04 |
antazoline |
WHO ATC |
|
0-L |
R01AC05 |
spaglumic acid |
WHO ATC |
|
0-L |
R01AC06 |
thonzylamine |
WHO ATC |
|
0-L |
R01AC07 |
nedocromil |
WHO ATC |
|
0-L |
R01AC08 |
olopatadine |
WHO ATC |
|
0-L |
R01AC51 |
cromoglicic acid, combinations |
WHO ATC |
|
0-L |
R01AD |
Corticosteroids |
WHO ATC |
|
0-L |
R01AD01 |
beclometasone |
WHO ATC |
|
0-L |
R01AD02 |
prednisolone |
WHO ATC |
|
0-L |
R01AD03 |
dexamethasone |
WHO ATC |
|
0-L |
R01AD04 |
flunisolide |
WHO ATC |
|
0-L |
R01AD05 |
budesonide |
WHO ATC |
|
0-L |
R01AD06 |
betamethasone |
WHO ATC |
|
0-L |
R01AD07 |
tixocortol |
WHO ATC |
|
0-L |
R01AD08 |
fluticasone |
WHO ATC |
|
0-L |
R01AD09 |
mometasone |
WHO ATC |
|
0-L |
R01AD11 |
triamcinolone |
WHO ATC |
|
0-L |
R01AD12 |
fluticasone furoate |
WHO ATC |
|
0-L |
R01AD52 |
prednisolone, combinations |
WHO ATC |
|
0-L |
R01AD53 |
dexamethasone, combinations |
WHO ATC |
|
0-L |
R01AD57 |
tixocortol, combinations |
WHO ATC |
|
0-L |
R01AD60 |
hydrocortisone, combinations |
WHO ATC |
|
0-L |
R01AX |
Other nasal preparations |
WHO ATC |
|
0-L |
R01AX01 |
calcium hexamine thiocyanate |
WHO ATC |
|
0-L |
R01AX02 |
retinol |
WHO ATC |
|
0-L |
R01AX03 |
ipratropium bromide |
WHO ATC |
|
0-L |
R01AX05 |
ritiometan |
WHO ATC |
|
0-L |
R01AX06 |
mupirocin |
WHO ATC |
|
0-L |
R01AX07 |
hexamidine |
WHO ATC |
|
0-L |
R01AX08 |
framycetin |
WHO ATC |
|
0-L |
R01AX09 |
hyaluronic acid |
WHO ATC |
|
0-L |
R01AX10 |
various |
WHO ATC |
|
0-L |
R01AX30 |
combinations |
WHO ATC |
|
0-L |
R01B |
NASAL DECONGESTANTS FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
R01BA |
Sympathomimetics |
WHO ATC |
|
0-L |
R01BA01 |
phenylpropanolamine |
WHO ATC |
|
0-L |
R01BA02 |
pseudoephedrine |
WHO ATC |
|
0-L |
R01BA03 |
phenylephrine |
WHO ATC |
|
0-L |
R01BA51 |
phenylpropanolamine, combinations |
WHO ATC |
|
0-L |
R01BA52 |
pseudoephedrine, combinations |
WHO ATC |
|
0-L |
R01BA53 |
phenylephrine, combinations |
WHO ATC |
|
0-L |
R02 |
THROAT PREPARATIONS |
WHO ATC |
|
0-L |
R02A |
THROAT PREPARATIONS |
WHO ATC |
|
0-L |
R02AA |
Antiseptics |
WHO ATC |
|
0-L |
R02AA01 |
ambazone |
WHO ATC |
|
0-L |
R02AA02 |
dequalinium |
WHO ATC |
|
0-L |
R02AA03 |
dichlorobenzyl alcohol |
WHO ATC |
|
0-L |
R02AA05 |
chlorhexidine |
WHO ATC |
|
0-L |
R02AA06 |
cetylpyridinium |
WHO ATC |
|
0-L |
R02AA09 |
benzethonium |
WHO ATC |
|
0-L |
R02AA10 |
myristyl-benzalkonium |
WHO ATC |
|
0-L |
R02AA11 |
chlorquinaldol |
WHO ATC |
|
0-L |
R02AA12 |
hexylresorcinol |
WHO ATC |
|
0-L |
R02AA13 |
acriflavinium chloride |
WHO ATC |
|
0-L |
R02AA14 |
oxyquinoline |
WHO ATC |
|
0-L |
R02AA15 |
povidone-iodine |
WHO ATC |
|
0-L |
R02AA16 |
benzalkonium |
WHO ATC |
|
0-L |
R02AA17 |
cetrimonium |
WHO ATC |
|
0-L |
R02AA18 |
hexamidine |
WHO ATC |
|
0-L |
R02AA19 |
phenol |
WHO ATC |
|
0-L |
R02AA20 |
various |
WHO ATC |
|
0-L |
R02AB |
Antibiotics |
WHO ATC |
|
0-L |
R02AB01 |
neomycin |
WHO ATC |
|
0-L |
R02AB02 |
tyrothricin |
WHO ATC |
|
0-L |
R02AB03 |
fusafungine |
WHO ATC |
|
0-L |
R02AB04 |
bacitracin |
WHO ATC |
|
0-L |
R02AB30 |
gramicidin |
WHO ATC |
|
0-L |
R02AD |
Anesthetics, local |
WHO ATC |
|
0-L |
R02AD01 |
benzocaine |
WHO ATC |
|
0-L |
R02AD02 |
lidocaine |
WHO ATC |
|
0-L |
R02AD03 |
cocaine |
WHO ATC |
|
0-L |
R02AD04 |
dyclonine |
WHO ATC |
|
0-L |
R02AX |
Other throat preparations |
WHO ATC |
|
0-L |
R02AX01 |
flurbiprofen |
WHO ATC |
|
0-L |
R03 |
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES |
WHO ATC |
|
0-L |
R03A |
ADRENERGICS, INHALANTS |
WHO ATC |
|
0-L |
R03AA |
Alpha- and beta-adrenoreceptor agonists |
WHO ATC |
|
0-L |
R03AA01 |
epinephrine |
WHO ATC |
|
0-L |
R03AB |
Non-selective beta-adrenoreceptor agonists |
WHO ATC |
|
0-L |
R03AB02 |
isoprenaline |
WHO ATC |
|
0-L |
R03AB03 |
orciprenaline |
WHO ATC |
|
0-L |
R03AC |
Selective beta-2-adrenoreceptor agonists |
WHO ATC |
|
0-L |
R03AC02 |
salbutamol |
WHO ATC |
|
0-L |
R03AC03 |
terbutaline |
WHO ATC |
|
0-L |
R03AC04 |
fenoterol |
WHO ATC |
|
0-L |
R03AC05 |
rimiterol |
WHO ATC |
|
0-L |
R03AC06 |
hexoprenaline |
WHO ATC |
|
0-L |
R03AC07 |
isoetarine |
WHO ATC |
|
0-L |
R03AC08 |
pirbuterol |
WHO ATC |
|
0-L |
R03AC09 |
tretoquinol |
WHO ATC |
|
0-L |
R03AC10 |
carbuterol |
WHO ATC |
|
0-L |
R03AC11 |
tulobuterol |
WHO ATC |
|
0-L |
R03AC12 |
salmeterol |
WHO ATC |
|
0-L |
R03AC13 |
formoterol |
WHO ATC |
|
0-L |
R03AC14 |
clenbuterol |
WHO ATC |
|
0-L |
R03AC15 |
reproterol |
WHO ATC |
|
0-L |
R03AC16 |
procaterol |
WHO ATC |
|
0-L |
R03AC17 |
bitolterol |
WHO ATC |
|
0-L |
R03AC18 |
indacaterol |
WHO ATC |
|
0-L |
R03AH |
Combinations of adrenergics |
WHO ATC |
|
0-L |
R03AK |
Adrenergics and other drugs for obstructive airway diseases |
WHO ATC |
|
0-L |
R03AK01 |
epinephrine and other drugs for obstructive airway diseases |
WHO ATC |
|
0-L |
R03AK02 |
isoprenaline and other drugs for obstructive airway diseases |
WHO ATC |
|
0-L |
R03AK03 |
fenoterol and other drugs for obstructive airway diseases |
WHO ATC |
|
0-L |
R03AK04 |
salbutamol and other drugs for obstructive airway diseases |
WHO ATC |
|
0-L |
R03AK05 |
reproterol and other drugs for obstructive airway diseases |
WHO ATC |
|
0-L |
R03AK06 |
salmeterol and other drugs for obstructive airway diseases |
WHO ATC |
|
0-L |
R03AK07 |
formoterol and other drugs for obstructive airway diseases |
WHO ATC |
|
0-L |
R03B |
OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS |
WHO ATC |
|
0-L |
R03BA |
Glucocorticoids |
WHO ATC |
|
0-L |
R03BA01 |
beclometasone |
WHO ATC |
|
0-L |
R03BA02 |
budesonide |
WHO ATC |
|
0-L |
R03BA03 |
flunisolide |
WHO ATC |
|
0-L |
R03BA04 |
betamethasone |
WHO ATC |
|
0-L |
R03BA05 |
fluticasone |
WHO ATC |
|
0-L |
R03BA06 |
triamcinolone |
WHO ATC |
|
0-L |
R03BA07 |
mometasone |
WHO ATC |
|
0-L |
R03BA08 |
ciclesonide |
WHO ATC |
|
0-L |
R03BB |
Anticholinergics |
WHO ATC |
|
0-L |
R03BB01 |
ipratropium bromide |
WHO ATC |
|
0-L |
R03BB02 |
oxitropium bromide |
WHO ATC |
|
0-L |
R03BB03 |
stramoni preparations |
WHO ATC |
|
0-L |
R03BB04 |
tiotropium bromide |
WHO ATC |
|
0-L |
R03BC |
Antiallergic agents, excl. corticosteroids |
WHO ATC |
|
0-L |
R03BC01 |
cromoglicic acid |
WHO ATC |
|
0-L |
R03BC03 |
nedocromil |
WHO ATC |
|
0-L |
R03BX |
Other drugs for obstructive airway diseases, inhalants |
WHO ATC |
|
0-L |
R03BX01 |
fenspiride |
WHO ATC |
|
0-L |
R03C |
ADRENERGICS FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
R03CA |
Alpha- and beta-adrenoreceptor agonists |
WHO ATC |
|
0-L |
R03CA02 |
ephedrine |
WHO ATC |
|
0-L |
R03CB |
Non-selective beta-adrenoreceptor agonists |
WHO ATC |
|
0-L |
R03CB01 |
isoprenaline |
WHO ATC |
|
0-L |
R03CB02 |
methoxyphenamine |
WHO ATC |
|
0-L |
R03CB03 |
orciprenaline |
WHO ATC |
|
0-L |
R03CB51 |
isoprenaline, combinations |
WHO ATC |
|
0-L |
R03CB53 |
orciprenaline, combinations |
WHO ATC |
|
0-L |
R03CC |
Selective beta-2-adrenoreceptor agonists |
WHO ATC |
|
0-L |
R03CC02 |
salbutamol |
WHO ATC |
|
0-L |
R03CC03 |
terbutaline |
WHO ATC |
|
0-L |
R03CC04 |
fenoterol |
WHO ATC |
|
0-L |
R03CC05 |
hexoprenaline |
WHO ATC |
|
0-L |
R03CC06 |
isoetarine |
WHO ATC |
|
0-L |
R03CC07 |
pirbuterol |
WHO ATC |
|
0-L |
R03CC08 |
procaterol |
WHO ATC |
|
0-L |
R03CC09 |
tretoquinol |
WHO ATC |
|
0-L |
R03CC10 |
carbuterol |
WHO ATC |
|
0-L |
R03CC11 |
tulobuterol |
WHO ATC |
|
0-L |
R03CC12 |
bambuterol |
WHO ATC |
|
0-L |
R03CC13 |
clenbuterol |
WHO ATC |
|
0-L |
R03CC14 |
reproterol |
WHO ATC |
|
0-L |
R03CC53 |
terbutaline, combinations |
WHO ATC |
|
0-L |
R03CK |
Adrenergics and other drugs for obstructive airway diseases |
WHO ATC |
|
0-L |
R03D |
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES |
WHO ATC |
|
0-L |
R03DA |
Xanthines |
WHO ATC |
|
0-L |
R03DA01 |
diprophylline |
WHO ATC |
|
0-L |
R03DA02 |
choline theophyllinate |
WHO ATC |
|
0-L |
R03DA03 |
proxyphylline |
WHO ATC |
|
0-L |
R03DA04 |
theophylline |
WHO ATC |
|
0-L |
R03DA05 |
aminophylline |
WHO ATC |
|
0-L |
R03DA06 |
etamiphylline |
WHO ATC |
|
0-L |
R03DA07 |
theobromine |
WHO ATC |
|
0-L |
R03DA08 |
bamifylline |
WHO ATC |
|
0-L |
R03DA09 |
acefylline piperazine |
WHO ATC |
|
0-L |
R03DA10 |
bufylline |
WHO ATC |
|
0-L |
R03DA11 |
doxofylline |
WHO ATC |
|
0-L |
R03DA20 |
combinations of xanthines |
WHO ATC |
|
0-L |
R03DA51 |
diprophylline, combinations |
WHO ATC |
|
0-L |
R03DA54 |
theophylline, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
R03DA55 |
aminophylline, combinations |
WHO ATC |
|
0-L |
R03DA57 |
theobromine, combinations |
WHO ATC |
|
0-L |
R03DA74 |
theophylline, combinations with psycholeptics |
WHO ATC |
|
0-L |
R03DB |
Xanthines and adrenergics |
WHO ATC |
|
0-L |
R03DB01 |
diprophylline and adrenergics |
WHO ATC |
|
0-L |
R03DB02 |
choline theophyllinate and adrenergics |
WHO ATC |
|
0-L |
R03DB03 |
proxyphylline and adrenergics |
WHO ATC |
|
0-L |
R03DB04 |
theophylline and adrenergics |
WHO ATC |
|
0-L |
R03DB05 |
aminophylline and adrenergics |
WHO ATC |
|
0-L |
R03DB06 |
etamiphylline and adrenergics |
WHO ATC |
|
0-L |
R03DC |
Leukotriene receptor antagonists |
WHO ATC |
|
0-L |
R03DC01 |
zafirlukast |
WHO ATC |
|
0-L |
R03DC02 |
pranlukast |
WHO ATC |
|
0-L |
R03DC03 |
montelukast |
WHO ATC |
|
0-L |
R03DC04 |
ibudilast |
WHO ATC |
|
0-L |
R03DX |
Other systemic drugs for obstructive airway diseases |
WHO ATC |
|
0-L |
R03DX01 |
amlexanox |
WHO ATC |
|
0-L |
R03DX02 |
eprozinol |
WHO ATC |
|
0-L |
R03DX03 |
fenspiride |
WHO ATC |
|
0-L |
R03DX05 |
omalizumab |
WHO ATC |
|
0-L |
R03DX06 |
seratrodast |
WHO ATC |
|
0-L |
R03DX07 |
roflumilast |
WHO ATC |
|
0-L |
R05 |
COUGH AND COLD PREPARATIONS |
WHO ATC |
|
0-L |
R05C |
EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS |
WHO ATC |
|
0-L |
R05CA |
Expectorants |
WHO ATC |
|
0-L |
R05CA01 |
tyloxapol |
WHO ATC |
|
0-L |
R05CA02 |
potassium iodide |
WHO ATC |
|
0-L |
R05CA03 |
guaifenesin |
WHO ATC |
|
0-L |
R05CA04 |
ipecacuanha |
WHO ATC |
|
0-L |
R05CA05 |
althea root |
WHO ATC |
|
0-L |
R05CA06 |
senega |
WHO ATC |
|
0-L |
R05CA07 |
antimony pentasulfide |
WHO ATC |
|
0-L |
R05CA08 |
creosote |
WHO ATC |
|
0-L |
R05CA09 |
guaiacolsulfonate |
WHO ATC |
|
0-L |
R05CA10 |
combinations |
WHO ATC |
|
0-L |
R05CA11 |
levoverbenone |
WHO ATC |
|
0-L |
R05CB |
Mucolytics |
WHO ATC |
|
0-L |
R05CB01 |
acetylcysteine |
WHO ATC |
|
0-L |
R05CB02 |
bromhexine |
WHO ATC |
|
0-L |
R05CB03 |
carbocisteine |
WHO ATC |
|
0-L |
R05CB04 |
eprazinone |
WHO ATC |
|
0-L |
R05CB05 |
mesna |
WHO ATC |
|
0-L |
R05CB06 |
ambroxol |
WHO ATC |
|
0-L |
R05CB07 |
sobrerol |
WHO ATC |
|
0-L |
R05CB08 |
domiodol |
WHO ATC |
|
0-L |
R05CB09 |
letosteine |
WHO ATC |
|
0-L |
R05CB10 |
combinations |
WHO ATC |
|
0-L |
R05CB11 |
stepronin |
WHO ATC |
|
0-L |
R05CB12 |
tiopronin |
WHO ATC |
|
0-L |
R05CB13 |
dornase alfa (desoxyribonuclease) |
WHO ATC |
|
0-L |
R05CB14 |
neltenexine |
WHO ATC |
|
0-L |
R05CB15 |
erdosteine |
WHO ATC |
|
0-L |
R05D |
COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS |
WHO ATC |
|
0-L |
R05DA |
Opium alkaloids and derivatives |
WHO ATC |
|
0-L |
R05DA01 |
ethylmorphine |
WHO ATC |
|
0-L |
R05DA03 |
hydrocodone |
WHO ATC |
|
0-L |
R05DA04 |
codeine |
WHO ATC |
|
0-L |
R05DA05 |
opium alkaloids with morphine |
WHO ATC |
|
0-L |
R05DA06 |
normethadone |
WHO ATC |
|
0-L |
R05DA07 |
noscapine |
WHO ATC |
|
0-L |
R05DA08 |
pholcodine |
WHO ATC |
|
0-L |
R05DA09 |
dextromethorphan |
WHO ATC |
|
0-L |
R05DA10 |
thebacon |
WHO ATC |
|
0-L |
R05DA11 |
dimemorfan |
WHO ATC |
|
0-L |
R05DA12 |
acetyldihydrocodeine |
WHO ATC |
|
0-L |
R05DA20 |
combinations |
WHO ATC |
|
0-L |
R05DB |
Other cough suppressants |
WHO ATC |
|
0-L |
R05DB01 |
benzonatate |
WHO ATC |
|
0-L |
R05DB02 |
benproperine |
WHO ATC |
|
0-L |
R05DB03 |
clobutinol |
WHO ATC |
|
0-L |
R05DB04 |
isoaminile |
WHO ATC |
|
0-L |
R05DB05 |
pentoxyverine |
WHO ATC |
|
0-L |
R05DB07 |
oxolamine |
WHO ATC |
|
0-L |
R05DB09 |
oxeladin |
WHO ATC |
|
0-L |
R05DB10 |
clofedanol |
WHO ATC |
|
0-L |
R05DB11 |
pipazetate |
WHO ATC |
|
0-L |
R05DB12 |
bibenzonium bromide |
WHO ATC |
|
0-L |
R05DB13 |
butamirate |
WHO ATC |
|
0-L |
R05DB14 |
fedrilate |
WHO ATC |
|
0-L |
R05DB15 |
zipeprol |
WHO ATC |
|
0-L |
R05DB16 |
dibunate |
WHO ATC |
|
0-L |
R05DB17 |
droxypropine |
WHO ATC |
|
0-L |
R05DB18 |
prenoxdiazine |
WHO ATC |
|
0-L |
R05DB19 |
dropropizine |
WHO ATC |
|
0-L |
R05DB20 |
combinations |
WHO ATC |
|
0-L |
R05DB21 |
cloperastine |
WHO ATC |
|
0-L |
R05DB22 |
meprotixol |
WHO ATC |
|
0-L |
R05DB23 |
piperidione |
WHO ATC |
|
0-L |
R05DB24 |
tipepidine |
WHO ATC |
|
0-L |
R05DB25 |
morclofone |
WHO ATC |
|
0-L |
R05DB26 |
nepinalone |
WHO ATC |
|
0-L |
R05DB27 |
levodropropizine |
WHO ATC |
|
0-L |
R05DB28 |
dimethoxanate |
WHO ATC |
|
0-L |
R05F |
COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS |
WHO ATC |
|
0-L |
R05FA |
Opium derivatives and expectorants |
WHO ATC |
|
0-L |
R05FA01 |
opium derivatives and mucolytics |
WHO ATC |
|
0-L |
R05FA02 |
opium derivatives and expectorants |
WHO ATC |
|
0-L |
R05FB |
Other cough suppressants and expectorants |
WHO ATC |
|
0-L |
R05FB01 |
cough suppressants and mucolytics |
WHO ATC |
|
0-L |
R05FB02 |
cough suppressants and expectorants |
WHO ATC |
|
0-L |
R05X |
OTHER COLD COMBINATION PREPARATIONS |
WHO ATC |
|
0-L |
R06 |
ANTIHISTAMINES FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
R06A |
ANTIHISTAMINES FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
R06AA |
Aminoalkyl ethers |
WHO ATC |
|
0-L |
R06AA01 |
bromazine |
WHO ATC |
|
0-L |
R06AA02 |
diphenhydramine |
WHO ATC |
|
0-L |
R06AA04 |
clemastine |
WHO ATC |
|
0-L |
R06AA06 |
chlorphenoxamine |
WHO ATC |
|
0-L |
R06AA07 |
diphenylpyraline |
WHO ATC |
|
0-L |
R06AA08 |
carbinoxamine |
WHO ATC |
|
0-L |
R06AA09 |
doxylamine |
WHO ATC |
|
0-L |
R06AA52 |
diphenhydramine, combinations |
WHO ATC |
|
0-L |
R06AA54 |
clemastine, combinations |
WHO ATC |
|
0-L |
R06AA56 |
chlorphenoxamine, combinations |
WHO ATC |
|
0-L |
R06AA57 |
diphenylpyraline, combinations |
WHO ATC |
|
0-L |
R06AB |
Substituted alkylamines |
WHO ATC |
|
0-L |
R06AB01 |
brompheniramine |
WHO ATC |
|
0-L |
R06AB02 |
dexchlorpheniramine |
WHO ATC |
|
0-L |
R06AB03 |
dimetindene |
WHO ATC |
|
0-L |
R06AB04 |
chlorphenamine |
WHO ATC |
|
0-L |
R06AB05 |
pheniramine |
WHO ATC |
|
0-L |
R06AB06 |
dexbrompheniramine |
WHO ATC |
|
0-L |
R06AB07 |
talastine |
WHO ATC |
|
0-L |
R06AB51 |
brompheniramine, combinations |
WHO ATC |
|
0-L |
R06AB52 |
dexchlorpheniramine, combinations |
WHO ATC |
|
0-L |
R06AB54 |
chlorphenamine, combinations |
WHO ATC |
|
0-L |
R06AB56 |
dexbrompheniramine, combinations |
WHO ATC |
|
0-L |
R06AC |
Substituted ethylene diamines |
WHO ATC |
|
0-L |
R06AC01 |
mepyramine |
WHO ATC |
|
0-L |
R06AC02 |
histapyrrodine |
WHO ATC |
|
0-L |
R06AC03 |
chloropyramine |
WHO ATC |
|
0-L |
R06AC04 |
tripelennamine |
WHO ATC |
|
0-L |
R06AC05 |
methapyrilene |
WHO ATC |
|
0-L |
R06AC06 |
thonzylamine |
WHO ATC |
|
0-L |
R06AC52 |
histapyrrodine, combinations |
WHO ATC |
|
0-L |
R06AC53 |
chloropyramine, combinations |
WHO ATC |
|
0-L |
R06AD |
Phenothiazine derivatives |
WHO ATC |
|
0-L |
R06AD01 |
alimemazine |
WHO ATC |
|
0-L |
R06AD02 |
promethazine |
WHO ATC |
|
0-L |
R06AD03 |
thiethylperazine |
WHO ATC |
|
0-L |
R06AD04 |
methdilazine |
WHO ATC |
|
0-L |
R06AD05 |
hydroxyethylpromethazine |
WHO ATC |
|
0-L |
R06AD06 |
thiazinam |
WHO ATC |
|
0-L |
R06AD07 |
mequitazine |
WHO ATC |
|
0-L |
R06AD08 |
oxomemazine |
WHO ATC |
|
0-L |
R06AD09 |
isothipendyl |
WHO ATC |
|
0-L |
R06AD52 |
promethazine, combinations |
WHO ATC |
|
0-L |
R06AD55 |
hydroxyethylpromethazine, combinations |
WHO ATC |
|
0-L |
R06AE |
Piperazine derivatives |
WHO ATC |
|
0-L |
R06AE01 |
buclizine |
WHO ATC |
|
0-L |
R06AE03 |
cyclizine |
WHO ATC |
|
0-L |
R06AE04 |
chlorcyclizine |
WHO ATC |
|
0-L |
R06AE05 |
meclozine |
WHO ATC |
|
0-L |
R06AE06 |
oxatomide |
WHO ATC |
|
0-L |
R06AE07 |
cetirizine |
WHO ATC |
|
0-L |
R06AE09 |
levocetirizine |
WHO ATC |
|
0-L |
R06AE51 |
buclizine, combinations |
WHO ATC |
|
0-L |
R06AE53 |
cyclizine, combinations |
WHO ATC |
|
0-L |
R06AE55 |
meclozine, combinations |
WHO ATC |
|
0-L |
R06AK |
Combinations of antihistamines |
WHO ATC |
|
0-L |
R06AX |
Other antihistamines for systemic use |
WHO ATC |
|
0-L |
R06AX01 |
bamipine |
WHO ATC |
|
0-L |
R06AX02 |
cyproheptadine |
WHO ATC |
|
0-L |
R06AX03 |
thenalidine |
WHO ATC |
|
0-L |
R06AX04 |
phenindamine |
WHO ATC |
|
0-L |
R06AX05 |
antazoline |
WHO ATC |
|
0-L |
R06AX07 |
triprolidine |
WHO ATC |
|
0-L |
R06AX08 |
pyrrobutamine |
WHO ATC |
|
0-L |
R06AX09 |
azatadine |
WHO ATC |
|
0-L |
R06AX11 |
astemizole |
WHO ATC |
|
0-L |
R06AX12 |
terfenadine |
WHO ATC |
|
0-L |
R06AX13 |
loratadine |
WHO ATC |
|
0-L |
R06AX15 |
mebhydrolin |
WHO ATC |
|
0-L |
R06AX16 |
deptropine |
WHO ATC |
|
0-L |
R06AX17 |
ketotifen |
WHO ATC |
|
0-L |
R06AX18 |
acrivastine |
WHO ATC |
|
0-L |
R06AX19 |
azelastine |
WHO ATC |
|
0-L |
R06AX21 |
tritoqualine |
WHO ATC |
|
0-L |
R06AX22 |
ebastine |
WHO ATC |
|
0-L |
R06AX23 |
pimethixene |
WHO ATC |
|
0-L |
R06AX24 |
epinastine |
WHO ATC |
|
0-L |
R06AX25 |
mizolastine |
WHO ATC |
|
0-L |
R06AX26 |
fexofenadine |
WHO ATC |
|
0-L |
R06AX27 |
desloratadine |
WHO ATC |
|
0-L |
R06AX28 |
rupatadine |
WHO ATC |
|
0-L |
R06AX53 |
thenalidine, combinations |
WHO ATC |
|
0-L |
R06AX58 |
pyrrobutamine, combinations |
WHO ATC |
|
0-L |
R07 |
OTHER RESPIRATORY SYSTEM PRODUCTS |
WHO ATC |
|
0-L |
R07A |
OTHER RESPIRATORY SYSTEM PRODUCTS |
WHO ATC |
|
0-L |
R07AA |
Lung surfactants |
WHO ATC |
|
0-L |
R07AA01 |
colfosceril palmitate |
WHO ATC |
|
0-L |
R07AA02 |
natural phospholipids |
WHO ATC |
|
0-L |
R07AA30 |
combinations |
WHO ATC |
|
0-L |
R07AB |
Respiratory stimulants |
WHO ATC |
|
0-L |
R07AB01 |
doxapram |
WHO ATC |
|
0-L |
R07AB02 |
nikethamide |
WHO ATC |
|
0-L |
R07AB03 |
pentetrazol |
WHO ATC |
|
0-L |
R07AB04 |
etamivan |
WHO ATC |
|
0-L |
R07AB05 |
bemegride |
WHO ATC |
|
0-L |
R07AB06 |
prethcamide |
WHO ATC |
|
0-L |
R07AB07 |
almitrine |
WHO ATC |
|
0-L |
R07AB08 |
dimefline |
WHO ATC |
|
0-L |
R07AB09 |
mepixanox |
WHO ATC |
|
0-L |
R07AB52 |
nikethamide, combinations |
WHO ATC |
|
0-L |
R07AB53 |
pentetrazol, combinations |
WHO ATC |
|
0-L |
R07AX |
Other respiratory system products |
WHO ATC |
|
0-L |
R07AX01 |
nitric oxide |
WHO ATC |
|
0-L |
S |
SENSORY ORGANS |
WHO ATC |
|
0-L |
S01 |
OPHTHALMOLOGICALS |
WHO ATC |
|
0-L |
S01A |
ANTIINFECTIVES |
WHO ATC |
|
0-L |
S01AA |
Antibiotics |
WHO ATC |
|
0-L |
S01AA01 |
chloramphenicol |
WHO ATC |
|
0-L |
S01AA02 |
chlortetracycline |
WHO ATC |
|
0-L |
S01AA03 |
neomycin |
WHO ATC |
|
0-L |
S01AA04 |
oxytetracycline |
WHO ATC |
|
0-L |
S01AA05 |
tyrothricin |
WHO ATC |
|
0-L |
S01AA07 |
framycetin |
WHO ATC |
|
0-L |
S01AA09 |
tetracycline |
WHO ATC |
|
0-L |
S01AA10 |
natamycin |
WHO ATC |
|
0-L |
S01AA11 |
gentamicin |
WHO ATC |
|
0-L |
S01AA12 |
tobramycin |
WHO ATC |
|
0-L |
S01AA13 |
fusidic acid |
WHO ATC |
|
0-L |
S01AA14 |
benzylpenicillin |
WHO ATC |
|
0-L |
S01AA15 |
dihydrostreptomycin |
WHO ATC |
|
0-L |
S01AA16 |
rifamycin |
WHO ATC |
|
0-L |
S01AA17 |
erythromycin |
WHO ATC |
|
0-L |
S01AA18 |
polymyxin B |
WHO ATC |
|
0-L |
S01AA19 |
ampicillin |
WHO ATC |
|
0-L |
S01AA20 |
antibiotics in combination with other drugs |
WHO ATC |
|
0-L |
S01AA21 |
amikacin |
WHO ATC |
|
0-L |
S01AA22 |
micronomicin |
WHO ATC |
|
0-L |
S01AA23 |
netilmicin |
WHO ATC |
|
0-L |
S01AA24 |
kanamycin |
WHO ATC |
|
0-L |
S01AA25 |
azidamfenicol |
WHO ATC |
|
0-L |
S01AA26 |
azithromycin |
WHO ATC |
|
0-L |
S01AA30 |
combinations of different antibiotics |
WHO ATC |
|
0-L |
S01AB |
Sulfonamides |
WHO ATC |
|
0-L |
S01AB01 |
sulfamethizole |
WHO ATC |
|
0-L |
S01AB02 |
sulfafurazole |
WHO ATC |
|
0-L |
S01AB03 |
sulfadicramide |
WHO ATC |
|
0-L |
S01AB04 |
sulfacetamide |
WHO ATC |
|
0-L |
S01AB05 |
sulfafenazol |
WHO ATC |
|
0-L |
S01AD |
Antivirals |
WHO ATC |
|
0-L |
S01AD01 |
idoxuridine |
WHO ATC |
|
0-L |
S01AD02 |
trifluridine |
WHO ATC |
|
0-L |
S01AD03 |
aciclovir |
WHO ATC |
|
0-L |
S01AD05 |
interferon |
WHO ATC |
|
0-L |
S01AD06 |
vidarabine |
WHO ATC |
|
0-L |
S01AD07 |
famciclovir |
WHO ATC |
|
0-L |
S01AD08 |
fomivirsen |
WHO ATC |
|
0-L |
S01AD09 |
ganciclovir |
WHO ATC |
|
0-L |
S01AX |
Other antiinfectives |
WHO ATC |
|
0-L |
S01AX01 |
mercury compounds |
WHO ATC |
|
0-L |
S01AX02 |
silver compounds |
WHO ATC |
|
0-L |
S01AX03 |
zinc compounds |
WHO ATC |
|
0-L |
S01AX04 |
nitrofural |
WHO ATC |
|
0-L |
S01AX05 |
bibrocathol |
WHO ATC |
|
0-L |
S01AX06 |
resorcinol |
WHO ATC |
|
0-L |
S01AX07 |
sodium borate |
WHO ATC |
|
0-L |
S01AX08 |
hexamidine |
WHO ATC |
|
0-L |
S01AX09 |
chlorhexidine |
WHO ATC |
|
0-L |
S01AX10 |
sodium propionate |
WHO ATC |
|
0-L |
S01AX11 |
ofloxacin |
WHO ATC |
|
0-L |
S01AX12 |
norfloxacin |
WHO ATC |
|
0-L |
S01AX13 |
ciprofloxacin |
WHO ATC |
|
0-L |
S01AX14 |
dibrompropamidine |
WHO ATC |
|
0-L |
S01AX15 |
propamidine |
WHO ATC |
|
0-L |
S01AX16 |
picloxydine |
WHO ATC |
|
0-L |
S01AX17 |
lomefloxacin |
WHO ATC |
|
0-L |
S01AX18 |
povidone-iodine |
WHO ATC |
|
0-L |
S01AX19 |
levofloxacin |
WHO ATC |
|
0-L |
S01AX21 |
gatifloxacin |
WHO ATC |
|
0-L |
S01AX22 |
moxifloxacin |
WHO ATC |
|
0-L |
S01B |
ANTIINFLAMMATORY AGENTS |
WHO ATC |
|
0-L |
S01BA |
Corticosteroids, plain |
WHO ATC |
|
0-L |
S01BA01 |
dexamethasone |
WHO ATC |
|
0-L |
S01BA02 |
hydrocortisone |
WHO ATC |
|
0-L |
S01BA03 |
cortisone |
WHO ATC |
|
0-L |
S01BA04 |
prednisolone |
WHO ATC |
|
0-L |
S01BA05 |
triamcinolone |
WHO ATC |
|
0-L |
S01BA06 |
betamethasone |
WHO ATC |
|
0-L |
S01BA07 |
fluorometholone |
WHO ATC |
|
0-L |
S01BA08 |
medrysone |
WHO ATC |
|
0-L |
S01BA09 |
clobetasone |
WHO ATC |
|
0-L |
S01BA10 |
alclometasone |
WHO ATC |
|
0-L |
S01BA11 |
desonide |
WHO ATC |
|
0-L |
S01BA12 |
formocortal |
WHO ATC |
|
0-L |
S01BA13 |
rimexolone |
WHO ATC |
|
0-L |
S01BA14 |
loteprednol |
WHO ATC |
|
0-L |
S01BA15 |
fluocinolone acetonide |
WHO ATC |
|
0-L |
S01BB |
Corticosteroids and mydriatics in combination |
WHO ATC |
|
0-L |
S01BB01 |
hydrocortisone and mydriatics |
WHO ATC |
|
0-L |
S01BB02 |
prednisolone and mydriatics |
WHO ATC |
|
0-L |
S01BB03 |
fluorometholone and mydriatics |
WHO ATC |
|
0-L |
S01BB04 |
betamethasone and mydriatics |
WHO ATC |
|
0-L |
S01BC |
Antiinflammatory agents, non-steroids |
WHO ATC |
|
0-L |
S01BC01 |
indometacin |
WHO ATC |
|
0-L |
S01BC02 |
oxyphenbutazone |
WHO ATC |
|
0-L |
S01BC03 |
diclofenac |
WHO ATC |
|
0-L |
S01BC04 |
flurbiprofen |
WHO ATC |
|
0-L |
S01BC05 |
ketorolac |
WHO ATC |
|
0-L |
S01BC06 |
piroxicam |
WHO ATC |
|
0-L |
S01BC07 |
bendazac |
WHO ATC |
|
0-L |
S01BC08 |
salicylic acid |
WHO ATC |
|
0-L |
S01BC09 |
pranoprofen |
WHO ATC |
|
0-L |
S01BC10 |
nepafenac |
WHO ATC |
|
0-L |
S01BC11 |
bromfenac |
WHO ATC |
|
0-L |
S01C |
ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION |
WHO ATC |
|
0-L |
S01CA |
Corticosteroids and antiinfectives in combination |
WHO ATC |
|
0-L |
S01CA01 |
dexamethasone and antiinfectives |
WHO ATC |
|
0-L |
S01CA02 |
prednisolone and antiinfectives |
WHO ATC |
|
0-L |
S01CA03 |
hydrocortisone and antiinfectives |
WHO ATC |
|
0-L |
S01CA04 |
fluocortolone and antiinfectives |
WHO ATC |
|
0-L |
S01CA05 |
betamethasone and antiinfectives |
WHO ATC |
|
0-L |
S01CA06 |
fludrocortisone and antiinfectives |
WHO ATC |
|
0-L |
S01CA07 |
fluorometholone and antiinfectives |
WHO ATC |
|
0-L |
S01CA08 |
methylprednisolone and antiinfectives |
WHO ATC |
|
0-L |
S01CA09 |
chloroprednisone and antiinfectives |
WHO ATC |
|
0-L |
S01CA10 |
fluocinolone acetonide and antiinfectives |
WHO ATC |
|
0-L |
S01CA11 |
clobetasone and antiinfectives |
WHO ATC |
|
0-L |
S01CB |
Corticosteroids/antiinfectives/mydriatics in combination |
WHO ATC |
|
0-L |
S01CB01 |
dexamethasone |
WHO ATC |
|
0-L |
S01CB02 |
prednisolone |
WHO ATC |
|
0-L |
S01CB03 |
hydrocortisone |
WHO ATC |
|
0-L |
S01CB04 |
betamethasone |
WHO ATC |
|
0-L |
S01CB05 |
fluorometholone |
WHO ATC |
|
0-L |
S01CC |
Antiinflammatory agents, non-steroids and antiinfectives in combination |
WHO ATC |
|
0-L |
S01CC01 |
diclofenac and antiinfectives |
WHO ATC |
|
0-L |
S01E |
ANTIGLAUCOMA PREPARATIONS AND MIOTICS |
WHO ATC |
|
0-L |
S01EA |
Sympathomimetics in glaucoma therapy |
WHO ATC |
|
0-L |
S01EA01 |
epinephrine |
WHO ATC |
|
0-L |
S01EA02 |
dipivefrine |
WHO ATC |
|
0-L |
S01EA03 |
apraclonidine |
WHO ATC |
|
0-L |
S01EA04 |
clonidine |
WHO ATC |
|
0-L |
S01EA05 |
brimonidine |
WHO ATC |
|
0-L |
S01EA51 |
epinephrine, combinations |
WHO ATC |
|
0-L |
S01EB |
Parasympathomimetics |
WHO ATC |
|
0-L |
S01EB01 |
pilocarpine |
WHO ATC |
|
0-L |
S01EB02 |
carbachol |
WHO ATC |
|
0-L |
S01EB03 |
ecothiopate |
WHO ATC |
|
0-L |
S01EB04 |
demecarium |
WHO ATC |
|
0-L |
S01EB05 |
physostigmine |
WHO ATC |
|
0-L |
S01EB06 |
neostigmine |
WHO ATC |
|
0-L |
S01EB07 |
fluostigmine |
WHO ATC |
|
0-L |
S01EB08 |
aceclidine |
WHO ATC |
|
0-L |
S01EB09 |
acetylcholine |
WHO ATC |
|
0-L |
S01EB10 |
paraoxon |
WHO ATC |
|
0-L |
S01EB51 |
pilocarpine, combinations |
WHO ATC |
|
0-L |
S01EB58 |
aceclidine, combinations |
WHO ATC |
|
0-L |
S01EC |
Carbonic anhydrase inhibitors |
WHO ATC |
|
0-L |
S01EC01 |
acetazolamide |
WHO ATC |
|
0-L |
S01EC02 |
diclofenamide |
WHO ATC |
|
0-L |
S01EC03 |
dorzolamide |
WHO ATC |
|
0-L |
S01EC04 |
brinzolamide |
WHO ATC |
|
0-L |
S01EC05 |
methazolamide |
WHO ATC |
|
0-L |
S01ED |
Beta blocking agents1) |
WHO ATC |
|
0-L |
S01ED01 |
timolol |
WHO ATC |
|
0-L |
S01ED02 |
betaxolol |
WHO ATC |
|
0-L |
S01ED03 |
levobunolol |
WHO ATC |
|
0-L |
S01ED04 |
metipranolol |
WHO ATC |
|
0-L |
S01ED05 |
carteolol |
WHO ATC |
|
0-L |
S01ED06 |
befunolol |
WHO ATC |
|
0-L |
S01ED51 |
timolol, combinations |
WHO ATC |
|
0-L |
S01ED52 |
betaxolol, combinations |
WHO ATC |
|
0-L |
S01ED54 |
metipranolol, combinations |
WHO ATC |
|
0-L |
S01ED55 |
carteolol, combinations |
WHO ATC |
|
0-L |
S01EE |
Prostaglandin analogues1) |
WHO ATC |
|
0-L |
S01EE01 |
latanoprost |
WHO ATC |
|
0-L |
S01EE02 |
unoprostone |
WHO ATC |
|
0-L |
S01EE03 |
bimatoprost |
WHO ATC |
|
0-L |
S01EE04 |
travoprost |
WHO ATC |
|
0-L |
S01EE05 |
tafluprost |
WHO ATC |
|
0-L |
S01EX |
Other antiglaucoma preparations |
WHO ATC |
|
0-L |
S01EX01 |
guanethidine |
WHO ATC |
|
0-L |
S01EX02 |
dapiprazole |
WHO ATC |
|
0-L |
S01F |
MYDRIATICS AND CYCLOPLEGICS |
WHO ATC |
|
0-L |
S01FA |
Anticholinergics |
WHO ATC |
|
0-L |
S01FA01 |
atropine |
WHO ATC |
|
0-L |
S01FA02 |
scopolamine |
WHO ATC |
|
0-L |
S01FA03 |
methylscopolamine |
WHO ATC |
|
0-L |
S01FA04 |
cyclopentolate |
WHO ATC |
|
0-L |
S01FA05 |
homatropine |
WHO ATC |
|
0-L |
S01FA06 |
tropicamide |
WHO ATC |
|
0-L |
S01FA56 |
tropicamide, combinations |
WHO ATC |
|
0-L |
S01FB |
Sympathomimetics excl. antiglaucoma preparations |
WHO ATC |
|
0-L |
S01FB01 |
phenylephrine |
WHO ATC |
|
0-L |
S01FB02 |
ephedrine |
WHO ATC |
|
0-L |
S01FB03 |
ibopamine |
WHO ATC |
|
0-L |
S01G |
DECONGESTANTS AND ANTIALLERGICS |
WHO ATC |
|
0-L |
S01GA |
Sympathomimetics used as decongestants |
WHO ATC |
|
0-L |
S01GA01 |
naphazoline |
WHO ATC |
|
0-L |
S01GA02 |
tetryzoline |
WHO ATC |
|
0-L |
S01GA03 |
xylometazoline |
WHO ATC |
|
0-L |
S01GA04 |
oxymetazoline |
WHO ATC |
|
0-L |
S01GA05 |
phenylephrine |
WHO ATC |
|
0-L |
S01GA06 |
oxedrine |
WHO ATC |
|
0-L |
S01GA51 |
naphazoline, combinations |
WHO ATC |
|
0-L |
S01GA52 |
tetryzoline, combinations |
WHO ATC |
|
0-L |
S01GA53 |
xylometazoline, combinations |
WHO ATC |
|
0-L |
S01GA55 |
phenylephrine, combinations |
WHO ATC |
|
0-L |
S01GA56 |
oxedrine, combinations |
WHO ATC |
|
0-L |
S01GX |
Other antiallergics |
WHO ATC |
|
0-L |
S01GX01 |
cromoglicic acid |
WHO ATC |
|
0-L |
S01GX02 |
levocabastine |
WHO ATC |
|
0-L |
S01GX03 |
spaglumic acid |
WHO ATC |
|
0-L |
S01GX04 |
nedocromil |
WHO ATC |
|
0-L |
S01GX05 |
lodoxamide |
WHO ATC |
|
0-L |
S01GX06 |
emedastine |
WHO ATC |
|
0-L |
S01GX07 |
azelastine |
WHO ATC |
|
0-L |
S01GX08 |
ketotifen |
WHO ATC |
|
0-L |
S01GX09 |
olopatadine |
WHO ATC |
|
0-L |
S01GX10 |
epinastine |
WHO ATC |
|
0-L |
S01GX51 |
cromoglicic acid, combinations |
WHO ATC |
|
0-L |
S01H |
LOCAL ANESTHETICS |
WHO ATC |
|
0-L |
S01HA |
Local anesthetics |
WHO ATC |
|
0-L |
S01HA01 |
cocaine |
WHO ATC |
|
0-L |
S01HA02 |
oxybuprocaine |
WHO ATC |
|
0-L |
S01HA03 |
tetracaine |
WHO ATC |
|
0-L |
S01HA04 |
proxymetacaine |
WHO ATC |
|
0-L |
S01HA05 |
procaine |
WHO ATC |
|
0-L |
S01HA06 |
cinchocaine |
WHO ATC |
|
0-L |
S01HA07 |
lidocaine |
WHO ATC |
|
0-L |
S01HA30 |
combinations |
WHO ATC |
|
0-L |
S01J |
DIAGNOSTIC AGENTS |
WHO ATC |
|
0-L |
S01JA |
Colouring agents |
WHO ATC |
|
0-L |
S01JA01 |
fluorescein |
WHO ATC |
|
0-L |
S01JA02 |
rose bengal sodium |
WHO ATC |
|
0-L |
S01JA51 |
fluorescein, combinations |
WHO ATC |
|
0-L |
S01JX |
Other ophthalmological diagnostic agents |
WHO ATC |
|
0-L |
S01K |
SURGICAL AIDS |
WHO ATC |
|
0-L |
S01KA |
Viscoelastic substances |
WHO ATC |
|
0-L |
S01KA01 |
hyaluronic acid |
WHO ATC |
|
0-L |
S01KA02 |
hypromellose |
WHO ATC |
|
0-L |
S01KA51 |
hyaluronic acid, combinations |
WHO ATC |
|
0-L |
S01KX |
Other surgical aids |
WHO ATC |
|
0-L |
S01KX01 |
chymotrypsin |
WHO ATC |
|
0-L |
S01L |
OCULAR VASCULAR DISORDER AGENTS |
WHO ATC |
|
0-L |
S01LA |
Antineovascularisation agents |
WHO ATC |
|
0-L |
S01LA01 |
verteporfin |
WHO ATC |
|
0-L |
S01LA02 |
anecortave |
WHO ATC |
|
0-L |
S01LA03 |
pegaptanib |
WHO ATC |
|
0-L |
S01LA04 |
ranibizumab |
WHO ATC |
|
0-L |
S01X |
OTHER OPHTHALMOLOGICALS |
WHO ATC |
|
0-L |
S01XA |
Other ophthalmologicals |
WHO ATC |
|
0-L |
S01XA01 |
guaiazulen |
WHO ATC |
|
0-L |
S01XA02 |
retinol |
WHO ATC |
|
0-L |
S01XA03 |
sodium chloride, hypertonic |
WHO ATC |
|
0-L |
S01XA04 |
potassium iodide |
WHO ATC |
|
0-L |
S01XA05 |
sodium edetate |
WHO ATC |
|
0-L |
S01XA06 |
ethylmorphine |
WHO ATC |
|
0-L |
S01XA07 |
alum |
WHO ATC |
|
0-L |
S01XA08 |
acetylcysteine |
WHO ATC |
|
0-L |
S01XA09 |
iodoheparinate |
WHO ATC |
|
0-L |
S01XA10 |
inosine |
WHO ATC |
|
0-L |
S01XA11 |
nandrolone |
WHO ATC |
|
0-L |
S01XA12 |
dexpanthenol |
WHO ATC |
|
0-L |
S01XA13 |
alteplase |
WHO ATC |
|
0-L |
S01XA14 |
heparin |
WHO ATC |
|
0-L |
S01XA15 |
ascorbic acid |
WHO ATC |
|
0-L |
S01XA18 |
ciclosporin |
WHO ATC |
|
0-L |
S01XA20 |
artificial tears and other indifferent preparations |
WHO ATC |
|
0-L |
S02 |
OTOLOGICALS |
WHO ATC |
|
0-L |
S02A |
ANTIINFECTIVES |
WHO ATC |
|
0-L |
S02AA |
Antiinfectives |
WHO ATC |
|
0-L |
S02AA01 |
chloramphenicol |
WHO ATC |
|
0-L |
S02AA02 |
nitrofural |
WHO ATC |
|
0-L |
S02AA03 |
boric acid |
WHO ATC |
|
0-L |
S02AA04 |
aluminium acetotartrate |
WHO ATC |
|
0-L |
S02AA05 |
clioquinol |
WHO ATC |
|
0-L |
S02AA06 |
hydrogen peroxide |
WHO ATC |
|
0-L |
S02AA07 |
neomycin |
WHO ATC |
|
0-L |
S02AA08 |
tetracycline |
WHO ATC |
|
0-L |
S02AA09 |
chlorhexidine |
WHO ATC |
|
0-L |
S02AA10 |
acetic acid |
WHO ATC |
|
0-L |
S02AA11 |
polymyxin B |
WHO ATC |
|
0-L |
S02AA12 |
rifamycin |
WHO ATC |
|
0-L |
S02AA13 |
miconazole |
WHO ATC |
|
0-L |
S02AA14 |
gentamicin |
WHO ATC |
|
0-L |
S02AA15 |
ciprofloxacin |
WHO ATC |
|
0-L |
S02AA16 |
ofloxacin |
WHO ATC |
|
0-L |
S02AA30 |
antiinfectives, combinations |
WHO ATC |
|
0-L |
S02B |
CORTICOSTEROIDS |
WHO ATC |
|
0-L |
S02BA |
Corticosteroids |
WHO ATC |
|
0-L |
S02BA01 |
hydrocortisone |
WHO ATC |
|
0-L |
S02BA03 |
prednisolone |
WHO ATC |
|
0-L |
S02BA06 |
dexamethasone |
WHO ATC |
|
0-L |
S02BA07 |
betamethasone |
WHO ATC |
|
0-L |
S02BA08 |
fluocinolone acetonide |
WHO ATC |
|
0-L |
S02C |
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION |
WHO ATC |
|
0-L |
S02CA |
Corticosteroids and antiinfectives in combination |
WHO ATC |
|
0-L |
S02CA01 |
prednisolone and antiinfectives |
WHO ATC |
|
0-L |
S02CA02 |
flumetasone and antiinfectives |
WHO ATC |
|
0-L |
S02CA03 |
hydrocortisone and antiinfectives |
WHO ATC |
|
0-L |
S02CA04 |
triamcinolone and antiinfectives |
WHO ATC |
|
0-L |
S02CA05 |
fluocinolone acetonide and antiinfectives |
WHO ATC |
|
0-L |
S02CA06 |
dexamethasone and antiinfectives |
WHO ATC |
|
0-L |
S02CA07 |
fludrocortisone and antiinfectives |
WHO ATC |
|
0-L |
S02D |
OTHER OTOLOGICALS |
WHO ATC |
|
0-L |
S02DA |
Analgesics and anesthetics |
WHO ATC |
|
0-L |
S02DA01 |
lidocaine |
WHO ATC |
|
0-L |
S02DA02 |
cocaine |
WHO ATC |
|
0-L |
S02DA03 |
phenazone |
WHO ATC |
|
0-L |
S02DA30 |
combinations |
WHO ATC |
|
0-L |
S02DC |
Indifferent preparations |
WHO ATC |
|
0-L |
S03 |
OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS |
WHO ATC |
|
0-L |
S03A |
ANTIINFECTIVES |
WHO ATC |
|
0-L |
S03AA |
Antiinfectives |
WHO ATC |
|
0-L |
S03AA01 |
neomycin |
WHO ATC |
|
0-L |
S03AA02 |
tetracycline |
WHO ATC |
|
0-L |
S03AA03 |
polymyxin B |
WHO ATC |
|
0-L |
S03AA04 |
chlorhexidine |
WHO ATC |
|
0-L |
S03AA05 |
hexamidine |
WHO ATC |
|
0-L |
S03AA06 |
gentamicin |
WHO ATC |
|
0-L |
S03AA07 |
ciprofloxacin |
WHO ATC |
|
0-L |
S03AA08 |
chloramphenicol |
WHO ATC |
|
0-L |
S03AA30 |
antiinfectives, combinations |
WHO ATC |
|
0-L |
S03B |
CORTICOSTEROIDS |
WHO ATC |
|
0-L |
S03BA |
Corticosteroids |
WHO ATC |
|
0-L |
S03BA01 |
dexamethasone |
WHO ATC |
|
0-L |
S03BA02 |
prednisolone |
WHO ATC |
|
0-L |
S03BA03 |
betamethasone |
WHO ATC |
|
0-L |
S03C |
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION |
WHO ATC |
|
0-L |
S03CA |
Corticosteroids and antiinfectives in combination |
WHO ATC |
|
0-L |
S03CA01 |
dexamethasone and antiinfectives |
WHO ATC |
|
0-L |
S03CA02 |
prednisolone and antiinfectives |
WHO ATC |
|
0-L |
S03CA04 |
hydrocortisone and antiinfectives |
WHO ATC |
|
0-L |
S03CA05 |
fludrocortisone and antiinfectives |
WHO ATC |
|
0-L |
S03CA06 |
betamethasone and antiinfectives |
WHO ATC |
|
0-L |
S03D |
OTHER OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS |
WHO ATC |
|
0-L |
V |
VARIOUS |
WHO ATC |
|
0-L |
V01 |
ALLERGENS |
WHO ATC |
|
0-L |
V01A |
ALLERGENS |
WHO ATC |
|
0-L |
V01AA |
Allergen extracts |
WHO ATC |
|
0-L |
V01AA01 |
feather |
WHO ATC |
|
0-L |
V01AA02 |
grass pollen |
WHO ATC |
|
0-L |
V01AA03 |
house dust mites |
WHO ATC |
|
0-L |
V01AA04 |
mould fungus and yeast fungus |
WHO ATC |
|
0-L |
V01AA05 |
tree pollen |
WHO ATC |
|
0-L |
V01AA07 |
insects |
WHO ATC |
|
0-L |
V01AA08 |
food |
WHO ATC |
|
0-L |
V01AA09 |
textiles |
WHO ATC |
|
0-L |
V01AA10 |
flowers |
WHO ATC |
|
0-L |
V01AA11 |
animals |
WHO ATC |
|
0-L |
V01AA20 |
various |
WHO ATC |
|
0-L |
V03 |
ALL OTHER THERAPEUTIC PRODUCTS |
WHO ATC |
|
0-L |
V03A |
ALL OTHER THERAPEUTIC PRODUCTS |
WHO ATC |
|
0-L |
V03AB |
Antidotes |
WHO ATC |
|
0-L |
V03AB01 |
ipecacuanha |
WHO ATC |
|
0-L |
V03AB02 |
nalorphine |
WHO ATC |
|
0-L |
V03AB03 |
edetates |
WHO ATC |
|
0-L |
V03AB04 |
pralidoxime |
WHO ATC |
|
0-L |
V03AB05 |
prednisolone and promethazine |
WHO ATC |
|
0-L |
V03AB06 |
thiosulfate |
WHO ATC |
|
0-L |
V03AB08 |
sodium nitrite |
WHO ATC |
|
0-L |
V03AB09 |
dimercaprol |
WHO ATC |
|
0-L |
V03AB13 |
obidoxime |
WHO ATC |
|
0-L |
V03AB14 |
protamine |
WHO ATC |
|
0-L |
V03AB15 |
naloxone |
WHO ATC |
|
0-L |
V03AB16 |
ethanol |
WHO ATC |
|
0-L |
V03AB17 |
methylthioninium chloride |
WHO ATC |
|
0-L |
V03AB18 |
potassium permanganate |
WHO ATC |
|
0-L |
V03AB19 |
physostigmine |
WHO ATC |
|
0-L |
V03AB20 |
copper sulfate |
WHO ATC |
|
0-L |
V03AB21 |
potassium iodide |
WHO ATC |
|
0-L |
V03AB22 |
amyl nitrite |
WHO ATC |
|
0-L |
V03AB23 |
acetylcysteine |
WHO ATC |
|
0-L |
V03AB24 |
digitalis antitoxin |
WHO ATC |
|
0-L |
V03AB25 |
flumazenil |
WHO ATC |
|
0-L |
V03AB26 |
methionine |
WHO ATC |
|
0-L |
V03AB27 |
4-dimethylaminophenol |
WHO ATC |
|
0-L |
V03AB29 |
cholinesterase |
WHO ATC |
|
0-L |
V03AB31 |
prussian blue |
WHO ATC |
|
0-L |
V03AB32 |
glutathione |
WHO ATC |
|
0-L |
V03AB33 |
hydroxocobalamin |
WHO ATC |
|
0-L |
V03AB34 |
fomepizole |
WHO ATC |
|
0-L |
V03AB35 |
sugammadex |
WHO ATC |
|
0-L |
V03AC |
Iron chelating agents |
WHO ATC |
|
0-L |
V03AC01 |
deferoxamine |
WHO ATC |
|
0-L |
V03AC02 |
deferiprone |
WHO ATC |
|
0-L |
V03AC03 |
deferasirox |
WHO ATC |
|
0-L |
V03AE |
Drugs for treatment of hyperkalemia and hyperphosphatemia |
WHO ATC |
|
0-L |
V03AE01 |
polystyrene sulfonate |
WHO ATC |
|
0-L |
V03AE02 |
sevelamer |
WHO ATC |
|
0-L |
V03AE03 |
lanthanum carbonate |
WHO ATC |
|
0-L |
V03AE04 |
calcium acetate and magnesium carbonate |
WHO ATC |
|
0-L |
V03AF |
Detoxifying agents for antineoplastic treatment |
WHO ATC |
|
0-L |
V03AF01 |
mesna |
WHO ATC |
|
0-L |
V03AF02 |
dexrazoxane |
WHO ATC |
|
0-L |
V03AF03 |
calcium folinate |
WHO ATC |
|
0-L |
V03AF04 |
calcium levofolinate |
WHO ATC |
|
0-L |
V03AF05 |
amifostine |
WHO ATC |
|
0-L |
V03AF06 |
sodium folinate |
WHO ATC |
|
0-L |
V03AF07 |
rasburicase |
WHO ATC |
|
0-L |
V03AF08 |
palifermin |
WHO ATC |
|
0-L |
V03AF09 |
glucarpidase |
WHO ATC |
|
0-L |
V03AF10 |
sodium levofolinate |
WHO ATC |
|
0-L |
V03AG |
Drugs for treatment of hypercalcemia |
WHO ATC |
|
0-L |
V03AG01 |
sodium cellulose phosphate |
WHO ATC |
|
0-L |
V03AH |
Drugs for treatment of hypoglycemia |
WHO ATC |
|
0-L |
V03AH01 |
diazoxide |
WHO ATC |
|
0-L |
V03AK |
Tissue adhesives |
WHO ATC |
|
0-L |
V03AM |
Drugs for embolisation |
WHO ATC |
|
0-L |
V03AN |
Medical gases |
WHO ATC |
|
0-L |
V03AN01 |
oxygen |
WHO ATC |
|
0-L |
V03AN02 |
carbon dioxide |
WHO ATC |
|
0-L |
V03AN03 |
helium |
WHO ATC |
|
0-L |
V03AN04 |
nitrogen |
WHO ATC |
|
0-L |
V03AN05 |
medical air |
WHO ATC |
|
0-L |
V03AX |
Other therapeutic products |
WHO ATC |
|
0-L |
V03AX02 |
nalfurafine |
WHO ATC |
|
0-L |
V03AZ |
Nerve depressants |
WHO ATC |
|
0-L |
V03AZ01 |
ethanol |
WHO ATC |
|
0-L |
V04 |
DIAGNOSTIC AGENTS |
WHO ATC |
|
0-L |
V04B |
URINE TESTS |
WHO ATC |
|
0-L |
V04C |
OTHER DIAGNOSTIC AGENTS |
WHO ATC |
|
0-L |
V04CA |
Tests for diabetes |
WHO ATC |
|
0-L |
V04CA01 |
tolbutamide |
WHO ATC |
|
0-L |
V04CA02 |
glucose |
WHO ATC |
|
0-L |
V04CB |
Tests for fat absorption |
WHO ATC |
|
0-L |
V04CB01 |
vitamin A concentrates |
WHO ATC |
|
0-L |
V04CC |
Tests for bile duct patency |
WHO ATC |
|
0-L |
V04CC01 |
sorbitol |
WHO ATC |
|
0-L |
V04CC02 |
magnesium sulfate |
WHO ATC |
|
0-L |
V04CC03 |
sincalide |
WHO ATC |
|
0-L |
V04CC04 |
ceruletide |
WHO ATC |
|
0-L |
V04CD |
Tests for pituitary function |
WHO ATC |
|
0-L |
V04CD01 |
metyrapone |
WHO ATC |
|
0-L |
V04CD03 |
sermorelin |
WHO ATC |
|
0-L |
V04CD04 |
corticorelin |
WHO ATC |
|
0-L |
V04CD05 |
somatorelin |
WHO ATC |
|
0-L |
V04CE |
Tests for liver functional capacity |
WHO ATC |
|
0-L |
V04CE01 |
galactose |
WHO ATC |
|
0-L |
V04CE02 |
sulfobromophthalein |
WHO ATC |
|
0-L |
V04CF |
Tuberculosis diagnostics |
WHO ATC |
|
0-L |
V04CF01 |
tuberculin |
WHO ATC |
|
0-L |
V04CG |
Tests for gastric secretion |
WHO ATC |
|
0-L |
V04CG01 |
cation exchange resins |
WHO ATC |
|
0-L |
V04CG02 |
betazole |
WHO ATC |
|
0-L |
V04CG03 |
histamine phosphate |
WHO ATC |
|
0-L |
V04CG04 |
pentagastrin |
WHO ATC |
|
0-L |
V04CG05 |
methylthioninium chloride |
WHO ATC |
|
0-L |
V04CG30 |
caffeine and sodium benzoate |
WHO ATC |
|
0-L |
V04CH |
Tests for renal function |
WHO ATC |
|
0-L |
V04CH01 |
inulin and other polyfructosans |
WHO ATC |
|
0-L |
V04CH02 |
indigo carmine |
WHO ATC |
|
0-L |
V04CH03 |
phenolsulfonphthalein |
WHO ATC |
|
0-L |
V04CH04 |
alsactide |
WHO ATC |
|
0-L |
V04CH30 |
aminohippuric acid |
WHO ATC |
|
0-L |
V04CJ |
Tests for thyreoidea function |
WHO ATC |
|
0-L |
V04CJ01 |
thyrotropin |
WHO ATC |
|
0-L |
V04CJ02 |
protirelin |
WHO ATC |
|
0-L |
V04CK |
Tests for pancreatic function |
WHO ATC |
|
0-L |
V04CK01 |
secretin |
WHO ATC |
|
0-L |
V04CK02 |
pancreozymin (cholecystokinin) |
WHO ATC |
|
0-L |
V04CK03 |
bentiromide |
WHO ATC |
|
0-L |
V04CL |
Tests for allergic diseases |
WHO ATC |
|
0-L |
V04CM |
Tests for fertility disturbances |
WHO ATC |
|
0-L |
V04CM01 |
gonadorelin |
WHO ATC |
|
0-L |
V04CX |
Other diagnostic agents |
WHO ATC |
|
0-L |
V06 |
GENERAL NUTRIENTS |
WHO ATC |
|
0-L |
V06A |
DIET FORMULATIONS FOR TREATMENT OF OBESITY |
WHO ATC |
|
0-L |
V06AA |
Low-energy diets |
WHO ATC |
|
0-L |
V06B |
PROTEIN SUPPLEMENTS |
WHO ATC |
|
0-L |
V06C |
INFANT FORMULAS |
WHO ATC |
|
0-L |
V06CA |
Nutrients without phenylalanine |
WHO ATC |
|
0-L |
V06D |
OTHER NUTRIENTS |
WHO ATC |
|
0-L |
V06DA |
Carbohydrates/proteins/minerals/vitamins, combinations |
WHO ATC |
|
0-L |
V06DB |
Fat/carbohydrates/proteins/minerals/vitamins, combinations |
WHO ATC |
|
0-L |
V06DC |
Carbohydrates |
WHO ATC |
|
0-L |
V06DC01 |
glucose |
WHO ATC |
|
0-L |
V06DC02 |
fructose |
WHO ATC |
|
0-L |
V06DD |
Amino acids, incl. combinations with polypeptides |
WHO ATC |
|
0-L |
V06DE |
Amino acids/carbohydrates/minerals/vitamins, combinations |
WHO ATC |
|
0-L |
V06DF |
Milk substitutes |
WHO ATC |
|
0-L |
V06DX |
Other combinations of nutrients |
WHO ATC |
|
0-L |
V07 |
ALL OTHER NON-THERAPEUTIC PRODUCTS |
WHO ATC |
|
0-L |
V07A |
ALL OTHER NON-THERAPEUTIC PRODUCTS |
WHO ATC |
|
0-L |
V07AA |
Plasters |
WHO ATC |
|
0-L |
V07AB |
Solvents and diluting agents, incl. irrigating solutions |
WHO ATC |
|
0-L |
V07AC |
Blood transfusion, auxiliary products |
WHO ATC |
|
0-L |
V07AD |
Blood tests, auxiliary products |
WHO ATC |
|
0-L |
V07AN |
Incontinence equipment |
WHO ATC |
|
0-L |
V07AR |
Sensitivity tests, discs and tablets |
WHO ATC |
|
0-L |
V07AS |
Stomi equipment |
WHO ATC |
|
0-L |
V07AT |
Cosmetics |
WHO ATC |
|
0-L |
V07AV |
Technical disinfectants |
WHO ATC |
|
0-L |
V07AX |
Washing agents etc. |
WHO ATC |
|
0-L |
V07AY |
Other non-therapeutic auxiliary products |
WHO ATC |
|
0-L |
V07AZ |
Chemicals and reagents for analysis |
WHO ATC |
|
0-L |
V08 |
CONTRAST MEDIA |
WHO ATC |
|
0-L |
V08A |
X-RAY CONTRAST MEDIA, IODINATED |
WHO ATC |
|
0-L |
V08AA |
Watersoluble, nephrotropic, high osmolar X-ray contrast media |
WHO ATC |
|
0-L |
V08AA01 |
diatrizoic acid |
WHO ATC |
|
0-L |
V08AA02 |
metrizoic acid |
WHO ATC |
|
0-L |
V08AA03 |
iodamide |
WHO ATC |
|
0-L |
V08AA04 |
iotalamic acid |
WHO ATC |
|
0-L |
V08AA05 |
ioxitalamic acid |
WHO ATC |
|
0-L |
V08AA06 |
ioglicic acid |
WHO ATC |
|
0-L |
V08AA07 |
acetrizoic acid |
WHO ATC |
|
0-L |
V08AA08 |
iocarmic acid |
WHO ATC |
|
0-L |
V08AA09 |
methiodal |
WHO ATC |
|
0-L |
V08AA10 |
diodone |
WHO ATC |
|
0-L |
V08AB |
Watersoluble, nephrotropic, low osmolar X-ray contrast media |
WHO ATC |
|
0-L |
V08AB01 |
metrizamide |
WHO ATC |
|
0-L |
V08AB02 |
iohexol |
WHO ATC |
|
0-L |
V08AB03 |
ioxaglic acid |
WHO ATC |
|
0-L |
V08AB04 |
iopamidol |
WHO ATC |
|
0-L |
V08AB05 |
iopromide |
WHO ATC |
|
0-L |
V08AB06 |
iotrolan |
WHO ATC |
|
0-L |
V08AB07 |
ioversol |
WHO ATC |
|
0-L |
V08AB08 |
iopentol |
WHO ATC |
|
0-L |
V08AB09 |
iodixanol |
WHO ATC |
|
0-L |
V08AB10 |
iomeprol |
WHO ATC |
|
0-L |
V08AB11 |
iobitridol |
WHO ATC |
|
0-L |
V08AB12 |
ioxilan |
WHO ATC |
|
0-L |
V08AC |
Watersoluble, hepatotropic X-ray contrast media |
WHO ATC |
|
0-L |
V08AC01 |
iodoxamic acid |
WHO ATC |
|
0-L |
V08AC02 |
iotroxic acid |
WHO ATC |
|
0-L |
V08AC03 |
ioglycamic acid |
WHO ATC |
|
0-L |
V08AC04 |
adipiodone |
WHO ATC |
|
0-L |
V08AC05 |
iobenzamic acid |
WHO ATC |
|
0-L |
V08AC06 |
iopanoic acid |
WHO ATC |
|
0-L |
V08AC07 |
iocetamic acid |
WHO ATC |
|
0-L |
V08AC08 |
sodium iopodate |
WHO ATC |
|
0-L |
V08AC09 |
tyropanoic acid |
WHO ATC |
|
0-L |
V08AC10 |
calcium iopodate |
WHO ATC |
|
0-L |
V08AD |
Non-watersoluble X-ray contrast media |
WHO ATC |
|
0-L |
V08AD01 |
ethyl esters of iodised fatty acids |
WHO ATC |
|
0-L |
V08AD02 |
iopydol |
WHO ATC |
|
0-L |
V08AD03 |
propyliodone |
WHO ATC |
|
0-L |
V08AD04 |
iofendylate |
WHO ATC |
|
0-L |
V08B |
X-RAY CONTRAST MEDIA, NON-IODINATED |
WHO ATC |
|
0-L |
V08BA |
Barium sulfate containing X-ray contrast media |
WHO ATC |
|
0-L |
V08BA01 |
barium sulfate with suspending agents |
WHO ATC |
|
0-L |
V08BA02 |
barium sulfate without suspending agents |
WHO ATC |
|
0-L |
V08C |
MAGNETIC RESONANCE IMAGING CONTRAST MEDIA |
WHO ATC |
|
0-L |
V08CA |
Paramagnetic contrast media |
WHO ATC |
|
0-L |
V08CA01 |
gadopentetic acid |
WHO ATC |
|
0-L |
V08CA02 |
gadoteric acid |
WHO ATC |
|
0-L |
V08CA03 |
gadodiamide |
WHO ATC |
|
0-L |
V08CA04 |
gadoteridol |
WHO ATC |
|
0-L |
V08CA05 |
mangafodipir |
WHO ATC |
|
0-L |
V08CA06 |
gadoversetamide |
WHO ATC |
|
0-L |
V08CA07 |
ferric ammonium citrate |
WHO ATC |
|
0-L |
V08CA08 |
gadobenic acid |
WHO ATC |
|
0-L |
V08CA09 |
gadobutrol |
WHO ATC |
|
0-L |
V08CA10 |
gadoxetic acid |
WHO ATC |
|
0-L |
V08CA11 |
gadofosveset |
WHO ATC |
|
0-L |
V08CB |
Superparamagnetic contrast media |
WHO ATC |
|
0-L |
V08CB01 |
ferumoxsil |
WHO ATC |
|
0-L |
V08CB02 |
ferristene |
WHO ATC |
|
0-L |
V08CB03 |
iron oxide, nanoparticles |
WHO ATC |
|
0-L |
V08CX |
Other magnetic resonance imaging contrast media |
WHO ATC |
|
0-L |
V08CX01 |
perflubron |
WHO ATC |
|
0-L |
V08D |
ULTRASOUND CONTRAST MEDIA |
WHO ATC |
|
0-L |
V08DA |
Ultrasound contrast media |
WHO ATC |
|
0-L |
V08DA01 |
microspheres of human albumin |
WHO ATC |
|
0-L |
V08DA02 |
microparticles of galactose |
WHO ATC |
|
0-L |
V08DA03 |
perflenapent |
WHO ATC |
|
0-L |
V08DA04 |
microspheres of phospholipids |
WHO ATC |
|
0-L |
V08DA05 |
sulfur hexafluoride |
WHO ATC |
|
0-L |
V09 |
DIAGNOSTIC RADIOPHARMACEUTICALS |
WHO ATC |
|
0-L |
V09A |
CENTRAL NERVOUS SYSTEM |
WHO ATC |
|
0-L |
V09AA |
Technetium (99mTc) compounds |
WHO ATC |
|
0-L |
V09AA01 |
technetium (99mTc) exametazime |
WHO ATC |
|
0-L |
V09AA02 |
technetium (99mTc) bicisate |
WHO ATC |
|
0-L |
V09AB |
Iodine (123I) compounds |
WHO ATC |
|
0-L |
V09AB01 |
iodine iofetamine (123I) |
WHO ATC |
|
0-L |
V09AB02 |
iodine iolopride (123I) |
WHO ATC |
|
0-L |
V09AB03 |
iodine ioflupane (123I) |
WHO ATC |
|
0-L |
V09AX |
Other central nervous system diagnostic radiopharmaceuticals |
WHO ATC |
|
0-L |
V09AX01 |
indium (111In) pentetic acid |
WHO ATC |
|
0-L |
V09AX03 |
iodine (124I) 2beta-carbomethoxy-3beta-(4 iodophenyl)-tropane |
WHO ATC |
|
0-L |
V09B |
SKELETON |
WHO ATC |
|
0-L |
V09BA |
Technetium (99mTc) compounds |
WHO ATC |
|
0-L |
V09BA01 |
technetium (99mTc) oxidronic acid |
WHO ATC |
|
0-L |
V09BA02 |
technetium (99mTc) medronic acid |
WHO ATC |
|
0-L |
V09BA03 |
technetium (99mTc) pyrophosphate |
WHO ATC |
|
0-L |
V09BA04 |
technetium (99mTc) butedronic acid |
WHO ATC |
|
0-L |
V09C |
RENAL SYSTEM |
WHO ATC |
|
0-L |
V09CA |
Technetium (99mTc) compounds |
WHO ATC |
|
0-L |
V09CA01 |
technetium (99mTc) pentetic acid |
WHO ATC |
|
0-L |
V09CA02 |
technetium (99mTc) succimer |
WHO ATC |
|
0-L |
V09CA03 |
technetium (99mTc) mertiatide |
WHO ATC |
|
0-L |
V09CA04 |
technetium (99mTc) gluceptate |
WHO ATC |
|
0-L |
V09CA05 |
technetium (99mTc) gluconate |
WHO ATC |
|
0-L |
V09CX |
Other renal system diagnostic radiopharmaceuticals |
WHO ATC |
|
0-L |
V09CX01 |
sodium iodohippurate (123I) |
WHO ATC |
|
0-L |
V09CX02 |
sodium iodohippurate (131I) |
WHO ATC |
|
0-L |
V09CX03 |
sodium iothalamate (125I) |
WHO ATC |
|
0-L |
V09CX04 |
chromium (51Cr) edetate |
WHO ATC |
|
0-L |
V09D |
HEPATIC AND RETICULO ENDOTHELIAL SYSTEM |
WHO ATC |
|
0-L |
V09DA |
Technetium (99mTc) compounds |
WHO ATC |
|
0-L |
V09DA01 |
technetium (99mTc) disofenin |
WHO ATC |
|
0-L |
V09DA02 |
technetium (99mTc) etifenin |
WHO ATC |
|
0-L |
V09DA03 |
technetium (99mTc) lidofenin |
WHO ATC |
|
0-L |
V09DA04 |
technetium (99mTc) mebrofenin |
WHO ATC |
|
0-L |
V09DA05 |
technetium (99mTc) galtifenin |
WHO ATC |
|
0-L |
V09DB |
Technetium (99mTc), particles and colloids |
WHO ATC |
|
0-L |
V09DB01 |
technetium (99mTc) nanocolloid |
WHO ATC |
|
0-L |
V09DB02 |
technetium (99mTc) microcolloid |
WHO ATC |
|
0-L |
V09DB03 |
technetium (99mTc) millimicrospheres |
WHO ATC |
|
0-L |
V09DB04 |
technetium (99mTc) tin colloid |
WHO ATC |
|
0-L |
V09DB05 |
technetium (99mTc) sulfur colloid |
WHO ATC |
|
0-L |
V09DB06 |
technetium (99mTc) rheniumsulfide colloid |
WHO ATC |
|
0-L |
V09DB07 |
technetium (99mTc) phytate |
WHO ATC |
|
0-L |
V09DX |
Other hepatic and reticulo endothelial system diagnostic radiopharmaceuticals |
WHO ATC |
|
0-L |
V09DX01 |
selenium (75Se) tauroselcholic acid |
WHO ATC |
|
0-L |
V09E |
RESPIRATORY SYSTEM |
WHO ATC |
|
0-L |
V09EA |
Technetium (99mTc), inhalants |
WHO ATC |
|
0-L |
V09EA01 |
technetium (99mTc) pentetic acid |
WHO ATC |
|
0-L |
V09EA02 |
technetium (99mTc) technegas |
WHO ATC |
|
0-L |
V09EA03 |
technetium (99mTc) nanocolloid |
WHO ATC |
|
0-L |
V09EB |
Technetium (99mTc), particles for injection |
WHO ATC |
|
0-L |
V09EB01 |
technetium (99mTc) macrosalb |
WHO ATC |
|
0-L |
V09EB02 |
technetium (99mTc) microspheres |
WHO ATC |
|
0-L |
V09EX |
Other respiratory system diagnostic radiopharmaceuticals |
WHO ATC |
|
0-L |
V09EX01 |
krypton (81mKr) gas |
WHO ATC |
|
0-L |
V09EX02 |
xenon (127Xe) gas |
WHO ATC |
|
0-L |
V09EX03 |
xenon (133Xe) gas |
WHO ATC |
|
0-L |
V09F |
THYROID |
WHO ATC |
|
0-L |
V09FX |
Various thyroid diagnostic radiopharmaceuticals |
WHO ATC |
|
0-L |
V09FX01 |
technetium (99mTc) pertechnetate |
WHO ATC |
|
0-L |
V09FX02 |
sodium iodide (123I) |
WHO ATC |
|
0-L |
V09FX03 |
sodium iodide (131I) |
WHO ATC |
|
0-L |
V09FX04 |
sodium iodide (124I) |
WHO ATC |
|
0-L |
V09G |
CARDIOVASCULAR SYSTEM |
WHO ATC |
|
0-L |
V09GA |
Technetium (99mTc) compounds |
WHO ATC |
|
0-L |
V09GA01 |
technetium (99mTc) sestamibi |
WHO ATC |
|
0-L |
V09GA02 |
technetium (99mTc) tetrofosmin |
WHO ATC |
|
0-L |
V09GA03 |
technetium (99mTc) teboroxime |
WHO ATC |
|
0-L |
V09GA04 |
technetium (99mTc) human albumin |
WHO ATC |
|
0-L |
V09GA05 |
technetium (99mTc) furifosmin |
WHO ATC |
|
0-L |
V09GA06 |
technetium (99mTc) stannous agent labelled cells |
WHO ATC |
|
0-L |
V09GA07 |
technetium (99mTc) apcitide |
WHO ATC |
|
0-L |
V09GB |
Iodine (125I) compounds |
WHO ATC |
|
0-L |
V09GB01 |
fibrinogen (125I) |
WHO ATC |
|
0-L |
V09GB02 |
iodine (125I) human albumin |
WHO ATC |
|
0-L |
V09GX |
Other cardiovascular system diagnostic radiopharmaceuticals |
WHO ATC |
|
0-L |
V09GX01 |
thallium (201Tl) chloride |
WHO ATC |
|
0-L |
V09GX02 |
indium (111In) imciromab |
WHO ATC |
|
0-L |
V09GX03 |
chromium (51Cr) chromate labelled cells |
WHO ATC |
|
0-L |
V09H |
INFLAMMATION AND INFECTION DETECTION |
WHO ATC |
|
0-L |
V09HA |
Technetium (99mTc) compounds |
WHO ATC |
|
0-L |
V09HA01 |
technetium (99mTc) human immunoglobulin |
WHO ATC |
|
0-L |
V09HA02 |
technetium (99mTc) exametazime labelled cells |
WHO ATC |
|
0-L |
V09HA03 |
technetium (99mTc) antigranulocyte antibody |
WHO ATC |
|
0-L |
V09HA04 |
technetium (99mTc) sulesomab |
WHO ATC |
|
0-L |
V09HB |
Indium (111In) compounds |
WHO ATC |
|
0-L |
V09HB01 |
indium (111In) oxinate labelled cells |
WHO ATC |
|
0-L |
V09HB02 |
indium (111In) tropolonate labelled cells |
WHO ATC |
|
0-L |
V09HX |
Other diagnostic radiopharmaceuticals for inflammation and infection detection |
WHO ATC |
|
0-L |
V09HX01 |
gallium (67Ga) citrate |
WHO ATC |
|
0-L |
V09I |
TUMOUR DETECTION |
WHO ATC |
|
0-L |
V09IA |
Technetium (99mTc) compounds |
WHO ATC |
|
0-L |
V09IA01 |
technetium (99mTc) antiCarcinoEmbryonicAntigen antibody |
WHO ATC |
|
0-L |
V09IA02 |
technetium (99mTc) antimelanoma antibody |
WHO ATC |
|
0-L |
V09IA03 |
technetium (99mTc) pentavalent succimer |
WHO ATC |
|
0-L |
V09IA04 |
technetium (99mTc) votumumab |
WHO ATC |
|
0-L |
V09IA05 |
technetium (99mTc) depreotide |
WHO ATC |
|
0-L |
V09IA06 |
technetium (99mTc) arcitumomab |
WHO ATC |
|
0-L |
V09IB |
Indium (111In) compounds |
WHO ATC |
|
0-L |
V09IB01 |
indium (111In) pentetreotide |
WHO ATC |
|
0-L |
V09IB02 |
indium (111In) satumomab pendetide |
WHO ATC |
|
0-L |
V09IB03 |
indium (111In) antiovariumcarcinoma antibody |
WHO ATC |
|
0-L |
V09IB04 |
indium (111In) capromab pendetide |
WHO ATC |
|
0-L |
V09IX |
Other diagnostic radiopharmaceuticals for tumour detection |
WHO ATC |
|
0-L |
V09IX01 |
iobenguane (123I) |
WHO ATC |
|
0-L |
V09IX02 |
iobenguane (131I) |
WHO ATC |
|
0-L |
V09IX03 |
iodine (125I) CC49-monoclonal antibody |
WHO ATC |
|
0-L |
V09IX04 |
fludeoxyglucose (18F) |
WHO ATC |
|
0-L |
V09IX05 |
fluorodopa (18F) |
WHO ATC |
|
0-L |
V09IX06 |
sodium fluoride (18F) |
WHO ATC |
|
0-L |
V09IX07 |
fluoromethylcholine (18F) |
WHO ATC |
|
0-L |
V09X |
OTHER DIAGNOSTIC RADIOPHARMACEUTICALS |
WHO ATC |
|
0-L |
V09XA |
Iodine (131I) compounds |
WHO ATC |
|
0-L |
V09XA01 |
iodine (131I) norcholesterol |
WHO ATC |
|
0-L |
V09XA02 |
iodocholesterol (131I) |
WHO ATC |
|
0-L |
V09XA03 |
iodine (131I) human albumin |
WHO ATC |
|
0-L |
V09XX |
Various diagnostic radiopharmaceuticals |
WHO ATC |
|
0-L |
V09XX01 |
cobalt (57Co) cyanocobalamine |
WHO ATC |
|
0-L |
V09XX02 |
cobalt (58Co) cyanocobalamine |
WHO ATC |
|
0-L |
V09XX03 |
selenium (75Se) norcholesterol |
WHO ATC |
|
0-L |
V09XX04 |
ferric (59Fe) citrate |
WHO ATC |
|
0-L |
V10 |
THERAPEUTIC RADIOPHARMACEUTICALS |
WHO ATC |
|
0-L |
V10A |
ANTIINFLAMMATORY AGENTS |
WHO ATC |
|
0-L |
V10AA |
Yttrium (90Y) compounds |
WHO ATC |
|
0-L |
V10AA01 |
yttrium (90Y) citrate colloid |
WHO ATC |
|
0-L |
V10AA02 |
yttrium (90Y) ferrihydroxide colloid |
WHO ATC |
|
0-L |
V10AA03 |
yttrium (90Y) silicate colloid |
WHO ATC |
|
0-L |
V10AX |
Other antiinflammatory therapeutic radiopharmaceuticals |
WHO ATC |
|
0-L |
V10AX01 |
phosphorous (32P) chromicphosphate colloid |
WHO ATC |
|
0-L |
V10AX02 |
samarium (153Sm) hydroxyapatite colloid |
WHO ATC |
|
0-L |
V10AX03 |
dysprosium (165Dy) colloid |
WHO ATC |
|
0-L |
V10AX04 |
erbium (169Er) citrate colloid |
WHO ATC |
|
0-L |
V10AX05 |
rhenium (186Re) sulfide colloid |
WHO ATC |
|
0-L |
V10AX06 |
gold (198Au) colloidal |
WHO ATC |
|
0-L |
V10B |
PAIN PALLIATION (BONE SEEKING AGENTS) |
WHO ATC |
|
0-L |
V10BX |
Various pain palliation radiopharmaceuticals |
WHO ATC |
|
0-L |
V10BX01 |
strontium (89Sr) chloride |
WHO ATC |
|
0-L |
V10BX02 |
samarium (153Sm) lexidronam |
WHO ATC |
|
0-L |
V10BX03 |
rhenium (186Re) etidronic acid |
WHO ATC |
|
0-L |
V10X |
OTHER THERAPEUTIC RADIOPHARMACEUTICALS |
WHO ATC |
|
0-L |
V10XA |
Iodine (131I) compounds |
WHO ATC |
|
0-L |
V10XA01 |
sodium iodide (131I) |
WHO ATC |
|
0-L |
V10XA02 |
iobenguane (131I) |
WHO ATC |
|
0-L |
V10XA53 |
tositumomab/iodine (131I) tositumomab |
WHO ATC |
|
0-L |
V10XX |
Various therapeutic radiopharmaceuticals |
WHO ATC |
|
0-L |
V10XX01 |
sodium phosphate (32P) |
WHO ATC |
|
0-L |
V10XX02 |
ibritumomab tiuxetan (90Y) |
WHO ATC |
|
0-L |
V20 |
SURGICAL DRESSINGS |
WHO ATC |
|